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Abstract 
The mechanism by which glucocorticoids (GCs) achieve negative feedback on the release of 
hypothalamo-pituitary-adrenal (HPA) axis hormones has long been under investigation. Annexin A1 
(ANXA1) is a key mediator of the effects of GCs within the neuroendocrine and immune systems. 
Previous research suggested the negative feedback effect of the GC-ANXA1 system on the pituitary 
release of adrenocorticotrophic hormone (ACTH) was mediated via a member of the formyl peptide 
receptor (Fpr in rodents, FPR in humans) family. The present work tested the hypothesis that 
specific Fpr/FPR subtypes modulate both pituitary and adrenal function in terms of stress hormone 
(ACTH and corticosterone) secretion (following exposure to secretagogues CRH and ACTH or the 
inflammogen LPS in rats), and their tissue distribution (mice and rats) will itself be upregulated following 
inflammogenic stress (LPS in mice and rats, multiple sclerosis in human tissue). This was achieved 
through 1) immunohistochemical detection of FPR1, FPR2/ALX, and FPR3 in human anterior pituitary 
sections, and of green fluorescent protein (GFP) in HPA axis tissues from Fpr2/3
-/-
, GFP
+/+
 mice; 2) 
measurement of basal and stimulated ACTH and GC release from dispersed rat anterior pituitary and 
adrenal cells, incubated with agonists and antagonists for FPR1, FPR2/ALX and FPR3, namely, formyl-
Met-Leu-Phe (fMLF), ANXA1 amino-acetylated peptide (ANXA1Ac2-26), Trp-Lys-Tyr-Met-Val-D-met 
(WKYMVm), haem-binding protein fragment (F2L), aspirin-triggered lipoxin A4 (15-epi-LXA4), and 
Trp-Arg-Trp-Trp-Trp-Trp (WRW4). These ligands were found to elicit a range of modulatory, 
concentration-dependent effects on pituitary ACTH and adrenal GC secretion. Evidence was found for 
the spatial distribution of: FPR3 and FPR2/ALX within the human anterior pituitary, and GFP (as a 
surrogate for Fpr2/3) colocalised with ACTH, growth hormone (GH), and prolactin (PRL) within the 
Fpr2/3
-/-
, GFP
+/+
 mouse pituitary. The findings contribute evidence in support of a role of Fpr/FPR 
subtypes and their ligands as modulators of pituitary and adrenal hormone release.  
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1.1 Background 
In 1929, Walter Cannon coined homeostasis as a term for the “coordinated physiological reactions which 
maintain most of the steady states in the body” (Cannon 1929) that were first observed and precisely 
described by Claude Bernard in 1878. Cannon also described the acute effects of stress on physiological 
systems, noting they were similar to injections of the adrenal gland hormone adrenin (epinephrine), under 
what is now commonly known as the ‘fight-or-flight response’ (Cannon 1914; 1915). Stress as a 
biological concept, however, was first described by Hans Selye as “a non-specific response to a variety of 
threatening situations” (Selye 1936). After four decades of researching the physiological effects of stress, 
he updated the nomenclature thusly:  
“Stress is the nonspecific response of the body to any demand. A stressor is an agent that produces stress 
at any time. The general adaptation syndrome (GAS) represents the chronologic development of the 
response to stressors when their action is prolonged. It consists of three phases: the alarm reaction, the 
stage of resistance and the stage of exhaustion” (Selye 1976). 
Since then, scientific research of stress has been prolific, and the term is in common parlance. Despite 
this, a disparity between high public awareness and poor biological definitions of stress, is being 
exploited by an industry offering pseudo-scientific diagnoses and treatments worth 18 billion dollars per 
annum in the USA alone (Patmore 2006; Weissmann 2007). Apart from these controversies, there is peer-
reviewed evidence to indicate stress can increase the risk of numerous health problems. Sepsis, for 
instance, is caused by bacterial cells, toxins or other components that enter the blood or other tissues 
distal to an infection site and if poorly managed can result in multiple organ failure and death. Stressors 
such as surgery, blood loss, and unhealed wounds increase both the risk and exacerbate the development 
of sepsis. This is thought to be due to bacterial proliferation that is unchecked by the suppressed immune 
system that typically follows stress. Similar risks are evident in patients receiving immunosuppressive 
agents such as anti-rejection drugs or analogues of steroids released during stress. Interestingly, increased 
doses of steroid therapy are required to counter inflammation and tissue damage that can occur during 
severe stress. Invasive surgery, for instance, is a major stressor and approximately 1 in 5 cases (19.5 per 
cent) of sepsis following operations in US hospitals between 1998-2006 resulted in death, versus 1 in 10 
deaths (11.7 per cent) for sepsis without surgery (Eber et al. 2010). Sepsis adds 8.1 billion dollars in 
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added hospitalisation costs per annum, and these costs are likely to rise if challenges of antibiotic 
resistance, natural population increases, and clinical management of patients under severe stress remain 
unaddressed. This underscores the importance of further research to improve our understanding of stress. 
For the purposes of understanding the present work, however, the terms stress, stressor, and stress 
response, will have distinct meanings. 
Stress (verb) is any challenge beyond an organism’s current capacity to coordinate the physiological 
reactions that maintain steady states in the body through homeostasis. 
A stressor (noun) is any cue that can cause stress. 
A stress response (noun) is an engagement of adaptive systems following any challenge beyond an 
organism’s current homeostatic capacity. 
An organism that is under stress (stressed) has been exposed to a stressor and is being challenged, either 
by an on-going stressor (e.g. predation), or by the effects of a preceding stressor (e.g. blood loss). Stress, 
therefore, is a problem that cannot be solved by inertia—whether physiological or behavioural—and is 
most severe when the problem is an urgent matter of survival. The first description of stress by Selye, 
however, was based on observations of a given stressor applied to a largely homogenous population of 
rats in a controlled laboratory environment (Selye 1936). From these experiments, Selye found that stress 
followed three stages: alarm, resistance, and exhaustion. The early, alarm stage was characterised by 
adrenal hypertrophy but with depleted carbon skeletons for cortical steroid and medullary catecholamine 
synthesis; hepatic and lymphoid atrophy; thymic, pleural and peritoneal oedema, and gastrointestinal 
ulceration. The stage of resistance included: adrenal repletion of cortical lipids, reduced oedema, 
upregulated pituitary basophilic cells, thyroid hyperplasia, curbed body growth, gonadal atrophy and 
cessation of lactation (Selye 1936). Finally, unresolved stress leads to the stage of exhaustion and 
ultimately, death. These observations seemed to indicate stress might somehow induce a response that 
prioritises the mobilisation of energy stores over functions that are not of immediate importance for 
survival.  
Stressors are varied in terms of type (tangible or intangible), origin (external or internal) and scale 
(magnitude and duration). These include, but are not limited to tangible cues, such as fighting, sexual 
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assault, or pathogens; or intangible cues, such as negative thoughts and social subordination. Since 
stressors are innumerable in type, origin, and scale, then there are many ways in which stress can be 
induced. The specificity of a response to a given stressor can also depend on numerous factors described 
later (Section 1.2.5). 
An appropriate stress response is timely and of a scale commensurate with the level of threat. The 
hypothalamo-pituitary-adrenal (HPA) axis is a critical, self-regulating, neuroendocrine system allowing 
vertebrates to respond to stress through i) enabling adaptation to survive the changes imposed by stress, 
and ii) restoration and regulation of homeostasis once stress is over. The timely release of stress hormones 
from the HPA axis enables adaptive responses to stress and also regulates a wide range of homeostatic 
functions, not limited to growth, metabolism, and reproduction. 
Conversely, an inappropriate stress response might be asynchronous (early or late) or disproportionate to 
the level of threat. If an inappropriate stress response continues, this may result in acute or chronic tissue 
damage, and might even contribute to the aetiology of autoimmune diseases such as multiple sclerosis 
(MS) (Mason et al. 1990; Gold et al. 2012), or provide immunosuppressive conditions conducive for the 
proliferation of pathogens and development of infections and sepsis, for instance after traumatic brain 
injury (Ayala et al. 1994; O'Sullivan et al. 1995). In these conditions, the exogenous administration of 
synthetic stress hormones such as hydrocortisone, is associated with an increase in the production of anti-
inflammatory cytokines and amelioration of some symptoms (van der Poll et al. 1996; Gayo et al. 1998). 
The evidence indicates the timing and concentration of stress hormones is influential in the aetiology and 
recovery from inflammatory stress, but our understanding of this relationship is still complicated and 
necessitates further research in order to simplify and find safe, efficacious drugs with fewer side effects 
than hydrocortisone (Schäcke et al. 2002). 
Having described the basic nomenclature, the following sections will describe: the physiology of the HPA 
axis in terms of its structure, function, and regulation in humans and rodents; how the stress response 
differs depending on the source of stress; the self-regulatory nature of the HPA axis and its role in host 
defence, and the molecular mediators of feedback regulation.   
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1.2 Anatomy and physiology of the HPA axis 
After a brief overview of the axis, this section focuses mainly on the key effectors of HPA axis functions, 
namely, the glucocorticoids (GCs), and describes their effects, modes of action, biosynthesis in the 
adrenal cortex, and the role of adrenocorticotrophic hormone (ACTH) in their regulated release. The 
focus then moves to the neurohumoral mechanism of controlling pituitary ACTH secretion involving the 
hypothalamic hormones arginine vasopressin (AVP) and corticotrophin-releasing hormone (CRH), and 
their roles during stress and quiescence. Finally, an outline of the negative feedback system illustrates 
how GCs regulate HPA axis activity and their own release.  
1.2.1 Overview of the HPA axis 
The HPA axis is a major system of neuroendocrine interactions between the hypothalamus, pituitary, and 
adrenal glands, whose hormones regulate many homeostatic processes as well as the stress response. 
Hypothalamic CRH and AVP synergistically stimulate the anterior pituitary to secrete ACTH that 
stimulates the adrenal cortex to produce and release GCs (Gillies et al. 1982). The GCs have widespread, 
tissue-specific effects that enable homeostatic mechanisms during quiescence and periods of stress, after 
which they effectively turn off their own release via feedback inhibition of pituitary ACTH secretion, and 
hypothalamic CRH and AVP secretion. 
The hypothalamus, extending sagittally from the optic chiasm to the mammillary bodies, comprises four 
major zones (pre-optic, anterior, middle, and posterior) and is situated above the third cerebral ventricle. 
Most hypothalamic cells have specialised neural and secretory activity, and are either organised in nuclei 
or scattered within the tissue. Distinct nuclei and neuronal sub-populations are also organised into 
systems with separate functions. The magnocellular neurons (>30 µm diameter) are situated in the 
paraventricular (PVN) and supraoptic (SON) nuclei where they synthesise oxytocin and AVP to be 
released from axonal projections at fenestrated capillary beds within the posterior pituitary gland (Stopa 
et al. 1993). Release of oxytocin is triggered by neural reflexes activated during lactation and parturition, 
whereas osmotic stimuli trigger magnocellular AVP release where it functions mainly as an antidiuretic 
hormone via renal V2 receptors (Manning et al. 2008). Parvocellular neurons (< 10 µm diameter) also 
produce AVP, along with CRH, but this AVP mainly modulates HPA axis function and does so in 
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synergy with CRH (Gillies et al. 1982). In fact, the release of the six hormones of the anterior pituitary 
gland is controlled by different parvocellular neurosecretory neurons in the hypothalamus. The medial 
parvocellular region of the hypothalamic paraventricular nucleus (PVNmp) contains neurosecretory 
neurons that regulate ACTH secretion from the anterior pituitary gland. On each side of the PVNmp in 
rats, there are around 2000 CRH neurons with fusiform bodies and bipolar dendrites, and axons 
terminating in the median eminence. Parvocellular AVP is synthesised and packaged into large dense core 
vesicles (LDCVs) with CRH in approximately half of these neurons, particularly in the dorsal PVNmp 
(Swanson et al. 1983; Whitnall et al. 1985). The rate of synthesis of parvocellular peptides is typically 
related to the rate of secretion, but also depends on feedback signals. Parvocellular CRH and AVP 
synthesis and release are sensitive to feedback inhibition by GCs although to different extents. Increased 
release of CRH and AVP—following adrenalectomy and loss of GC feedback, for instance—is related to 
an increased expression of CRH and AVP genes. Synthesis of these peptides follows gene transcription 
and translation events before processing into LDCVs for axonal transport (6-8 mm/h) to neurosecretory 
terminals in the median eminence. Neurosecretion of CRH and AVP is unidirectional and dependent on 
depolarisation and Ca
2+
 influx induced by action potentials generated in the soma. The Ca
2+
 induces 
membrane docking of LDCVs and exocytosis of their contents into the hypophyseal portal vasculature, 
that perfuses the cells of the anterior pituitary with hypothalamic hormones (Jacobsson & Meister 1996).  
The hypophyseal portal system services the whole pituitary gland for vascular communication between 
the endocrine and nervous systems (Popa & Fielding 1930; Harris 1948). A direct link from the 
hypothalamus to the anterior lobe, for instance, begins with the internal carotid arteries extending into 
three pairs of hypophyseal arteries. The superior hypophyseal arteries enter the median eminence, 
breaking into a plexus surrounding hypothalamic nerve endings, and then long portal veins down the pars 
tuberalis into the capillaries of the anterior lobe. The middle and inferior hypophyseal arteries supply the 
posterior lobe but also have short portal vessels to the anterior lobe. This allows the cells of the anterior 
lobe to respond to their respective parvocellular hormones and other mediators to regulate the secretion of 
hormones into systemic circulation, whereupon they have access to target tissues, including the adrenal 
glands. 
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The pituitary gland sits in the sella turcica of the sphenoid bone beneath the hypothalamus. It comprises 
two embryologically distinct lobes: the epithelial anterior lobe, and the neuro-glial posterior lobe. The 
anterior lobe can be further sub-divided in three: pars distalis, pars intermedia, and pars tuberalis. The 
pars distalis and intermedia contain numerous endocrine cell types in proportions (percentage of total) 
that vary slightly between species and are distinguished by the types of hormones they secrete. In 
humans, the largest proportion is made up of the large ovoid somatotrophs (growth hormone, GH; 50 per 
cent), then lactotrophs (prolactin, PRL; 25 per cent), corticotrophs (ACTH; 20 per cent), gonadotrophs 
(follicle-stimulating hormone (FSH) and luteinising hormone (LH); 10 per cent), and thyrotrophs 
(thyroid-stimulating hormone (TSH); less than 5 per cent) (Stevens & Lowe 2011). 
The adrenal glands are located above the kidneys and comprise two distinct systems for hormone 
biosynthesis and secretion: i) the neuroendocrine adrenal medulla for catecholamines, and ii) the adrenal 
cortex for steroid hormones and their precursors, with several relevant to HPA axis function. Enclosed 
between the fibrous external capsule and the adrenal medulla, the adrenal cortex contains three 
histologically and functionally distinct zones, namely, the zona glomerulosa (ZG), the zona fasciculata 
(ZF), and zona reticularis (ZR). The sub-capsular ZG is a thin, unevenly distributed layer of cells that 
secrete mineralocorticoids (mainly aldosterone and deoxycorticosterone). The ZF is the largest cortical 
layer and contains rectangular, vacuolated cells with lipid-rich cytoplasms and is the main site of GC 
production, and secretion in response to ACTH. The ZR is the second largest cortical layer with 
eosinophilic cells containing the pale-brown pigment lipofuscin, in columnar arrangement around 
capillaries, and is the main androgenic site secreting dehydroepiandrosterone (DHEA). Conversely, the 
chromaffin cells of the adrenal medulla contain the catecholamines, epinephrine, norepinephrine, and 
dopamine, as well as the monoamine, serotonin (5-hydroxtryptophan; 5-HT) (Holzwarth & Brownfield 
1985). The adrenal gland thus produces numerous, and chemically diverse hormones, but most of the 
effects of the HPA axis, however, are achieved through the widespread, tissue-specific actions of its chief 
end products—the GCs. 
1.2.2 Role of glucocorticoids 
GCs are steroid hormones common to all vertebrate species. In mammals, the main site of GC synthesis is 
the adrenal cortex. Adrenal steroidogenesis is a biosynthetic reaction series, and starts with the rate-
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limiting step of converting cholesterol to pregnenolone. Thirty or more GCs have been isolated from the 
mammalian cortex, but (in most mammalian species) many of these are not released into the circulation as 
they are intermediaries for the production of the main endogenous GCs—cortisol and corticosterone. The 
ratio in which these are released over 24 hours varies between mammalian species. Whereas cortisol 
predominates corticosterone 3:1 in humans, the inverse applies to rodents (1:2) (van der Vies 1961; 
Nishida et al. 1977).  
The GCs have wide ranging effects on the body, and give rise to net catabolic effects by: stimulating 
gluconeogenesis; decreasing cellular concentrations of glucose and protein (except in the liver); 
mobilising fatty acids, glucose, and amino acids. The GCs also have profound anti-inflammatory effects 
that will be described later (Section 1.2.2.2), but it is helpful to first look at the common mechanisms of 
GC actions. 
1.2.2.1 Molecular mechanisms of GC action 
As steroid hormones, GCs exhibit molecular mechanisms that are similar to the classical steroid hormone 
receptor pathway, but they also have other mechanisms that are perhaps unique to GCs. The next 
subsection will describe the actions of GCs in terms of i) differences in the structure, expression, 
transcriptional regulation, activation by ligands, and modes of action of their receptor subtypes; ii) their 
pre-receptor metabolism; and iii) genomic and non-genomic mechanisms and target proteins. 
1.2.2.1.1 Glucocorticoid receptors 
Receptors for GCs can be one of two known major subtypes: mineralocorticoid receptors (MRs), and 
glucocorticoid receptors (GRs) (de Kloet et al. 1998). Both MRs and GRs are members of the ligand-
regulated nuclear receptor family. The MR has a high and similar affinity (Kd 0.5–2 nmol.l
-1
) for cortisol, 
corticosterone, and the mineralocorticoid, aldosterone (Moguilewsky & Raynaud 1980). It is expressed in 
certain tissues including those that depend on aldosterone to regulate Na
+
/K
+
 balance, namely, in the 
distal renal tubule, sweat glands, parotid, colon, but also the limbic, entorhino-cortical, and hypothalamic 
regions of the brain. The GR has ten-fold lower affinity (Kd 10-20 nmol.l
-1
) for GCs, but is GC-selective 
with negligible aldosterone affinity. Unlike MRs, GRs are expressed ubiquitously, and mediate the 
majority of GC actions in vivo. The GR structure comprises functionally specialised domains for ligand 
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binding, transactivation, and DNA binding (Giguère et al. 1986). Constitutive alternative splicing of GR 
mRNA results in two receptor isoforms—GRα and GRβ. GRβ has a low affinity for GCs, and can act as a 
dominant repressor over GRα activation (Hollenberg et al. 1985; Oakley et al. 1996). In addition to the 
differential affinities above, ligand binding also depends on pre-receptor metabolism. 
1.2.2.1.2 Pre-receptor metabolism of GCs 
Pre-receptor metabolism of GCs by the 11β-hydroxysteroid dehydrogenase isozymes (11β-HSD1 and 
11β-HSD2) governs the availability of active GCs for binding to GRs and MRs (Funder et al. 1988). The 
distribution of these isozymes is tissue-specific. 11β-HSD2 is evident mainly where mineralocorticoid 
effects predominate (kidney, colon) and inactivates cellular GCs through conversion of cortisol to 
cortisone, thus freeing up the MRs for aldosterone (White et al. 1997). The effects of the 11β-HSD 
isozymes on GC concentration and activity are local, and have no effect on circulating GC concentrations 
(Kershaw et al. 2005). The 11β-HSD1 isozyme is particularly abundant within the endoplasmic reticular 
lumens of hepatic and adipose tissues. As an oxidoreductase, 11β-HSD1 catalyses opposing reactions that 
are each limited by co-factor availability (Agarwal et al. 1990); however, reductase activity predominates 
in most tissues in vivo given adequate production of nicotinamide adenine dinucleotide phosphate 
(NADPH) by hexose 6-phosphate dehydrogenase (H6PDH) (Bujalska et al. 2005; Lavery et al. 2006). 
Interestingly, 11β-HSD1 appears to be essential for the target tissue conversion of orally administered 
cortisone and prednisone to their active forms—cortisol and prednisolone, respectively (Stewart et al. 
1999; Rask et al. 2001). 
1.2.2.1.3 Genomic mechanisms 
Unbound GRs reside in the cytosol in association with heat shock proteins (hsp90 and hsp70) (Beato et 
al. 1996). Ligand binding to the GR induces conformational change, and the resulting dissociation 
permits the translocation of GR via nuclear pores. The DNA binding domain interacts with specific GC 
response elements (GREs) to modulate the transcription of GC-responsive genes through transactivation 
or transrepression. The classical mechanism of transactivation is well understood, and requires the 
formation of GR homodimers about a binding domain, specifically, the second zinc finger motif (Beato et 
al. 1989). Although the mechanism is less clear, some have posited that transrepression could occur via 
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negative GREs (nGREs) and so might explain the negative feedback action of GCs on the 
proopiomelanocortin (POMC) promoter and its proteolysed products, including ACTH (Charron & 
Drouin 1986). Upon binding of GR to specific GREs, further modulation of transcription is afforded by 
the recruitment of corepressor and coactivator molecules, many of which have native histone 
acetyltransferase actions that unwind and accelerate the transcription of downstream DNA. Such 
transcription factors include cyclic adenosine monophosphate (cAMP) response element binding protein 
(CREB), cAMP binding protein (CBP), and p300. In particular, CBP can also recruit activator protein-1 
(AP-1), nuclear factor kappa B (NF-κB), and members of the signal transducer and activator of 
transcription (STAT) family. AP-1 is a Fos and Jun oncoprotein heterodimer that (as well as interacting 
with GR) exerts regulation of inflammatory processes via its own response element. NF-κB is a key 
regulator of inflammation, and often amplifies pro-inflammatory pathways when not interacting with GR 
in the cytosol (De Bosscher et al. 2003) and will be discussed in more detail later (Section 1.5). Other GR 
coactivators include steroid receptor coactivator 1 (SRC-1), transcription factor intermediary factor 2 
(TIF-2), GR-interacting protein 1 (GRIP-1), and p300/CBP co-integrator-associated protein (p/CIP). The 
inflammatory activity of many of these factors is limited in part by their interaction with GR. Conversely, 
transcriptional corepressors have native histone deacetylase activity and some (e.g. RAP46) are able to 
limit GC-induced, GR-mediated transactivation by binding to the GR hinge region (Kullmann et al. 1998; 
Kivimäki et al. 2002). The stoichiometry of these interactions with the GR before the transcription of 
inflammatory or anti-inflammatory genes is a determinant of net cellular inflammation. 
1.2.2.1.4 Non-genomic mechanisms 
The non-genomic actions of GCs are more rapid in relation to those that require transcription of genes. 
With regard to the immunosuppressive and anti-inflammatory effects of GCs, there are at least three 
hypotheses for how the rapid actions occur via i) GC-induced changes in membrane structure, ii) 
membrane-bound GRs (mGRs), and iii) cytoplasmic GRs.  
First, there is some evidence that high concentrations of GCs can intercalate with membrane 
phospholipids and proteins and reduce Na
+
-K
+
-ATPase and Ca
2+
-ATPase activity. In activated immune 
cells such as lymphocytes, a reduction in energy-dependent inflammatory pathways is evident shortly 
after exposure to high GCs, and is thought to occur to conserve energy (Schmid et al. 2000).  
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Secondly, evidence of membrane-bound GRs (mGRs) came first in cells from amphibians, and were later 
found to be upregulated in human peripheral blood mononuclear cells (PBMCs) stimulated with 
lipopolysaccharide (LPS) in vitro or isolated from rheumatoid arthritis sites (Bartholome et al. 2004).  
Third, the rapid effects of GCs on phospholipase A2 (Croxtall et al. 2002) and nitric oxide synthase 
release (Limbourg et al. 2002) have—because they are blocked by GR antagonists but not transcriptional 
inhibitors—been suggested to occur via cytoplasmic GRs without nuclear translocation (Limbourg & 
Liao 2003). 
These hypothetical mechanisms have been bolstered to different extents by evidence over the years, but 
can be considered speculative, as they are not predictive of the major anti-inflammatory effects of GCs. 
An additional non-genomic mechanism of GC action, however, involves the mediation of GC effects via 
GC-induced proteins, and, given the substantial body of evidence, this deserves its own section (see 
Section 1.4). 
1.2.2.2 Cellular mechanisms of GC action 
The following subsection describes the mechanisms through which GCs regulate cellular function, with 
special reference to the discovery of their anti-inflammatory effects that paved the way for understanding 
their cellular actions via GC-inducible proteins and interactions with other mediators.  
1.2.2.2.1 Reconciling anti-inflammatory effects with molecular mechanisms 
The GCs are renowned for their anti-inflammatory and immunosuppressive effects, and have been for 
decades. Despite this, the use of GCs is not without risks or side effects, and questions regarding their 
precise mode of action are still a fertile area of research. Before looking at the details and remaining 
questions for elucidating these anti-inflammatory mechanisms, it is worthwhile to consider the key 
milestones of research achievements to date. 
The importance of GCs to human survival was established by Dunlop’s review of Addison’s disease 
patient outcomes between 1928 and 1962 (Dunlop 1963), noting the landmark availability of cortisone in 
1948 (Hench et al. 1949b). Prior to this point (‘before cortisone’), patient life expectancy and survival 
rates post-diagnoses were mediocre for those receiving mineralocorticoids (2 - 5 years), but prior to 1939 
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(‘before corticosteroids’), the prognoses were abysmal (median 1 year; maximum 2 years). By 1930, 
however, it became clear that adrenalectomised animals were much more susceptible to stressors in 
general (e.g. infectious, psychological) whereupon the adrenal cortex in intact animals responds with two 
classes of steroid, namely, mineralocorticoids and glucocorticoids (Hartman & Brownell 1930; Rowntree 
et al. 1930; Swingle & Pfiffner 1930). These terms were coined by Hans Selye in observation of their 
principal actions on salt and carbohydrate metabolism respectively (Selye 1946). Further investigation, 
however, ascertained that of the two steroids, the general stress-resistance actions were ascribed to the 
GCs (Hench et al. 1949a).  
The mode of action and effects of GCs have been under continuous research since cortisone was first used 
therapeutically in 1948 (Hench et al. 1949a). Early hypotheses that cortisone had little affinity for GC 
receptors and conversion to cortisol was necessary for its GC function in patients were vindicated 
empirically. Not all of these early hypotheses were to be as propitious, however. Nobody researching GCs 
in the 1940s had predicted their suppressive or anti-inflammatory effects and some, hypothesised quite 
the opposite. It was thought Selye’s syndrome could lead to ‘diseases of adaption’ such as rheumatoid 
arthritis, when excessive ACTH and GCs were released (Selye 1946). Kendall recited Selye’s hypothesis 
that “administration of ACTH would not relieve the symptoms of rheumatoid arthritis; rather, it would 
cause an exacerbation of symptoms” (Kendall 1971). It came as a surprise, therefore, when high doses of 
either ACTH or GCs in fact led to the relief of rheumatoid arthritis (Hench et al. 1949a; Kendall 1950). 
These effects were charged as being merely pharmacological phenomena, partly because of the high 
doses required, but also because they suppressed inflammation—with the premise that inflammation is a 
defence mechanism—and so were seemingly at odds with evidence that GCs conferred stress-resistance 
(Sayers 1950; Baxter 1976). 
The charge was countered by arguments based on emerging knowledge of GC receptor expression and 
function. Indeed, shortly after their discovery (Munck & Brinck-Johnsen 1968; Schaumburg & Bojesen 
1968), evidence emerged that GC receptors are common in both their expression within virtually all 
nucleated cell types, and in their basic molecular mechanism for effecting GC actions (Baxter 1976; 
Munck & Leung 1977). Further experiments demonstrated the anti-inflammatory actions were steroid-
specific, concentration-dependent, and blocked by protein and RNA synthesis inhibitors or GC receptor 
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antagonists, and were therefore consistent with other (less contentious) physiological actions via the GR 
(Danon & Assouline 1978; Russo-Marie et al. 1979; Hirata et al. 1980). As with other amphipathic 
steroids—β-methasone (Lewis & Piper 1978), for instance—the non-specific effects of GCs were found 
to be antecedent (Homo et al. 1980) and inverse to receptor binding (Munck & Brinck-Johnsen 1968), 
and so could be attributed to membrane binding (Munck 1976; Fahey et al. 1981).  
There was no difference in the primary mode of action between GCs, whether exogenous or endogenous, 
or stimulated or basal (Tsurufuji et al. 1979; 1980).  On this basis, it was argued that there was: first, a 
common mechanism for GC actions whether anti-inflammatory or stress-resistant; and second, therefore, 
no empirical basis for labelling the anti-inflammatory effects as being pharmacological (Fahey et al. 
1981; Guyre et al. 1982). 
Once the false premises of the actions of GCs being pharmacological and pro-inflammatory had been 
countered, it became necessary to approach further research questions under a new hypothesis. Alan 
Munck and colleagues proposed that:  
“(1) the physiological function of stress-induced increases in glucocorticoid levels is to protect not against 
the source of stress itself, but against the normal defence reactions that are activated by stress; and (2) the 
glucocorticoids accomplish this function by turning off those defence reactions, thus preventing them 
from overshooting and themselves threatening homeostasis” (Munck et al. 1984). 
This was substantiated by the observation that most effects of GCs were either suppressive by direct 
action on target cells (Araki et al. 1981; Rabbani et al. 1981), or they induced enzymes and other 
mediators which brought about similar effects. The mediation of the effects of GCs, and their regulatory 
actions on a known network of intercellular mediators (Fahey et al. 1981; Guyre et al. 1982), was central 
to this new hypothesis.  
1.2.2.2.2 Glucocorticoid mediators and inducible proteins 
From the inception of Munck’s hypothesis, there was already much evidence that GCs inhibited the 
production, and often the actions, of numerous intercellular mediators, namely: (1) phospholipase A2 and 
the production of arachidonic acid (Ney et al. 1967; Rabbani et al. 1981) and its metabolites 
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(prostaglandins, thromboxanes, and leukotrienes) (Gemzell et al. 1951); (2) signalling proteins and 
peptides such as bradykinin and cytokines such as IL-1 and IFN-γ that stimulate Fc-receptor augmenting 
factor (FRAF), macrophage activating factor (MAF), natural killer (NK) cells, and colony stimulating 
factor (CSF) (Newcombe et al. 1977); (3) neuroendocrine hormones such as ACTH (Guillemin et al. 
1977), CRH (Vale et al. 1981), AVP, and POMC (Roberts et al. 1982) and its cleavage products such as 
the opioid β-endorphin (Guyre et al. 1982); (4) neurotransmitters such as serotonin and histamine 
(Gryglewski et al. 1975); and (5) neutral proteases such as plasminogen activator and collagenase (Seifert 
1978; Crutchley et al. 1981).  
Overall, these mediators shared several features in that they were: regulated by GCs in a common 
mechanism; well characterised with clear roles in host defence, vascular permeability, coagulation, and 
oedema; and secreted in response to stress. On this basis, then the GCs were viewed as suppressors of 
defensive or restorative inflammatory mechanisms. 
1.2.3 Regulation of glucocorticoid release 
This subsection focuses on the role of ACTH in the regulation of GC release, but begins with a primer on 
the biosynthesis of GCs and other steroids in the adrenal gland, and how these  processes are regulated by 
local factors. The circadian and ultradian rhythms of GC secretion are summarised before the 
hypothalamic control of ACTH secretion.  
1.2.3.1 Glucocorticoid biosynthesis 
As with all other steroids, the precursor of GCs is cholesterol. The majority (90% (Plump et al. 1996)) of 
adrenal cholesterol is selectively transported into the adrenal cortex upon binding of high-density 
lipoproteins (HDL) (Gwynne et al. 1976) to adrenocortical scavenger receptor BI (SR-BI) (Rigotti et al. 
1996; Wang et al. 1996; Temel et al. 1997), and the remainder is from low density lipoproteins (LDL) or 
synthesised de novo. Esters of cholesterol are stored in lipid droplets until a hydrolase produces free 
cholesterol for sterol carrier proteins to shuttle cholesterol into the mitochondria. Here, enzymatic side-
chain cleavage by cholesterol desmolase of the cytochrome P450 superfamily (P450scc) converts 
cholesterol to pregnenolone, which is then transported to the smooth endoplasmic reticulum 
(Constantopoulos & Tchen 1961). As well as subcellular compartmentation, the production of different 
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classes of steroids is compartmented across the adrenal cortex, with each zone containing steroidogenic 
enzymes acting at similar carbon positions (Ishimura & Fujita 1997). Within the zona glomerulosa (ZG), 
some pregnenolone is dehydrogenated forming progesterone. From these two steroids, the final secreted 
product depends on which cortical zone any further reactions take place. Within the Zg, progesterone is 
serially converted to 11-deoxycorticosterone, corticosterone, 18-hydroxycorticosterone, and ultimately, 
aldosterone. Alternatively, some of the pregnenolone and progesterone can be transported to the zona 
fasciculata (ZF) by the trans-zonal enzyme 17α-hydroxylase (P450c17; CYP17), producing 17α-
hydroxypregnenolone and 17α-hydroxyprogesterone, respectively. Staying with the enzymes of the ZF, 
these products are converted to form the secretable steroids—11-deoxycortisol, and cortisol. 
Alternatively, the trans-zonal enzyme CYP17 converts them into DHEA, and androstenedione, 
respectively, within the zona reticularis (ZR) (Pelletier et al. 2001).   
There are numerous local mechanisms that regulate adrenal steroidogenesis governed by interacting cell 
types and communication systems, including: the juxtaposition of cortical cells with chromaffin cells of 
the medulla; adrenal vasculature and endothelial cell products; an intra-adrenal CRH/ACTH system; as 
well as adrenal immune cells, cytokines, and peptide growth factors. In mammals such as humans 
(Bornstein et al. 1994) and rats (Gallo-Payet et al. 1987), whilst being largely confined to the cortex and 
medulla, the steroidogenic and catecholaminergic cells can also be interspersed within islets or single 
cells within both compartments, but particularly in the cortical ZG (Palacios & Lafarga 1975). These 
areas of colocalisation are not separated by extracellular matrices or fluids, and thus provide direct, 
cortico-chromaffin, paracrine interactions. This is particularly evident between the ZR and the medulla, 
where splanchnic nerve innervation maintains diurnal variations in GC production (Ottenweller & Meier 
1982; Dijkstra et al. 1996) and enhanced ACTH sensitivity in response to splanchnic epinephrine 
(Bornstein et al. 1990a; Guse-Behling et al. 1992). Interestingly, basal GC secretion in response to 
ACTH1-24 is higher in cultures containing both cortical and chromaffin cells, thus highlighting the 
importance of such interactions (Haidan 1998). Evidence of other steroidogenic regulators, such as 5-HT, 
have been found within chromaffin cells of the mouse (Ritzen et al. 1965) and rat (Holzwarth & 
Brownfield 1985), and within mast cells of the human adrenal, where 5-HT stimulates GC production 
(Lefebvre et al. 2001).  
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The vasculature of the adrenal gland provides a rich source of modulators of GC secretion and release. 
The adrenal gland is well perfused and receives a high proportion of cardiac output relative to its mass; 
the rat adrenal gland, for instance, comprises 0.02% of total body mass, yet receives 0.14% of cardiac 
output (Sapirstein & Goldman 1958). Adrenal blood flow at rest is known to be stimulated by ACTH, and 
this has been attributed to ACTH-stimulated release of vasoactive histamine and 5-HT from sub-capsular, 
degranulation of mast cells native to the adrenal (Sapirstein & Goldman 1958). This vasodilatory effect of 
ACTH can thus be abolished by disodium cromoglycate (mast cell stabiliser) (Hinson et al. 1989; 1991a). 
Studies of whole adrenals from dogs (Frank et al. 1955; Urquhart 1965), rats (Urquhart 1965), and calves 
(Jones et al. 1990), have demonstrated a positive relationship between adrenal blood flow and GC 
secretion that is not dependent on the plasma concentration of ACTH (Sibley et al. 1981; Hinson et al. 
1986), but rather the rate of its presentation to the adrenal (Jones et al. 1990). In contrast, these flow-
induced changes are absent in collagenase-dispersed cells superfused on a column, which prompted the 
suggestion that a factor within the vasculature contributes to these changes (Hinson et al. 1986). 
Endothelin-1, for instance, acts via endothelin receptor-B (ETB) to stimulate GC secretion from rat and 
human adrenals (Hinson et al. 1991b; Belloni et al. 1996). Similarly, endogenous nitric oxide synthesis is 
dependent on substrate availability of l-arginine, which, when limited, leads to decreased basal secretion 
of GCs (ACTH response unaffected) (Cameron & Hinson 1993).  
There is evidence of an intra-adrenal CRH-ACTH system that works independently of the central 
hypothalamo-pituitary system. This is substantiated by morphometric observations and functional data. 
Immunoreactive ACTH and CRH has been found within discrete adrenal medulla cells from rats (Bagdy 
et al. 1990; Mazzocchi et al. 1993; Venihaki et al. 1997) and humans (Suda et al. 1984), with a similar 
pattern evident in cattle and dogs (Bruhn et al. 1987a, b; Minamino et al. 1988). This ACTH and CRH 
immunoreactivity is particularly abundant at the cortico-medullary junction (Bruhn et al. 1987a, b), and is 
increased in response to splanchnic nerve stimulation (Edwards & Jones 1988; Jones & Edwards 1990), 
haemorrhage (Bruhn et al. 1987b), nicotine (Venihaki et al. 1997), AVP (Mazzocchi et al. 1997), and IL-
1 (Andreis et al. 1991a; Mazzocchi et al. 1993; Venihaki et al. 1997). Experiments involving peripheral 
administration of CRH provided functional evidence of the intra-adrenal CRH-ACTH system. 
Intravenous CRH (1 mg/kg) increased the ratio of cortisol to ACTH secretion in healthy adult humans 
(Azar et al. 1992). Similarly high concentrations of CRH led to increased adrenal steroidogenesis, mass, 
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and ACTH-stimulated corticosterone secretion (De Souza & Van Loon 1984; van Oers et al. 1992) in rats 
(Bornstein et al. 1990b) and calves (Jones & Edwards 1992), despite hypophysectomy. This ostensibly 
direct, stimulatory effect of CRH on GC secretion, however, is blocked in vivo by anti-CRH antibodies, 
without affecting plasma ACTH (van Oers & Tilders 1991), and in vitro by corticotrophin-inhibiting 
peptide (Andreis et al. 1991b; Andreis 1992), suggesting the CRH requires intra-adrenal ACTH for its 
stimulation of GC release. Further support for the existence of the intra-adrenal CRH-ACTH system 
comes from evidence it can compensate for the removal of the central CRH-ACTH system. In 
hypophysectomised animals, for instance, the intra-adrenal content of CRH and ACTH increase as a 
function of time since surgery (Bagdy et al. 1990), but this is prevented by ACTH infusion (Edwards & 
Jones 1988; Mazzocchi et al. 1994). In rats, GC treatment reduces adrenal ACTH secretion after 2 days, 
and adrenal CRH content after 7 days (Bagdy et al. 1990). This suggests that as with the central system, 
the intra-adrenal CRH-ACTH system is subject to feedback inhibition from adrenal GCs and ACTH. 
1.2.3.2 Role of ACTH 
ACTH secreted from the anterior pituitary regulates the basal and stress-induced release of GCs from the 
adrenal cortex. ACTH constitutes a single polypeptide chain of 39 amino acids, with residues of serine-1 
to tyrosine-23 forming the hormonally active part of the molecule, and residues 24-39 forming a 
stabilising tail that varies slightly between species by substitution of amino acids (Li 1972; Clark et al. 
1986; Hanukoglu et al. 1990). These differences generally affect neither the activity nor the half-life of 
ACTH in vivo, which in humans is 8 – 24 minutes (Gemzell et al. 1951; Besser et al. 1971; Willoughby et 
al. 1977; Park et al. 2012), and in rats, 8 minutes (López & Negro-Vilar 1988; Carnes et al. 1990; Windle 
et al. 1998; Tomlinson et al. 2004; Atkinson et al. 2006), but they can contribute to antigenicity in 
heterologous species. The half-life of ACTH1-24 is lower than full-length ACTH, at around 5 minutes 
(Makara et al. 1970; Loudon et al. 1994; Darmon et al. 1999; Waite et al. 2012).  
ACTH binds to its receptor on the membrane of the GC-secreting, adrenocortical cells of the inner two 
zones of the adrenal cortex (ZF and ZR). These type 2 melanocortin receptor (MC2R) is coupled with the 
stimulatory G-protein (Gs) that activates adenylyl cyclase to produce cyclic adenosine monophosphate 
(cAMP). The cAMP then binds and activates protein kinase A (PKA) which upregulates the activity of 
cholesteryl ester hydrolase (CEH) by phosphorylating it. As a result, more cholesterol is liberated and 
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converted to pregnenolone, supplying a biosynthetic reaction series that produces the steroid hormones, 
including corticosterone and cortisol, which are then secreted. Prolonged periods of ACTH activity (> 2 
h) also result in upregulated expression of the P450 enzymes involved in steroid biosynthesis (Hanukoglu 
et al. 1990). 
Models that remove ACTH have substantiated the importance of its effects on both the adrenal rate of GC 
secretion and sensitivity to further stimulation. Hypophysectomy in dogs results in a decline in GC 
secretion within 1 hour to very low levels (Scharrer 1954). ACTH also increases the sensitivity of the 
adrenal to repeated doses of ACTH. This is evident in patients with hypopituitarism or 
hypophysectomised animals where within 24 hours of surgery, a single administration of ACTH is no 
longer able to increase GC secretion, and repeated injections are required to progressively restore adrenal 
sensitivity to ACTH (Ney et al. 1967). ACTH, therefore, is a vital effector molecule for eliciting an 
adequate circulating concentration of GCs, whether their release is basal or stimulated, for their 
permissive and stress-resistant effects, respectively.  
1.2.3.3 Patterns of GC release 
An ultradian rhythm—a pulsatile secretion of GCs at approximately hourly intervals, punctuated by 
periods of very low secretion—has been observed in each of these mammalian species: rats (Windle et al. 
1998), hamsters (Loudon et al. 1994), horses (Cudd et al. 1995), goats (Carnes et al. 1992), monkeys 
(Tapp et al. 1984), and humans (Henley et al. 2009). This secretory pattern varies with adolescence 
(Evuarherhe et al. 2009), sex (Seale et al. 2004), and lactation (Windle et al. 1997). Alterations to this 
pattern have also been observed in several disease states, with changes in the frequency and amplitude of 
pulses commonly reported in mood disorders and following chronic stress (Yehuda et al. 1996).  
In investigating the origin of the pulsatile pattern of GC release, Spiga and coworkers detected GC pulses 
within 5 minutes of an ACTH pulse, which after 15 minutes were followed by upregulated transcription 
of steroidogenic acute response (StAR) and P450 side chain cleavage enzymes (Spiga et al. 2011a, b). In 
similar experimental models, parallel changes have been detectable because of advances in telemetry 
devices that allow continuous measurement of circulating GCs in free-living animals (Waite et al. 2012). 
A major upshot of this work is that since the secretion of GCs alternates between periods of HPA axis 
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activation and stress-sensitivity, and periods of inhibition and stress-refractivity, then GC secretion 
following a stressor will be lower during a refractive period than in a sensitive one. 
The pulsatile release of GCs at least seems to continue following hypothalamic deafferentation, with 
evidence for this from sheep (Engler et al. 1990), and rats (Makara et al. 1970). Despite this, the origin of 
GC pulsatility was not clear until the following strands of evidence were obtained. First, evidence that 
ultradian corticosterone pulsatility does not depend on circadian variations, but rather, nadir levels are 
increased when circadian inputs are inhibited (Waite et al. 2012). Second, mathematical modelling 
highlighted several interesting relationships, the simplest being the delay in pituitary-adrenal stimulation 
and the rapid, non-linear, negative feedback of GCs from the adrenals (Keenan et al. 2001). In particular, 
the model revealed pituitary-adrenal oscillations (corroborating the deafferentation studies) suggesting a 
supra-pituitary (hypothalamic) pulse generator is not required for driving ultradian GC secretion. 
Although hypothalamic CRH does, however, contribute to the amplitude of ACTH and GC release, it 
need not be pulsatile to do this.  
Circadian rhythms of GC secretion, unlike their ultradian rhythm, require supra-pituitary pulse generation 
in the suprachiasmatic nuclei (SCN). Evidence for this comes from experiments which have disrupted 
SCN inputs to the HPA axis through lesions to the SCN (Buijs et al. 1993; 1999) or constant light 
exposure for instance, in rats (Park et al. 2012). The human circadian rhythm of cortisol secretion reaches 
nadir around midnight and after 2-3 hours of sleep it increases to a peak at around 9 am, and, as in rats, is 
controlled by the SCN. The rhythm encompasses 15-18 pulses of ACTH at different amplitudes, and 
pulses of CRH are released from the parvocellular CRH/AVP neurons of the PVN (Carnes et al. 1990). 
The PVN receives multiple direct connections from the SCN along with many indirect inputs, for 
instance, via the dorsomedial hypothalamus (Roland & Sawchenko 1993; Dai et al. 1998; Aston-Jones et 
al. 2001). The anterior pituitary corticotrophs then secrete ACTH following binding of CRH/AVP to their 
receptors. In addition, the SCN has direct connections to the adrenal cortex where it can stimulate adrenal 
GC release directly and before CRH release is increased (Watts 2003; Thorn et al. 2004). Whilst the SCN 
is the site of the pulse generator for HPA axis activity, it is the hypothalamus that provides the 
neuroendocrine mechanisms through which the rest of the body is synchronised with such rhythms.  
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1.2.4 Hypothalamic control of ACTH secretion 
This subsection will focus on the role of the hypothalamus—including the neurohumoral mechanism and 
synergistic actions of CRH and AVP—on the secretion of ACTH from the anterior pituitary gland.  
1.2.4.1 Neurohumoral control  
The posterior lobe of the pituitary gland, as part of the neurohypophysis, has an extensive network of 
nervous tissue and is dependent on neural connections to the hypothalamus for its secretory activity. The 
anterior pituitary gland, however, although it too depends on neural activity, lacks a widespread neural 
network. To explain this, some hypothesised a neurohumoral mechanism of pituitary control whereby 
nervous stimuli from the hypothalamus reach the median eminence of the neurohypophysis, and are then 
humorally transmitted via the portal system across the pars distalis of the anterior pituitary (Green & 
Harris 1947; Harris 1948). This hypothesis had foundations in several strands of preceding evidence. 
Popa and Fielding contributed an anatomical description of the portal system of the blood vessels in the 
pituitary stalk that seemingly led to the hypothalamus (Popa & Fielding 1930; 1933). Their conclusions 
were partly supplanted by those of Wislocki and King (1936) that suggested a unidirectional flow of 
blood from the median eminence down to the pars distalis of the anterior pituitary. The first functional 
evidence for the neurovascular control of anterior pituitary secretions came from the link between 
ovulation and brain stimulation in the hypothalamus-pituitary-gonadal axis in rabbits (Harris 1937). 
Building on this, and the emerging evidence for a role of ACTH during stress, the Harris lab investigated 
whether such neurohumoral control could be applicable to the HPA axis too. Stimulation of the 
mammillary body or the tuber cinereum in rabbits led to reduced blood lymphocyte count (lymphopenia) 
and lymphoid tissue mass (thymic involution). These effects were analogous to those of stress or 
injections of ACTH, but were specific to stimulation of certain hypothalamic areas (De Groot & Harris 
1950). The tuber cinereum, for instance, was the only location for anterior pituitary grafts to effectively 
revascularise and restore adrenal weight, structure, and HPA function in hypophysectomised rats (Harris 
& Jacobsohn 1952). Once the neurohumoral mechanism for mediators of ACTH release was established 
in evidence, interest in the interplay of these mediators opened up, particularly for CRH and AVP.   
1.2.4.2 Synergistic actions of CRH/AVP 
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This subsection will describe the physiological role of CRH and AVP on the regulation of pituitary 
ACTH secretion, the evidence for their synergistic actions, and the site, dynamics, and mechanisms of 
these actions. 
The sequencing of CRH revealed that it is a 41-amino acid peptide (Vale et al. 1981) whereas AVP is a 9-
amino acid peptide. Each circulates unbound in the blood, with a plasma half-life of between 4 and 15 
min in humans (Schürmeyer et al. 1984). The physiological effects of these peptides are mediated via 
different receptor subtypes. Whereas CRH acts on Class B G-protein coupled receptors (GPCRs), namely 
CRH-R1 and CRH-R2, the physiological effects of AVP are mediated via three subtypes of Class A 
GPCRs, namely, V1a, V1b, and V2 receptors (Lolait et al. 2007; Young et al. 2007). Of these, the CRH-
R1 and V1b receptor subtypes are of most relevance to their effects on ACTH secretion. The V1b 
receptor is coupled to phospholipase C (PLC) and signal pathways that stimulate ACTH secretion 
(Guillon et al. 1987). This effect is evinced by observations that V1b receptor knockout mice have lower 
ACTH secretion (Lolait et al. 2007) and show less aggressive behaviour (Wersinger et al. 2002) than 
wildtype mice. The upregulatory effects of CRH on HPA axis activation, ACTH secretion, and anxiety-
relevant behaviour are mediated via CRH-R1 (Liebsch et al. 1999), which at nanomolar concentrations of 
CRH activates the adenylyl cyclase pathway (Grigoriadis et al. 2006).  
Hypothalamic nuclei are the major endogenous sites of CRH and AVP synthesis. Prior to the sequencing 
of these peptides, it was known that AVP potentiates the stimulatory effect of CRH on the anterior 
pituitary gland secretion of ACTH in vivo (Yates et al. 1971). Despite this, there was still some debate as 
to whether the ACTH releasing hormone from the hypothalamus was a single peptide (Schally et al. 
1973) or a complex of peptides (Pearlmutter et al. 1975; Sayers et al. 1980). It became evident from 
several studies of adrenalectomised rats that the parvocellular and magnocellular cell bodies within the 
PVN contained both CRH and AVP with terminals in the median eminence, compared with the 
supraoptic nucleus that contained only AVP (Roth et al. 1982; Tramu et al. 1983; Kiss et al. 1984; 
Sawchenko et al. 1984). Analysis of PVN neurons by electron microscope revealed that half of their 
secretory granules had CRH and AVP colocalised within them (Whitnall et al. 1985; 1987). The 
synergistic actions of CRH and AVP became evident when their co-application at low concentrations 
elicited a substantial release of ACTH whereas individually they were much less effective (Gillies et al. 
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1982). Hypothalamic CRH and AVP directly stimulate the anterior pituitary gland to secrete ACTH, and 
AVP enhances the effect of the more potent secretagogue CRH, rather than the other way round (Gillies 
et al. 1982; Turkelson et al. 1982; DeBold et al. 1984). This effect of CRH on ACTH secretion is also 
potentiated by factors other than AVP, including, oxytocin (Antoni et al. 1983), angiotensin II (Abou-
Samra et al. 1986; Schoenenberg et al. 1987), epinephrine and norepinephrine (Vale et al. 1983). 
Elsewhere, the synergy of CRH with AVP also enhances the release of insulin from pancreatic beta cells 
(O’Carroll et al. 2008), and thus demonstrates biological coherence as a mechanism. 
Once the anterior pituitary gland was established as the major site of their synergistic actions, the 
mechanism by which AVP potentiates the effect of CRH was then investigated. The prevailing 
hypotheses explored to date are that the synergy between AVP and CRH is explained by 1) crosstalk of 
second messengers downstream of their receptors, and/or 2) allosteric regulation by mutual receptor 
dimerisation. Potential levels of crosstalk between CRH-R1 and V1b receptor signal pathways include the 
second messengers diacylglycerol (DAG) and inositol phosphate (IP) downstream of the V1b receptor 
and the accumulation of cAMP downstream of CRH-R1. Collectively, the actions of these signals 
converge to increase cytosolic Ca
2+
 concentration and upregulate the ACTH secretory mechanism. Early 
work into this hypothesis found that AVP increases CRH-induced cAMP accumulation in corticotrophs 
(Giguère & Labrie 1982; Labrie et al. 1984). This was recapitulated by synthetic protein kinase C (PKC) 
agonists (phorbol esters) (Cronin et al. 1986; Abou-Samra et al. 1987) that mimic the actions of DAG on 
PKC activation (Nishizuka 1984). Although fluorescence/bioluminescence resonance energy transfer 
(FRET/BRET) studies have obtained evidence for the dimerisation of receptors for CRH and AVP, the 
precise mechanism behind their synergistic action requires further investigation (Mikhailova et al. 2007; 
Albizu et al. 2010; Murat et al. 2012). Interestingly, pharmacological blockade of the V1b receptor using 
an antagonist (Org) reduced the LPS-induced release of ACTH, but not GCs, without affecting basal HPA 
axis activity in vivo, suggesting that AVP is perhaps more instrumental during stress than at rest (Spiga et 
al. 2009). Whatever the molecular details of this mechanism, the fact that a potent secretagogue of ACTH 
release (CRH) can be substantially enhanced by AVP and multiple other mediators has important 
implications for the stress response.  
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1.2.5 The stress response 
This subsection will focus on how the HPA axis responds to stress, through a mechanism that involves 
ascending and descending neural pathways, and blood-borne factors impinging on CRH/AVP neurons 
that form the start of a final common pathway leading to increased GC release. 
1.2.5.1 CRH/AVP neurones—the final common pathway leading to GC secretion 
The increased secretion of GCs following stress is largely achieved by a convergence of factors on the 
hypothalamus that trigger the release of the two major ACTH-releasing hormones from their eponymous 
CRH/AVP neurons. CRH and AVP are: i) synthesised by the neurons of the PVNmp that project to the 
median eminence (Sawchenko et al. 1984); ii) released into the hypothalamo-hypophyseal portal blood 
vessels that perfuse the anterior pituitary gland; iii) synergistic in their stimulation of ACTH release 
(Gillies et al. 1982), which in turn stimulates the adrenal cortex to synthesise and release GCs. The nature 
of the stimulus also plays a major part in the relative contribution of nerve pathways, blood-borne factors, 
and local mediators to the final activation of the CRH/AVP neurones. These receive, for instance, 
noradrenergic inputs from the brain stem during hypotensive stress, C-fibre inputs during cold stress, and 
inputs from the limbic system during emotional stress. Some of the most severe stressors, however, are 
those that pose a threat to homeostasis by challenging the immune system (Section 1.3). Tangible 
stressors such as blood loss, and cold temperature involve the rapid recruitment of brainstem and 
hypothalamic regions, whereas intangible stressors such as social subordination and deadlines involve the 
engagement of higher brain centres associated with emotion (amygdala and prefrontal cortex (PFC)), 
learning and memory (hippocampus) and decision-making (PFC). Whilst the stress response will typically 
involve the secretion of adrenal GCs, driven by the release of ACTH from pituitary corticotrophs, these 
cells are also modulated by stressor-specific combinations of release-controlling factors secreted by 
neurons into the hypothalamo-hypophysial portal circulation.  
There are three main neural pathways with excitatory inputs to the CRH/AVP neurons; some connect 
directly, others co-opt multi-synaptic afferents of the basal forebrain and hypothalamic nuclei. Firstly, 
interoception of physiological stressors (hypotension, hypoglycaemia, and pain, for instance) is conveyed 
by afferents converging on the PVN from the nucleus tractus solitarius (NTS) including A2/C2 
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noradrenergic groups, the ventral medullary A1/C1 noradrenergic groups, the locus coeruleus (LC), the 
serotonergic dorsal raphe nuclei, and the cholinergic lateral dorsal tegmental nuclei (LDT) and 
pedunculopontine nucleus (PPN). Secondly, blood-borne signals such as blood osmolarity, cytokines, and 
hormones, are conveyed to the PVN via angiotensinergic projections from circumventricular organs, 
namely, the subfornical organ (SFO) and the organum vasculosum of the lamina terminalis (OVLT). 
Thirdly, complex signals for intangible stressors—such as social defeat or isolation—are integrated in the 
sensory and association cortex, passed to the amygdala, and lateral septum, which then activate the PVN 
indirectly via bisynaptic glutamate-glutamate or γ-aminobutyric acid (GABA)-GABA connections. The 
amygdala and lateral septum signal by glutamate-glutamate, or GABA-GABA bisynaptic connections 
with the PVN. The basal forebrain, certain hypothalamic nuclei, and the multi-synapses peripheral to the 
PVN, constitute the final neurons with projections to the PVN and the HPA axis. Overall, the key sites for 
the evaluation of stressors are the extra-hypothalamic structures of the hippocampus and amygdala, with 
direct and indirect inputs into the hypothalamic parvocellular system of CRH/AVP neurons for the 
integration of multiple signals as the final pathway for the HPA axis stress response. These are elicited 
through a system of descending and ascending neural pathways described below.  
1.2.5.2 Descending and ascending neural pathways 
The CRH/AVP neurones receive inputs from multiple ascending and descending nerve pathways, 
primarily those of the ascending noradrenergic tracts, but also the largely GABAergic pathways 
descending from the hypothalamus, preoptic area (PoA), and bed nucleus of the stria terminalis (BNTS), 
as well as the cortico-limbic areas, including the raphe nuclei (RN), the hippocampus, and the amygdala. 
The descending neural pathways are predominantly involved with inhibitory or disinhibitory inputs to the 
PVN. Stressors that can be anticipated to some extent, for instance, social defeat stress, are transduced by 
sensory pathways and are evaluated in the medial forebrain by the medial PFC, hippocampus, and ventral 
subiculum (vSub). These then inhibit the PVN via excitation of bisynaptic glutamate-GABA pathways 
and thus inhibit three local GABAergic PVN-projecting regions posterior to the anterior commissure: the 
BNTS, hypothalamic nuclei (medial preoptic area, dorsomedial hypothalamus, anterior hypothalamic 
area, SCN), and to the peri-PVN zone of interneurons. This circuitry is also sensitive to GC negative 
feedback (Section 1.2.6). 
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The main ascending pathways with projections to the mpPVN can be divided into those originating from 
the brainstem, and those from the circumventricular organs, including lamina terminalis areas. 
Retrogradal labelling of neurons, for instance, within the PVN-projecting nuclei, and direct 
neurotransmitter labelling of the PVN fibre plexus, allowed identification of the key brain areas involved 
in the stress response. Within the brainstem, these include: the norepinephrine (NE)-positive A2 regions 
and NTS; the epinephrine-positive C2 regions; the acetylcholine (ACh)-positive laterodorsal tegmental 
nucleus; and the 5-HT-positive raphe nucleus (Schwaber et al. 1982). Within the circumventricular 
organs, the key areas include the angiotensin II (AII)-positive SFO, areas of the OVLT and median 
preoptic areas (McKinley et al. 1996). 
Ascending catecholaminergic pathways from the brainstem to the PVN are critical for the HPA response 
to stress (Plotsky et al. 1989). This was demonstrated by local administration of electricity or NE causing 
an increased release of CRH akin to those induced by stress (Plotsky 1987; Szafarczyk et al. 1987). 
Following stress, the HPA axis is activated, and NE is released from the PVN (Pacák et al. 1995), 
whereas local damage to the PVN attenuates HPA activation following stress (Szafarczyk et al. 1987). 
Interestingly, the nature of the stressor leads to differential recruitment of certain ascending 
catecholaminergic pathways and modulations in the pattern of CRH, ACTH and GC secretion (Gaillet et 
al. 1991). For instance, damage to the ventral noradrenergic bundle blocks GC release in response to ether 
but not restraint stress whereas the removal of all ascending medullary pathways blocks cFos-indexed 
PVN activation in response to IL-1β but not footshock (Li et al. 1996). In other words, the nature of the 
stress response depends on the nature of the stressor, which in turn induces specific neuronal pathways.  
Other ascending pathways modulate activity of the PVN (and thus the HPA axis), but lack direct 
connections. The central amygdaloid nucleus (CeA), for instance, increase PVN activity via projections to 
the NTS (Schwaber et al. 1982), which have noradrenergic and non-catecholaminergic connections to the 
medial parvocellular PVN (Horst & Luiten 1987). The LC appears to exert trans-synaptic PVN activation 
(Ziegler & Herman 2002) via the amygdala, prefrontal cortex and hippocampus (Grant & Redmond 1981) 
as no direct connections to the PVN have been found (Cunningham & Sawchenko 1988). The 
neurotransmitters 5-HT and ACh activate the HPA axis in vivo (Plotsky 1987; Ohmori 1995; Jørgensen et 
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al. 1998) and upregulate CRH, ACTH and GC release when administered to the PVN—despite 
containing minimal and sparse 5-HT (Sawchenko et al. 1983) and ACh (Mesulam et al. 1983) inputs.  
The circumventricular organs, including the SFO and the OVLT, provide the medial parvocellular PVN 
with rich innervation. The SFO promotes CRH biosynthesis and secretion (Aguilera et al. 1995) via ATII-
ergic projections and likely permits the HPA axis response to osmotic stress (Kovács & Sawchenko 
1993). Other circumventricular organs may exert indirect, trans-synaptic modulation on HPA activity, 
including the area postrema via the NTS.  
Collectively, these ascending brainstem pathways convey rapid transmission of reactive stimuli for 
interoception, arousal, and nociception, and can be co-opted by descending cortico-limbic pathways for 
trans-synaptic modulation of PVN, and hence, HPA activities. 
1.2.5.3 Limbic system inputs 
Early suggestions that the hippocampus was involved in the stress response were based on its role in 
learning, memory, and emotional evaluation as part of the limbic system, and evidence of its projections 
to the hypothalamus (Nauta 1956). The hippocampus has since been shown to influence HPA activity in 
terms of the stress response, and circadian rhythm, but primarily as a site of GC feedback inhibition 
(McEwen et al. 1968; Canny 1990). Within the hippocampal formation, the hippocampus and subiculum 
have major projections to the BNST, cerebral cortex, mammillary complex, nucleus accumbens, anterior 
olfactory nucleus, the anterior and lateral thalamic nuclei, and ventromedial hypothalamic nuclei (VMH) 
(Swanson & Cowan 1977). The major source of hippocampal formation inputs to the hypothalamic nuclei 
appears to be the ventral subiculum (Herman et al. 1998). Transection of the fornix reduces the sensitivity 
of CRH, AVP, and oxytocin to GC feedback (Sapolsky et al. 1989), and hippocampectomy increases 
CRH and AVP gene expression (Herman et al. 1989). These measures do not completely abolish GC 
feedback however, suggesting other areas are involved. Elsewhere within the limbic system, the 
amygdala, for instance, has extensive afferents to the BNST that predominate those from the 
hippocampus (Cullinan et al. 1993). In terms of the route taken by the hippocampal efferents which 
modulate CRH/AVP neurons and thus ACTH release, most are seemingly indirect, although direct 
projections from the ventral subiculum to the PVN have been labelled by retrogradal but not anterogradal 
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transport of markers (Sawchenko & Swanson 1983). Less direct routes from the hippocampal formation 
to the PVN are via the fornix to the lateral septum and the BNST as well as via the medial 
corticohypothalamic tract to the VMH (Swanson & Sawchenko 1983). Overall the evidence for the 
mechanism of this role suggests the limbic structures such as the amygdala and hippocampus affect HPA 
axis activity through modulating the sensitivity of hypothalamic CRH/AVP neurons to GC feedback 
inhibition. 
1.2.6 Negative feedback control of CRH/AVP and ACTH secretion 
This subsection will describe the different phases of GC feedback on HPA axis activity, to permit a clear 
differentiation between the slow feedback inhibition of CRH/AVP and POMC synthesis, and the more 
rapid actions that inhibit the exocytosis of preformed ACTH and CRH/AVP from storage vesicles. The 
final paragraph alludes to evidence for one of the secondary mediators of feedback, but mechanistic 
details will be covered in later sections. 
The feedback inhibition by GCs on CRH/AVP and ACTH secretion operates over at least two time 
domains (Beckford et al. 1983).  
Rapid negative feedback effects occur within minutes (2 - 60 minutes) and are unaffected by inhibitors of 
transcription and protein synthesis, and therefore involve non-genomic actions of GCs (Keller-Wood & 
Dallman 1984). Rapid feedback involves the inhibition of exocytotic release of pre-formed ACTH and 
CRH/AVP from vesicles. One of the first observations of a rapid feedback effect of GCs was made by 
Dallman and Yates, whereby GCs injected into rats, from 15 seconds and up to 5 minutes prior to 
histamine injection, rapidly (10 – 12 minutes) inhibited the release of endogenous GCs whilst plasma GC 
concentrations were rising. Conversely, this effect of GCs was absent in rats that received either 
injections 15 minutes prior to, or 2 minutes after histamine (Dallman & Yates 1969; Jones et al. 1972), or 
a laparotomy (Yates et al. 1961), and the degree of inhibition was proportional to the rate at which GCs 
were administered (Dallman & Yates 1969; Besser et al. 1971; Abe & Critchlow 1977). 
Delayed negative feedback effects occur over longer durations (more than 2 hours) and require classical 
genomic actions of GCs and their nuclear receptors to mediate changes in gene expression. The delayed 
feedback domain primarily involves suppressing the synthesis of CRH/AVP and ACTH. Initial 
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experiments investigating the ability of endogenous GCs to exhibit inhibitory effects found a delayed 
feedback window of between 45 and 120 minutes, outside of which the stimulatory effects of histamine 
on CRH/AVP were not inhibited (Dallman & Yates 1969). Different receptor subtypes for GCs are 
ostensibly in operation for each temporal domain of feedback. This is evident from observations that 
although 11-deoxycorticosterone and 11-deoxycortisol antagonise the fast feedback effect of 
corticosterone and cortisol, these are in fact effective mediators of delayed feedback (Jones et al. 1974). 
The magnitude and duration over which exogenous GCs exhibit delayed feedback effects depends on 
integrating factors including the total dose of GCs administered (Sirett & Gibbs 1969) and the circulating 
GC concentration achieved (Dallman & Yates 1969), which in turn determines the duration and latency of 
inhibition since administration (Abe & Critchlow 1980). Maximal inhibition occurs between 2 and 4 
hours after administration (Takebe et al. 1971), and within this delayed feedback window the degree of 
inhibition is proportional to the dose of GCs (Fehm et al. 1979).  
Within the hypothalamic PVN, negative feedback occurs over rapid and delayed domains, involving 
reduced stimulation of CRH neurosecretion (10 minutes) and downregulated CRH and AVP transcription 
(2 to 3 hours). The activity of neurons (when evoked) can be said to depend on the balance between 
excitatory and inhibitory neurotransmission. Rapid excitation of neurons is chiefly mediated by the 
transmission of glutamate, which acts via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) and N-Methyl-D-aspartate (NMDA) receptors, whereas GABA largely achieves inhibition of 
neuronal activity. The rapid feedback effects of GCs in the PVN are mediated via non-genomic actions of 
GCs interacting with extracellular, mGRs on the parvocellular CRH/AVP neurons. Exposure of these 
neurons to GCs in vitro was found to decrease glutamate release and although this was unaffected by GR 
or MR antagonists (Di et al. 2003), this rapid inhibition was abolished in GR knockout mice (Haam et al. 
2010; Tasker & Herman 2011). Activation of the mGRs by GCs, induces a retrograde endocannabinoid 
signalling system across the synaptic cleft, activating presynaptic cannabinoid receptor-1 (CB1) and Gαs 
to inhibit the release of glutamate and CRH (Di et al. 2003; 2009). These effects are blocked by co-
application of GCs with a CB1 receptor antagonist (Di et al. 2003; Wamsteeker et al. 2010).  
Within the pituitary, rapid GC negative feedback effects on ACTH secretion has been demonstrated in 
experiments where the administration of GCs prior to application of a stressor or injection of CRH results 
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in rapid inhibition of ACTH release (Dayanithi & Antoni 1989; Cole et al. 2000; Hinz & Hirschelmann 
2000). A second messenger protein induced by GCs has since been shown to mediate this inhibition 
(Taylor et al. 1993). The original GC second messenger hypothesis was conceived from observations of 
GCs repressing biosynthesis of prostaglandins within lung tissue from guinea pigs (Gryglewski et al. 
1975). This occurred without affecting enzymes or transport (Lohrer et al. 2000), but rather, from 
inhibiting the production of arachidonic acid as a prostaglandin precursor (Lewis & Piper 1975). Since 
the cell membrane is a major source of phospholipids for arachidonic release, a GC second messenger 
with membrane activity was hypothesised as a simple explanation for the inhibition (Flower & Blackwell 
1979). Annexin A1 (ANXA1; formerly macrocortin, renocortin, lipomodulin, and lipocortin-1), had such 
properties and was discovered following the elegant work of Blackwell and Flower in 1980 (Blackwell et 
al. 1980). Thus, ANXA1 emerged as a candidate for mediating the feedback effects of GCs and 
modulating the HPA axis response to inflammogenic stress (Section 1.4).  
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1.3 HPA axis responses to inflammogenic stress 
All types of stress stimulate the HPA axis. This section will focus on inflammogenic stress caused by 
infections or pathogen associated molecular patterns (PAMPs) such as LPS, as these pose major 
challenges to the host defence system and overall homeostasis. In addition, several disease states that are 
exacerbated by inflammogens are also associated with HPA axis dysfunction, not limited to rheumatoid 
arthritis (Sternberg et al. 1989; Neeck et al. 1990), autoimmune thyroiditis (Schauenstein et al. 1987), 
multiple sclerosis (Levine et al. 1980; MacPhee et al. 1989), and sepsis (Marik et al. 2008). 
1.3.1 The HPA-immune system 
On noting that GC release is increased following all stressors, including infections, Besedovsky and 
colleagues substantiated the physiological role for glucocorticoids in regulating immune responses in the 
1970s and 1980s (Besedovsky et al. 1975; 1981). They found that physiological concentrations of GCs 
had clear effects at multiple levels of immune system function, and argued that GCs helped to restrain the 
host-defence responses and thus prevented damage to the host. This gave way to the concept of an HPA-
immune system, on the basis of the following strands of evidence. 
First, immune responses were clearly shown to increase the release of GCs (Besedovsky et al. 1975).  
Second, circulating concentrations of GCs are increased to similar levels whether in response to foreign 
antigens directly, through Newcastle Disease Virus (NDV), for instance, or to lymphokines generated by 
a previous immune reaction. This was demonstrated in rats, which at the peak of their immune response 
to sheep red blood cell exposure, had raised plasma ACTH and GC concentrations no different from rats 
injected with autologous lymphocytes stimulated in vitro (Besedovsky et al. 1975; 1981). The elevation 
in plasma GC concentrations, however, was abolished in hypophysectomised animals, underscoring the 
importance of pituitary ACTH, and thus demoting that of lymphoid or adrenal sources of ACTH at much 
lower concentrations (Besedovsky et al. 1985).   
Third, physiological concentrations of GCs were associated with reduced splenic mass and volume of 
immunoglobulin-secreting B lymphocytes (Del Rey et al. 1984).  
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Fourth, antigenic specificity (where a given immune reaction is favoured over others) was facilitated by 
the raised, immunosuppressive, concentrations of GCs typical of primary immune responses. It was 
reasoned that GC-mediated antigenic specificity, achieved by non-specific immunosuppression, prevents 
unrestricted expansion of lymphocytes with “little or no affinity for antigen”. The authors acknowledged 
that this was analogous to lateral inhibition of surrounding neurons that increase the signal-to-noise ratio 
when a specific, discriminatory response is required (Besedovsky et al. 1979b).  
Fifth, a feedback circuit between cells of the immune system and adrenal cortex was established. Immune 
cells released a Glucocorticoid Increasing Factor (GIF) that stimulated the adrenal cortex to produce and 
release GCs. The GIF was shown to require ACTH (at pituitary rather than lymphoid concentrations) for 
its steroidogenic effect (Besedovsky et al. 1985) and was identified as being IL-1 (Berkenbosch et al. 
1987; Sapolsky et al. 1987).  
Sixth, changes in hypothalamic norepinephrine turnover (Besedovsky et al. 1979a) and electrical activity  
(Besedovsky et al. 1977) were observed in parallel to peak plasma GC and lymphocyte concentrations in 
rats exposed to NDV and sheep red blood cells. This led to the suggestion that hypothalamic hormones 
were involved in the immunomodulation of GC release. CRH was shown to be stimulated by IL-1 
(Berkenbosch et al. 1987; Sapolsky et al. 1987), and the means by which the immune response would 
drive HPA axis activity, increasing adrenal GC release, and in turn, increasing antigenic specificity.  
1.3.2 Mechanisms of HPA activation during infection 
The HPA axis is critical to homeostatic balance. The GCs modulate the stress response through molecular 
mechanisms, altering expression, transcription, and translation of a multitude of genes in diverse 
pathways. The overall effect is inhibition of inflammatory cell function through the inhibition of pro-
inflammatory cytokines such as IL-1 and IL-6, and tumour necrosis factor-α (TNF-α). The central 
effectors of the stress response are the CRH and LC-NE/sympathetic systems. These systems are able to 
activate the stress response but can develop defects that have been associated with inflammatory diseases 
(e.g. rheumatoid arthritis, multiple sclerosis), and can be modulated by inflammatory mediators such as 
cytokines, as well as by hormones and neurotransmitters. 
1.3.2.1 Role of cytokines 
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Cytokines are proteins released by cells upon activation by an antigen, and through cell-to-cell 
communication at membrane-bound receptors they modulate leukocyte function and immune responses. 
There a several types of cytokines released from different cell types, and include the interleukins (from 
leucocytes), lymphokines (from lymphocytes), interferons, and tumour necrosis factor.  
1.3.2.1.1 Interleukin-1 (IL-1) 
The work of Besedovsky and coworkers (1986) demonstrated a role for cytokines in mediating the 
neuroendocrine responses to NDV. The circulating concentrations of ACTH and GCs were raised in mice 
inoculated with NDV or cultures of NDV-stimulated leukocytes from human peripheral blood or mouse 
spleens. They ascribed this stimulation of ACTH and GC secretion to the release of proteins from the 
NDV-stimulated leukocytes, namely, IL-1, since its immuno-neutralisation blocked the stimulation 
(Besedovsky et al. 1986). In 1985, IL-1α and IL-1β were isolated from a human macrophage cDNA 
library, and were the first of 11 members of the IL-1 family of proteins to be cloned (March et al. 1985). 
IL-1β is more potent than IL-1α (in its HPA axis stimulation), and its release typically follows the 
stimulation of macrophages and monocytes by PAMPs, such as, LPS (Rivier et al. 1989; Quan et al. 
1998). The mechanism by which IL-1β increases plasma ACTH and GC concentration was believed to be 
by the direct IL-1-mediated stimulation of hypothalamic CRH neurons (Berkenbosch et al. 1987; 
Sapolsky et al. 1987) (despite only minimal [<0.1%] IL-1β crossing the blood brain barrier (Coceani et 
al. 1988; Ferreira et al. 1988)). This was based on evidence that IL-1-stimulated ACTH release was 
blocked in vivo by anti-CRH immunoneutralisation and in vitro by application of IL-1 to dispersed 
pituitary cells without optimal concentrations of CRH. Indirect mediation by other hormones, or by IL-1-
induced lymphocytes was ruled out since the IL-1 induced HPA axis activation was present in nude (T-
cell- and therefore IL-2-deficient) mice (Besedovsky et al. 1986). Taken together, this suggested the 
neuroendocrine response to inflammogenic stress, elicited by the host defence and mediated by IL-1, was 
specific to the HPA axis hormones. 
Several features of the HPA axis can feedback to inhibit the effects of IL-1β, including those mediated by 
GCs (Wahl et al. 1975; Gillis et al. 1979; Snyder & Unanue 1982; Kelso & Munck 1984), and ANXA1 
on IL-1-stimulated CRH release (Sudlow et al. 1996), and some can enhance them, including CRH 
(Karalis et al. 1991; Renner et al. 1998). These interactions will be described later (Section 1.4).  
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1.3.2.1.2 Interleukin-6 (IL-6) 
Similar to IL-1, but less potent, persistent, and slower acting (Besedovsky et al. 1991), IL-6 has been 
shown to increase the secretion of ACTH in rats in vivo (Naitoh et al. 1988). IL-6 stimulates the in vitro 
release of CRH (Navarra et al. 1991), ACTH (Fukata et al. 1989), and GCs (Tominaga et al. 1991) from 
cells of the hypothalamus, pituitary gland, and adrenal cortex, respectively.  The expression of IL-6 in the 
HPA axis and lymphoid tissues can be induced by inflammogenic PAMPs such as LPS (Muramami et al. 
1993). IL-6 is essential for mediating the adrenal steroidogenic effect of bacterial and viral infections, and 
its actions are enhanced by ACTH in rats and humans (Bethin et al. 2000; Silverman et al. 2004; 
Zarkovic et al. 2008). 
1.3.2.1.3 Tumour necrosis factor-α (TNF-α) 
TNF-α, like IL-1 and IL-6, stimulates the HPA axis and increases GC secretion, with a similar potency to 
IL-1 and does so more rapidly than both IL-1 and IL-6 (Tracey et al. 1987; Sharp et al. 1989; Besedovsky 
et al. 1991). During infection, the level of TNF-α reaches picomolar concentrations in human blood 
plasma (Girardin et al. 1988; Michie et al. 2013), and 100 – 1000 picomolar TNF-α significantly raises 
plasma ACTH concentration in rats within 20 minutes, versus 60 minutes with equimolar IL-1β (Sharp et 
al. 1989). The stimulatory effects of TNF-α, are thought to occur at a different site to those of IL-β 
(median eminence), as unlike IL-1β, intracerebroventricular (i.c.v.) administration of TNF-α does not 
stimulate the HPA axis (Sharp et al. 1989). Rats exposed to LPS (0.03 μg/kg) by intraperitoneal injection 
exhibit a rapid (less than 20 minutes) rise in plasma TNF-α, ACTH, and GC levels (Waage 1987). This 
stimulation of the HPA axis is completely blocked by immunoneutralisation with anti-TNF-α antiserum, 
but not by IL-1 receptor antagonist (IL-1RA), except following higher doses of LPS (10 μg/kg) where 
both TNF-α and IL-1β appear to stimulate the HPA axis (Ebisui et al. 1994). 
In summary, the cytokines IL-1α, IL-1β, IL-6, and TNF-α, and their synergistic effects (Perlstein et al. 
1993), are key to the immunomodulation and interaction of the HPA axis and immune system, and each is 
subject to upregulation by inflammogens such as LPS.  
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1.3.3 Evidence for inflammogen receptors within the pituitary gland 
Lipopolysaccharides are constituents of gram-negative bacteria like Escherichia coli. The initial host 
defence against such bacterial infections involve toll-like receptors (TLR) that can detect and respond to 
LPS and other microbial ligands. The induction of cytokines is part of the initial response to LPS 
mediated by TLRs. There is evidence of TLR expression within the pituitary folliculostellate cells where 
cytokine production, for instance IL-6, can be induced by LPS, and impinges on signal cascades 
favouring ACTH secretion. This has been demonstrated in various pituitary models, including, the 
immortalised TtT/GF cell line (Lohrer et al. 2000), and mouse primary pituitary cultures (Renner et al. 
1998). Toll-like receptor 4 (TLR4) is the main receptor for the mediating the effects of LPS, and is 
expressed in corticotroph-like AtT20 cells and human pituitary adenomas (Tichomirowa et al. 2005). In 
addition, cluster of differentiation 14 (CD14), which comprises the LPS-TLR4 receptor complex 
necessary for transducing the effects of LPS, is known to be expressed in TtT/GF cells (Lohrer et al. 
2000).  
The folliculostellate cells express S100 calcium binding protein b (S100b), CD14, CD45, CD54, major 
histocompatability complex (MHC) class I and II antigens and complement receptors, making them 
replete with signalling molecules for inflammogens, particularly LPS (Baes et al. 1987; Whiteside et al. 
2001; Solito et al. 2003). The CD14 expressed in folliculostellate cells enables LPS complexes with 
TLR4 to signal via NF-κB to transcriptionally upregulate pro-inflammatory cytokines, such as, IL-6, IL-
1β, IL-1 receptor antagonist and TNF-α (Lohrer et al. 2000). LPS, IL-1β and IL-6 are known to stimulate 
ACTH release in vitro and in vivo whereas TNF-α inhibits CRH-induced ACTH release (Solito et al. 
2006).  
1.3.4 Evidence for inflammogen receptors within the adrenal gland 
LPS can induce cytokine expression in the adrenal cortex, and evidence that LPS receptors are expressed 
here supports the notion of locally mediated effects (Kanczkowski et al. 2011). Initally, LPS appears to 
stimulate GC release in a cyclooxygenase-2 (COX-2)-dependent mechanism (Vakharia & Hinson 2004; 
Zacharowski et al. 2006). There is a direct stimulatory effect of LPS on the production of GCs from 
human adrenocortical cells (Vakharia et al. 2002) but following this, the secretory response to LPS or 
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ACTH is attenuated (Liu et al. 2011). Receptors for LPS, TLR2 and TLR4 have been shown to be 
expressed in human adrenals (Fava et al. 1989; Traverso et al. 1998; Gerke & Moss 2002; Bornstein et al. 
2004a), and over-expression of TLR4 (but not TLR2) has been shown to inhibit basal and stimulated GC 
secretion (Fava et al. 1989; Tsao et al. 1995; Rosengarth et al. 2001; Rosengarth & Luecke 2003; Davies 
et al. 2007; Kanczkowski et al. 2011). Counter-intuitively, TLR4 knockout mice also have impaired GC 
secretion despite enlarged adrenal glands and cortices (Zacharowski et al. 2006) whereas TLR2 knockout 
mice have elevated plasma ACTH concentrations (Bornstein et al. 2004b). Other TLRs, such as TLR9 are 
also implicated in adrenal GC release, and such activity is associated with cytokines TNF-α, IL-1β, -6, -9, 
-12, in both mice and humans (Tran et al. 2007). There are a range of TLRs expressed within the human 
adrenal cortex (Kanczkowski et al. 2009) and different subtypes other than TLR4 might play a role in the 
inflammatory response, including, TLR9 for instance (Tran et al. 2007). There is also a degree of cross 
talk between TLRs and nuclear hormone receptors such as those for GCs (Ogawa et al. 2005).  
There is growing evidence of a paradoxical impairment of steroidogenesis coupled with local 
inflammation within the adrenal gland following exposure to LPS. This has been demonstrated in murine 
models of endotoxaemia (Buss 2010; Mohn et al. 2011). Liu and colleagues found that pretreatment with 
LPS resulted in adrenocortical cells that were refractory both to further LPS challenge, but also to ACTH 
(Liu et al. 2011). This work substantiated the concept of adrenocortical tolerance to LPS. In investigating 
the mechanisms, they found that endotoxin treatment resulted in downregulated adrenocortical expression 
of both TLR4 and MC2R (the ACTH receptor) and inhibited various enzymes in the corticosterone 
biosynthetic series. In addition, numerous cytokine networks are evident downstream of adrenal TLR4 
receptors for LPS, but the precise mechanisms underpinning endotoxaemia-induced adrenal insufficiency, 
however, are yet to be fully elucidated (Engström et al. 2008). Despite this, there are several strands of 
evidence that suggest adrenal insufficiency is of pathological relevance to sepsis. There is very little de 
novo synthesis of cholesterol in the adrenal glands. The availability of cholesteryl ester obtained from 
LDL and HDL, therefore, is critical for adrenocortical steroidogenesis (Prigent et al. 2004). It has been 
shown repeatedly that both experimental endotoxaemia and clinical sepsis are associated with 
adrenocortical depletion of lipid droplets (Marik 2002; Buss 2010; Peng & Du 2010). In these 
circumstances, further steroidogenesis depends on adrenal uptake of cholesteryl ester from LDL and HDL 
molecules upon their binding to SR-BI (Temel et al. 1997). Unfortunately, during advanced 
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endotoxaemia and sepsis, there is an aberration in the SR-BI pathway and this coincides with 
hypocortisolemia (Cai et al. 2008). The development of adrenocortical insufficiency and tolerance to LPS 
is similar to the effects of the pro-inflammatory cytokines, TNF-α (Mikhaylova et al. 2007) and IL-6 
(Zarkovic et al. 2008). Human adrenal cells exposed to TNF-α for 48 hours in culture, for instance, 
largely developed adrenocortical apoptosis and overall cortisol release was reduced. In the few cells still 
viable, however, cortisol release was increased (Mikhaylova et al. 2007). This adrenocortical 
inflammation and apoptosis has been replicated elsewhere (Kanczkowski et al. 2013). These 
inflammatory mediators may act as initial stimulants of GC release, but then ostensibly led to 
adrenocortical apoptosis, lipid depletion, and adrenocortical insufficiency. The adrenocortical resistance 
to ACTH during endotoxaemia might occur via one of several mechanisms. There is some evidence that 
neutrophil-derived corticostatins (ACTH receptor antagonists (Zhu & Solomon 1992)) may compete with 
ACTH for binding sites on MC2R (Bornstein et al. 2008). Pathogens, such as the coronavirus that causes 
severe acute respiratory syndrome (SARS), can have areas of homology with the ACTH sequence, which 
could permit direct binding via MC2R (Wheatland 2004). It is conceivable then, that an endogenous 
antibody against such pathogens might also immunoneutralise the ACTH in circulation, but this is 
speculative. The strongest evidence so far, however, is for adrenocortical insufficiency to take place via 
downregulation of MC2R and TLR4 (Liu et al. 2011).  
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1.4 Role of annexin A1 in modulating HPA axis function  
This section begins with a brief description of the basic biology of the annexin A1 protein and outlines 
the evidence for its anti-inflammatory actions and effects on the HPA axis, before focussing on its 
modulation of the HPA axis response to inflammogenic challenges. Finally, the description of its 
molecular mechanisms delineates the case for involvement of members of the formyl peptide receptor 
family. 
1.4.1 Basic annexin A1 biology 
Annexin A1 (ANXA1; formerly lipocortin 1) is a 37 kDa protein from the annexin superfamily of 
structurally related proteins. ANXA1 was the first of 13 members of the annexin family to be 
characterised by their ability to bind to acidic phospholipids in a Ca
2+
-dependent mechanism, owing to 
their highly conserved carboxylic acid (C)-terminal core domain of 70 amino acids. The amino (N)-
terminal domain of the annexin subtypes are unique, vary in length (44 amino acids in ANXA1) and in 
their composition of phosphorylation and glycosylation motifs (Btaouri et al. 1996; Buckingham 1996; 
Kalinec et al. 2009) that determine their functional specificity (Fava et al. 1989; Peers et al. 1993; Gerke 
& Moss 2002; Lu et al. 2007). The N-terminal domains undergo conformational change in line with 
increased Ca
2+
 concentration, resulting in ANXA1 being open to ligand binding, and thus influencing 
biological activity (Rosengarth et al. 2001; Rosengarth & Luecke 2003). 
ANXA1 was first posited as being a mediator of GC actions in leukocytes of the innate immune system 
(Blackwell et al. 1980). Early investigations found that removal of GCs by adrenalectomy downregulates 
ANXA1 synthesis, and this is reversed by reintroduction of GCs to rat macrophages (Blackwell et al. 
1982). Other researchers verified this relationship between the concentration of GCs and expression of 
ANXA1 in other cell types, both in vitro and in vivo (Baes et al. 1987; Fuller & Verity 1989; Vishwanath 
et al. 1992; Whiteside et al. 2001), including the hypothalamus and pituitary gland (Loxley et al. 1993; 
Smith et al. 1993; Taylor et al. 1993). These effects were blocked by mifepristone (GC receptor 
antagonist) (Peers et al. 1993; Taylor et al. 1993; Herkenham 2005) and unaffected by mineralocorticoid 
or sex steroids (Baes et al. 1987; Solito et al. 2001; Chapman et al. 2002), and thus substantiated the 
primacy of GCs in the regulation of ANXA1 expression. Given that secretion of GCs is increased 
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following inflammation and tissue injury (Taylor et al. 1993; Buckingham 1996; Castro-Caldas et al. 
2001; Philip et al. 2001), and these sites attract leukocytes such as neutrophils expressing ANXA1 
(Perretti et al. 1996), this partly explains why expression of ANXA1 is markedly upregulated at sites of 
inflammation.  
The expression of ANXA1 in a variety of tissues has now been identified, including the brain (Smith et 
al. 1993), anterior pituitary gland (Ozawa et al. 2002), adrenal gland (Davies et al. 2007), neutrophils 
(Fava et al. 1989), cochlear Hensen cells (Kalinec et al. 2009), lung (Dreier et al. 1998), skeletal muscle 
and adipose tissue (Warne et al. 2006). Expression of ANXA1 is evident throughout the endocrine 
system. ANXA1 is abundantly expressed within the anterior pituitary gland, mainly along projections of 
non-endocrine folliculostellate cells, particularly those in apposition with endocrine cells (Christian et al. 
1997; Ozawa et al. 2002). Expression of ANXA1 is also high within the hypothalamus, particularly 
within the median eminence (Buckingham 1996; Traverso et al. 1998; Solito et al. 2001; Hannon et al. 
2003); the ependymal cells (Dreier et al. 1998) surrounding the third ventricle (Christian et al. 1997); in 
activated astrocytes; and small amounts in microglia (Hannon et al. 2003). There is also evidence of 
ANXA1 expression within the endocrine pancreas (Ohnishi et al. 1995), testis (Cover et al. 2002), ovary 
(Tsao et al. 1995), thyroid (Btaouri et al. 1996), thymus (Fava et al. 1989), placenta (Tsao et al. 1995), 
and the adrenal cortex (Davies et al. 2007). 
1.4.2 Effects of ANXA1 within the HPA axis 
The adrenal glands are the original source of the first annexin to be described, annexin A7 (Creutz et al. 
1978), which was isolated from the chromaffin cells of the medulla, where ANXA1 was also observed 
later (Drust & Creutz 1991; Wang & Creutz 1992). Primary adrenal cell cultures derived from ANXA1
-/- 
mice were found to have a higher release of corticosterone in response to ACTH1-24 than wildtype 
adrenals, and this effect occurred without any change in MC2R expression, suggesting a short, ANXA1-
mediated, negative feedback loop, controlling adrenal GC release (Omer et al. 2005). This was further 
substantiated by findings that adrenal extracellular ANXA1 was upregulated by GCs within 3 hours of 
exposure, and ACTH1-24-stimulated corticosterone release was greater in ANXA1
-/-
 adrenals than 
wildtypes (Davies et al. 2007). This suggested that ANXA1 played a role in the adrenal responsiveness to 
ACTH1-24 and possibly mediated short-loop feedback sensitivity to GCs. 
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ANXA1 is expressed within the hypothalamus, hippocampus, cortex, and other parts of the brain (Philip 
et al. 1997) but in lesser amounts than the anterior pituitary and adrenal. Within the hypothalamus, 
ANXA1 is concentrated within the median eminence, the ependymal cells surrounding the third ventricle, 
as well as the SON and PVN (Smith et al. 1993). Whilst ANXA1 is expressed within activated glial cells 
it is not evident in hypothalamic neurons, including those for CRH/AVP. As in the anterior pituitary, GCs 
regulate both the synthesis and the cellular disposition of ANXA1 in the hypothalamus, again, not in the 
endocrine cells but in the adjacent cells (Loxley et al. 1993). Here, ANXA1 suppresses the CRH neuron 
response to pro-inflammatory cytokines in vivo (Loxley et al. 1993). The findings that ANXA1 is not 
expressed by CRH/AVP neurons or corticotrophs, but is present in the non-endocrine activated microglia 
and folliculostellate cells, and is rapidly translocated to cell membranes in timings consistent with the 
feedback domains of GCs, prompted the hypothesis that ANXA1 mediates the inhibitory effects on 
CRH/AVP and ACTH release (Smith et al. 1993). 
1.4.3 Mechanism of action of annexin A1 within the anterior pituitary gland 
This section will deal with the mode of action of ANXA1 within the anterior pituitary gland, its 
localisation to non-endocrine folliculostellate cells, and its inducement by non-genomic steroid action and 
serine phosphorylation prior to translocation to the cell membrane, and the evidence for its externalisation 
via an ABCA1 transporter system. 
1.4.3.1 Annexin A1 is a paracrine mediator of GC-inhibited ACTH release  
Around the time of ANXA1’s discovery, Denef and coworkers began to investigate the possibility of 
paracrine communication between the various epithelial cell subtypes of the anterior pituitary gland 
(Denef et al. 1989). By separating these cells based on their unit gravity of sedimentation (secretory 
granule diameter) and re-aggregating them at increasing ratios of endocrine to non-endocrine lineage, 
they found that preparations containing more non-endocrine (agranular) folliculostellate cells had reduced 
hormone secretion (Baes et al. 1987). The effect was paralleled by applying conditioned medium from 
folliculostellates to separate endocrine cells, and suggested the folliculostellate cells produced a paracrine 
factor. 
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A paracrine factor was not identified until the early 1990’s, when Amanda Taylor and colleagues were 
exploring the mechanisms used by GCs to feedback and inhibit the exocytosis of ACTH following the 
stress response (Loxley et al. 1993; Smith et al. 1993; Taylor et al. 1993). Immunohistochemistry and cell 
fractionation studies provided evidence of ANXA1 expression within the non-endocrine, folliculostellate 
cells of the anterior pituitary, where it is compartmented between the cytoplasm, and the organellar and 
extracellular membranes (Philip et al. 1997; Traverso et al. 1999). This distribution and synthesis of 
ANXA1 is regulated by the action of GCs both within the anterior pituitary and the hypothalamus 
(Loxley et al. 1993; Taylor et al. 1993). The de novo synthesis of ANXA1 is induced by GCs via classic 
genomic actions and is slow in onset (more than 2 hours), whereas the translocation of cytoplasmic 
ANXA1 to the extracellular membrane is evident within 15 minutes of exposure to GCs whether in vivo 
or in vitro (Philip et al. 1997). These two methods of modulating ANXA1 expression and distribution are 
therefore consistent with the biphasic (rapid and delayed) feedback domains of GCs. 
The absence of ANXA1 expression within CRH/AVP neurons or ACTH-positive corticotrophs, alongside 
abundant expression within adjacent S100b-positive folliculostellates, prompted the hypothesis that 
ANXA1 mediates the feedback inhibition of GCs on stress hormone release via a paracrine mechanism. 
Within the anterior pituitary, this was supported by five tessellating pieces of evidence. First, ANXA1 is 
predominately expressed within the folliculostellate cells and at high concentrations at points of contact 
with endocrine cells (Traverso et al. 1999). Second, the GC-induced release of ANXA1 to the 
extracellular membrane coincides with the rapid (<30 min) GC-induced inhibition of ACTH secretion 
(Loxley et al. 1993; Taylor et al. 1995c; Buckingham et al. 1996)—effects which are blocked by drugs 
that prevent protein transport (e.g. monensin), antagonise GR (McArthur et al. 2009), or inhibit PKC 
(John et al. 2002). Third, the corticotrophs have high-affinity, (Kd 14 nmol.l
-1
) ANXA1-binding sites 
which, when enzymatically disrupted, impairs both GC- and ANXA1-mediated inhibition of ACTH 
release (Christian et al. 1997). Fourth, release of immunogold labelled ANXA1 is evident at focal points 
where folliculostellate projections are in apposition with endocrine cells (Chapman et al. 2002). Fifth, 
murine co-cultures of the ANXA1-positive, folliculostellate-like TtT/GF cell line, with the ANXA1-
negative, corticotrophic AtT20 D1 cells, exhibited reduced CRH-stimulated ACTH release by GCs, and 
antisense oligodeoxynucleotides confirmed this effect was ANXA1-dependent (Tierney et al. 2003). 
Interestingly, AtT20 D1 cells cultured alone respond to ANXA1 and ANXA1Ac2-26 peptide (but not GCs), 
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whereupon CRH-induced ACTH release is inhibited dose-dependently (Tierney et al. 2003). This further 
substantiates the role of folliculostellates as a source of the ANXA1 required to mediate the feedback 
inhibition of ACTH release by GCs. 
1.4.3.2 Annexin A1 translocation involves an ABCA1 transporter 
The rapid nature of the GC-induced translocation of ANXA1 that was blocked by GC receptor 
antagonists but unaffected by inhibitors of transcription or translation (Philip et al. 1998), suggested a 
novel, non-genomic, GC receptor-mediated mechanism was involved. The translocation of ANXA1 to the 
extracellular membrane of the folliculostellates was also shown to be unaffected by inhibitors of Golgi-
mediated exocytosis (namely, nocodazole and brefeldin A) and thus ruled out the release of ANXA1 
within vesicles (Philip et al. 1997). Instead, analysis of membrane-bound ANXA1 found that 
phosphorylation by PKC was influential in this association, critically at serine residues, and to a lesser 
extent tyrosine residues (John et al. 2002; 2003). This was demonstrated by the fact that blockade of PKC 
prevented the GC-induced serine phosphorylation and translocation of ANXA1 to the extracellular 
membrane of primary folliculostellate cells, whereas inhibition of tyrosine phosphorylation was not 
critical. The role of serine phosphorylation was further substantiated by experiments using the human 
folliculostellate cell line (PDFS), whereby the actions of GCs on ANXA1 translocation were found to be 
mediated via a non-genomic pathway downstream of GRs, involving phosphatidylinositol-3-kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) in addition to PKC (Solito et al. 2003). To 
determine which serine residues specifically linked phosphorylation with membrane binding, site-directed 
mutagenesis of ANXA1 found that serine-27 and serine-45 were important (Solito et al. 2006; McArthur 
et al. 2009). The mechanism by which ANXA1 reaches the extracellular membrane, however, is less 
clear, although immunoreactive ANXA1 was evidently co-localised with the adenosine triphosphate 
(ATP)-binding cassette transporter protein type A1 (ABCA1) in primary folliculostellates, suggesting this 
protein might be involved (Chapman et al. 2003). In the same study, blockade of ABCA1 with glyburide 
prevented both the GC-induced translocation of ANXA1 and its inhibition of ACTH release from primary 
pituitary tissue. The caveat to these findings is that glyburide, as well as blocking ABCA1, also opens 
ATP-sensitive K
+
 channels which when blocked (by chromokalim for instance), have been shown to 
induce ANXA1 translocation in TtT/GF cells. Although the contribution of ABCA1 to the translocation 
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of ANXA1 might be less than that of ATP-sensitive K
+
 channels, the fact that glyburide prevented GC-
induced ANXA1 translocation and inhibition of ACTH release, is consistent with the paracrine model of 
ANXA1 action (Chapman et al. 2003). 
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1.5 Annexin A1 signalling and the role of the formyl peptide receptor (Fpr/FPR) family 
The paracrine model by which ANXA1 mediates the feedback inhibition of GCs on ACTH release via 
membrane-associated receptors on corticotrophs and other endocrine cells is well supported (Christian et 
al. 1997). In investigating the structure-activity relationship of ANXA1 action in different systems, 
evidence suggests the actions of ANXA1 could be mediated by more than one receptor subtype. Removal 
of the second repeat unit of the core domain (ANXA11-188) and most of the first repeat (ANXA11-50) result 
in peptides which inhibit ACTH release, but are significantly less potent, despite equal efficacy with full 
length ANXA11-346 (John et al. 2002). The N-terminal acetylated peptide ANXA1Ac2-26, however, is less 
potent (10
5
 times) and less efficacious than ANXA11-346,
 
but equipotent to ANXA11-188, whereas shorter 
sequences have no effect whatever, indicating that the N-terminal is critical for the inhibition of ACTH 
release mediated by ANXA1 in vitro. This was corroborated by immunoneutralisation with antibodies 
against this N-terminal epitope, which blocked the inhibitory effect of GCs on ACTH release in vivo 
(Taylor et al. 1995c). In models of inflammation, however, ANXA1Ac2-26 has been shown to be as 
efficacious, but 100 times less potent than full length ANXA11-346 at reducing PMN infiltration, whereas 
ANXA11-188 is 10 times less potent (Perretti et al. 1996). Given the divergence in potency of ANXA1 
peptides in different tissue systems, it seems likely that more than one receptor subtype mediates the 
endogenous actions of ANXA1. The discovery that ANXA1 interacted with a G-protein coupled formyl 
peptide receptor (Fpr in rodents, FPR in man) in leukocytes (Walther et al. 2000), opened up the 
possibility that ANXA1 actions within the HPA axis were mediated via an Fpr/FPR subtype. This 
research seeks to identify an Fpr/FPR subtype that modulates pituitary and adrenal stress hormone release 
because this could then be targeted with ligands that modulate HPA axis function without the use of GCs 
and their associated side effects (Schäcke et al. 2002).  
1.5.1 Biology of the Fpr/FPR family 
This subsection will describe the discovery of a family of G-protein coupled receptors, the formyl peptide 
receptors (Fpr in rodents, FPR in man); tabulate their tissue distribution; and describe their structural 
similarities and their function with regard to the relative affinities for agonists and antagonists, and 
signalling mechanisms. 
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Phylogenetic analysis of the different Fpr/FPR subtypes between species suggests that the Fpr/FPR family 
has undergone differential expansion (Figure 1.2). There are rodent-specific Fpr subtypes that have 
resulted from numerous gene duplication events, so that there are 8 functional mouse genes (Fpr1, Fpr2, 
Fpr3/Alx, Fpr-rs3, Fpr-rs4, Fpr-rs6, Fpr-rs7, and Fpr-rs8) on chromosome 17 A3.2, and 7 rat genes (Fpr1, 
Fpr2, Fpr2l/Alx, Fpr3, Fpr-rs3, Fpr-rs4, and Fpr-rs6) on chromosome 1q12, compared with only 3 human 
genes, FPR1, FPR2/ALX, and FPR3, on chromosome 19 (Gao et al. 1998; Rabiet et al. 2005).  
The discovery of the first formyl peptide receptor, namely FPR1 began with the hypothesis that 
leukocytes are attracted to sites of infection through bacterial signals (chemotaxis). These signals were 
narrowed down to peptides containing the initiation sequence for prokaryotic protein synthesis, N-formyl 
methionine (Schiffmann et al. 1975a). After many compounds were tested, formyl-methionyl-leucyl-
phenylalanine (fMLF) was found to be most potent in eliciting neutrophil chemotaxis, with a pEC50 10.05 
- 10.16 (Showell et al. 1976; Freer et al. 1980). The identification of FPR1 itself was borne out of the 
cloning of a cDNA library which conferred transfected cells with high-affinity receptors for fMLF 
(Boulay et al. 1990). N-formyl-methionine, whilst highly potent, was found to be not necessary for ligand 
binding and responses via Fpr/FPR subtypes (Gao et al. 1994). In fact, collectively the Fpr/FPR are a 
family of highly promiscuous receptors, because they bind to a wide variety of chemically diverse 
ligands, typically with low selectivity (Hartt et al. 1999; Migeotte et al. 2006). On the basis that many of 
these ligands were present within bacteria, and because Fprs/FPRs are abundantly expressed on 
leukocytes, the Fpr/FPR family was thought to have evolved primarily to chemoattract leukocytes to the 
sites of bacterial infection (Prossnitz & Ye 1997). However, formylated peptides are also produced by 
mitochondria (Rabiet et al. 2005), and Fpr/FPR subtypes are expressed in a variety of cell types, 
including those of the chemosensory vomeronasal organ in rodents (Liberles et al. 2009; Rivière et al. 
2009). These discoveries suggest that Fpr/FPR subtypes have diverse biological roles beyond leukocyte 
chemotaxis. 
Each human FPR subtype will now be described in terms of their structural and functional similarities 
with the rodent (murine and rat) Fpr subtypes, the relative affinities of their most selective ligands and 
their binding domains, their regulation in terms of phosphorylation, internalisation, and desensitisation, 
and interactions with Fpr/FPR subtypes and other molecules such as β-arrestins. The signalling 
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mechanisms will be briefly covered in terms of their molecular mediators and how much of the evidence 
from leukocytes relates to pro-inflammatory (chemotaxis, superoxide generation, and degranulation 
events) or anti-inflammatory actions.  
1.5.2 Formyl peptide receptor 1 (FPR1) 
In terms of function, the human FPR1 and murine Fpr1 show high affinity for N-formyl peptides, 
especially fMLF, which is the most selective and potent ligand for human FPR1 and mouse Fpr1 with a 
pEC50 of 9.3 and 7.0, respectively (Koo et al. 1982; Hartt et al. 1999; He et al. 2000). Similarly, fMLF 
binding via the rat Fpr1 has a pKd of 7.5 (Marasco et al. 1983) (see Table 1.3). It is on this basis, and their 
high nucleotide sequence identity (77%), that murine Fpr1 and rat Fpr1 are recognised as the structural 
and functional orthologues of human FPR1. Expression of human FPR1 is evident within: the endocrine 
system (adrenal, ovary, placenta); leukocytes (macrophages, monocytes, polymorphonuclear (PMN) cells, 
dendritic cells) and platelets; lymphoid tissues (bone marrow, spleen); and the cells (astrocytes and 
microglia) and tissues (hippocampus, hypothalamus) of the nervous system (see Table 1.2) (Becker et al. 
1998; Czapiga et al. 2005; Ye et al. 2009). The expression of Fpr1, the murine orthologue of human 
FPR1, is broadly similar (Gao et al. 1999; Hartt et al. 1999; Dai et al. 2005; Mandal et al. 2005; Buss 
2010). Although expression of the rat Fpr1 is evident within leukocytes such as neutrophils, its wider 
tissue distribution remains to be investigated (Marasco et al. 1985; Remes et al. 1991). 
Several groups have attempted to determine the ligand binding domains of the Fpr/FPR subtypes. 
Receptor chimera studies in which the first and third extracellular loops of FPR2/ALX were replaced with 
those of FPR1, increased the affinity (Kd) for fMLF from 400 to 18 nmol.l
-1
 for FPR2/ALX, compared 
with 1 nmol.l
-1
 for FPR1 (Quehenberger et al. 1993). Further experiments which introduced positively 
charged amino acid residues at key positions, namely, Arg84 and Lys85, were able to increase the affinity 
of these chimeric receptors for fMLF to within 1.6 nmol.l
-1
 (Quehenberger et al. 1997). The fMLF 
binding region on FPR1 was confirmed by photolabelling experiments in which fMLF was visible 
between residues 83 and 87 encompassed by transmembrane domain 2 and the first extracellular loop 
(Mills et al. 2000). These findings are important because they demonstrate that the residues for high 
affinity fMLF binding are typically only found on FPR1, and explain the Fpr1/FPR1 selectivity of fMLF 
in human, mouse, and rat systems (see Table 1.3). 
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Upon binding to Fpr1/FPR1, fMLF is associated with NF-κB-mediated transcription of chemokines and 
endoplasmic reticular Ca
2+
 release via Gβ-mediated upregulation of phospholipase C-β (PLC-β), giving 
rise to diacylglycerol (DAG)-mediated stimulation of protein kinase C (PKC) (Naccache et al. 1979). 
This occurs alongside cytoskeletal actin reorganisation which follows the Gγ-mediated upregulation of 
phosphoinositide 3-kinase (PI3K) activity (Homma et al. 1985). In addition, fMLF upregulates Ca
2+
 
mobilisation, superoxide anion production and ultimately cell degranulation in mouse neutrophils (Gao & 
Murphy 1993; Pivot-Pajot et al. 2010). Although these signalling events could be relevant to pituitary and 
adrenal stress hormone secretion, the available evidence suggests that fMLF and rat and mouse Fpr1 is 
not involved, but this does not exclude a role for human FPR1 (Section 1.5.5). 
1.5.3 Formyl peptide receptor 2/ lipoxin receptor (FPR2/ALX) 
Human FPR2/lipoxin receptor (ALX) shares 76% and 73% of its nucleotide sequence with murine Fpr2 
and Fpr3/Alx respectively, compared with only 68% with Fpr1/FPR1. Similarly, FPR2/ALX has 77% and 
74% sequence identity with rat Fpr2 and Fpr2l/Alx, but the rat Fpr1 is not far behind at 73% (Table 1.1). 
Despite the similarities in structure between FPR2/ALX and particularly Fpr2, attempts to discern which 
murine/rat Fpr subtype is the functional orthologue of human FPR2/ALX based on the effects of a ligand 
in a given system are fodder for scholarly debate. The most selective ligands for human FPR2/ALX and 
mouse Fpr2 are the peptide agonist, Trp-Lys-Tyr-Met-Val-D-met (WKYMVm) with a pEC50 of 12.0 and 
9.3, respectively (Le et al. 1999; He et al. 2013a), and the peptide antagonist Trp-Arg-Trp-Trp-Trp-Trp 
(WRW4) with a pIC50 of 6.7 and 6.6, respectively (Bae et al. 2004; Stenfeldt et al. 2007; Önnheim et al. 
2008).  
Receptor chimera experiments have been performed to determine which binding domains and residues are 
responsible for high affinity binding at FPR2/ALX. It was found that transmembrane domain 7 of human 
FPR2/ALX was responsible for binding the eicosanoid ligand, lipoxin A4 (LXA4) (Chiang et al. 2000). In 
addition, separate sites containing N-glycosylation domains at Asn4 and Asn179 were found to be 
responsible for binding of the peptide agonists MMK-1 and MHC that were blocked by deglycosylation, 
whereas LXA4 activity was retained (Chiang et al. 2000). Given that bacteria and viruses manipulate 
glycosylation events to improve pathogenicity, the retention of ligand-specific activity via FPR2/ALX 
could have implications for modulation of the local response to infectious agents and inflammogens (Kim 
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& Cunningham 1993). Additional chimeric clones of FPR1 and FPR2/ALX found that the N-terminal 
region and the second extracellular loop form an anti-inflammatory ligand-binding domain required for 
ANXA1-mediated signalling, whereas LXA4 signalling occurs via the third extracellular loop 
(Brancaleone et al. 2011; Bena et al. 2012). The ligand serum amyloid A also requires the second 
extracellular loop but instead mediates pro-inflammatory signalling via FPR2/ALX, ostensibly because it 
does not bind to the N-terminal region, whereas ANXA1 does (Bena et al. 2012). The identification of 
distinct ligand binding domains on FPR2/ALX is important, as they are predictive of the dichotomous 
ligand-specific effects via this receptor.  
The phosphorylation of FPR2/ALX (as with FPR1) is ligand-dependent and is likely to involve the 
recruitment of alternative kinases depending on the agonist. Phosphorylation events are known to be 
influential in the internalisation of FPR1 and GPCRs in general, but these are yet to be fully elucidated for 
FPR2/ALX. Evidence obtained thus far suggests that ligand-bound FPR2/ALX (for instance, with 
WKYMVM) is internalised by clathrin-mediated endocytosis and recycled via the perinuclear endosome 
pathway. This can be blocked by siRNAs against clathrin or the knockout of β-arrestins 1 and 2, but can 
be restored by either β-arrestin (Ernst et al. 2004a; Huet et al. 2007). This suggests a level of redundancy 
in the molecular systems that facilitate the internalisation of Fpr/FPR subtypes. 
Signalling via FPR2/ALX has been shown to elicit either pro-inflammatory or anti-inflammatory effects, 
depending on the ligand involved. FPR2/ALX was the first GPCR to be cloned that binds to both peptide 
and lipid ligands (Brink et al. 2003; Ye et al. 2009). The majority of the peptide agonists for FPR2/ALX 
upregulate pro-inflammatory signalling, including the nuclear translocation of NF-κB, Ca2+ mobilisation, 
superoxide generation, and phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), all of 
which facilitate leukocyte chemotaxis (Sodin-Semrl et al. 2004). The eicosanoid ligand LXA4, and its 
stable analogues such as 15-epi-LXA4, however, have been shown to elicit actin reorganization within 
monocytes, but not in neutrophils despite expression of FPR2/ALX (Maderna et al. 2002). High affinity 
binding of LXA4 to FPR2/ALX cloned in Chinese hamster ovary cells led to the recruitment of Gαi 
proteins (Fiore et al. 1994). Whereas peptide ligands binding to FPR2/ALX activate pro-inflammatory 
signalling, LXA4 did not lead to ERK1 or ERK2 phosphorylation even at high micromolar concentrations 
(Bae et al. 2003a, b). Upon FPR2/ALX binding, the partial agonist Quin-C1 promotes ERK2 
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phosphorylation events (Nanamori et al. 2004), yet whilst LXA4 can induce ERK2 phosphorylation, it 
does so independently of FPR2/ALX and FPR3 (but possibly not FPR1) (Christophe et al. 2002). 
Interestingly, whole protein and peptide derivatives of recombinant and GC-generated endogenous 
ANXA1, were shown to interact with FPR2/ALX and mediate anti-inflammatory effects in human 
leukocytes (Perretti et al. 2002). Given the divergent effects elicited by ligands acting via FPR2/ALX and 
the evidence of distinct binding domains for the activation of pro-inflammatory or anti-inflammatory 
signalling, it is evident that FPR2/ALX is able to mediate ligand-specific effects. It remains to be 
determined whether mouse Fpr2 and Fpr3/Alx, and rat Fpr2 and Fpr2l/Alx share the divergent functions 
of FPR2/ALX and are relevant for modulating pituitary and adrenal stress hormone release. 
1.5.4 Formyl peptide receptor 3 (FPR3) 
The nucleotide sequence of human FPR3 is 63% and 60% identical to mouse Fpr2 and Fpr3/Alx, 
respectively, versus 56% with Fpr1. In rats, the subtypes Fpr2 and Fpr2l/Alx are each 77% identical to 
FPR3, whereas rat Fpr1 shares 68% sequence identity. FPR3 is expressed within the adrenal gland, 
placenta, testes, mature dendritic cells, macrophages, monocytes, spleen, hypothalamus, liver, and lung 
(Durstin et al. 1994; Yang et al. 2002; Ye et al. 2009). Unlike FPR1 and FPR2/ALX, neutrophils do not 
express FPR3 (Murphy et al. 1992). FPR3 is co-expressed with FPR2/ALX and FPR1 in monocytes, and 
the stoichiometry is subject to the route of monocyte differentiation. The dendritic cell route involves 
progressive down-regulation of FPR2/ALX (Yang et al. 2001) then FPR1 during maturation when FPR3 
dominates (Yang et al. 2002; Migeotte et al. 2005). Compared with FPR1 and FPR2/ALX, FPR3 is 
constitutively phosphorylated in the absence of ligand binding (Christophe et al. 2001). It is still a matter 
of speculation, however, as to whether this relates to its internalisation and expression on cell membranes. 
The most potent and selective ligand for FPR3 is the amino-acetylated haem-binding protein fragment 
(F2L) with a pEC50 of 8.00, but F2L also has activity via FPR2/ALX, albeit with lower affinity with a 
pEC50 of 6.3 (Migeotte et al. 2005). The only known antagonist for FPR3 is WRW4 (Shin et al. 2006). 
FPR3 is also activated by the mitochondrial peptide agonist for FPR2/ALX, fMMY-ALF (Rabiet et al. 
2005). In mice, the only receptor with F2L activity is Fpr2 with a pEC50 of 6.4 (notably similar to human 
FPR2/ALX) (Gao et al. 2007). There are currently no data for F2L activity via rat Fpr subtypes.  
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1.5.5 Translation of rodent Fpr and human FPR biology 
There is evidence that ANXA1 and its derivative peptide ANXA1Ac2-26 non-selectively binds to human 
FPR1 and FPR2/ALX, and murine Fpr1, Fpr2, and Fpr3/Alx, but also to rat Fpr2 (Table 1.3). Within the 
mouse and rat pituitary, there is evidence of Fpr2, Fpr3/Alx, and Fpr-rs6, but Fpr1 does not appear to be 
expressed and its germ line deletion had no effect on GCs/ANXA1-mediated ACTH inhibition (John et 
al. 2007). More selective Fpr/FPR ligands than ANXA1 have also been shown to inhibit ACTH release. 
These include LXA4 (the selective agonist for FPR2/ALX, Fpr3/Alx, and Fpr2l/Alx in humans, mice and 
rats, respectively) but also the Fpr1-/FPR1-selective fMLF which inhibits ACTH release at high 
concentrations conducive for recruitment of Fpr2/FPR2/ALX but with lower affinity than Fpr1/FPR1 
(Table 1.3) (John et al. 2007). The non-selective, Fpr1/FPR1 and Fpr2/FPR2/ALX antagonist, N-Boc-
MLF (Table 1.4), can block the inhibition of ACTH release mediated by Fpr/FPR agonists, but also by 
GCs, giving further credence to the hypothesis that an Fpr/FPR subtype modulates stress hormone release 
(Taylor et al. 1993; 1997; 2000b; John et al. 2002). The identity of the relevant Fpr/FPR subtype for 
mediating these actions, and of the GCs and ANXA1 is still under investigation, however.  
The rat Fpr1 was first characterised pharmacologically whereby tritiated-fMLF was found to bind Fpr1 in 
rat neutrophils with an antilog of the equilibrium dissociation constant (pKd) of 7.5 which is similar to its 
murine and human counterparts (Marasco et al. 1983) (Table 1.3). Rat Fpr2 putatively mediates the anti-
nociceptive effects of ANXA1 on the dorsal root ganglion response to inflammogenic complete Freund’s 
adjuvant in vivo (Pei et al. 2011). Confocal analysis of primary rat glial cells provided evidence of Fpr2 
co-localisation with ligands for the receptor for advanced glycation end products (RAGE), such as S100b, 
and the downstream production of cAMP and phosphorylated ERK1/2 was inhibited by the Fpr2-
/FPR2/ALX-selective antagonist WRW4, underscoring this relationship (Slowik et al. 2012). In an ex vivo 
rat cerebral cortex model of bacterial meningitis induced by Streptococcus pneumoniae and Neisseria 
meningitides conditioned media, the resulting cAMP-evoked activation of glial cells was associated with 
upregulated expression of Fpr2, and blocked by WRW4 (Braun et al. 2011). It was the rat Fpr2l/Alx gene 
product, however, that was cloned and found to be responsive to LXA4 like its human and mouse 
counterparts (Chiang et al. 2003; Motohashi et al. 2005). The remaining rat subtypes, Fpr3 and Fpr-rs3, 
Fpr-rs4, and Fpr-rs6, have been studied in the vomeronasal organ for their potential role in pheromone 
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detection (Liberles et al. 2009). Given this evidence, it seems plausible that the rat Fpr subtypes Fpr2 and 
Fpr2l/Alx are potential targets for modulating pituitary and adrenal stress hormone release. 
Most of the mouse Fpr subtypes Fpr-rs3 to Fpr-rs8 are expressed within the vomeronasal organ and 
evidence points to their role in pheromone sensing in this rodent tissue (Liberles et al. 2009; Rivière et al. 
2009; Bufe et al. 2012). Mouse Fpr1 is the structural and functional orthologue of human FPR1, whereas 
the nucleotide and amino acid sequences of Fpr2 and Fpr3/Alx are equally related to both FPR2/ALX and 
FPR3 (Gao & Murphy 1993; Takano et al. 1997; Gao et al. 1998; Wang & Ye 2002). In terms of their 
affinity for agonists, the mouse Fpr3 gene encodes the mouse lipoxin receptor (Fpr3/Alx), and since it 
shares this property with the human lipoxin receptor (FPR2/ALX), it can be said to be a functional 
orthologue (but not the). Whilst 15-epi-LXA4 is certainly selective for Fpr3/Alx and FPR2/ALX, mouse 
Fpr2 appears to be a lower affinity receptor (Takano et al. 1997; Wang & Ye 2002). This is perhaps 
owing to the structural similarity between mouse Fpr3/Alx and Fpr2, and those with human FPR2/ALX 
(Vaughn et al. 2002). Other ligands which bind FPR2/ALX selectively, such as serum amyloid A and 
amyloid-β, also bind mouse Fpr2 (Ye et al. 2009). Conversely, the human FPR3-selective ligand F2L 
(Migeotte et al. 2005) binds specifically to mouse Fpr2 (Gao et al. 2007). Given this evidence, it seems 
plausible that the mouse Fpr subtypes Fpr2 and Fpr3/Alx are candidates for modulating pituitary and 
adrenal stress hormone release. 
In summary, the structures of the Fpr/FPR subtypes are similar both within and between species, but this 
homology is not necessarily predictive of the functional orthologues of the human subtypes in rodents. 
Although ligand activities via a given human FPR subtype do, however, seem to be shared between 
multiple mouse subtypes. The inhibitory effects of GCs and ANXA1Ac2-26 on pituitary ACTH release, for 
instance, were the same in rat and mouse preparations, and these effects were unaffected by genetic 
knockout or pharmacological blockade of Fpr1 (John et al. 2007). Therefore, it would appear that 
pituitary ACTH release from glands derived from rats and mice at least, is modulated in a similar way by 
given Fpr/FPR ligands, particularly those which also bind human FPR2/ALX. This suggests the 
mechanism is conserved between species, in which case, finding ligands and Fpr subtypes that modulate 
stress hormone secretion in rodents could allow more specific targets to be investigated in human trials. 
The hypothesis that ANXA1 interacts with an Fpr/FPR subtype to regulate pituitary ACTH secretion has 
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not been refuted by any evidence to date. More research is needed, however, to delineate the primacy of 
the individual Fpr/FPR subtypes and whether their activity is predictive of pituitary ACTH and adrenal 
GC release. This is important because the Fprs/FPRs are targets for upregulation by inflammogens and 
HPA axis activators such as LPS (Section 1.6), and this research could therefore be of relevance to 
understanding the dissociation of pituitary-adrenal function evident in endotoxaemia or sepsis (Marik & 
Zaloga 2003; Mohn et al. 2011). 
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1.6 Effects of inflammogens on HPA axis activity, ANXA1, and the Fpr/FPR family 
This section will describe the effect of experimental endotoxaemia on HPA axis function, and the 
mechanistic involvement of mediators such as ANXA1 and the Fpr/FPR family. This will build up to a 
discussion of the paradoxical effects of LPS on the expression of ANXA1 and Fprs/FPRs within the 
pituitary and adrenal gland, but not the hypothalamus and the hippocampus. Outside the HPA axis, there 
is also evidence for a similar effect of LPS within the host defence system. 
Experimental models of endotoxaemia typically involve injection of an endotoxin such as LPS. 
Inflammogenic stressors such as LPS are known to induce cytokines like IL-6, TNF-α, and IL-1β, as well 
as raising the circulating concentration of GCs (Spengler et al. 1990; Elenkov et al. 1995; Hasko et al. 
1995). To investigate whether LPS-induced cytokines affect ANXA1 expression and activity, research 
groups have used animals with cytokines knocked out. In IL-6 knockout (IL-6 KO) mice, for instance, the 
increase in plasma GC concentration following LPS injection paralleled the wildtypes, but the IL-6 KO 
mice had higher TNF-α and IL-1β levels. Recombinant ANXA1 administered to IL-6 KO mice before an 
LPS challenge induced less TNF-α release versus wildtypes, and recombinant IL-6 injections upregulated 
ANXA1 expression to wildtype levels. The authors concluded that ANXA1 is controlled by TNF-α and 
IL-6, and functions to resolve inflammation following systemic endotoxaemia through negative feedback 
on TNF-α release (de Coupade et al. 2001). This is supported by observations from ANXA1 KO mice, 
where LPS induced death within 48 hours unless low doses of exogenous ANXA1 were given. This 
lethality was preceded by impaired cytokine release, and increased leukocyte adhesion in the capillaries 
of ANXA1 KO mice (Damazo et al. 2005). Elsewhere, ANXA1 has been shown to inhibit LPS-induced 
cytokines (IL-6, TNF-α, IL-1β) via glucocorticoid-induced leucine zipper (GILZ)-modulated signalling 
pathways. In addition, the expression of GILZ is in turn dependent on ANXA1 activity, which via GILZ, 
inhibits the activation of ERK, MAPK, and NF-κB, leading to reduced translation of IL-6, TNF-α, and 
IL-1β (Yang et al. 2009). Overall, the evidence suggests that the (moderately) FPR2/ALX-selective 
agonist ANXA1 mediates communication between the HPA axis and immune system in response to 
inflammogens such as LPS. 
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1.6.1 The role of pituitary ANXA1 and the Fpr/FPR family in response to an inflammogen 
The effect of inflammogens such as LPS on pituitary function has been well characterised. The 
stimulatory action of LPS on pituitary ACTH secretion is mediated via the folliculostellate cells that 
release pro-inflammatory cytokines, namely, IL-6, which acts on neighbouring corticotrophic cells. 
Studies using a co-culture of two immortalised murine pituitary cell lines murine TtT/GF 
(folliculostellate-like cells) and AtT20 D16:16 (corticotroph-like), were used to determine the role of NF-
κB in mediating LPS-induced ACTH secretion. These cell lines express mRNAs for CD-14, TLR4, and 
TLR2, which are involved in LPS signalling. The stimulation of IL-6 and ACTH release, by both LPS 
and CRH, acting alone or synergistically, took place via an NF-κB-mediated mechanism that was 
inhibited by GCs (Mehet et al. 2012). Following LPS treatment, ANXA1 is translocated to the cell 
surface and its cytoplasmic expression is later upregulated (Solito et al. 2006). The incubation of LPS 
with the folliculo-stellate-like TtT/GF cell line resulted in serine27-phosphorylation of ANXA1 and its 
translocation to the extracellular membrane (Solito et al. 2006). Taken together, this suggests that LPS 
stimulates ACTH release via NF-κB and IL-6 signalling, evoking increased secretion of GCs that inhibit 
ACTH release through ANXA1 phosphorylation. 
1.6.2 The role of adrenal ANXA1 and the Fpr/FPR family in response to an inflammogen 
The ANXA1-null mouse was used as a model to investigate the role of ANXA1 in adrenal 
steroidogenesis (Davies et al. 2007). The adrenal gland of wildtype littermates was found to contain an 
abundance of immunoreactive ANXA1 within the ZG of the outer cortex and the sub-capsular region, and 
was translocated to the extracellular surface by GC treatment for 3 h. Incubation of the cells with an N-
terminal peptide portion of ANXA1 had an inhibitory effect on GC release, whereas the smaller adrenals 
from ANXA1-null mice had significantly higher ACTH-stimulated corticosterone release versus wildtype 
adrenals (Davies et al. 2007). In light of this work, this would suggest that ANXA1 is part of a 
mechanism that governs both adrenal size and overall steroidogenic capacity. During experimental 
endotoxaemia, however, LPS has interesting effects on the histological and functional characteristics of 
the adrenal gland of mice. As expected, the intraperitoneal administration of LPS induced an infiltration 
of leukocytes into the adrenal gland, but this was unaffected by deletion of either ANXA1 or Fpr2/3 
(Buss 2010). However, although LPS was associated with a loss of sterol vacuolation, this effect was 
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reduced in animals with a germ line deletion of ANXA1 or Fpr2/3 (Buss 2010). The loss of sterol 
vacuolation induced by LPS has been demonstrated elsewhere (Lomnitski et al. 2000; Kanczkowski et al. 
2013), and also occurs following immobilisation stress (Pellegrini et al. 1998), possibly as a result of lipid 
peroxidation (Portoles et al. 1993). Taken together, these findings permit the hypothesis that blockade of 
ANXA1 and Fpr2/3 might prevent adrenal insufficiency during sepsis-related experimental 
endotoxaemia. 
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1.7 Hypothesis, aims, and objectives 
While it is clear that the rodent Fpr family have a role in modulating pituitary-adrenal stress hormone 
responses to inflammogens such as LPS, relatively little is known about the individual roles of subtypes 
of this family. This project therefore aimed to advance knowledge on the expression of individual 
mouse/rat Fpr subtypes (with the closest structural and functional homology to the human FPR subtypes) 
within the pituitary-adrenal system and determine the functional significance of Fpr activation within 
pituitary and adrenal tissue. 
Specifically, it tested the hypothesis, that formyl peptide receptor subtypes modulate both pituitary and 
adrenal function in terms of stress hormone (ACTH and corticosterone) secretion (following exposure to 
secretagogues CRH and ACTH1-24 or the inflammogen LPS in rats), and their tissue distribution (mice 
and rats) will itself be upregulated following inflammogenic stress (LPS in mice and rats, multiple 
sclerosis in human tissue). 
The principal objectives were to: 1) obtain morphometric evidence of the distribution of Fpr/FPR 
subtypes and stress hormones within the pituitary-adrenal axis from mouse, rat, and human tissues 
following inflammogenic stress; 2) perform tissue culture studies involving incubation of rat anterior 
pituitary and adrenal tissue with Fpr/FPR ligands to ascertain which Fpr/FPR subtypes modulate ACTH 
and corticosterone release; and 3) perform in vivo studies to determine whether an Fpr/FPR ligand 
modulates the effects of experimental endotoxaemia on cerebral, lymphoid, and pituitary-adrenal axis 
tissue morphology, and stress hormone secretion (see Figure 1.3) 
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Table 1.1 Percentage nucleotide sequence identity between subtypes of formyl peptide 
receptors/lipoxin receptors in humans (FPR/ALX), and mice and rats (Fpr/Alx). 
 human FPR1 human FPR2/ALX human FPR3 
mouse Fpr1 77 68 56 
mouse Fpr2 64 76 63 
mouse Fpr3/Alx 59 73 60 
rat Fpr1 77 73 68 
rat Fpr2 71 77 71 
rat Fpr2l/Alx 69 74 71 
rat Fpr3 77 74 71 
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Table 1.2 Expression of formyl peptide receptors within human (FPR) and mouse (Fpr) tissues. 
System Tissue FPR1 FPR2/ALX FPR3 Fpr1 Fpr2 Fpr3/Alx Fpr-rs3 Fpr-rs4 Fpr-rs6 Fpr-rs7 Fpr-rs8 
 adrenal ✓  ✓ ✓ ✓ ✓      
 anterior pituitary    ✓ ✓ ✓      
Endocrine ovary ✓           
 placenta ✓ ✓ ✓         
 testis   ✓      ✓   
 pancreas          ✓  
 Dendritic cells (DCs)   ✓ ✓ ✓       
 DCs - immature ✓ ✓          
Immune macrophages ✓ ✓ ✓ ✓       ✓ 
 monocytes ✓ ✓ ✓        ✓ 
 neutrophils ✓ ✓  ✓ ✓ ✓     ✓ 
Lymphoid bone marrow ✓ ✓         ✓ 
 spleen ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓ 
Nervous hippocampus ✓   ✓ ✓ ✓      
 hypothalamus ✓ ✓ ✓ ✓ ✓ ✓      
  astrocytes ✓ ✓          
 microglia ✓ ✓  ✓ ✓ ✓      
Other liver ✓ ✓ ✓ ✓  ✓    ✓  
 lung ✓ ✓ ✓ ✓ ✓ ✓    ✓  
 vomeronasal      ✓ ✓ ✓ ✓ ✓  
References  
(Becker et al. 
1998; Czapiga 
et al. 2005) 
(Murphy et al. 
1992; Durstin 
et al. 1994) 
(Durstin et al. 
1994; Yang et 
al. 2002) 
(Gao et al. 
1999; Hartt et 
al. 1999; Dai 
et al. 2005; 
Mandal et al. 
2005; Buss 
2010) 
(Iribarren et al. 
2005; Chen et 
al. 2010) 
(Takano et al. 
1997; Gao et 
al. 1998) 
(Rivière et al. 
2009) 
(Liberles et al. 
2009) 
(Wang & Ye 
2002) 
(Wang & Ye 
2002) 
(Tiffany et al. 
2011) 
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Table 1.3 Affinity data (pEC50 / pKd) for agonists binding to human (FPR) and rodent (Fpr) formyl peptide receptor subtypes.  
  
                                                          
1 The murine lipoxin A4 receptor (Alx) identified by (Takano et al. 1997) is identical to the product of Fpr3 (formerly, Fpr-rs1) identified by (Gao et al. 1998), whereas 
the LXAR-R (8C10) homologue identified by (Vaughn et al. 2002) is homologous to Fpr2 (formerly, Fpr-rs2) identified by (Gao et al. 1998).  
2
 Authors used ANXA1Ac1-25. 
 Human Mouse Rat 
 
FPR1 
FPR2 
/ALX 
FPR3 Fpr1 Fpr2 
Fpr3 
/Alx1 
Fpr1 Fpr2 
Fpr2l 
/Alx 
fMLF 
9.3 5.3 x 7 5.3 x 7.5*   
(Koo et al. 
1982) 
(Fiore & Serhan 
1995) 
 (He et al. 2000) (He et al. 2000)  
(Marasco et al. 
1983) 
 
 
WKYMVm 
9 12 8.5 9.3 10.1 ≈6    
(Kang et al. 
2005) 
(Le et al. 1999) 
(Christophe et 
al. 2001) 
(He et al. 
2013a) 
(He et al. 
2013a) 
(He et al. 
2013a) 
 
 
 
F2L 
x 6.3 8.2 x 6.4 x    
(Migeotte et al. 
2005) 
(Migeotte et al. 
2005) 
(Migeotte et al. 
2005) 
(Gao et al. 
2007) 
(Gao et al. 
2007) 
(Gao et al. 
2007) 
 
 
 
ANXA1 
6.1 6.8 
 
6.6 ✔ ✔  ✔  
(Walther et al. 
2000) 
(Hayhoe et al. 
2006) 
 
(Perretti et al. 
2001) 
   
(Pei et al. 2011) 
 
ANXA1Ac2-26 
5.9 5.7 52 ✔ ✔ ✔  ✔ 6.1* 
(Hayhoe et al. 
2006) 
(Hayhoe et al. 
2006) 
(Ernst et al. 
2004b) 
    
(Pei et al. 2011) (Chiang et al. 
2003) 
15-epi-LXA4  
7.8 
  
✔ 8.8*   8.3* 
 
(Chiang et al. 
2006b) 
  
(Vaughn et al. 
2002) 
(Takano et al. 
1997) 
 
 (Chiang et al. 
2003) 
          
pEC50 / pKd 11+ 9 – 10.9 7 – 8.9 5 – 6.9 < 5 * = pKd ✔ = binding 
x = no 
binding 
 = no data 
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Table 1.4 Affinity data (pIC50 / pKd) for antagonists binding to human (FPR) and rodent (Fpr) formyl peptide receptor subtypes.  
                                                          
3 The murine lipoxin A4 receptor (Alx) identified by (Takano et al. 1997) is identical to the product of Fpr3 (formerly, Fpr-rs1) identified by (Gao et al. 1998), whereas 
the LXAR-R (8C10) homologue identified by (Vaughn et al. 2002) is homologous to Fpr2 (formerly, Fpr-rs2) identified by (Gao et al. 1998).  
4
 Boc1 = Boc-Met-Leu-Phe (Boc-MLF), and Boc2 = Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) 
 
 Human Mouse Rat 
 
FPR1 
FPR2 
/ALX 
FPR3 Fpr1 Fpr2 
Fpr3 
/Alx3 
Fpr1 Fpr2 
Fpr2l 
/Alx 
WRW4 
≈5.1 6.7 < 5  6.6   6.9  
(Stenfeldt et al. 
2007) 
(Bae et al. 
2004; Stenfeldt 
et al. 2007) 
(Shin et al. 
2006) 
 
(Önnheim et al. 
2008) 
  
(Braun et al. 
2011) 
 
Boc14 
6.2 < 5        
(Stenfeldt et al. 
2007) 
(Stenfeldt et al. 
2007) 
       
Boc2 
 
6.6 ≈5.1  ✔ ✔     
(Stenfeldt et al. 
2007) 
(Stenfeldt et al. 
2007) 
 
(Gavins et al. 
2003) 
(Gavins et al. 
2003) 
    
Cyclosporin H 
7.1 < 5        
(Wenzel-Seifert 
& Seifert 1993) 
(Stenfeldt et al. 
2007) 
       
Cyclosporin A 
6.1         
(Yan et al. 
2006) 
        
Spinorphin 
   ≈4.5 x x    
   
(Liang et al. 
2001) 
(Liang et al. 
2001) 
(Liang et al. 
2001) 
   
          
pIC50 / pKd 11+ 9 – 10.9 7 – 8.9 5 – 6.9 < 5 * = pKd ✔ = binding 
x = no 
binding 
 = no data 
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Figure 1.1 Pharmacology of the most selective ligands for the human formyl peptide receptor 
subtypes (FPR1, FPR2/ALX, and FPR3) and their closest functional counterparts in mice (Fpr1, 
Fpr2, Fpr3/Alx) and rats (Fpr1, Fpr2, Fpr2l/Alx).    
The peptide formyl-methionyl-leucyl-phenylalanine (fMLF) is an FPR1/Fpr1-selective agonist with a 
50% maximal effective concentration (EC50) of 1 nmol.l
-1
 at FPR1 or 1 μmol.l-1 at Fpr1. The peptide 
tryptophan-lysine-tyrosine-methionine-valine-dextro-methionine (WKYMVm) is an agonist with an EC50 
of 1-75 pmol.l
-1
 at FPR2/ALX and 1 nmol.l
-1
 at Fpr2. The peptide tryptophan-arginine-tryptophan-
tryptophan-tryptophan-tryptophan (WRW4) is an antagonist with a 50% maximal inhibitory concentration 
(IC50) of 0.2 μmol.l
-1
 for FPR2/ALX and Fpr2. The amino-acetylated haem-binding protein fragment 
(F2L) is an agonist with an EC50 of 10 nmol.l
-1
 for FPR3 and 200 nmol.l
-1
 for Fpr2. Lipoxin A4 (LXA4) is 
an eicosanoid agonist with an EC50 of 1 nmol.l
-1
 for FPR2/ALX and 1.5 nmol.l
-1
 for mouse Fpr3/Alx and 
similar for rat Fpr2l/Alx. 
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Figure 1.2 Phylogenetic tree of the mammalian formyl peptide receptor (Fpr/FPR) genes.  
Branch points illustrate the evolution of genes through duplication or speciation events. Mouse Fpr 
subtypes are highlighted in red, rat in purple, and human FPR subtypes in blue. The upper rodent-specific 
branch is due to several duplication events. The scale bar length denotes the percentage of nucleotides 
substituted. Adapted from (Liberles et al. 2009).  
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Figure 1.3 Overview of research objectives and the studies performed to meet them in addressing 
the hypothesis. 
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 Materials and Methods Chapter Two:
  
80 
2.1 Overview 
Objective 1: Obtain morphometric evidence of the distribution of Fpr/FPR subtypes and stress hormones 
within the pituitary-adrenal axis from mouse, rat, and human tissues following inflammatory stress 
In order to demonstrate whether proteins encoded at formyl peptide receptor 2 and 3 (Fpr2 and Fpr3) 
gene loci are translated within lymphoid (thymus, spleen), cerebral (hippocampal formation), and HPA 
axis tissues, green fluorescent protein (GFP)-transgenic (GFP
+/+
), Fpr2 and Fpr3 knockout (Fpr2/3
-/-
) mice 
were used. The Fpr2/3
-/-
 mice have a sequence encoding a pgk-neo cassette and GFP transgene inserted 
in-frame within the shared exon (exon 2) of the Fpr2 and Fpr3 gene loci (Dufton et al. 2011). In the 
absence of specific antibodies for murine Fpr2 and Fpr3, the detection of immunoreactive GFP translated 
from loci of the Fpr2/3 genes, provided a proxy indication of their translation within tissues from Fpr2/3
-/-
 
mice. (Initial microscopic investigation of tissue sections from Fpr2/3
-/-
 mice found that native GFP 
fluorescence was not detectible). In order to determine whether an inflammogen induces such translation, 
and whether the genetic manipulation of the Fpr2/3 gene loci modulated the tissue response to the 
inflammogen, lipopolysaccharide (LPS) was injected intraperitoneally and tissues were examined 
histologically. LPS was the inflammogen of choice because it had been shown to upregulate the 
expression of Fpr2 and Fpr3 transcripts (Iribarren et al. 2005). Therefore, Fpr2/3
-/-
 mice and wildtype 
littermates received intraperitoneal (i.p.) injections of either LPS or vehicle (phosphate buffered saline, 
PBS) and killed 2, 4, and 6 hours later and perfusion fixed to preserve tissue morphology (Section 2.4.1). 
Wildtype littermates were used as a control for the genetic manipulation of the Fpr2/3
-/-
 mice so that 
differences in the tissue response to LPS could be attributed to these genes. Separate groups of mice 
receiving injections of PBS were used to control for the vehicle of LPS injections. Tissue sections from 
the wildtype littermates of Fpr2/3
-/-
, and sections from an irrelevant GFP transgenic mouse were used as 
negative and positive controls for the immunohistochemical detection of GFP. The experimental design 
was done in collaboration with Bradley Spencer-Dene (London Research Institute) who also supervised 
the author, provided positive control tissue sections, and helped with the qualitative interpretation of 
slides.  
To determine the distribution of human formyl peptide receptor (FPR) subtypes within the human 
anterior pituitary gland, such tissues were obtained from the United Kingdom Multiple Sclerosis (MS) 
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and Parkinson’s disease (PD) tissue bank. All of the tissues were from diseased donors (MS and PD) as 
control tissues were not available at the time. The anterior pituitary glands were formalin fixed and 
embedded in paraffin, before sections were taken to enable immunohistochemical detection of FPR1, 
FPR2/ALX, and FPR3, and any colocalisation with adrenocorticotrophic hormone (ACTH) and S100 
calcium binding protein b (S100b). The experimental design was done in collaboration with Bradley 
Spencer-Dene (London Research Institute) who also supervised the author, provided positive control 
tissues, and helped with the qualitative interpretation of slides. Federico Roncaroli (Imperial College 
London) also helped with the latter. 
Objective 2: Perform tissue culture studies involving incubation of rat anterior pituitary and 
adrenal tissue with Fpr/FPR ligands to ascertain which Fpr/FPR subtypes modulate ACTH and 
corticosterone release 
In order to ascertain which Fpr ligands modulate pituitary and adrenal function, glands were taken from 
male rats. Given the Home Office Project Licence restricted in vivo work on HPA axis function to rats 
and mice, rats were the species of choice primarily because they have larger glands than mice, and yield 
more dispersed cells with fewer animals. This was in keeping with the ethos of the National Centre for 
the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Initial experiments 
involved pituitary glands from male Sprague-Dawley rats, but male Wistar rats were used in later 
pituitary and adrenal experiments that included the Fpr2-/FPR2/ALX-selective antagonist, Trp-Arg-Trp-
Trp-Trp-Trp (WRW4). This decision to change strain was made due to relocating from a lab that studied 
Sprague-Dawley rats to one that studied Wistar rats, and pituitary and adrenal glands were generally 
discarded in each lab. Therefore, for some pilot experiments, glands were obtained from untreated control 
animals studied by colleagues. Glands were dispersed enzymatically then cultured for between 2 and 72 
hours, before 4 hours of contact with drugs. The dispersed rat anterior pituitary cells received 
corticotrophic releasing hormone (CRH) as a secretagogue for ACTH release, whereas the dispersed rat 
adrenal cells received ACTH1-24 as a positive control for stimulated corticosterone (CORT) release. The 
cells were incubated (separately) with a range of chemically diverse Fpr agonists, alone, and in 
combination with secretagogue and/or WRW4. The Fpr agonists were selected based on evidence of their 
relative affinity for structurally related human and mouse FPR/Fpr subtypes, and were the most selective 
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agonists available for these species (Section 2.2.1). At the time, however, little was known about the 
effect of these ligands on the rat Fpr subtypes but these were predicted to be structurally similar to the 
murine Fpr subtypes. Following 4 hours of contact with drugs, conditioned media were collected and 
frozen prior to radioimmunoassay (RIA, Section 2.6.1) and enzyme immunoassay (EIA, Section 2.6.6) of 
ACTH and corticosterone concentration, respectively. 
Objective 3: Perform in vivo studies to determine whether an Fpr/FPR ligand modulates the effects of 
experimental endotoxaemia on cerebral, lymphoid, and pituitary-adrenal axis tissue morphology, and 
stress hormone secretion 
Previous work had shown that the reduction in adrenal sterol vacuolation following LPS in vivo in 
wildtype mice was limited in Fpr2/3
-/-
 mice (Buss 2010). Therefore, in order to investigate whether 
pharmacological blockade of Fpr2 had any effect on the response to in vivo LPS, the Fpr2-/FPR2/ALX-
selective antagonist WRW4 was co-administered with LPS in male Wistar rats. To measure the effects of 
i.p. injections of LPS and WRW4 on cerebral, lymphoid, and HPA axis tissue morphology, and pituitary 
and adrenal function, the animals were decapitated after 4 hours in order to collect tissues, namely, trunk 
blood (to assay plasma ACTH and corticosterone concentrations), and brain, thymus, spleen, and adrenal 
gland were collected, weighed, and post-fixed for histology. The four hour time-point was hypothesised 
to be the point at which maximal inhibition of adrenal function occurs in vivo, based on the inhibitory 
effect of LPS on release from dispersed rat adrenal cells in vitro after 4 hours in contact, and histological 
evidence of reduced sterol vacuolation 4 hours after LPS in Fpr2/3
-/-
 mice (Buss 2010).  
To determine the effect of LPS on HPA axis activity as a function of time, rats received i.p. injections of 
LPS and were killed 0, 2, 4, and 24 hours later to obtain trunk blood for immunoradiometric (IRMA) 
assay and EIA of plasma ACTH and corticosterone concentration, respectively. Right adrenals were taken 
for primary culture to determine the effect of LPS in vivo on adrenal corticosterone release in response to 
graded concentrations of ACTH1-24 in vitro. Remaining adrenals were collected along with thymus, brain, 
pituitary, and spleen for histological examination. 
In order to determine whether pharmacological blockade of Fpr2 modifies the effect of LPS on HPA axis 
activity, rats received i.p. injections of the Fpr2-/FPR2/ALX-selective antagonist WRW4, LPS, WRW4 
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and LPS, or PBS, and were killed 4 hours later. Trunk blood was collected for ACTH and corticosterone 
determination. Adrenals were taken for primary culture, and the brain, thymus, and spleen were fixed for 
histology, following measurement of the mass of each tissue. 
For detection of ACTH in plasma, IRMA is optimal for two-site detection of whole ACTH with 
negligible detection of fragments. Single-site RIA is sufficient for the detection of ACTH from in vitro 
experiments given that conditioned media contains fewer proteolytic enzymes such as pepsin, than in 
plasma or whole blood, therefore degradation of ACTH is less of an issue. Since RIA is well validated for 
detection of ACTH in conditioned media, whereas the IRMA kit was validated for detection of whole 
ACTH from plasma samples, each assay was used for these separate purposes.  
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2.2 Materials 
2.2.1 Drugs 
Corticotrophin releasing hormone (CRH) is a potent endogenous secretagogue of ACTH release, and a 
selective agonist for human CRH-receptor 1 (CRH-R1 pEC50 = 9.6), rat CRH-receptor 2α (CRH-R2α 
pEC50 = 8.3), and mouse CRH-receptor 2β (CRH-R2β pEC50 = 8.5) (Donaldson et al. 1996). CRH has an 
identical 41-amino acid sequence in humans, rats, and mice: Ser - Glu - Glu - Pro - Pro - Ile - Ser - Leu - 
Asp -Leu - Thr - Phe - His - Leu - Leu - Arg - Glu - Val - Leu - Glu - Met - Ala - Arg - Ala - Glu - Gln - 
Leu - Ala - Gln - Gln - Ala - His - Ser - Asn - Arg - Lys - Leu - Met - Glu - Ile - Ile -NH2. Recombinant 
CRH (4757.45 g.mol
-1
, Cat. C3042, Sigma, Poole, Dorset, UK) was diluted in water and stored at -20 °C 
in 10 μmol.l-1 aliquots, then used at 10-7 mol.l-1 (pH 7.74).  
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF) is a potent peptide agonist for human FPR1 
(pEC50 = 9.3 (Koo et al. 1982)), mouse Fpr1 (pEC50 = 7 (He et al. 2000)) and rat Fpr1 (pKd = 7.5 
(Marasco et al. 1983). fMLF (437.55 g.mol
-1
, Cat. F3506, Sigma, Poole, Dorset, UK) was diluted in 2.5% 
acetic acid and stored at -20 °C in 100 μmol.l-1 aliquots, then used at 10-5 mol.l-1 (0.025% acetic acid, pH 
6.88). 
The amino terminal acetylated peptide fragment of haem-binding protein (1-21), F2L, is a selective 
agonist of human FPR3 (pEC50 = 8.2 (Migeotte et al. 2005)), and mouse Fpr2 (pEC50 = 6.4 (Gao et al. 
2007)). There are no pharmacological data published for F2L and the rat Fpr subtypes. Recombinant 
human F2L (2478.99 g.mol
-1
, Cat. 072-29, Phoenix Europe GmBH, Karlsruhe, Germany) with the 
following amino acid sequence: Ac - Met - Leu - Gly - Met - Ile - Lys - Asn - Ser - Leu - Phe - Gly - Ser - 
Val - Glu - Thr - Trp - Pro - Trp - Gln - Val - Leu was diluted in dimethyl sulphoxide (DMSO) and stored 
at -20 °C in 1200 nanomol.l
-1
 aliquots, then used at 8 x 10
-7
 mol.l
-1
 (0.4% DMSO, pH 7.81 for 
experiments including WRW4; or 2.5% DMSO pH 8.31). 
The hexapeptide NH2-Trp-Lys-Tyr-Met-Val-D-Met-COOH (WKYMVm) is a synthetic agonist selective 
for human FPR2/ALX (pEC50 = 12 (Le et al. 1999)) and mouse Fpr2 (pEC50 = 10.1 (He et al. 2013a)). 
There are no pharmacological data published for WKYMVm and the rat Fpr subtypes. WKYMVm 
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(855.41 g.mol
-1
, Cat. 1800, Tocris Bioscience, Abingdon, Oxfordshire, UK) was diluted in 2.5% acetic 
acid and stored at -20 °C in 100 μmol.l-1 aliquots, then used at 10-6 mol.l-1 (0.025% acetic acid, pH 6.88). 
The nitrosyl terminal of annexin-A1 protein, ANXA1Ac2-26 is an agonist of human FPR2/ALX (pEC50 = 
6.8 (Hayhoe et al. 2006)) and FPR1 (pEC50 = 6.1 (Walther et al. 2000)), and mouse Fpr1 (pEC50 = 6.6 
(Perretti et al. 2001)). There are no pharmacological data published for ANXA1Ac2-26 and the rat Fpr 
subtypes. ANXA1Ac2-26 (3089.46 g.mol
-1
, Cat. 1845, Tocris Bioscience, Abingdon, Oxfordshire, UK) with 
the following amino acid sequence: Ac - Ala - Met - Val - Ser - Glu - Phe - Leu - Lys - Gln - Ala - Trp - 
Phe - Ile - Glu - Asn - Glu - Glu - Gln - Glu - Tyr - Val - Gln - Thr - Val – Lys, was diluted in water and 
stored at -20 °C in 30 μmol.l-1 aliquots, then used at 3 x 10-5 mol.l-1 (pH 7.74). 
The carbon 15 epimer of lipoxin A4, 15(R)-LXA4, (5S,6R,15R)-5,6,15-Trihydroxy-7,9,13-trans-11-cis-
eicosatetraenoic acid (15-epi-lipoxin A4), is a potent agonist of human FPR2/ALX (pEC50 = 7.8 (Chiang 
et al. 2006b)), mouse Fpr3/Alx (pKd = 8.8 (Takano et al. 1997)), and rat Fpr2 (pKd = 8.3 (Chiang et al. 
2003)). 15-epi-lipoxin A4 (352.50 g.mol
-1
, Cat. 437725, Calbiochem, Merck, Nottingham, UK) was 
diluted in 1.42% ethanol and stored at -20 °C in 1 μmol.l-1 aliquots, then used at 10-7 mol.l-1 (0.014% 
ethanol, pH 7.19). 
Adrenocorticotrophic hormone 1-24 (ACTH1-24) is a synthetic analogue of the endogenous 39-amino acid 
polypeptide ACTH and a full agonist that is selective for the mouse type 2 melanocortin receptor (pKd = 
9.1 (Kapas et al. 1996)). ACTH1-24 is identical to the first 24 amino acids of ACTH in humans, rats, and 
mice: Ser1-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-
Tyr-Pro24-Asn-Val26-Ala-Glu-Asn29-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe. The sequence of full-
length human ACTH differs from these rodent species (Rodent → Human) only at amino acid positions 
26 (Val → Gly) and 29 (Asn → Asp). ACTH1-24, supplied as 1 mg.ml
-1
 aliquots at 341 μmol.l-1 (2933.44 
g.mol
-1
, tetracosactide acetate, Alliance Pharmaceuticals Ltd, Hammersmith Hospital Pharmacy, London, 
UK), was diluted in water immediately before use in culture medium (pH 7.74). 
Lipopolysaccharide (LPS) from Escherichia coli 0111:B4, is an agonist for toll like receptor-4 (TLR4, 
pEC50 = 6.2 in the RAW 264.7 mouse macrophage cell line (Du et al. 1999)). LPS, purified by ion 
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exchange chromatography, (Cat. L3024, Sigma, Poole, Dorset, UK) was diluted in phosphate buffered 
saline and stored at -20 °C in 1 μmol.l-1 aliquots, then used at 750 μg.kg-1 (pH 7.74). 
Trp-Arg-Trp-Trp-Trp-Trp (WRW4) is a potent synthetic antagonist selective for human FPR2/ALX 
(pIC50 = 6.7 (Stenfeldt et al. 2007)), and mouse Fpr2 (pIC50 = 6.6 (Önnheim et al. 2008)). There are no 
pharmacological data published for WRW4 and the rat Fpr subtypes. WRW4 (1104.28 g.mol
-1
, Cat. 2262, 
Tocris Bioscience, Abingdon, Oxfordshire, UK) was diluted in water and stored at -20 °C in 10 μmol.l-1 
aliquots, then used at 10
-6
 mol.l
-1
 (pH 7.74).  
2.2.2 Human tissues 
Human pituitary tissue samples were used to determine the immunohistochemical distribution and degree 
of colocalisation of FPR1, FPR2/ALX, and FPR3, with ACTH and S100b.   
Human pituitary glands were donated under ethics committee approval by the UK Multiple Sclerosis 
(MS) Tissue Bank, funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland 
(registered charity 207495) and supplied as formalin-fixed paraffin-embedded tissue blocks. All 
pituitaries were from diseased donors with either MS or Parkinson’s disease (PD) (Table 2.1). Control 
tissues were requested but were not available at the time. 
Table 2.1 Donor data for the human pituitary tissue samples 
Case 
Age | y Sex Post-mortem delay | h 
MS469 52 F 47 
MS476 67 M 31 
PD404 84 M 48 
PD418 70 M 22 
PD419 83 M 36 
PD420 77 M 32 
PD422 75 M 39 
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2.3 Animals  
All animals were used in accordance with the Animals (Scientific Procedures) Act 1986 under project 
licence PPL 70/6623 which permitted in vivo procedures on up to 500 rats and 500 mice. Optimal group 
sizes (n) were determined by power calculation (Equation 2.1), based on 95% power where SD = 
standard deviation, and ∆ = expected difference to be observed, based on previous observations. 
Equation 2.1 
 n        
  
 
    
2.3.1 Fpr2 and Fpr3 knockout (Fpr2/3-/-) mice 
2.3.1.1 Background 
Fpr2 and Fpr3 knockout (Fpr2/3
-/-
) mice were generated as part of a collaborative project between 
Professors Roderick Flower and Mauro Perretti (William Harvey Research Institute, London), John 
Morris (University of Oxford), and Julia Buckingham (Imperial College London). The molecular biology 
behind these mice is reproduced below:  
“Genomic clones containing Fpr sequences were isolated from a 
bacteriophage lambda library (129/SvJ; Stratagene, California, USA) 
by plaque hybridisation. Inserts from positive plaques were subcloned 
into pZero (Invitrogen, San Diego, California), end-sequenced and 
then aligned with the Fpr locus on Chromosome 17. A pgk-neo 
cassette was inserted into one of these clones (p2.1) just downstream 
of the ATG start codon for Fpr2, via site-specific recombination in 
bacteria. Using the plasmid pPGK-neo-FRT as a template for PCR 
with primers (forward 5'-TCA GAA GGA GCC AAA TAT CTG 
AGA AAT GGT TGT TTT TGA AAA CTT TCA GGT GCA GAC 
AAA ATG GCT AGC CCT TCT GCT TAA TTT GTG CCT GG, 
and reverse 5'-TGC TGT GAA AGA AAA GTC AGC CAA TGC 
TAG ATT CAG ATA CCA GAT AGT GGT GAC AGT GTG TGG 
CGT AGA GGA TCT GCL TCA TGT TTG AC) resulted in a 2.2 
kilobase fragment containing the pgk-neo cassette in reverse 
orientation, flanked by 63 basepair arms with homology to Fpr2. This 
fragment was electroporated along with plasmid p2.1 into E.coli 
strain HS996 using the RED-ET subcloning kit supplied by Gene 
Bridges. The novel Nhe I site (gctagc) located immediately after the 
ATG start codon in the forward primer was used for the subsequent 
in-frame insertion of GFP (Qbiogene, California, USA). All steps 
were confirmed by sequencing. The targeting vector was linearised 
by digestion with SnaBI and electroporated into ES cells (strain 
129SvEv). Neomycin resistant colonies were selected and screened 
for correct insertion by Southern blotting using probes located beyond 
both the 5' and 3' ends of the vector arms, and also a probe for GFP. 
Clones showing homologous recombination into the Fpr2 locus were 
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expanded, karyotyped by G-banding, and then injected into the 
blastocysts of C57Bl6 females (Caliper Life Sciences, Cambridge, 
MS). Male chimaeras showing greater than 95% agouti coat colour 
were paired with C57Bl6 females. F1 offspring were screened by 
PCR of tail clip DNA for germline transmission of the targeted allele 
using the Extract-N-Amp system (Sigma-Aldrich)” (Dufton et al. 
2010). 
Since publication of this molecular biology information, the official International Union of Basic and 
Clinical Pharmacology (IUPHAR) nomenclature of the human and mouse formyl peptide receptors was 
updated (Ye et al. 2009). This prompted the original report of the Fpr2
 
(formerly Fpr-rs2) knockout (Fpr2
-
/-
) genotype to be updated to a double knockout of both Fpr2 and Fpr3 (Fpr2/3
-/-
) in a correction to the 
paper, in which their: 
 “targeting strategy would also delete Fpr3 itself because this gene 
also incorporates an exon found in Fpr2, and so insertion of the GFP 
reporter and the presence of the pgk-neo cassette in the cds (exon 2) 
of “Fpr-rs2” (as described in our paper) would prevent expression of 
this gene also. The transcription of the Fpr1 gene is unaffected” 
(Dufton et al. 2011). 
2.3.1.2 Genotyping 
To confirm the genotype of the animals, polymerase chain reaction (PCR) was performed on DNA 
isolates from ear clips (n = 6) taken from Fpr2/3
-/-
 mice and their wildtype littermates, and C57Bl6 mice. 
Purified DNA samples were then prepared using a DNA extraction kit (Nucleospin, Macherey-Nagel, 
Duren, Germany) and a PCR kit (AmpliTaq Gold, Applied Biosystems, Foster City CA, Country), 
according to the manufacturer’s instructions. Briefly, ear clips were lysed in 200 µl of 10% proteinase 
K/lysis buffer held in a water bath at 56 °C overnight. To each sample a further 200 µl of lysis buffer was 
added (70 °C, 10 min) plus 210 µl of 70% ethanol, before loading on to a column for centrifugation 
(11,000 rcf, 1 min). For each column, wash buffer was added twice, centrifuged, tube contents discarded, 
and centrifuged, and DNA eluted using elution buffer. The DNA concentration of each sample was 
checked by measuring the absorbance of ultraviolet light on a spectrophotometer (NanoDrop ND-1000 
UV, NanoDrop Technologies). 
The following primers were designed and manufactured (Sigma, Poole, UK): Fpr3 forward 5'-TAG AGG 
GAT CAT CAG GTT CA-3' and Fpr3 reverse 5'-TCT CTG GAG ACG AGA AGA CA-3'; Fpr2 forward 
5'-ACT GTG AGC CTG GCT AGG AA and Fpr2 reverse 5'-CAG ACT TCA TGG GGC CTT TTA-3'; 
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glyceraldehyde pyruvate dehydrogenase (GAPDH) forward 5'-AAG GTG AAG GTC GGA GTC AAC 
G-3' and GAPDH reverse 5'-GGC AGA GAT GAT GAC CCT TTT GGC-3'. On receipt, primers were 
reconstituted to 100 µmol.l
-1
 in molecular grade water and stored (-20 °C) until diluted to 10 µmol.l
-1
 
stocks for PCR. For each PCR, 2 µl forward primer, 2 µl reverse primer, 25 µl AmpliTaq Gold PCR 
Mastermix, 1 µl DNA sample (0.1 µg), and molecular grade water were added to a total volume of 50 µl. 
Following a hot start Taq-polymerase activation step (5 min, 95 °C), there were 33 PCR cycles (30 s 92 
°C, 30 s 54 °C, and 15 s 72 °C) followed by a final 10 min at 72 °C, and then held at 4 °C (Hybaid 
HBPX110 Thermal Cycler, Thermo Fisher Scientific, Loughborough, UK). 10 µl of each PCR product 
was then mixed with 3 µl Orange-G loading buffer, and 1 µl of 1-1000 kilobase ladder mixed with 9 µl 
water and 3 µl loading buffer. The samples and ladder were then loaded onto a 1% agarose gel containing 
ethidium bromide (1 µg/ml) in 0.5 mol.l
-1
 tris-borate-ethylenediaminetetraacetic acid (TBE) buffer and 
electrophoresed at 130 V for 45 min. The gel was then visualised using an ultraviolet gel documentation 
system. 
2.3.1.3 Phenotyping 
In order to confirm the genotyping, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and western blot experiments were performed to detect Fpr2 in lung samples from Fpr2/3
-/-
 mice 
and wildtype littermates. The lung was chosen based on a report that Fpr2 was abundantly expressed in 
lung tissue (Dufton et al. 2010). The total tissue protein content was extracted and then quantified using 
the Bradford protein assay (Section 2.6.7). To detect Fpr2, an affinity-purified, rabbit polyclonal anti-
human FPR2/anti-mouse Fpr2/3 IgG (rabbit anti-mouse Fpr2/3; sc-18191-R, Santa Cruz; Insight Biotech, 
Wembley, UK) was used in western blotting experiments following SDS-PAGE (Section 2.6.8). 
2.3.2 Rats 
Rats were used to determine the effects of: 1) an inflammogen and transcriptional upregulator of Fpr2 and 
Fpr3 expression, namely, LPS, on pituitary-adrenal axis activity in vivo (plasma ACTH and 
corticosterone concentration), the adrenal corticosterone response to ACTH1-24 in vitro, and the histology 
of the brain, pituitary, adrenal, and lymphoid tissues (spleen and thymus), as a function of time (0, 2, 4, 
and 24 h); 2) a 4 h exposure to LPS and the Fpr2-/FPR2/ALX-selective antagonist WRW4 on pituitary-
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adrenal axis activity in vivo and histology of the brain, pituitary, adrenal, and lymphoid tissues; and 3) 
agonists with differential affinities for FPR1, FPR2/ALX, and FPR3, alone and in combination with the 
Fpr2-/FPR2/ALX-selective antagonist WRW4 on secretagogue-stimulated and basal release of ACTH and 
corticosterone from dispersed anterior pituitary cells and adrenal cells in vitro.  
During pilot experiments, adult male Sprague-Dawley rats were used to determine the effects of FPR1, 
FPR2/ALX, and FPR3 agonists on secretagogue-stimulated and basal release of ACTH from dispersed 
anterior pituitary cells. This initial choice of strain was based on three practical reasons. Firstly, Sprague-
Dawley rats are conventionally used to investigate HPA axis function as they are thought to have low 
basal HPA axis activity in response to handling protocols versus the Fischer 344 strain, for instance 
(Dhabhar et al. 1993; Viau et al. 1993). Secondly, the supplier (Charles River Laboratories) offered a 
grant on this strain to graduates of the MRes Integrative Mammalian Biology course at Imperial College. 
Thirdly, at the time, the lab was affiliated with members of the Division of Cellular and Molecular 
Neuroscience whom mainly worked with Sprague-Dawley animals. The intention was to obtain pituitary 
and adrenal tissues from control animals of colleagues to reduce the number of animals required for ex 
vivo and in vitro work. The decision to switch to male Wistar rats was based on the lab relocating to the 
Section of Investigative Medicine where the majority of in vivo work was (is) with male Wistar rats.   
Adult male Sprague-Dawley or Wistar rats weighing approximately 200 ± 20 g were used (Charles River 
Laboratories, Margate, Kent, UK). Upon arrival they were housed in groups of four per cage in a room 
with controlled lighting (lights on between 08:00 and 20:00) and temperature (21 ± 2 °C) with standard 
laboratory chow and water available ad libitum for at least 7 days prior to experiments. The same people 
handled rats each morning for a total of 5 days. In vivo experiments were always started between 08:00 
and 09:30 to minimise circadian rhythm-associated variation in measurements. All procedures were 
carried out under license in accordance with the UK Animals (Scientific Procedures) Act, 1986.  
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2.4 In vivo methods 
2.4.1 Time course of responses to intraperitoneal injection of lipopolysaccharide into male Fpr2/3-/- 
mice and wildtype littermates 
Male wildtype littermates and Fpr2/3
-/-
 mice (n = 4) received injections of either LPS (750 μg.kg-1 i.p.) or 
saline (100 μl 0.9% NaCl i.p.) prior to CO2 asphyxiation at 2, 4, and 6 hours later. The time course study 
design was adopted mainly to determine the time at which LPS maximally upregulated GFP expression. 
Transcardial injections of 50 ml PBS per mouse were given to clear the tissues of blood, and then 
perfusion-fixed with 50 ml of 4% paraformaldehyde (PFA, w/v PBS) per mouse. The cranial, peritoneal 
and cardio-thoracic cavities were exposed by dissection to allow rapid tissue penetration of fixative 
during whole-animal immersion in 250 ml of 10% formalin (CH2O w/v ddH2O) for 24 hours, after which 
the formalin was replaced with 70% ethanol (v/v ddH2O). Tissues taken for embedding in paraffin 
included the brain, pituitary gland, thymus, spleen, and adrenal glands. Tissue sections (4 μm, performed 
by Bradley Spencer-Dene, Experimental Pathology, London Research Institute) were then taken on a 
microtome and placed onto slides ready for the IHC protocol (Section 2.5.1).  
2.4.2 Time course of responses to intraperitoneal injection of lipopolysaccharide into male Wistar rats 
Male Wistar rats (n = 4) received injections of LPS (750 μg.kg-1 i.p.) using insulin myjector needles 
(Terumo, U-100 insulin, 0.5 ml syringe and needle), before decapitation at 2, 4, or 24 hours post-
injection. Control rats (0 h) received no injection. The guillotine and sink below were washed before and 
after every decapitation to minimise the smell of blood in the procedure room. Blood (approximately 8 
ml) was collected into EDTA-coated tubes and left on ice for up to 10 minutes. Tubes were centrifuged at 
6000 rcf for 10 min to allow separation of the plasma (top layer) using disposable Pasteur pipettes. 
Plasma was then aliquoted into 3 Eppendorf tubes per sample (500 μl per tube) before storage at -80 °C 
for determination of ACTH and corticosterone concentration, by immunoradiometric assay (IRMA, 
Section 2.6.5) and EIA (Section 2.6.6), respectively. In addition to trunk blood, the following tissues were 
collected from each rat: brain, thymus, spleen, pituitary gland, and both adrenal glands, were weighed and 
masses recorded in grams to 3 decimal places (d.p.) along with body mass (grams, 2 d.p.). The left 
adrenal glands were placed into the buffer used for static incubation of dispersed adrenal cells with 
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ACTH1-24 (Sections 2.6.2 and 2.6.2.2) and thus determine the variation in adrenal corticosterone release in 
response to ACTH1-24 in vitro following i.p. LPS in vivo (Section 2.6.6). The thymus, spleen, and 
pituitary gland, were post-fixed in 10% neutral-buffered formalin. These tissues were then routinely 
formalin-fixed and paraffin-embedded (FFPE) into blocks (Paul Nya, Histopathology, Hammersmith 
Hospital) prior to taking 8 µm sections by microtome. The brains were mounted onto circular cork boards 
with OCT embedding compound (Bright Instruments, Huntingdon, UK), and held in freezing isopentane 
before snap-freezing in liquid nitrogen, after which they were stored at -80 °C until tissue sections (10 
µm) were taken by cryostat. 
2.4.3 Intraperitoneal injection of lipopolysaccharide and an Fpr2-/FPR2/ALX-selective antagonist 
(WRW4) into male Wistar rats 
Male Wistar rats (200 - 220 g, n = 6) were injected with LPS (750 μg.kg-1 i.p.) or vehicle (PBS, i.p.), or 
the Fpr2-/FPR2/ALX-selective antagonist WRW4 (250 μg.kg
-1
 i.p.), or LPS and WRW4 in combination. 
Needles and syringes were numbered with doses prepared for the body mass of a given rat, and volume-
matched to 500 μl and refrigerated the night before administration. Drugs were dissolved in PBS and 
preparations were checked prior to the injection period to ensure the drugs had remained in solution. To 
minimise the influence of circadian variations, the experiment followed a schedule, with injections 
between 08:00 – 08:30 am, and tissue collection between 12:00 – 13:30 pm, accounting for a maximum 
lag of 90 minutes between the first and last injection. At 4 hours post-injection, the animals were 
decapitated. Adrenal glands were harvested into Earle’s Balanced Salt Solution (EBSS) for primary 
culture. The brain, thymus, and spleen were isolated and placed into 4% paraformaldehyde (PFA) and 
then routinely formalin-fixed and paraffin-embedded (FFPE) into blocks (Paul Nya, Histopathology, 
Hammersmith Hospital) prior to taking 8 µm sections by microtome. Trunk blood was collected into 
EDTA-coated tubes, mixed, and centrifuged at 6000 rcf before separation of plasma (top layer) to 
determine the concentration of plasma ACTH (by IRMA, Section 2.6.5) and corticosterone (by EIA, 
Section 2.6.6).  
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2.5 Histological methods 
2.5.1 Fpr2/3-/- mouse tissues: brain, pituitary, thymus, spleen, adrenal 
In order to determine the spatial distribution of Fpr2 and Fpr3 within mouse tissues, it was necessary to 
target the product of the green fluorescent protein (GFP) transgene inserted as a surrogate marker in the 
absence of the two receptors in Fpr2/3
-/-
 mice. Initial investigations found that the native fluorescence one 
would typically expect from GFP was either absent or negligible under microscopic analysis, and so this 
necessitated a means of signal amplification. For this reason, well-validated primary anti-GFP antibodies 
were used initially in non-fluorescent, immunohistochemical (IHC) experiments.  
2.5.1.1 Immunohistochemical (IHC) staining for green fluorescent protein (GFP) within tissues from 
Fpr2/3
-/-
 mice and wildtype littermates 
The formalin fixed tissues were embedded in a permanent preparation of agarose and paraffin before 
taking 4 μm sections on a sled microtome (Bright 8000 Microtome, Bright Instruments, Huntingdon, 
UK). Paraffin-embedded sections were then dewaxed in fresh xylene (3 x 3 min) then dehydrated in 
100% industrial methylated spirit (IMS; 2 x 3 min) and rinsed in water (5 min) and then in PBS (2 x 5 
min). The sections were microwaved (12 min, medium power, Panasonic NE1027 1000W model, 
Panasonic, Bracknell, UK) in boiling citrate buffer pH 6 (2.94 g tri-sodium citrate plus 22 ml 0.2 mol.l
-1
 
HCl in dd H2O and cooled for 15 min at room temperature. The slides were placed briefly in PBS and 
then incubated sequentially with 1.6% H2O2 in PBS for 10 min (to block endogenous peroxidase) then in 
0.3 % normal sera in PBS for 5 min before being subjected to three 5 minute washes in PBS then distilled 
water. The slides were drained and wiped, and the tissue sections were encircled with a hydrophobic fluid 
using a PAP pen, then placed into a humid incubator tray at room temperature. Normal serum (10% v/v in 
1% BSA in PBS) from the species in which the secondary antibody was raised (e.g. donkey anti-rabbit 
required normal donkey serum) was applied to block non-specific background, and the slides were 
incubated for 60 min. The serum was then displaced without rinsing, before application of 20 - 200 μl 
primary antiserum to cover the section.  
All antibodies were prepared in 1% BSA/PBS at varying dilutions (primary polyclonal goat anti-GFP 
antibody at 1/200 for 1 hour, Cat. ab6673, Abcam, Cambridge, UK). The antibody was drained from the 
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slides that were then washed three times in PBS for 5 minutes. Secondary antibody was then applied 
(donkey anti-goat-biotinylated antibody, 1/250 for 1 hour, Cat. 705-065-147, Jackson ImmunoResearch, 
Newmarket, UK). The avidin biotin complex (ABC, Vectastain Elite ABC Kit, Vector Laboratories, 
Burlingame, USA) solution was prepared and allowed to complex at room temperature for 30 min prior to 
use (one drop of A, one drop of B, in 5 ml PBS, where one drop = 35 μl). Slides were drained of antibody 
and washed three times in PBS before addition of the ABC reagent and incubation for a further 30 min. 
The sections were then washed in PBS for 5 min. Diaminobenzidine (DAB) staining solution containing 
one 35 μl drop of buffer, 70 μl of DAB chromagen, and one 35 μl drop of H2O2 in 2.5 ml PBS was 
prepared immediately prior to use. Sections were then incubated with DAB solution until observable stain 
intensity developed; typically after 2 - 5 min. Adjacent sections were then counterstained with a weak 
blue haematoxylin solution (1 min, room temperature) and mounted with DPX-coated coverslips. 
2.5.1.2 Double immunofluorescence (IF) staining for GFP and cell lineage markers within pituitary 
glands from Fpr2/3
-/-
 mice and wildtype littermates 
In order to map the GFP distribution to markers of specific cell lineages within the anterior pituitary 
gland, an immunofluorescence (IF) approach was taken because of the ease at which a multitude of IF 
probes can be detected simultaneously from complexes of secondary and primary antibodies bound to 
epitopes within a given tissue section, without compromising signal amplification. Thus, the IF approach 
permitted simultaneous staining of GFP (as a proxy of Fpr2/Fpr3) and markers of anterior pituitary cell 
lineage, namely, S100b (folliculostellates), ACTH (corticotrophic), GH (somatotrophic), LH 
(gonadotrophic), PRL (lactotrophic), and TSH (thyrotrophic). 
Sections were stained using either a goat polyclonal anti-GFP (GxGFP; ab6673, Abcam, Cambridge, UK) 
or a rabbit polyclonal anti-GFP (RxGFP; ab6556, Abcam, Cambridge, UK), each used at 1 in 200 v/v in 
PBS, and counterstained adjacent sections with haematoxylin. In order to co-stain GFP with anterior 
pituitary hormones, antibodies for GFP (goat and rabbit) were raised in different species from the 
hormone antibodies, to minimise cross-reactivity (Table 2.2). 
For each stain there were three slides, each with two pituitary sections, and each section requiring 100 μl 
of primary antibody mixture, prepared as follows: for GH/GFP stains, a 300 μl mixture of rabbit anti-GH 
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(1 in 250 v/v, 1.2 μl), goat anti-GFP (1 in 200 v/v, 1.5 μl) and 297.3 μl 1% BSA/PBS; for ACTH/GFP 
stains, a 300 μl mixture of rabbit anti-ACTH (1 in 1000 v/v, 0.3 μl), goat anti-GFP (1 in 200 v/v, 1.5 μl) 
and 298.2 μl 1% BSA/PBS; for PRL/GFP stains, a 300 μl mixture of rabbit anti-PRL (1 in 500 v/v, 0.6 
μl), goat anti-GFP (1 in 200 v/v, 1.5 μl) and 297.9 μl 1% BSA/PBS; for LH/GFP stains, a 300 μl mixture 
of rabbit anti-LH (1 in 100 v/v, 3.0 μl), goat anti-GFP (1 in 200 v/v, 1.5 μl) and 295.5 μl 1% BSA/PBS; 
for TSH/GFP stains, a 300 μl mixture of guinea pig anti-TSH (1 in 100 v/v, 3.0 μl), rabbit anti-GFP (1 in 
200 v/v, 1.5 μl) and 295.5 μl 1% BSA/PBS. 
For single stains of GFP, rabbit anti-GFP only slides received 100 μl of antibody mixture (RxGFP, 1 in 
200 v/v, 0.5 μl in 499.5 μl 1% BSA/PBS) and goat-anti-GFP only slides also received 100 μl of antibody 
mixture (GxGFP, 1 in 200 v/v, 0.5 μl in 499.5 μl 1% BSA/PBS). For no primary controls, each slide 
received 100 μl of the secondary antibody, and for no secondary controls, each slide received 100 µl of 
the antibody diluent (1% BSA/PBS). 
Each primary incubation lasted 1 hours at room temperature and was followed by 3 x 5 min washes in 
PBS. Secondary antibodies were also prepared in 1% BSA/PBS and secondary incubations lasted 45 min 
at room temperature. Secondary antibody mixtures (1200 μl) for GFP/GH, GFP/ACTH, GFP/PRL, and 
GFP/LH were made up of donkey anti-rabbit
488
 (1 in 300 v/v, 4.0 μl) and donkey anti-
goat
biotin/
streptavidin
555
 (1 in 300 v/v, 4.0 μl) and 1196 μl 1% BSA/PBS.  The secondary antibody mixture 
for GFP/TSH was made up of goat anti-guinea pig
488
 (1 in 300 v/v, 0.3 μl) and donkey anti-rabbit488 (1 in 
300 v/v, 0.3 μl) and 199.4 μl 1% BSA/PBS. 
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Table 2.2 Antibodies used in immunofluorescence (IF) experiments with Fpr2/3
-/-
 mouse tissue and 
wildtype littermates.  
Superscripts denote the fluorochromes Alexa Fluor
488
 (green), and Alexa Fluor
546
 and Alex Fluor
555
 (red). 
Primary 
Dilution Secondary/tertiary complex Dilution 
Goat anti-GFP 
(ab6673, Abcam) 
1/200 
Donkey anti-goat
biotin
/streptavidin
555 
  
(ab7124, Abcam; S21381, Invitrogen) 
1/300 
Rabbit anti-GFP 
(ab6556, Abcam) 
1/1000 
Donkey anti-rabbit
546  
(A21206, Invitrogen) 
1/300 
Rabbit anti-ACTH 
(AFP6328031, NIDDK) 
1/1000 
Donkey anti-rabbit
488
  
(A21206, Invitrogen) 
1/300 
Rabbit anti-LH 
(AFP-10250C, NIDDK) 
1/100 
Donkey anti-rabbit
488
  
(A21206, Invitrogen) 
1/300 
Rabbit anti-PRL 
(AFP-131581570, NIDDK) 
1/500 
Donkey anti-rabbit
488
  
(A21206, Invitrogen) 
1/300 
Rabbit anti-GH 
(AFP5672099, NIDDK) 
1/250 
Donkey anti-rabbit
488
  
(A21206, Invitrogen) 
1/300 
Guinea pig anti-TSH 
(AFP329691Rb, NIDDK) 
1/100 
Goat anti-guinea pig
488
  
(ab6966, Abcam) 
1/300 
Rabbit anti-S100b 
(ab4066, Abcam) 
1/70 
Donkey anti-rabbit
488
  
(A21206, Invitrogen) 
1/300 
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2.5.2 Human pituitary 
Human pituitaries (n = 6) were formalin-fixed and paraffin-embedded before 4 µm sections were taken by 
microtome and placed onto slides. In order to immunostain the sections, the following antibodies and 
dilutions were used using a protocol similar to that described in Section 2.5.1.2: 
 Mouse anti-ACTH monoclonal (ab21003, Abcam), 1/300, 60 min 
 Mouse anti-S100b monoclonal (SAB1404351, Sigma), 1/35, 60 min 
 Rabbit anti-human FPR1 (ab113531, Abcam), 1/200, 60 min 
 Rabbit anti-human FPR2/ALX (HPA029154, Atlas) 1/75, 60 min 
 Rabbit anti-human FPR3 (NLS3735 Novus Biologicals), 1/35, 60 min 
 Donkey anti-mouse Alexa Fluor 488 (Invitrogen), 1/150, 60 min 
 Donkey anti-rabbit Alexa Fluor 555 (Invitrogen), 1/150, 60 min 
Confocal images (pinhole = airy 1) of the medial area between the lateral wings of the anterior pituitary 
(9 x 246 µm areas per section, minimum three sections per subject) were acquired on a confocal laser-
scanning microscope (Leica SP5) with a 63.3 objective at 1024 by 1024 pixel resolution.  
The anterior pituitary was reconstructed in 3D stacks of images (step size = 0.14 μm) and then analysed 
using Fiji is Just Image J software with the LOCI BioFormats Import plugin and the Just Another 
Colocalisation Plugin (JACoP). The confocal images were used to establish whether an individual 
corticotroph or folliculostellate was co-immunoreactive for lineage markers ACTH or S100b, with 
FPR1/FPR2/FPR3 subtypes, according to the following criteria: 1) a given corticotrophic cell had clear 
staining of ACTH and a nucleus; 2) a given folliculostellate cell had clear staining of S100b and a 
nucleus; 3) co-immunoreactive cells met criterion 1) or 2), and also had evidence of cytoplasmic or 
membranous staining of FPR1/FPR2/FPR3.  
2.5.3 Wistar rat tissues: brain, pituitary, thymus, spleen, adrenal 
Tissues were processed into FFPE tissue blocks by Paul Nya (Histopathology, Hammersmith Hospital). 
Sections (8 µm) of each tissue were taken my microtome and floated in water onto microscope slides 
before drying (37 
o
C, 20 min). Sections were deparaffinised in xylene for 5 min initially, and a further 
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three times (2 min). Sections were then dehydrated in 100%, 75%, and 50% ethanol, in series for 2 min 
each, and then washed in distilled water (3 min).  
2.5.3.1 Haematoxylin & Eosin (H&E) Staining 
Sections were covered with Gill’s No1 haematoxylin for 75 s, then gently rinsed with (sections facing 
away from) running tap water for 10 min. Eosin Y solution (5% w/v dH2O) was acidified with acetic acid 
(50 µl per 200 ml) until a brilliant red develops from dark red. Acidified Eosin Y solution was then added 
to the slides for 2 min to detect neutrophils, or 7 min to increase staining of eosinophils, and thus 
differentiate from other polymorphonuclear leukocytes (PMNs). Sections were then rinse in running tap 
water (4 s), dehydrated in 75% ethanol for 30 s, twice, then 100% ethanol for 30s, twice. Sections were 
then covered in xylene for 1 min, twice, before mounting coverslips to the slides with DPX. Slides were 
evaluated using a light microscope, whereby the cytoplasm is stained pink, nuclei dark blue, red blood 
cells orange, and fibrin deep pink. 
2.5.3.2 Congo Red staining 
By hydrogen bonding of amine groups to hydroxyl radicals within eosinophils, Congo Red stains 
cytoplasmic granules of eosinophils an orange-red colour (Meyerholz et al. 2009). Sections were covered 
in Gill’s No1 haematoxylin for 75 s. Sections were rinsed with distilled water to remove excess 
haematoxylin. A solution of 0.5% Congo Red in 50% ethanol was prepared (pH 8.2). Sections were 
covered in the 0.5% Congo Red solution for 5 min, then rinsed with distilled water. Sections were then 
left to dry, and coverslips mounted with DPX. Slides were evaluated using a light microscope.
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2.6 In vitro methods 
2.6.1 Primary culture of dispersed anterior pituitary cells from rats 
Male Sprague-Dawley or Wistar rats (200 – 220 g) were handled daily (11:00 am – 12:00 pm), to 
habituate them to a tight grip, and thus limit the effect of handling on the stress response at the time of 
culling (t = 0 h). Animals were decapitated individually and the skull was opened bilaterally using bone 
crushing forceps and the brain tilted back to expose the pituitary in the sphenoid bone posterior to the 
optic chiasm. Using sharp forceps, the posterior lobe of the pituitary was dissected in situ and discarded. 
By loosening the connective tissue that straddles the gland, the anterior pituitary was then collected into 
ice-cold culture medium (10 ml per 10 glands).  
The sterile culture medium was prepared within a class II microbiological safety cabinet the day before 
culling with: 500 ml Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Paisley, UK) containing 
4.5 g.l
-1
 D-glucose and 44 mmol.l
-1
 NaHCO3, 111 μmol.l
-1
 sodium pyruvate and 4 mmol.l
-1
 L-alanyl-L-
glutamine (Invitrogen, Paisley, UK); 5 ml non-essential amino acids containing: 100 μmol.l-1 L-alanine, 
98 μmol.l-1 L-asparagine, 8.8 μmol.l-1 L-aspartic acid, 10 μmol.l-1 L-glutamic acid, 1 μmol.l-1 glycine, 10 
mmol.l
-1
 L-proline, and 10 μmol.l-1 L-serine (Invitrogen, Paisley, UK); 50 ml (10% v/v working) fetal calf 
serum (FCS, Invitrogen, Paisley, UK); 5 ml penicillin-streptomycin (mixture of penicillin at 100 IU/ml) 
and streptomycin at 100 mg.l
-1
 stock); 1.5 g (0.3% w/v working) bovine serum albumin (BSA); 5 ml 
insulin transferrin sodium selenite (ITS, mixture of 5 mg.l
-1
 insulin, 5 mg.l
-1
 transferrin, and sodium 
selenite 116 μmol.l-1), and 0.5 μmol.l-1 tri-iodo-L-thyronine sodium salt (T3, 30 pmol.l
-1
).  
Blood was washed from the glands by aspiration in a shortened 1 ml pipette tip, after which small blocks 
of tissue (0.5 mm length) were produced using a sterile razor blade on the back of an autoclaved coplin 
lid. The pituitaries were centrifuged in culture medium (800 rcf 5 min, 4 °C, and the pellet resuspended in 
a dissociating medium containing trypsin (0.25% v/v culture medium) before agitation (37 °C, 800 rcf, 25 
min). The medium was then supplemented with trypsin inhibitor (0.1 mg.ml
-1
; and DNAseI (0.01% w/v; 
Sigma, Poole, UK) before centrifugation (700 rcf, 5 min, 4 °C). The pellet was resuspended in 50 ml ice-
cold medium before filtration through a 40 μm pore nylon mesh (BD, Franklin Lakes NJ, USA). A final 
centrifugation (700 rcf, 5 min, 4 °C) was followed by four medium changes, before taking a cell-viability 
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count using a haemocytometer (Kova Slide 10, Hycor Biomedical, Penicuik, UK) and trypan blue (0.4% 
v/v stock) to identify dead cells (Section 2.6.3). Cells were plated at an equal density (10
5
 cells/ml) in 24-
well or 96-well plates in medium and incubated at 95% O2, 5% CO2, 37 °C. At t = 24 hours, the medium 
was removed from the cells for washing in PBS (2 ml per well) before replacing with fresh medium until 
t = 48 hours when the cells were incubated with low serum medium (1% FCS in DMEM). At t = 72 
hours, the medium was aspirated and the cells washed twice with PBS and were then incubated with 
drugs for 4 h. 
2.6.1.1 Static incubation of dispersed anterior pituitary cells from untreated male Sprague-Dawley rats 
with CRH and graded concentrations of Fpr agonists 
Dispersed anterior pituitary cells from untreated male Sprague-Dawley rats (n = 4 wells from a cell 
suspension of 20 pooled glands) were plated onto 24-well plates and incubated for 4 hours in the presence 
or absence of the ACTH secretagogue CRH (100 nmol.l
-1
 after (Mehet 2007)) with or without one of the 
following drugs for each experiment: 1) the Fpr1-/FPR1-selective agonist fMLF (10
-9
, 10
-8
, 10
-7
, 10
-6
, and 
10
-5
 mol.l
-1
); 2) the Fpr2-/FPR2/ALX-selective agonist WKYMVm (10
-10
, 10
-9
, 10
-8
, 10
-7
, and 10
-6
 mol.l
-
1
); 3) the Fpr2-/FPR3-selective agonist F2L (0.5, 1, 2, 4, and 8 x 10
-7
 mol.l
-1
), and 4) the Fpr3/Alx-
/FPR2/ALX-selective agonist, 15-epi-lipoxin A4 (10
-10
, 10
-9
, 10
-8
, and 10
-7
 mol.l
-1
). The conditioned 
media were collected into separate tubes and stored (-80 °C) prior to RIA of ACTH (Section 2.6.1). 
2.6.1.2 Static incubation of dispersed anterior pituitary cells from untreated male Wistar rats with CRH 
and/or the Fpr2-/FPR2/ALX-selective antagonist WRW4 and graded concentrations of Fpr 
agonists 
Dispersed anterior pituitary cells from untreated male Wistar rats (n = 6 wells per condition, from a cell 
suspension of 20 pooled glands) were plated onto 96-well plates and incubated 4 hours in the presence or 
absence of the ACTH secretagogue CRH (100 nmol.l
-1
) and/or the Fpr2-/FPR2/ALX-selective antagonist 
WRW4 (10
-6
 mol.l
-1
) with or without one of the following drugs for each experiment: 1) the Fpr1-/FPR1-
selective agonist fMLF (10
-7
, 10
-6
, and 10
-5
 mol.l
-1
); 2) the Fpr2-/FPR2/ALX-selective agonist 
WKYMVm (10
-8
, 10
-7
, and 10
-6
 mol.l
-1
); 3) the Fpr2-/FPR3-selective agonist F2L (4, 40, and 400 nmol.l
-
1
); 4) the Fpr3/Alx-/FPR2/ALX-selective agonist, 15-epi-lipoxin A4 (10
-9
, 10
-8
, and 10
-7
 mol.l
-1
), and 5) 
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the non-selective Fpr agonist, ANXA1Ac2-26 (3 x 10
-7
, 3 x 10
-6
, and 3 x 10
-5
 mol.l
-1
). The conditioned 
media were collected into separate tubes and stored (-80 °C) prior to RIA of ACTH (Section 2.6.1). 
2.6.2 Static incubation of dispersed adrenal cells from rats 
Adrenal glands from male Wistar rats were collected into 10 ml of Earle's Balanced Salt Solution (EBSS; 
with 2.2 g.l
-1 
sodium bicarbonate, pH 7.4 (Cat. E3024, Sigma, Poole, Dorset, UK)), which had been pre-
gassed with 95% O2, 5% CO2. EBSS provided a buffering system to maintain a physiological pH (7.2 - 
7.6). One litre of EBSS also contained: .265 g CaCl2.2H2O, .098 g MgSO4, .4 g KCl, 2.2 g NaHCO3, 6.8 
g NaCl, and 0.122 g NaH2PO4. Samples were kept at room temperature until dispersion, which was 
conducted immediately following sampling. The adrenals were cut into small pieces (1 mm length) using 
a razor blade and then transferred into 2 ml of EBSS with collagenase from Clostridium histolyticum 
(Collagenase, Cat. 2674, Sigma, Poole, Dorset, UK) used at 2 mg.ml
-1
. 
The end of a 1 ml pipette tip was cut short to facilitate dispersion of cells by aspiration every 10 minutes 
for 1 hour, along with gassing with 95% O2, 5% CO2. The cell suspension was filtered through a 100 μm 
gauze into 50 ml Falcon tubes. The filtrate was centrifuged at 1000 rcf for 15 minutes. The pellet was 
resuspended (5 ml) and centrifuged again as above. The pellet was resuspended in 5 ml prior to counting 
cells using a haemocytometer for a target of 10
6
 cells/ml (Section 2.6.3).  
Cells were then plated into 96-well plates (200 μl per well) and incubated for 1 hour (95% O2/5% CO2, 37 
°C), prior to the addition of drugs. Drugs were prepared in EBSS immediately prior to the end of this 
incubation period. Plates of cells were then centrifuged at 2000 rcf for 10 s, before inverting and blotting 
supernatant onto tissue paper. The drugs were diluted to working concentration in EBSS and were then 
added to each well (300 μl per well) for a contact period of 4 h. The plates were then centrifuged as above 
and conditioned media removed to assay corticosterone by EIA (Section 2.6.6) and stored at -20 °C. 
2.6.2.1 Static incubation of ACTH1-24 with dispersed adrenals from untreated male Wistar rats 
Dispersed adrenal cells from untreated male Wistar rats (n = 8 wells per condition, from a cell suspension 
of 12 glands) were incubated for 4 hours in the presence or absence of graded concentrations of the 
corticosterone secretagogue ACTH1-24 (10
-10
, 10
-9
, 10
-8
, 10
-7
, 10
-6
, 10
-5
, and 10
-4
 mol.l
-1
). The conditioned 
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media were collected into separate tubes and stored (-80 °C) prior to EIA of corticosterone (Section 
2.6.6). 
2.6.2.2 Static incubation of ACTH1-24 with dispersed adrenals from male Wistar rats injected with LPS (2, 
4, 24 h) 
Dispersed adrenal cells from male Wistar rats either injected with LPS (750 µg/kg i.p.) or untreated (n = 8 
wells per condition, from a cell suspension of 6 glands) were incubated for 4 hours in the presence or 
absence of graded concentrations of the corticosterone secretagogue ACTH1-24 (10
-11
, 10
-10
, 10
-9
, 10
-8
, and 
10
-7
 nmol.l
-1
). The conditioned media were collected into separate tubes and stored (-80 °C) prior to EIA 
of corticosterone (Section 2.6.6). 
2.6.2.3 Static incubation of ACTH1-24 and Fpr agonists and the Fpr2-/FPR2/ALX-selective antagonist 
WRW4 with dispersed adrenals from untreated male Wistar rats 
Dispersed adrenal cells from untreated male Wistar rats (n = 8 wells per condition, from a cell suspension 
of 12 glands) were incubated for 4 hours in the presence or absence of the corticosterone secretagogue 
ACTH1-24 (100 nmol.l
-1
) and/or the Fpr2-/FPR2/ALX-selective antagonist WRW4 (10
-6
 mol.l
-1
) with or 
without one of the following drugs for each experiment: 1) the Fpr1-/FPR1-selective agonist fMLF (10
-7
, 
10
-6
, and 10
-5
 mol.l
-1
); 2) the Fpr2-/FPR2/ALX-selective agonist WKYMVm (10
-8
, 10
-7
, and 10
-6
 mol.l
-1
); 
3) the Fpr2-/FPR3-selective agonist F2L (4, 40, and 400 nmol.l
-1
); 4) the Fpr3/Alx-/FPR2/ALX-selective 
agonist, 15-epi-lipoxin A4 (10
-9
, 10
-8
, and 10
-7
), and 5) the non-selective Fpr agonist, ANXA1Ac2-26 (3 x 
10
-7
, 3 x 10
-6
, and 3 x 10
-5
 mol.l
-1
). The conditioned media were collected into separate tubes and stored (-
80 °C) prior to EIA of corticosterone (Section 2.6.6). 
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2.6.3 Cell counts and viability determination 
One volume of culture medium containing primary cells was counted by mixing with one volume of 0.4% 
trypan blue and incubated for 3 minutes at room temperature. A 10 μl drop of the mixture was applied to 
a disposable haemocytometer (Kova Slide II; Cat. 87100, Hycor Biomedical, Edinburgh, UK) and 
analysed under a microscope. The unstained (viable) and blue-stained (nonviable) cells were counted 
separately, and the percentage of viable cells was always at least 95%, as calculated by (Equation 2.2). 
Equation 2.2 
 ia le cells (%)= 
total nu  er o   ia le cells  er l o  ali uot
total nu  er o  cells  er l o  ali uot
      
2.6.4 Radioimmunoassay of ACTH 
ACTH from the in vitro studies was assayed by one-site radioimmunoassay (RIA) using reagents 
supplied by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda MD, 
USA) (Nicholson et al. 1984). The results were expressed as pictograms/ml in reference to a standard of 
human ACTH (AFP-2938C, NIDDK, Bethesda MD, USA). A standard curve was made by double 
dilution of 10000 pg.ml
-1
ACTH peptide down to 10 pg.ml
-1
 in 200 μl assay buffer, containing: 12.7 
mmol.l
-1
 EDTA; 68.2 mmol.l
-1
 disodium hydrogen phosphate (Na2HPO4); 3 mmol.l
-1
 sodium azide 
(NaN3); 1% Triton X-100; dithiothreitol (DTT); and 0.033% bovine serum albumin (BSA).  
The ACTH to be used as the radiolabel was iodinated with Iodine-125 by colleagues (Prof. Mohammed 
Ghatei and Michael Patterson, Section of Investigative Medicine, Imperial College London) using the 
Iodo-Gen method, then purified on a G75 Sephadex column in assay buffer and finally used at 4000-6000 
cpm per 100 μl (Salacinski et al. 1981). The antibody (rabbit anti-human ACTH) was used at a working 
dilution of 1 in 60,000 (v/v). Tubes were numbered and the following reagents added: 1-3 (Total) 100 μl 
label; 4-6 (NSB) 300 μl buffer + 100 μl label; 7-9 (Ref) 100 μl buffer + 200 μl antibody + 100 μl label; 
10-42 (Standards) 100 μl standard + 200 μl antibody + 100 μl label; and remaining tubes contained 100 μl 
sample + 200 μl antibody + 100 μl label. After incubation (72 h, 4 °C), the bound antibody was separated 
from free tracer by further incubating samples (30 min, RTP) with horse serum/0.9% saline (50% v/v) 
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followed addition of polyethylene glycol (PEG, 18% w/v in 0.05 mol.l
-1
 PO4) before centrifugation (30 
min, 2400 rcf, 4 °C) (Desbuquois & Aurbach 1971). The supernatant was aspirated and the bound 
fraction of Iodine-125 ACTH in the pellet was measured (counts per minute) for 120 s per tube (Cobra-II 
Auto-Gamma, Packard Bioscience, Pangbourne, UK). 
2.6.5 Immunoradiometric assay of plasma ACTH 
ACTH in plasma samples was assayed in triplicate using a double antibody immunoradiometric assay 
(IRMA) kit (Cat. 27065, DiaSorin, Stillwater, Minnesota, USA). The kit contained: polystyrene beads 
coated with polyclonal mouse anti-goat antibody; 125-Iodine (125-I) tracer containing polyclonal goat 
anti-ACTH and 125-I labelled-mouse monoclonal anti-ACTH diluted in buffered serum containing red 
dye and 0.1% sodium azide; wash solution containing concentrated buffered surfactant, diluted to 500 ml 
final volume in ultra-pure water; and controls of human plasma spiked with synthetic human ACTH (30, 
109, and 387 pg.ml
-1
), containing 0.1% sodium azide.  
The IRMA detects the whole molecule of ACTH1-39 by using two ACTH antibodies—each one specific 
for different regions of the ACTH molecule—ACTH1-17 and ACTH26-39. The two antibodies are raised 
against N- and C-terminal regions of the ACTH1-39 peptide, thereby reducing the likelihood of the assay 
detecting ACTH fragments. The iodinated tracer contains a polyclonal goat antibody specific for 
ACTH26-39, and an Iodine-125 labelled monoclonal antibody specific for ACTH1-17. During incubation 
with the tracer and mouse anti-goat coated polystyrene beads, the ACTH-specific antibodies will bind to 
the ACTH1-39 present in the sample. Any unbound radioactivity is washed away and the radioactivity 
bound to the bead is measured (counts per minute) over a 120 s counting period (Bloom & Long 2011) 
and is directly proportional to the ACTH1-39 concentration in a given sample. Results are calculated by 
comparing the cpm of each sample to the cpm for the ACTH standard curve using logistic regression. 
2.6.6 Enzyme immunoassay of corticosterone 
Corticosterone was determined in the conditioned media from the primary dispersed adrenal cultures and 
plasma by a corticosterone enzyme immunoassay (EIA) kit (Cat. 500655-96 wells, Cayman Chemical, 
Ann Arbor, Michigan, USA). The kit contained a pre-coated rabbit anti-sheep IgG 96-well plate, Ellman's 
reagent, EIA buffer 10X-concentrate, wash buffer 400X-concentrate, corticosterone acetycholinesterase 
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(AChE) tracer, sheep anti-corticosterone antiserum, and corticosterone standard. The EIA buffer was 
diluted with 90 ml of ultra-pure water. The wash buffer was diluted the 5 ml vial to 2 l and added 1 ml 
Tween 20. AChE tracer was reconstituted with 6 ml of EIA buffer. A bulk standard of 50 ng.ml
-1
 
corticosterone was prepared by diluting 500 ng.ml
-1
 corticosterone 1/10 in ultra-pure water. A standard 
curve was prepared by diluting the bulk standard 1/10 in EIA buffer to make the top standard of 5,000 
pg.ml
-1
 (S1). This top standard was then serially diluted by 1/1.5 to prepare standards S2 - S8 of 2000, 
800, 320, 128, 51.2, 20.5, and 8.2 pg.ml
-1
 corticosterone. A 96-well plate was then prepared with wells to 
control for non-specific binding (NSB; containing 100 μl EIA buffer and 50 μl tracer); maximum binding 
(B0; 50 μl EIA buffer, 50 μl tracer, and 50 μl antiserum); as well as blank wells, standards (S1 - S8; 50 μl 
standard, 50 μl tracer, 50 μl antiserum), and total activity (5 μl tracer).  
Adrenal culture conditioned media samples were diluted 1/800, plasma samples were diluted 1/10 (50 μl 
diluted sample, 50 μl tracer, and 50 μl antiserum). The plate was then covered and incubated for two 
hours at room temperature (22 °C) with gentle shaking on a plate shaker. The plate was then washed 
using the supplied wash buffer and a multi-channel pipette. Then 5 μl tracer was added to the total 
activity (TA) well and 200 μl Ellman's reagent was added to all wells and the plate was covered and 
incubated in the dark for 90 min with gentle shaking. The plate was then read on a spectrophotometer at 
415 nm wavelength light to measure absorbance and calculate the concentration of samples from the 
equation of the standard curve. 
2.6.7 Bradford protein assay 
Fragments of previously frozen (-20 °C mouse lungs (25-35 mg) from LPS-stimulated Fpr2/3
-/-
 mice and 
wildtype littermates (n = 4), were homogenised using an electric sonicator (Soniprep 150, MSE, London, 
UK) in ice-cold Radio-Immuno Precipitation Assay (RIPA)-based lysis buffer (100 μl per 50 mg tissue) 
containing sodium chloride 150 mmol.l
-1
, Triton X-100 (1%), sodium deoxycholate (0.5%), sodium 
dodecyl sulphate (0.1%), and Tris pH 8.0 (50 mmol.l
-1
). This also included a cocktail of protease and 
phosphatase inhibitors, namely, protease inhibitor (Complete LysisM tablets, Roche, Mannheim, 
Germany), serine/cysteine protease inhibitor (PMSF, 1 mmol.l
-1
), tyrosine phosphatase inhibitor 
(Na3VO3, 0.5 mmol.l
-1
), and serine/threonine phosphatase inhibitor (NaF, 0.05 mmol.l
-1
). The protein 
concentration of the homogenate was determined using the Bradford assay (Bradford 1976) to allow 
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loading of 40 μg per well for each sample. This involved a standard curve from 20 to 100 mg/ml, and 4 μl 
of each standard in duplicate and 4 μl of sample with 4 replicates in a 96-well plate. Then 200 μl of 
Coomassie G250 solution (20% methanol, 10% phosphoric acid, 10% ammonium sulphate, 0.12% G-
250) was added to each well. After 2 minutes in the dark, sample absorbance was recorded at 595 nm 
using a microplate spectrophotometer (Anthos HT2, Anthos Labtec, Salzburg, Austria). 
2.6.8 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting 
10% SDS v/v polyacrylamide gels were prepared using the cassette manufacturers protocol (Invitrogen, 
Paisley, UK) and consisted of 10% w/v acrylamide, 0.3% w/v bisacrylamide, 0.001% w/v SDS, 0.1 mol.l
-
1
 Tris/bicine, 2% w/v ammonium persulphate, 0.1% w/v N,N,N1,N1 tetramethylethylene diamine 
(TEMED); stacking gel: 7.5% w/v acrylamide, 0.2% w/v bisacrylamide, ammonium persulphate (40 μl, 
10% solution), and 0.66% TEMED (all from Sigma, UK). Samples were mixed 1:2 volumes with 3x 
working concentration of Laemmli sample buffer (Laemmli 1970) and boiled (100 °C, 5 min) before 
loading to 40 µg each well (Protein concentrations determined by Bradford Protein Assay, Section 2.6.7). 
For electrophoresis, a tank was filled with 4% TRIS-glycine w/v dd H2O buffer and the gel exposed to a 
current of 200 mA, 100 V until the ladder was vertically distributed across the gel (after approximately 90 
min). The gel was transferred to a pre-wet (10 min in H2O, 10 min in transfer buffer, 25% methanol v/v 
Tris-Glycine) nitro-cellulose membrane (0.45 μm pore size) using semi-dry transfer apparatus (Semi-Phor 
TE 70, General Electric, Amersham, UK) set at 5 V, 50 mA, 1 h. The membrane was then blocked with 
5% skimmed milk v/v TBS-Tween for 1 hour, RTP. The membrane was then incubated in a heat-sealed 
polyethylene pouch overnight at 4 °C with the primary antibody (Fpr2/3 (N-20)-R, sc-18191-R, Santa 
Cruz; Insight Biotech, Wembley, UK) diluted at 1 in 200 volumes of TBS-Tween. 
The secondary antibody was goat anti-rabbit HRP-conjugated IgG (7074, Cell Signalling, Danvers MA, 
USA) diluted at 1 in 1000 v/v of TBS-Tween, and rotated (1 h, RTP). The membrane was then blocked 
with 5% skimmed milk v/v TBS-Tween (1 h, RTP) to reduce secondary background noise. The blot was 
developed by enzymatic chemiluminescent (ECL) reagent (General Electric, Amersham, UK) for 1 
minute in a dark room, prior to exposure to Amersham HyperFilm (General Electric, Amersham, UK) for 
1 minute. A section of the membrane was incubated with mouse anti-GAPDH (MAB374, Millipore, 
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Town, Country) diluted at 1 in 300 volumes (1 h, RTP) followed by secondary horse anti-mouse (7076, 
Cell Signalling, Danvers MA, USA) diluted at 1 in 2000 v/v (1h, RTP). 
The molecular weights of the bands of immunoreactive Fpr2/3 were determined by comparison with the 
migration of molecular weight markers (myosin 250kDa, phosphorylase 148 kDa, BSA 98 kDa, glutamic 
dehydrogenase 64 kDa, alcohol dehydrogenase 50 kDa, carbonic anhydrase 36 kDa, myoglobin red 22 
kDa, lysozyme 16 kDa, aprotinin 6 kDa, and insulin B chain 4 kDa; SeeBlue Plus2 LC5925 molecular 
weight markers, Invitrogen, Paisley, UK). The blots were scanned using an HP Color LaserJet 9500 MFP 
(HP, Bracknell, UK). 
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2.7 Statistics 
Data are presented as arithmetic mean ± standard error of mean (SEM). Kolmogorov-Smirnov tests were 
performed to ensure the data met the assumption of being normally distributed—a prerequisite for 
parametric statistics. Data were then analysed by either two-way analysis of variance (ANOVA) with post 
hoc Bonferroni correction, or three-way ANOVA with Bonferroni correction for multiple comparisons. 
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3.1 Introduction 
The following paragraphs will describe: the links between the hypothalamo-pituitary-adrenal (HPA) axis, 
the immune system and the formyl peptide receptor (Fpr/FPR) family and their relevance to 
inflammogenic disease; the expression of Fpr/FPR subtypes in terms of tissue distribution and cellular 
disposition and how these are affected by the inflammogen, lipopolysaccharide (LPS). 
3.1.1 The HPA axis, immune system, and Fpr/FPR family 
The relationship between the immune system and the HPA axis response to stress is a fertile area of 
research. Whilst the glucocorticoids (GCs) are among the most potent classes of immunosuppressant and 
anti-inflammatory drugs available, the nature of their actions and side effects remain poorly understood 
(Auphan et al. 1995). Dysfunctional release of GCs is implicated in numerous disease states, but is 
scarcely more critical than during systemic inflammatory response syndromes (SIRS) such as sepsis and 
septic shock following an infection. Severe organ damage during sepsis can lead to septic shock, defined 
as persistent hypotension of < 90 mmHg systolic blood pressure for > 1 h despite administration of fluids 
and vasopressors such as epinephrine. Whilst the actions of GCs are necessary to reverse septic shock, the 
relationship between patient mortality rates and circulating GC concentration is at best U-shaped, 
meaning an optimum dose is difficult to determine (Annane et al. 2009; Minneci et al. 2009; Sligl et al. 
2009).
5
 In addition, whilst GCs are effective for treating inflammation within the central nervous system 
(CNS), their suppressive effects on neurogenesis (Gould et al. 1992) means they are contraindicated for 
treating inflammatory neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer’s disease 
(AD), and Parkinson’s disease (PD).  
 
Without understanding the nature of GC actions, it is unlikely that their unwanted side effects will be 
militated against or avoided. Increasing knowledge in this area, therefore, could help in the search for safe 
                                                          
5
 Typically, under 3% of sepsis patients have absolute adrenal insufficiency, but up to 50% have relative 
adrenal insufficiency, with 82% mortality if >30 mcg/dL basal GCs and <9 mcg/dL increased GC 
secretion in response to cosyntropin (Annane et al. 2009). 
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and efficacious alternatives to GCs in the treatment of inflammogenic stress and disease. This highlights 
the need to contribute data on secondary mediators and mimetics of GC actions, particularly in terms of 
the function and expression of their target receptors within endocrine and lymphoid tissues. The Fpr/FPR 
family, for instance, mediate the effects of ligands which direct leukocytes and lymphocytes towards 
inflammatory sites (chemotaxis) (Hoshi & Ushiki 1999), as well as those which modulate the secretions 
of the anterior pituitary (Pompeo et al. 1997; John et al. 2007; McArthur et al. 2009) and adrenal glands 
(Buss 2010). Therefore, the Fpr/FPR family are potential mediators of the interactions between the 
immune system and HPA axis, and could be of relevance to endocrine and lymphoid tissue responses to 
inflammogenic stress. The contribution of individual Fpr/FPR subtypes to these systems, however, is not 
presently clear. The most relevant tissues in these systems will now be described in terms of their gross 
anatomy, links with the HPA axis and the response to stressors, particularly LPS, and evidence of 
Fpr/FPR expression. 
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3.1.1.1 Dentate gyrus of the hippocampal formation 
The hippocampal formation is located in the medial temporal lobe of the brain. Within the hippocampal 
formation, the dentate gyrus (DG) is a site of prolific neurogenesis and hypothalamic afferents with a 
crucial role in learning and memory along with negative feedback effects on the HPA axis (Gould et al. 
1999). From development into adulthood, neurogenesis occurs within the DG with neural stem/progenitor 
cells (NSPCs) forming within the hilus (Hil) and extending into the granule cell layer (GCL) and 
subgranular zone (SGZ). During the stress response the DG is exposed to increased plasma GCs, which 
inhibit granule cell production and proliferation via a mechanism involving an upregulation of glutamate 
release and N-Methyl-D-aspartate (NMDA)-receptor mediated excitation (Moghaddam et al. 1994; 
Cameron et al. 1995) and downregulated brain derived neurotrophic factor (BDNF). Stress-induced 
impairment in neurogenesis is observed within the DG following exposure to GCs or chronic stress, 
which reverses the increase in neurogenesis following adrenalectomisation (Gould et al. 1992; Rodriguez 
et al. 1998; Mineur et al. 2007). The inhibition of HPA axis activity is substantiated by the increase in 
corticotrophic releasing hormone (CRH) and arginine vasopressin (AVP) mRNA in the medial 
parvocellular neurons within the paraventricular nucleus of the hypothalamus upon hippocampectomy 
(Herman et al. 1989). During inflammogenic stress, such as that elicited by peripheral LPS, there is a 
subsequent upregulation of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α) and activation of 
microglia within the DG, and anti-IL-6 neutralisation restores neurogenesis in co-cultures of DG 
progenitor cells and LPS-activated microglia in vitro (Monje et al. 2003). With regard to hippocampal 
expression of Fpr/FPR subtypes, mouse Fpr2 was shown to be upregulated in the DG of amyloid 
precursor protein/presenilin 1 (APP/PS1) transgenic mice, and the Fpr2-antagonist Trp-Arg-Trp-Trp-Trp-
Trp (WRW4) prevented amyloid beta 1-42 (Aβ42) induced senescence of NSPCs (He et al. 2013b) and 
glial cells (Slowik et al. 2012). An in situ hybridisation study found evidence of transcripts for Fpr2 along 
with CRH-R1 and V1b within the DG and hippocampal formation, and this finding was validated by a 
qRT-PCR study which also found evidence of Fpr1, Fpr3 and annexin A1 (ANXA1), as well as Fpr2 
(Buss 2010). It is not clear whether these hippocampal Fpr transcripts are translated into functional 
proteins, or if this process is subject to regulation by LPS in experimental models of inflammogenic 
stress. 
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3.1.1.2 Paraventricular nucleus of the hypothalamus 
Within the anterior hypothalamus, the paraventricular nucleus (PVN) is adjacent to the third ventricle 
(3V) and encompasses the neurons for CRH/AVP that stimulate pituitary adrenocorticotrophic hormone 
(ACTH) release in response to stress. The release of CRH and AVP are regulated by bisynaptic 
glutamate-GABA connections under the control of nitric oxide (NO) and norepinephrine (NE) (Herman 
et al. 2002). A major input to the PVN comes from the brainstem locus coeruleus (LC)/NE 
catecholaminergic system, and blockade of this tract blunts the HPA axis response to LPS and IL-1β 
(Givalois et al. 1995), which otherwise induce cFos mRNA and Fos protein within the nucleus tractus 
solitarius (NTS) and ventrolateral medulla (Day & Akil 1996). Increases in PVN NE turnover following 
LPS or IL-1β are blocked by IL-1 receptor antagonist, suggesting IL-1 is involved in mediating the 
effects of LPS in the PVN (MohanKumar et al. 1999). Toll-like receptor 4 (TLR4) is expressed on 
LC/NE terminals, and within 2 hours of LPS injection, IL-1β and nitric oxide synthase (NOS) mRNA 
transcription is induced and peaks between 4 and 6 hours within the PVN (Wong et al. 1996). Whilst the 
PVN is highly vascularised, it is largely protected by the blood-brain barrier (BBB), whereas the 
CRH/AVP neurons themselves have projections that extend beyond the BBB to the median eminence and 
the pituitary. Though it is debatable whether LPS crosses the BBB in significant amounts, NOS within 
the PVN is, however, induced by LPS which in turn leads to the transcription of CRH and AVP (Uribe et 
al. 1999), and an increase in NE turnover that parallels increases in ACTH and GC secretion (Francis et 
al. 2000). The Fpr/FPR ligand ANXA1 has also been shown to be expressed within key loci of the 
hypothalamus particularly the ependymal cells around 3V and the median eminence, including the PVN 
(Woods et al. 1990; Strijbos et al. 1991; Smith et al. 1993). It remains unclear whether Fpr/FPR subtypes 
are involved in the regulation of CRH or AVP release, but there is evidence that members of the Fpr/FPR 
family are expressed within the hypothalamus. A quantitative reverse transcriptase-polymerase chain 
reaction (qRT-PCR) study found evidence of Fpr1, Fpr2, and Fpr3/Alx transcripts expressed within the 
hypothalamus, whereas of these, only Fpr2 was evident within the hypothalamus upon in situ 
hybridisation (Buss 2010). It remains to be determined whether the transcripts from the Fpr/FPR genes 
are ultimately translated into functional proteins within the hypothalamus, and if so, whether these are 
relevant to HPA axis function. 
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3.1.1.3 Anterior pituitary gland 
The anterior pituitary gland comprises the pars distalis, pars intermedia, and pars tuberalis. The anterior 
pituitary secretes ACTH in response to the hypothalamic secretagogues CRH and AVP. Within the 
medial region of the pars distalis, the corticotrophs synthesise and secrete ACTH and are polygonal cells 
of medium diameter (10-13 μm) that constitute between 15-20% of total cells within the anterior pituitary 
(see Krause 2005; Ross & Pawlina 2010; Stevens & Lowe 2011). There are several other endocrine and 
non-endocrine cell types within the anterior pituitary. The somatotrophs are oval cells of medium 
diameter (10-13 μm) that synthesise and secrete growth hormone (GH) and make up 40-50% of total 
cells, and are situated within the lateral wings of the pars distalis. The lactotrophs are large (14-20 μm), 
polygonal cells that synthesise and secrete prolactin (PRL), are uniformly scattered throughout the pars 
distalis and constitute 20-25% of total cells. The gonadotrophs are small (<10 μm), oval cells that 
synthesise and secrete luteinising hormone (LH)/follicle stimulating hormone (FSH), accounting for 10% 
of total cells and are uniformly scattered throughout the pars distalis. The thyrotrophs are large (14-20 
μm), polygonal cells that produce thyroid-stimulating hormone (TSH) and are situated in the most 
anterior region of the gland, constituting 10% of total cells. The folliculostellates are small to medium 
diameter star-shaped cells accounting for 5-10% of total cells (Allaerts et al. 1996), and express S100 
calcium binding protein b (S100b), as well as the Fpr/FPR ligand, ANXA1 (Traverso et al. 1999). 
Several of the hormones of the anterior pituitary have receptors and functions on cells of the immune 
system. There are receptors for ACTH, GH, and PRL on T lymphocytes, B cells, natural killer (NK) cells, 
macrophages, and monocytes (Weigent & Blalock 1987). GH has been shown to maintain the 
competence of T and B cells and macrophages, and stimulate antibody production and NK cell activity; it 
also has haematopoietic and chemotactic roles within cells of the thymus, spleen, lymph nodes, and bone 
marrow (Welniak et al. 2002). On the other hand, PRL stimulates the clonal expansion of lymphoid cell 
populations and appears to have mitogenic activity on NK cells and macrophages, at least in vitro 
(Clevenger et al. 1998; Sun et al. 2004b). Administration of ACTH in humans affects the circulating 
concentration of leukocytes, increasing neutrophils and decreasing lymphocytes and eosinophils (Hills et 
al. 1948), and enhances T-cell mediated cytotoxicity (Johnson et al. 2005) but otherwise generally 
inhibits immune responses (Johnson et al. 1982).   
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In response to inflammogenic stress elicited by LPS, changes in the expression and secretion of pituitary 
hormones is subject to mediation by cytokines such as IL-1β, IL-6, and TNF-α, as well as eicosanoids, 
and NO. The cells of the anterior pituitary, express a number of cytokines along with their receptors and 
other cellular mediators. In response to LPS or IL-1β, pituitary cyclooxygenase expression is upregulated 
(Cover et al. 2001) and the production of eicosanoids in turn leads to increased IL-6 release by the 
folliculostellate cells which has been shown to stimulate ACTH release from the rat pituitary (Spangelo et 
al. 1991). This mechanism also involves NfκB-mediated transcription within the folliculostellates (Mehet 
et al. 2012) which in response to LPS or GCs release macrophage inhibitory factor (MIF) that limits the 
steroid-mediated inhibition of IL-6 release (Tierney et al. 2005). Conversely, the release of ACTH from 
the anterior pituitary has been shown to be inhibited by various Fpr/FPR ligands, including ANXA1 
(Pompeo et al. 1997; John et al. 2007). ANXA1 is upregulated by LPS or GCs, and thus appears to 
function as a mediator of GC negative feedback for the pituitary-adrenal axis. 
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3.1.1.4 Thymus gland 
The thymus gland is located within the mediastinum of the thoracic cavity, beneath the sternum and 
superior to the heart. The thymus gland is a primary lymphoid organ in which bone marrow-derived T 
cell precursors undergo differentiation and migration prior to maturity when they are circulated for 
secondary lymphoid organs such as the spleen, lymph nodes, Peyer’s patches, and tonsils (Surh & Sprent 
1994). The maturation process involves serial expression of clusters of differentiation (CD) and 
rearrangement of T cell receptor (TCR) genes and is compartmented to microenvironments conducive for 
the development of T cells as they migrate through the gland. The structure of the thymus can be 
visualised by routine haematoxylin and eosin (H&E) staining and consists of numerous lobules separated 
by trabeculae. Each lobule contains an outer thymic cortex and an inner medulla, separated by a cortico-
medullary junction. Compared with the medulla, the thymic cortex is darkly stained by H&E and 
comprises branched thymic epithelial cells (TECs) in close association with immature thymocytes, as 
well as macrophages scattered throughout the cortex with roles in clearing apoptotic thymocytes (Billard 
et al. 2011). Thymocytes are apoptosed by default if their TCRs are not functionally expressed following 
its genetic rearrangement (Surh & Sprent 1994; Vacchio & Ashwell 1997). Conversely, thymocytes 
whose TCRs react with a major histocompatibility complex (MHC) on nonlymphoid cells are able to 
differentiate through positive or negative selection steps (Chiu et al. 1999; Doyle et al. 2003). This occurs 
under the influence of GCs (Surh & Sprent 1994; Sacedon et al. 1999) acting via GRs (Miller et al. 
1998). The outer layer of the cortex is a site of immature thymocyte proliferation, whereas inner cortical 
thymocytes are predominantly immature T cells undergoing thymic selection. The thymic medulla 
encompasses mature thymocytes (single-positive for either CD4 or CD8 co-receptor), medullary 
epithelial cells, and bone-marrow derived macrophages and dendritic cells, and Hassall’s corpuscles 
encapsulate sites of cell death (Williams & Felten 1981; King et al. 1995). 
The interaction of the thymus gland with the HPA axis is achieved by neuroendocrine, humoral, and 
neural communication. The humoral link is maintained by reciprocal communication between thymic 
hormones such as thymulin, thymosin-α1, and thymopoietin, and the hormones of the HPA axis, as well 
as pituitary PRL, GH, and LH. Thymulin, for instance, inhibits secretion of PRL (Hadley et al. 1997) but 
stimulates ACTH which also has a role in the release of thymulin (Buckingham et al. 1992), hence the 
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communication between the thymus and HPA axis is reciprocal. In 1936, Hans Selye described the 
involution of the thymus in animals exposed to stressors (Selye 1936). During the stress response, the 
thymus shrinks in proportion to the circulating concentration of GCs that suppress the formation of 
thymus (T)-lymphocytes that make up the bulk of thymic tissue prior to their secretion. In addition, 
because GCs inhibit IL-1 and interferon-gamma (IFN-γ) release, circulating T-lymphocytes are less 
responsive to pathogens but are susceptible to GC-induced apoptosis or clearance from the circulation 
towards lymphoid tissues or sites of infection (Dhabhar & McEwen 1996). Following exposure to LPS, 
for instance, T-lymphocytes undergo apoptosis and thymic atrophy occurs as a result (Zhang et al. 1993; 
Norimatsu et al. 1995). In TLR4-null mice, there is evidence of ANXA1 expression on apoptotic 
thymocytes (Weyd et al. 2013). In addition to thymic atrophy, the Fpr/FPR ligand lipoxin is upregulated 
and inhibits neutrophil functions (Billard et al. 2011). There is evidence of Fpr/FPR expression within the 
thymus, particularly mouse Fpr1 and Fpr2 (Rivière et al. 2009). Interestingly, there is evidence that 
formylated peptides are involved with the positive selection steps involving TCR binding with major 
histocompatibility complex (MHC) class Ib molecules H2-M3 (Chiu et al. 1999; Doyle et al. 2003). It 
remains unclear which Fpr/FPR subtype could be involved in mediating thymic function across the highly 
compartmented microenvironments and how this affects the response to inflammogenic stressors. 
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3.1.1.5 Zona fasciculata of the adrenal cortex 
The adrenal cortex can be divided into three zones of cellular organisation. The zona glomerulosa (ZG) is 
the narrow outer zone and accounts for 15% of the total adrenocortical volume. The zona fasciculata (ZF) 
is a thick central zone of the cortex, constituting up to 80% of the total volume. The innermost zona 
reticularis (ZR) makes up between 5% and 7% of the cortical volume (Henrikson 1997). The ZF is the 
major site for the steroidogenesis of GCs. The cells of the ZF are large, polyhedral structures arranged in 
elongated mono- or bi-cellular cords separated by sinusoidal capillaries. Histologically, these cells 
typically have a lightly stained spherical nucleus or two nuclei, and the cytoplasms are acidophilic with 
numerous lipid droplets. These droplets may appear as sterol vacuolations following routine histological 
sections owing to dehydration steps extracting lipids. The lipid droplets contain fatty acids, cholesterol, 
and phospholipid precursors for steroidogenesis of GCs. The GCs have overall inhibitory effects on the 
immune and inflammatory responses, inhibiting wound healing. The GCs have receptors on T and B 
cells, neutrophils, monocytes, and macrophages, and have been shown to suppress IL-1 and IL-2 
production by lymphocytes and macrophages. The GCs modulate the production of cytokines such as 
inhibition of IL-12 from antigen presenting cells (APCs) as well as inducing a shift from TH1 to TH2 
cytokines (Elenkov et al. 1996; Miller et al. 1998). The GCs also upregulate the apoptosis of lymphocytes 
and inhibit the mitosis of transformed lymphoblasts.  
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3.2 Methodology 
Based on the above evidence, it was hypothesised that 1) proteins translated from the transcripts of the 
Fpr2 and Fpr3 exons, will be expressed within cerebral, lymphoid, and HPA axis tissues following 
peripheral LPS injections; 2) the spatial distribution of green fluorescent protein (GFP) as a surrogate of 
Fpr2 and Fpr3 within the anterior pituitary of Fpr2/3-knockout, GFP-transgenic (Fpr2/3
-/-
) mice will be 
evident within the endocrine cell types (expressing ACTH, GH, PRL, LH, TSH) but not the S100b-
positive folliculostellates; and 3) immunoreactivity from the human FPR subtypes FPR2/ALX or FPR3 
will be colocalised with ACTH- but not S100b-positive cells.  
In the present work we used HPA tissues from Fpr2/3
-/-
, GFP-positive mice to elucidate the distribution of 
GFP as a proxy of Fpr2/3 within the hypothalamus, pituitary, and adrenal, as well as thymus. In addition, 
we used antibodies to target epitopes on the human FPR1, FPR2/ALX, and FPR3 subtypes to map their 
distribution alongside ACTH and S100b-positive cells of the human anterior pituitary gland. 
In order to test these hypotheses, mice with the Fpr2 and Fpr3 genes knocked-out and transgenic for GFP 
(Fpr2/3
-/-
) were used. This model was selected because colleagues had recently generated the Fpr2/3
-/-
 
mice and, at the time, there were no specific antibodies to detect the spatial distribution of murine Fpr2 or 
Fpr3 epitopes within tissues by IHC. Since measures of Fpr2 and Fpr3 gene transcripts had already been 
obtained (Buss 2010), it was important to advance this knowledge by determining whether these 
transcripts are translated into proteins, and if so, their spatial distribution within tissues. Therefore, to 
determine how peripheral administration of LPS in vivo, might affect the spatial distribution of GFP as a 
proxy of Fpr2 and Fpr3 protein expression within tissues, Fpr2/3
-/-
 mice and wildtype littermates received 
intraperitoneal injections of either LPS or vehicle over a brief time course of 2, 4, and 6 hours. Well-
validated antibodies that target GFP were used in IHC experiments to detect GFP as a surrogate of Fpr2 
and Fpr3 within murine tissues. Tissue sections from wildtype littermates were used as negative controls, 
and those from irrelevant GFP transgenic mice were used as positive controls, so that the staining pattern 
observed could be attributed to the presence of GFP signal above background autofluorescence (if any), 
and, therefore, indicative of the expression of Fpr2 and/or Fpr3 proteins within the tissue.  
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To determine which cell types of the mouse anterior pituitary gland contain translation products from the 
mouse Fpr2 and/or Fpr3 gene exons, formalin-fixed paraffin embedded anterior pituitaries from LPS or 
vehicle injected Fpr2/3
-/-
 mice or wildtype littermates were immunostained with antibodies for S100b, a 
marker of folliculostellate cells, and for each endocrine lineage (ACTH, GH, PRL, LH, and TSH) in 
conjunction with antibodies for GFP. Since the presence of GFP could only come from the translation of 
GFP transcribed from the GFP transgene inserted in the Fpr2/Fpr3 exon, this allowed inferences to be 
made about which cell types express Fpr2 and/or Fpr3.  
To determine whether the genes for human FPR1, FPR2/ALX, and FPR3 are translated within the human 
anterior pituitary gland, commercially available antibodies specific to epitopes on each human FPR 
subtype were used along with those for ACTH and S100b. Fluorescently labelled secondary antibodies 
were added to allow detection of immunofluorescence from FPR subtypes and ACTH or S100b and to 
therefore quantify colocalisation by confocal microscopy. 
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3.3 Results 
3.3.1 Genotyping of Fpr2/3-/- mice 
Figure 3.1 shows the results of genotyping experiments with primers specific for nucleotide sequences of 
DNA for the mouse genes Fpr2, Fpr3, and the housekeeping gene, glyceraldehyde 3-phosphate 
(GAPDH). Genotyping was performed prior to further studies in order to sort GFP transgenic, Fpr2 and 
Fpr3 knockout (Fpr2/3
-/-
) mice and their wildtype littermates (WT) into experimental group allocations 
befitting their reported phenotypes (Dufton et al. 2010; 2011). From the collection of ear clips of Fpr2/3
-/-
, WT, and positive control C57BL/6 mice, the genotyping experiments were performed blind to minimise 
the effect of bias (knowledge of the suspected genotype) on the results. Following DNA extraction and 
PCR, the products were separated by electrophoresis through an agarose gel containing ethidium bromide 
to resolve bands of DNA fragments by exposure to ultra-violet light. The size of the resulting amplicons 
were concordant with those predicted by the basic local alignment search tool (BLAST; 
http://blast.ncbi.nlm.nih.gov/) for primer alignment with gene sequences, whereby the expected size for 
amplicons of Fpr2 was 650 base pairs (bp), Fpr3 was 475 bp, and GAPDH was 363 bp. The results 
confirmed the Fpr2/3
-/- 
mice were all negative for the Fpr2 gene, but in some mice the Fpr3 gene was 
knocked-down but not completely knocked-out. In samples from these mice, a band for Fpr3 was present 
but less concentrated than the Fpr3 amplicons from WT and C57BL/6 mice. The presence of the 
housekeeping gene GAPDH was unaffected by the genetic modification at the Fpr2 and Fpr3 gene loci in 
the Fpr2/3
-/-
 mice. The water control confirmed the molecular grade water was not a source of 
contamination.  
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Figure 3.1: Agarose gel electrophoretogram of polymerase chain reaction (PCR) products of 
amplified DNA from formyl peptide receptor 2 and 3 knockout (Fpr2/3
-/-
) mice, wildtype 
littermates (WT), and C57BL/6 positive control mice.  
Ear clips were taken from Fpr2/3
-/-
, WT, and C57BL/6 mice (n = 4) and DNA was extracted prior to 
performing PCR with specific primers for Fpr2, Fpr3, and the glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) housekeeping gene. PCR products and loading buffer were loaded into each lane (except 
ladder and blank) on a 1% agarose gel containing ethidium bromide, before running the gel (140 V, 40 
min). DNA bands were visualised on an ultraviolet gel documentation system. The experiment was 
performed blind. 
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3.3.2 Western blotting for Fpr2/3 in lung extracts of Fpr2/3-/- mice and wildtype littermates 
Figure 3.2 shows the result of the SDS-PAGE of protein extracts from the lung tissue taken from Fpr2/3
-/-
 
and WT mice followed by western blot with a polyclonal rabbit anti-mouse Fpr2/3 antibody (sc-18191-R) 
immunoreactive with mouse Fpr2/3 and human FPR2. Molecular weight markers for alcohol 
dehydrogenase (39 kDa) and glutamic dehydrogenase (51 kDa) from the SeeBlue® Plus2 Prestained 
Standard ladder were used to determine the size of the immunoreactive epitope. The predicted monomeric 
size of Fpr3 is 351 amino acids (aa) or 39.5 kDa, and Fpr2 is 351 aa or 39.4 kDa. The result indicates the 
presence of an immunoreactive epitope of a molecular weight between 39 and 51 kDa present within the 
lung extracts of WT mice that is absent from Fpr2/3
-/- 
mice.  
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Figure 3.2: Immunoreactive formyl peptide receptor 2 (Fpr2) or 3 (Fpr3) in lung extracts from 
wildtype (WT) littermates of Fpr2 and Fpr3 knockout (Fpr2/3
-/-
) mice, detected by western blot.  
WT and Fpr2/3
-/-
 mice (n = 4) received an intraperitoneal injection of lipopolysaccharide (LPS; 750 µg/kg 
i.p.). Lung tissues were sonicated and extracted proteins then separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a methanol-activated polyvinylidene 
fluoride (PVDF) membrane. This was then incubated with primary rabbit polyclonal anti-mouse Fpr2/3 
(Fpr2/3 (N20)-R, Cat: sc-18191-R, Santa Cruz; Insight Biotech, Wembley, UK) diluted 1 in 200 v/v in 
tris-buffered saline (TBS)/Tween overnight at 4 °C. Molecular weight markers indicate the band in the 
WT lane is between 39 and 51 kDa. 
Fpr2/3-/- WT 
kDa 
 
51 
 
 
 
 
39 
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3.3.3 Immuno-fluorescent detection of GFP within anterior pituitary sections taken from Fpr2/3-/- mice 
and wildtype littermates 
The following results are from a study in which sections of anterior pituitaries from Fpr2/3
-/-
 and WT 
mice were fluorescently immunostained for GFP and pituitary cell lineage markers, namely, ACTH, GH, 
PRL, and S100b. Mice were injected with LPS (750 μg/kg i.p.) and then killed by CO2 asphyxiation 4 
hours later, and perfusion fixed. Pituitary glands were then dissected out for formalin fixation and 
paraffin embedding. Immuno-fluorescent staining was performed on anterior pituitary sections from both 
Fpr2/3
-/-
 and WT mice, with the latter serving as a negative control to provide an indication of 
background and endogenous fluorescence without the presence of the GFP transgene in the Fpr2/3
-/-
 mice.  
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3.3.3.1 Adrenocorticotrophic Hormone 
Figure 3.3 shows the immunofluorescence from antibodies detecting GFP and ACTH epitopes on anterior 
pituitary sections from Fpr2/3
-/- 
mice and wildtype littermates. Specifically, the red signal in Figure 3.3(d) 
indicates nuclear GFP immunoreactivity, and the green signal in Figure 3.3(b) indicates cytoplasmic 
ACTH immunoreactivity. Figure 3.3(f) shows the close association of the red and green signals within 
cellular structures, indicating GFP and ACTH co-immunoreactivity within cells. In contrast, the wildtype 
littermates lacked the red, nuclear GFP immunoreactivity altogether (Figure 3.3 c) but exhibited a similar 
pattern of cytoplasmic ACTH (Figure 3.3 a) as compared with the Fpr2/3
-/- 
mice. These results are 
enumerated in Figure 3.4, which shows the results of counting cells with either red GFP 
immunoreactivity, green ACTH signal, or both GFP and ACTH. No cells with GFP signal were observed 
in the wildtype mouse sections. In the Fpr2/3
-/- 
sections, cells with both ACTH+GFP outnumbered those 
of ACTH alone (***P < .001) and GFP alone (&&P < .01). These results indicate a significant 
colocalisation of ACTH and GFP within cells in the anterior pituitary of Fpr2/3
-/- 
mice, but not in 
wildtype littermates. 
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Figure 3.3: Immunofluorescence of adrenocorticotrophic hormone (ACTH) and green fluorescent 
protein (GFP) within the pars distalis of anterior pituitary sections from GFP transgenic, formyl 
peptide receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
ACTH and anti-GFP followed by secondary antisera tagged with the fluorochromes Alexa Fluor 488 
(green, for ACTH) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings of 
the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). 
Arrows denote immunofluorescence for cytoplasmic and membranous ACTH (a and e; b and f), 
perinuclear GFP (d), and arrowheads denote GFP and ACTH colocalisation (f). 
(a) WT ACTH (b) Fpr2/3-/- ACTH 
(c) WT GFP (d) Fpr2/3-/- GFP 
(e) WT merge (f) Fpr2/3-/- merge 
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Figure 3.4: Number of cells with immunofluorescence for adrenocorticotrophic hormone (ACTH) 
and/or green fluorescent protein (GFP) within the pars distalis of anterior pituitary sections from 
GFP transgenic, formyl peptide receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) 
littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
ACTH and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa 
Fluor 488 (green, for ACTH) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained 
with diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings 
of the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). 
Data are mean number of cells ± standard error of mean (n = 4 mice) counted per 1 mm
2
 on the basis of 
being positive for ACTH, GFP, or both, and compared by two-way ANOVA: ACTH vs. ACTH+GFP 
***P < .001; ACTH vs. GFP ###P < .001; and GFP vs. ACTH+GFP &&P < .01. 
WT Fpr2/3-/-
200
400
600
800
ACTH
ACTH & GFP
GFP *** 
###
&&
c
e
ll
s
 ×
 m
m
-2
129 
3.3.3.2 Growth Hormone 
Figure 3.5 shows the immunofluorescence from antibodies detecting GFP and GH epitopes on anterior 
pituitary sections from Fpr2/3
-/- 
mice and wildtype littermates. Specifically, the red signal in Figure 3.5(d) 
indicates nuclear GFP immunoreactivity, and the green signal in Figure 3.5(b) indicates cytoplasmic GH 
immunoreactivity. Figure 3.5(f) illustrates an association of the red and green signals within cellular 
structures, indicating there was GFP and GH co-immunoreactivity within cells. In contrast, the wildtypes 
littermates lacked the red, nuclear GFP immunoreactivity altogether (Figure 3.5 c) but exhibited a similar 
pattern of cytoplasmic GH (Figure 3.5 a) as compared with the Fpr2/3
-/- 
mice. These results are 
enumerated in Figure 3.6, which shows the results of counting cells with either red GFP 
immunoreactivity, green GH signal, or both GFP and GH. No cells with GFP signal were observed in the 
wildtype mouse sections. In the Fpr2/3
-/- 
sections, cells with both GH+GFP outnumbered those of GH 
alone (***P < .001) and GFP alone (&&&P < .001). In addition, there were fewer cells with GFP alone 
than GH alone (###P < .001). These results indicate that in sections from the anterior pituitary of Fpr2/3
-/- 
mice (but not from wildtype littermates) the majority of GH-positive cells had colocalisation of GH and 
GFP within their structures. There also appeared to be a subset of GH-positive structures that were not 
GFP-positive.  
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Figure 3.5: Immunofluorescence of growth hormone (GH) and green fluorescent protein (GFP) 
within the pars distalis of anterior pituitary sections from GFP transgenic, formyl peptide receptor 
2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
GH and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa Fluor 
488 (green, for GH) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei (not shown). The region within the lateral wing of the 
pars distalis was imaged by fluorescence microscopy (40x). Arrows denote GH staining (b), perinuclear 
GFP staining (d), and arrowheads denote GFP and GH colocalisation (f). 
(a) WT GH (b) Fpr2/3-/- GH 
(c) WT GFP (d) Fpr2/3-/- GFP 
(e) WT merge (f) Fpr2/3-/- merge 
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Figure 3.6: Number of cells with immunofluorescence for growth hormone (GH) and/or green 
fluorescent protein (GFP) within the pars distalis of anterior pituitary sections from GFP 
transgenic, formyl peptide receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) 
littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
GH and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa Fluor 
488 (green, for GH) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei (not shown). The region within the lateral wing of the 
pars distalis was imaged by fluorescence microscopy (40x). Data are mean number of cells ± standard 
error of mean (n = 4 mice) counted per 1 mm
2
 on the basis of being positive for GH, GFP, or both, and 
compared by two-way ANOVA: GH vs. GH & GFP *** = P < .001; GH vs. GFP ### = P < .001; and 
GFP vs. GH & GFP &&& = P < .001.  
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3.3.3.3 Prolactin 
Figure 3.7 shows the immunofluorescence from antibodies detecting GFP and PRL epitopes on anterior 
pituitary sections from Fpr2/3
-/- 
mice and wildtype littermates. Specifically, the red signal in Figure 3.7(d) 
indicates nuclear GFP immunoreactivity, and the green signal in Figure 3.7(b) indicates cytoplasmic PRL 
immunoreactivity. Figure 3.7(f) illustrates there was an association of the red and green signals within 
cellular structures, thus indicating co-immunoreactivity of GFP and PRL within cells. In contrast, the 
wildtypes littermates lacked the red, nuclear GFP immunoreactivity altogether (Figure 3.7 c) but 
exhibited a similar pattern of cytoplasmic PRL (Figure 3.7 a) as compared with the Fpr2/3
-/- 
mice. These 
results are enumerated in Figure 3.8, which shows the results of counting cells with either red GFP 
immunoreactivity, green PRL signal, or both GFP and PRL. No cells with GFP signal were observed in 
the wildtype mouse sections. In the Fpr2/3
-/- 
sections, cells with both PRL+GFP outnumbered those of 
PRL alone (***P < .001) and GFP alone (&&&P < .001). In addition, there were more cells with GFP 
alone than PRL alone (#P < .05). These results indicate that in sections from the anterior pituitary of 
Fpr2/3
-/- 
mice (but not from wildtype littermates) the majority of PRL-positive cells had colocalisation of 
PRL and GFP within their structures. There also appeared to be a subset of PRL-positive structures that 
were not GFP-positive. 
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Figure 3.7: Immunofluorescence of prolactin (PRL) and green fluorescent protein (GFP) within the 
pars distalis of anterior pituitary sections from GFP transgenic, formyl peptide receptor 2 and 3 
knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
PRL and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa Fluor 
488 (green, for PRL) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings of 
the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). 
Arrows denote PRL staining (b), perinuclear GFP staining (d), and arrowheads denote GFP and PRL 
colocalisation (f). 
(a) WT PRL (b) Fpr2/3-/- PRL 
(c) WT GFP (d) Fpr2/3-/- GFP 
(e) WT merge (f) Fpr2/3-/- merge 
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Figure 3.8: Number of cells with immunofluorescence for prolactin (PRL) and/or green fluorescent 
protein (GFP) within the pars distalis of anterior pituitary sections from GFP transgenic, formyl 
peptide receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
PRL and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa Fluor 
488 (green, for PRL) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings of 
the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). Data 
are mean number of cells ± standard error of mean (n = 4 mice) counted per 1 mm
2
 on the basis of being 
positive for PRL, GFP, or both, and compared by two-way ANOVA: PRL vs. PRL & GFP *** = P < 
.001; PRL vs. GFP # = P < .05; and GFP vs. PRL & GFP &&& = P < .001. 
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3.3.3.4 S100b 
Figure 3.9 shows the immunofluorescence from antibodies detecting GFP and S100b epitopes on anterior 
pituitary sections from Fpr2/3
-/- 
mice and wildtype littermates. Specifically, the red signal in Figure 3.9(d) 
indicates nuclear GFP immunoreactivity, and the green signal in Figure 3.9(b) indicates cytoplasmic 
S100b immunoreactivity. Figure 3.9(f) indicates there was no association of the red and green signals 
within cellular structures, indicating there was zero GFP and S100b co-immunoreactivity within cells. In 
contrast, the wildtypes littermates lacked the red, nuclear GFP immunoreactivity altogether (Figure 3.9 c) 
but exhibited a similar pattern of cytoplasmic S100b (Figure 3.9 a) as compared with the Fpr2/3
-/- 
mice. 
These results are enumerated in Figure 3.10, which shows the results of counting cells with either red 
GFP immunoreactivity, green S100b signal, or both GFP and S100b. No cells with GFP signal were 
counted in the wildtype mouse sections. In the Fpr2/3
-/- 
sections, cells with GFP alone outnumbered those 
of S100b alone (###P < .001). These results indicate there was no colocalisation of S100b and GFP 
within cell structures in sections from the anterior pituitary of Fpr2/3
-/- 
mice, or from wildtype littermates. 
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Figure 3.9: Immunofluorescence of S100b and green fluorescent protein (GFP) within the pars 
distalis of anterior pituitary sections from GFP transgenic, formyl peptide receptor 2 and 3 
knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
S100b and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa 
Fluor 488 (green, for S100b) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained 
with diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings 
of the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). 
Arrows denote S100b staining (b) and perinuclear GFP (d). 
(a) WT S100b (b) Fpr2/3-/- S100b 
(c) WT GFP (d) Fpr2/3-/- GFP 
(e) WT merge (f) Fpr2/3-/- merge 
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Figure 3.10: Number of cells with immunofluorescence for S100b and/or green fluorescent protein 
(GFP) within the pars distalis of anterior pituitary sections from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates.  
Transverse sections (4 μm) of anterior pituitary glands taken from WT and Fpr2/3-/- mice (n = 4) 4 h after 
intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 750 μg/kg i.p.) were stained with primary anti-
S100b and anti-GFP followed by fluorescent secondary antisera tagged with the fluorochromes Alexa 
Fluor 488 (green, for S100b) or biotin-streptavidin-Alexa Fluor 555 (red, for GFP), and counterstained 
with diamidino phenylindole (DAPI) to identify nuclei (not shown). The region between the lateral wings 
of the pars distalis and anterior to the pars intermedia was imaged by fluorescence microscopy (40x). 
Data are mean number of cells ± standard error of mean (n = 4 mice) counted per 1 mm
2
 on the basis of 
being positive for S100b, GFP, or both, and compared by two-way ANOVA: S100b vs. GFP ### = P 
<.001.
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3.3.4 Immuno-histochemical detection of GFP in key regions of the adrenal glands, thymus, and 
brains from Fpr2/3
-/- 
mice and wildtype littermates 
The following results are from a study in which tissue sections of tissues from Fpr2/3
-/- 
mice and wildtype 
littermates were immunostained for green fluorescent protein (GFP). The tissue areas assessed were the 
dentate gyrus (DG) of the hippocampal formation, the paraventricular nucleus (PVN) of the 
hypothalamus, the follicles of the thymus gland, and the zona fasciculata (ZF) of the adrenal cortex. 
3.3.4.1 Adrenal zona fasciculata 
Figure 3.11 and Figure 3.12 show the effects of injections of LPS or PBS vehicle 2 hours or 6 hours 
previously, on the distribution of immunoreactive GFP observed within the ZF of the adrenal cortex from 
Fpr2/3
-/- 
mice and wildtype littermates (WT). The data indicate that in animals injected 2 hours 
previously, GFP immunoreactivity was evident in the LPS treated Fpr2/3
-/- 
mice (Figure 3.11 d), but was 
not observed in the wildtype littermates (Figure 3.11 c) or the vehicle (PBS) injected control mice of 
either genotype. In adrenals taken from animals injected 6 hours previously, GFP immunoreactivity was 
only scarcely evident in sections from LPS treated Fpr2/3
-/- 
mice (Figure 3.12 d) versus those injected 2 
hours previously (Figure 3.11 d). There was no GFP observed in the wildtype littermates or the saline 
injected controls of either genotype.  
Figure 3.13 shows the result of morphometric analyses of adrenal sections immunostained for GFP. The 
adrenal cortex was imaged by microscope and the ZF analysed by manually counting the total number of 
cells per square millimetre, the number of cells with brown, nuclear, GFP immunoreactivity, and the 
number of vacuolated cells across the section. Sterols are evident as circular vacuolations. In terms of 
total cell counts, there was a modest but significant reduction in the number of cells per square millimetre 
in the adrenal cortex from wildtype animals 2 hours after receiving i.p. LPS (550.0 ± 17.7) versus vehicle 
injected controls (575.3 ± 7.6, † = P < .05). This reduction in cell counts was also observed in wildtype 
animals 6 hours after receiving i.p. LPS (540.8 ± 14.6) versus vehicle injected controls (597.0 ± 7.7, † = P 
< .05). There was no significant difference in the number of cells counted within the ZF of the adrenal 
glands from any of the Fpr2/3
-/-
 mice (ns = P > .05). 
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In terms of the number of GFP-positive cells, sections of the adrenal cortex from most treatment groups 
did not show evidence of GFP immunoreactivity. The only two treatment groups to show evidence of 
GFP-positive cells were the Fpr2/3
-/-
 mice that received i.p. injections of LPS then killed after 2 hours and 
6 h. There were GFP-positive cells evident within the ZF of adrenal glands from the Fpr2/3
-/-
 mice after 2 
hours of receiving LPS (79.8 ± 5.2) and by comparison were significantly reduced in the Fpr2/3
-/-
 mice 
injected with LPS in the six-hour group (9.0 ± 1.3, *** = P < .001). With regard to sterol vacuolation, the 
LPS treatment significantly reduced the degree of sterol vacuolation in the adrenal cortex of the wildtype 
animals after 2 hours (68.0 ± 6.4), versus vehicle controls (207.8 ± 10.9, ††† = P < .001). A similar effect 
was observed in the wildtype littermates receiving LPS after 6 hours (108.3 ± 4.7), versus PBS controls 
(221.8 ± 22.7, ††† = P < .001). In the Fpr2/3-/- mice, however, there was no significant reduction in sterol 
vacuolation following LPS in either the two-hour or six-hour groups versus the respective vehicle injected 
controls (ns = P > .05). 
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Figure 3.11: Immunostain for green fluorescent protein (GFP) within the zona fasciculata (ZF) of adrenal sections from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 2 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Transverse sections (4 μm) of adrenal glands taken from WT and Fpr2/3-/- mice (n = 4) 2 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-
GFP and secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin 
solution (HX, blue). The medial region of the ZF within the cortex and axial to the medulla was imaged by light microscopy (20x, scale bar = 10 μm). Arrows denote 
sterol vacuolation (SV) or positive perinuclear staining for GFP.  
  
(b) Fpr2/3-/- PBS 2 h 
(d) Fpr2/3-/- LPS 2 h 
(a) WT PBS 2 h 
(c) WT LPS 2 h 
SV 
SV 
SV 
SV 
SV 
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Figure 3.12: Immunostain for green fluorescent protein (GFP) within the zona fasciculata (ZF) of adrenal sections from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 6 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Transverse sections (4 μm) of adrenal glands taken from WT and Fpr2/3-/- mice (n = 4) 6 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-
GFP and secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin 
solution (HX, blue). The medial region within the ZF of the cortex and axial to the medulla was imaged by light microscopy (20x, scale bar = 10 μm). Arrows denote 
sterol vacuolation (SV), polymorphonuclear leukocytes (L), or positive perinuclear staining for GFP.  
(b) Fpr2/3-/- PBS 6 h 
(d) Fpr2/3-/- LPS 6 h 
(a) WT PBS 6 h 
(c) WT LPS 6 h 
L 
SV 
SV 
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Figure 3.13 Morphometric analysis of immunostained green fluorescent protein (GFP) within the 
zona fasciculata (ZF) of adrenal sections from GFP transgenic, formyl peptide receptor 2 and 3 
knockout (Fpr2/3
-/-
) mice and wildtype (WT) littermates 2 h and 6 h following intraperitoneal (i.p.) 
injection of lipopolysaccharide (LPS) or phosphate buffered saline (PBS) vehicle.  
Transverse sections (4 µm) of adrenal glands from WT and Fpr2/3
-/-
 mice (n = 4) 2 h and 6 h after 
receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-GFP and secondary horseradish 
peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) 
and a weak haematoxylin solution (HX, blue). The medial region within the ZF of the cortex and axial to 
the medulla was imaged by light microscopy (20x). Data are mean number of cells (n = 4 mice) ± 
standard error of mean counted per 1 mm
2
 on the basis of being positive for blue HX-stained nuclei, dark 
brown DAB-stained GFP, or sterol vacuolation, and compared by two-way ANOVA: KO LPS 6 h vs. KO 
LPS 2 h * = P < .05, ** = P < .01, *** = P < .001; and LPS vs. PBS † = P < .05, ††† = P < .001. 
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3.3.4.2 Dentate gyrus of the hippocampal formation 
Figure 3.14 and Figure 3.15 show the results of immunostaining in coronal sections of the mouse brain, 
within the dentate gyrus (DG) of the hippocampus. Sections were taken between the septal nuclei 
rostrally and the temporal cortex caudally, where the DG had a characteristic banana-shape structure. 
Within the DG structure, the medial blade (mb) was observed for any changes in GFP immunoreactivity 
and in the thickness of the granule cell layer (GCL), subgranular zone (sgz), and the molecular layer 
(ML) in Fpr2/3
-/-
 versus WT mice, 2 hours and 6 hours following intraperitoneal injections of LPS or 
PBS. In a region incorporating dendrites of dentate granule cells, as well as interneurons and perforant 
path fibres from the enthorhinal cortex, the ML exhibited a typical thickness of around 60 μm. There 
were no obvious differences in the thickness of ML in the Fpr2/3
-/-
 mice versus wildtypes, or following 
LPS or vehicle. The ML did not contain any immunoreactive staining for GFP in either the Fpr2/3
-/-
 or the 
WT sections. The granule cell layer (GCL) includes the densely packed granule cells and other neuronal 
structures such as the pyramidal basket cells along the periphery and characteristically partly enclosed the 
polymorphic layer (PML). Taken together, the data indicate that in animals injected either 2 hours or 6 
hours previously there was no observable GFP immunoreactivity in the ML, GCL or PML within the DG 
of the hippocampal formation of brain sections from Fpr2/3
-/-
 mice or wildtype littermates, irrespective of 
LPS or saline treatment. 
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Figure 3.14: Immunostain for green fluorescent protein (GFP) within the hippocampus of sectioned brains taken from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 2 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Coronal sections (4 μm) of brains taken from WT and Fpr2/3-/- mice (n = 4) 2 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-GFP and 
secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin solution (HX, 
blue). The medial blade of the dentate gyrus within the hippocampus was imaged by light microscopy (20x, scale bar = 10 μm). Arrows denote granular neurons, and 
the granule cell layer (GCL) and subgranular zone (sgz) are annotated. 
(b) Fpr2/3-/- PBS 2 h Hippocampus  
(d) Fpr2/3-/- LPS 2 h Hippocampus 
(a) WT PBS 2 h Hippocampus 
(c) WT LPS 2 h Hippocampus 
GCL 
GCL 
sgz sgz 
GCL 
GCL sgz 
sgz 
 145 
Figure 3.15: Immunostain for green fluorescent protein (GFP) within the hippocampus of sectioned brains taken from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 6 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Coronal sections (4 μm) of brains taken from WT and Fpr2/3-/- mice (n = 4) 6 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-GFP and 
secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin solution (HX, 
blue). The medial blade of the dentate gyrus within the hippocampus was imaged by light microscopy (20x, scale bar = 10 μm). Arrows denote granular neurons, and 
the granule cell layer (GCL) and subgranular zone (sgz) are annotated. 
(b) Fpr2/3-/- PBS 6 h Hippocampus  
(d) Fpr2/3-/- LPS 6 h Hippocampus 
(a) WT PBS 6 h Hippocampus 
(c) WT LPS 6 h Hippocampus 
GCL 
sgz 
GCL 
sgz 
GCL 
sgz 
GCL 
sgz 
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3.3.4.3 The paraventricular nucleus of the hypothalamus 
Figure 3.16 and Figure 3.17 show the results of immunostaining in coronal sections of the hypothalamus. 
The area of assessment was the paraventricular nucleus (PVN) situated above the third ventricle and 
median eminence. The data indicate that in animals injected either 2 hours or 6 hours previously, there 
was no observable GFP immunoreactivity in sections from Fpr2/3
-/-
 mice or wildtype littermates, 
irrespective of LPS or saline treatment. 
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Figure 3.16: Immunostain for green fluorescent protein (GFP) within the hypothalamus of sectioned brains taken from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 2 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Coronal sections (4 μm) of brains taken from WT and Fpr2/3-/- mice (n = 4) 2 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-GFP and 
secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin solution (HX, 
blue). The region superior to the paraventricular nuclei (PVN) of the hypothalamus and lateral to the third ventricle (3V) was imaged by light microscopy (20x, scale 
bar = 10 μm). 
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Figure 3.17: Immunostain for green fluorescent protein (GFP) within the hypothalamus of sectioned brains taken from GFP transgenic, formyl peptide 
receptor 2 and 3 knockout (Fpr2/3
-/-
) mice versus wildtype (WT) littermates 6 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or 
phosphate buffered saline (PBS) vehicle.  
Coronal sections (4 μm) of brains taken from WT and Fpr2/3-/- mice (n = 4) 6 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-GFP and 
secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin solution (HX, 
blue). The region superior to the paraventricular nuclei (PVN) of the hypothalamus and lateral to the third ventricle (3V) was imaged by light microscopy (20x, scale 
bar = 10 μm). 
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3.3.4.4 Thymic follicles 
Figure 3.18 and Figure 3.19 show the results of immunostaining for GFP in sections of the thymus. The 
area of assessment was the thymic follicles within the cortex of the thymus. The thymus glands observed 
in the Fpr2/3
-/-
 and WT mice all exhibited a characteristic structure with an outer cortex surrounded by an 
external capsule, and an inner medulla region. The cortex encompassed multiple lobules separated by 
intralobular septa or trabeculae and contained blood vessels, thymocytes, and macrophages. As well as 
being central and having a lighter haematoxylin-staining pattern, the medulla was distinct from the cortex 
by the presence of Hassall’s corpuscles. The data indicate that in animals injected 2 hours previously, 
GFP immunoreactivity was evident in the LPS treated Fpr2/3
-/- 
mice (Figure 3.18 d), but was not 
observed in the wildtype littermates (Figure 3.18 c) or the saline injected controls of either genotype. 
Conversely, in the animals injected 6 hours previously, GFP immunoreactivity was no longer evident in 
the LPS treated Fpr2/3
-/- 
mice (Figure 3.19 d) versus those injected 2 hours previously (Figure 3.18 d). 
But, as in the two-hour group, no GFP was observed in the wildtype littermates (Figure 3.19 c) or the 
saline injected controls of either genotype. 
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Figure 3.18: Immunostain for green fluorescent protein (GFP) within the thymus taken from GFP transgenic, formyl peptide receptor 2 and 3 knockout 
(Fpr2/3
-/-
) mice versus wildtype (WT) littermates 2 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or phosphate buffered saline (PBS) 
vehicle.  
Transverse sections (4 μm) of the thymus taken from WT and Fpr2/3-/- mice (n = 4) 2 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-
GFP and secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin 
solution (HX, blue). The medial thymic follicles encompassing the cortex and medulla were imaged by light microscopy (20x, scale bar = 10 μm). Arrows denote 
positive GFP staining. 
 
(b) Fpr2/3-/- PBS 2 h Thymus (a) WT PBS 2 h Thymus
(d) Fpr2/3-/- LPS 2 h Thymus(c) WT LPS 2 h Thymus
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Figure 3.19: Immunostain for green fluorescent protein (GFP) within the thymus taken from GFP transgenic, formyl peptide receptor 2 and 3 knockout 
(Fpr2/3
-/-
) mice versus wildtype (WT) littermates 6 h following intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) or phosphate buffered saline (PBS) 
vehicle.  
Transverse sections (4 μm) of the thymus taken from WT and Fpr2/3-/- mice (n = 4) 6 h after receiving LPS (750 μg/kg i.p.) or PBS were stained with primary anti-
GFP and secondary horseradish peroxidase (HRP)-conjugated antisera, then counterstained with diaminobenzidine (DAB, dark brown) and a weak haematoxylin 
solution (HX, blue). The medial thymic follicles encompassing the cortex and medulla were imaged by light microscopy (20x, scale bar = 10 μm). 
(b) Fpr2/3-/- PBS 6 h Thymus 
(d) Fpr2/3-/- LPS 6 h Thymus
(a) WT PBS 6 h Thymus
(c) WT LPS 6 h Thymus
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3.3.5 Immunofluorescent detection of formyl peptide receptors (FPR1, FPR2/ALX, and FPR3) in the 
human anterior pituitary 
The following results are confocal micrographs and colocalisation data, including cytofluorograms and 
cell counts, from experiments in which human anterior pituitary sections were immunostained with 
antibodies for ACTH or S100b, along with those for FPR1, FPR2/ALX, and FPR3. The cytofluorograms 
are scatterplots of red pixel intensities against green pixel intensities and are annotated with three 
coefficients of colocalisation generated by the Just Another Colocalisation Plugin (JACoP) in the ImageJ 
software from the National Institute of Health (Cordelieres & Bolte 2008). Pearson’s correlation 
coefficient (rP) enumerates the percentage of variability in channel 1 (red) that is equal to variability in 
channel 2 (green). The values for rP range from -1 to +1, with -1 indicating total negative correlation, 0 
indicative of random correlation, and +1 indicating total positive correlation. The Manders’ colocalisation 
coefficient (M1) is the percentage of pixels above background in the first channel (red) that overlap pixels 
above background in the second channel (green), whereas M2 is the percentage of above-background 
pixels in the second channel that overlap those in the first channel (Manders et al. 1993). The background 
within images can be automatically subtracted using Costes’ method, giving values for rP, and M1 and 
M2 that avoid human bias, and analyses are thus consistent both within and between images. Costes’ 
method involves a scatterplot of pixel intensities from the red and green channels, with a curve whose 
slope is determined by orthogonal regression with least-squares fit (Costes et al. 2004). The point of 
highest intensity on the curve (T) is used to calculate rP for all pixels below T, and regression continues to 
reduce the value of T until rP equals zero, indicating random correlation. This is then the threshold by 
which pixels are counted above background for each image. Costes’ method also tests the values for rP in 
each image against scrambled iterations of the second image to simulate random overlap, and the 
resulting P-value is the probability of real colocalisation in the original images at the 95% confidence 
level.  
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3.3.5.1 ACTH 
Figure 3.20, Figure 3.21, and Figure 3.22 show the confocal micrographs of immunostaining for ACTH 
and the three human formyl peptide receptors subtypes, FPR1, FPR2/ALX, and FPR3, respectively. In all 
cases, the stain for ACTH worked well and shows clear ACTH immunoreactivity (shown in green) 
compared with the no primary antibody stain (not shown). These results are also enumerated in Figure 
3.26, which shows the results of manually counting cells with red FPR1, FPR2/ALX, or FPR3 
immunoreactivity, green ACTH signal, or both FPR and ACTH. In all experiments, the number of 
ACTH-positive cells counted was the same (ns P > .05), irrespective of whether the sections were 
immunostained for FPR1, FPR2/ALX, or FPR3.  
The experiments resulted in very clear positive staining for FPR1 immunoreactivity, although these cells 
were few in number, with between 1 and 10 cells in the field of view. Given their size and horse-shoe 
shaped nuclei these FPR1-positive cells were possibly indicative of monocytes (10 µm), or possibly 
macrophage infiltrates in the case of some larger cells (20 µm) with round nuclei (Krombach et al. 1997). 
Some larger, anucleated bodies of red fluorescence were observed, and these are likely to be from 
pituitary mucins which have immunoglobulin G (IgG)/fragment of crystallisation (Fc)-binding activity 
and thus permit non-specific binding of antibodies (Harada et al. 1997). The manual counting data 
indicated that there was no colocalisation of FPR1 immunoreactivity with ACTH, and the number of 
ACTH-positive cells was significantly greater than the number of FPR1-positive cells (*** P < .001). 
These data were corroborated by the cytofluorogram (Figure 3.20 d) for the representative image, and the 
overall results for the wider tissue area from several cases, as tabulated in Table 3.1.  
In Figure 3.20 for instance, the values are .002 for M1 and .329 for M2. This indicates that, in the Costes’ 
automatically thresholded images, .2% of the red pixels for FPR1 overlapped with the green pixels for 
ACTH, and that 32.9% of the green pixels for ACTH overlapped with the red pixels for FPR1. The value 
for rP, however, is .000 indicating that there was no correlation between the variation in pixel intensities 
in the red and green channels. This was concordant with the overall findings across all samples for ACTH 
and FPR1 (Table 3.1) because Pearson’s coefficient indicated zero correlation between ACTH and FPR1 
pixel variation (rP = -.036 ± .029), and Costes’ P value indicated this relationship was not significant at the 
95% confidence level (P = 72.44% ± 14.81). 
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With regard to the immunostain of FPR2/ALX and ACTH, the manual cell count observed a number of 
cells that were positive for both ACTH and FPR2/ALX immunofluorescence (Figure 3.26), but the 
majority of ACTH-positive cells did not contain FPR2/ALX (*** P < .001). In Figure 3.21, the Manders’ 
coefficients (M1 = .999, M2 = .624) indicated that, in the Costes’ background-subtracted images, 99.9% 
of the red pixels for FPR2/ALX overlapped with the green pixels for ACTH, and that 62.4% of the green 
pixels for ACTH overlapped with the red pixels for FPR2. The value for Pearson’s correlation coefficient 
equals -.113, which indicated a negative correlation between the variation in pixel intensities for ACTH 
and FPR2/ALX immunofluorescence. This was concordant with the overall findings for ACTH and 
FPR2/ALX across all cases (Table 3.1) in which Pearson’s coefficient indicated a negative correlation 
between ACTH and FPR2/ALX pixel variation (rP = -.024 ± .018), and Costes’ P value indicated this 
relationship was not significant at the 95% confidence level (P = 83.86% ± 11.61). 
The FPR3-positive cells were largely clustered into acini and were therefore suggestive of groups of 
corticotrophic, ACTH-positive cells. The manual cell count indicated there was little colocalisation of 
FPR3 with ACTH (Figure 3.26), but within the images obtained there is evidence of clustering of FPR3-
positive cells neighbouring a body of ACTH-positive cells within acini (Figure 3.22). In fact, there were 
more FPR3-positive cells than ACTH-positive cells (*** P < .001). In Figure 3.22, the Manders’ 
coefficients indicated that, 99.9% of the red pixels for FPR3 overlapped with the green pixels for ACTH, 
and that 95.6% of the green pixels for ACTH overlapped with the red pixels for FPR3. The Pearson’s 
correlation coefficient of .544 indicated a positive correlation between the variation in pixel intensities for 
ACTH and FPR3 immunofluorescence. This is concordant with the overall findings across all samples for 
ACTH and FPR3 (Table 3.1) in which Pearson’s coefficient indicated a positive correlation between 
ACTH and FPR3 pixel variation (rP = .126 ± .039) and Costes’ P value indicated that this relationship was 
significant at the 99.9% confidence level (P = 100.00% ± 0.00). 
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Figure 3.20: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 1 (FPR1) and adrenocorticotrophic hormone (ACTH) within the pars distalis of sectioned 
anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS). 
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR1 and anti-ACTH followed by secondary antisera tagged with Alexa Fluor 
555 (red, for FPR1) or Alexa Fluor 488 (green, for ACTH), and counterstained with diamidino 
phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view analysed 
from one of six pituitary glands. The region between the lateral wings of the pars distalis and anterior to 
the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 μm). Arrows 
denote immunofluorescence for perinuclear FPR1 (a) and cytoplasmic and membranous ACTH (b). The 
cytofluorogram (e) plots the pixel intensities from the red channel (FPR1, y-axis) versus green channel 
(ACTH, x-axis) and is annotated with Pearson correlation (rP) and Costes’ automatically thresholded 
Manders’ colocalisation (M1 and M2) coefficients.  
(a) FPR1 (b) ACTH 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR1 (red) against ACTH (green) 
rP = .000 
M1 = .002 
M2 = .329 
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Figure 3.21: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 2 (FPR2/ALX) and adrenocorticotrophic hormone (ACTH) within the pars distalis of 
sectioned anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS).  
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR2/ALX and anti-ACTH followed by secondary antisera tagged with Alexa 
Fluor 555 (red, for FPR2/ALX) or Alexa Fluor 488 (green, for ACTH), and counterstained with 
diamidino phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view 
analysed from one of six pituitary glands. The region between the lateral wings of the pars distalis and 
anterior to the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 
μm). Arrows denote immunofluorescence for perinuclear FPR2/ALX (a) and cytoplasmic and 
membranous ACTH (b). The cytofluorogram (e) plots the pixel intensities from the red channel 
(FPR2/ALX, y-axis) versus green channel (ACTH, x-axis) and is annotated with Pearson correlation (rP) 
and Costes’ automatically thresholded Manders’ colocalisation (M1 and M2) coefficients.  
rP = -.113 
M1 = .999 
M2 = .624 
(a) FPR2 (b) ACTH 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR2 (red) against ACTH (green) 
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Figure 3.22: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 3 (FPR3) and adrenocorticotrophic hormone (ACTH) within the pars distalis of sectioned 
anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS).  
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR3 and anti-ACTH followed by secondary antisera tagged with Alexa Fluor 
555 (red, for FPR3) or Alexa Fluor 488 (green, for ACTH), and counterstained with diamidino 
phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view analysed 
from one of six pituitary glands. The region between the lateral wings of the pars distalis and anterior to 
the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 μm). Arrows 
denote immunofluorescence for perinuclear FPR3 (a) and cytoplasmic and membranous ACTH (b). The 
cytofluorogram (e) plots the pixel intensities from the red channel (FPR3, y-axis) versus green channel 
(ACTH, x-axis) and is annotated with Pearson correlation (rP) and Costes’ automatically thresholded 
Manders’ colocalisation (M1 and M2) coefficients. 
rP = .544 
M1 = .999 
M2 = .956 
(a) FPR3 (b) ACTH 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR3 (red) against ACTH (green) 
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3.3.5.2 S100b 
Figure 3.23, Figure 3.24, and Figure 3.25 show the results of immunostaining for S100b and the three 
human formyl peptide receptors subtypes, FPR1, FPR2/ALX, and FPR3. The results of the manual cell 
counts are enumerated in Figure 3.26, and these indicated that there was no colocalisation of FPR1, 
FPR2/ALX, or FPR3 with S100b immunoreactivity and there were no differences in the number of 
S100b-positive cells counted on separate sections stained for FPR1, FPR2/ALX, or FPR3 (ns P > .05).  
With regard to FPR1 and S100b immunofluorescence evident in Figure 3.23, the Manders’ coefficients 
indicated that 94.9% of the red pixels for FPR1 overlapped with the green pixels for S100b, and that 
78.3% of the green pixels for S100b overlapped with the red pixels for FPR1. The Pearson’s correlation 
coefficient of .067 indicated a slight correlation between the variation in pixel intensities for S100b and 
FPR1 immunofluorescence. In the overall results across all samples (Table 3.1), although the Pearson’s 
correlation coefficient indicated a slight correlation between S100b and FPR1 pixel variation (rP = .055 ± 
.016), the Costes’ P value, however, indicated that this relationship was not significant at the 95% 
confidence level (P = 95.18% ± 5.57). 
With regard to FPR2/ALX and S100b immunofluorescence, Figure 3.24 shows that the Manders’ 
coefficients of .983 for M1 and .604 for M2 indicated that, in the Costes’ automatically thresholded 
images, 98.3% of the red pixels for FPR2/ALX overlapped with the green pixels for S100b, and that 
60.4% of the green pixels for S100b overlapped with the red pixels for FPR2. The Pearson’s correlation 
coefficient of .236 indicated a positive correlation between the variation in pixel intensities for S100b and 
FPR2/ALX immunofluorescence. In the overall results across all samples (Table 3.1), although the 
Pearson’s correlation coefficient indicated a positive correlation between S100b and FPR2/ALX pixel 
variation (rP = .024 ± .015), this relationship was not significant as Costes’ P value was lower than the 
95% confidence level (P = 67.49% ± 17.56). 
With regard to FPR3 and S100b immunofluorescence, Figure 3.25 shows that the Manders’ coefficients 
of .000 for M1 and .000 for M2 indicated that, in the Costes’ automatically thresholded images, 0.0% of 
the red pixels for FPR3 overlapped with the green pixels for S100b, and that 0.0% of the green pixels for 
S100b overlapped with the red pixels for FPR3. The Pearson’s correlation coefficient of .000 indicated 
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there was no correlation between the variation in pixel intensities for S100b and FPR3 
immunofluorescence. In the overall results across all samples (Table 3.1), although Pearson’s correlation 
coefficient indicated a slight correlation between S100b and FPR2/ALX pixel variation (rP = .028 ± .048), 
the Costes’ P value, however, indicated that this relationship was not significant at the 95% confidence 
level (P = 90.97% ± 7.33). 
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Figure 3.23: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 1 (FPR1) and S100 calcium binding protein b (S100b) within the pars distalis of sectioned 
anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS).  
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR1 and anti-S100b followed by secondary antisera tagged with Alexa Fluor 
555 (red, for FPR1) or Alexa Fluor 488 (green, for S100b), and counterstained with diamidino 
phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view analysed 
from one of six pituitary glands. The region between the lateral wings of the pars distalis and anterior to 
the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 μm). Arrows 
denote immunofluorescence for perinuclear FPR1 (a) and cytoplasmic and membranous S100b (b). The 
cytofluorogram (e) plots the pixel intensities from the red channel (FPR1, y-axis) versus green channel 
(S100b, x-axis) and is annotated with Pearson correlation (rP) and Costes’ automatically thresholded 
Manders’ colocalisation (M1 and M2) coefficients.  
(a) FPR1 (b) S100b 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR1 (red) against S100b (green) 
rP = .067 
M1 = .949 
M2 = .783 
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Figure 3.24: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 2 (FPR2/ALX) and S100 calcium binding protein b (S100b) within the pars distalis of 
sectioned anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS).  
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR2/ALX and anti-S100b followed by secondary antisera tagged with Alexa 
Fluor 555 (red, for FPR2/ALX) or Alexa Fluor 488 (green, for S100b), and counterstained with diamidino 
phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view analysed 
from one of six pituitary glands. The region between the lateral wings of the pars distalis and anterior to 
the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 μm). Arrows 
denote immunofluorescence for perinuclear FPR2/ALX (a) and cytoplasmic and membranous S100b (b). 
The cytofluorogram (f) plots the pixel intensities from the red channel (FPR2/ALX, y-axis) versus green 
channel (S100b, x-axis) and is annotated with Pearson correlation (rP) and Costes’ automatically 
thresholded Manders’ colocalisation (M1 and M2) coefficients.  
rP = .236 
M1 = .983 
M2 = .604 
(a) FPR2 (b) S100b 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR2 (red) against S100b (green) 
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Figure 3.25: Confocal micrographs and cytofluorogram from an immunostain for formyl peptide 
receptor 3 (FPR3) and S100 calcium binding protein b (S100b) within the pars distalis of sectioned 
anterior pituitary glands obtained post mortem from humans with multiple sclerosis (MS).  
Transverse sections (4 μm) of anterior pituitary glands taken from deceased MS patients (n = 6) were 
stained with primary anti-FPR3 and anti-S100b followed by secondary antisera tagged with Alexa Fluor 
555 (red, for FPR3) or Alexa Fluor 488 (green, for S100b), and counterstained with diamidino 
phenylindole (DAPI) to identify nuclei. Images are from one of nine adjacent fields of view analysed 
from one of six pituitary glands. The region between the lateral wings of the pars distalis and anterior to 
the pars intermedia was imaged by confocal fluorescence microscopy (63.3x, scale bar = 50 μm). Arrows 
denote immunofluorescence for perinuclear FPR3 (a) and cytoplasmic and membranous S100b (b). The 
cytofluorogram (f) plots the pixel intensities from the red channel (FPR3, y-axis) versus green channel 
(S100b, x-axis) and is annotated with Pearson correlation (rP) and Costes’ automatically thresholded 
Manders’ colocalisation (M1 and M2) coefficients.  
rP = .000 
M1 = .000 
M2 = .000 
(a) FPR3 (b) S100b 
(c) DAPI (d) Merge 
(e) Cytofluorogram – FPR3 (red) against S100b (green) 
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Figure 3.26: Morphometry of human anterior pituitary sections immunostained for formyl peptide 
receptors (FPR1, FPR2/ALX, FPR3) and adrenocorticotrophic hormone (ACTH), or S100 calcium 
binding protein b (S100b).  
Data are representative of mean ± standard error of mean of n = 6 pituitaries, compared by two-way 
ANOVA: ***P < .001 = ACTH vs. FPR subtype. 
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Table 3.1 Results of computer automated colocalisation analysis of confocal images of sections of 
human anterior pituitary glands (n = 6) immunofluorescently stained for formyl peptide receptors 
(FPR1, FPR2/ALX, FPR3) detected in channel 2, and either adrenocorticotrophic hormone 
(ACTH) or S100 calcium binding protein b (S100b) in channel 1.  
Pearson’s coefficient (rp), Manders’ coefficients (M1 and M2), and Costes’ P value (%) for significance at 
the 95% confidence level (*** = P > 99%, ns = not significant) were calculated using Just another 
colocalisation plugin (JACoP) on Fiji is Just Image J (Fiji).  
  
Channel 1 Channel 2 rP M1 M2 Costes' P value 
 ACTH FPR1 -.036 ± .029 .100 ± .088 .171 ± .053 72.44 ± 14.81 ns 
ACTH FPR2 -.024 ± .018 .887 ± .111 .592 ± .075 83.86 ± 11.61 ns 
ACTH FPR3 .126 ± .039 .978 ± .017 .799 ± .024 100.00 ± 0.00 *** 
       
S100b FPR1 .055 ± .016 .658 ± .169 .599 ± .143 95.18 ± 5.57 ns 
S100b FPR2 .024 ± .015 .223 ± .179 .414 ± .132 67.49 ± 17.56 ns 
S100b FPR3 .028 ± .048 .013 ± .008 .135 ± .055 90.97 ± 7.33 ns 
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3.4 Discussion 
The studies will be discussed in terms of: their main findings; the novel aspects of the study design; the 
consistency of the findings with previous research and reasons for discrepancies; the meaning of the 
findings and their implications for the stress response to inflammogens; limitations of the study design in 
terms of assumptions, precision, accuracy, and bias; and finally, a discussion of the areas for further work 
and future directions will be followed by a conclusion. 
These studies sought to determine the spatial distribution of Fpr/FPR subtypes and stress hormones within 
the pituitary-adrenal axis from mouse and human tissues following inflammogenic stress, and in doing so 
achieved several main findings. First, the spatial distribution of GFP immunofluorescence—as a proxy of 
Fpr2/3 within the anterior pituitary gland of Fpr2/3
-/-
 mice—was colocalised with that of ACTH, GH, and 
PRL, but not S100b. Second, adrenal glands taken from wildtype mice after 2 and 6 hours following i.p. 
LPS had significantly fewer vacuolated cells than mice receiving only vehicle, but this effect of LPS was 
not observed in sections from the Fpr2/3
-/-
 mice. Third, GFP immunofluorescence was upregulated within 
the adrenal glands taken from Fpr2/3
-/-
 mice two hours after peripheral administration of LPS versus 
vehicle-injected controls, but the signal was significantly reduced after six hours. Fourth, automated 
analysis of confocal images of human pituitary gland sections from MS donors exhibited a spatial 
distribution of ACTH and S100b immunofluorescence that was not generally colocalised with FPR1, 
FPR2/ALX, or FPR3, except for a significant colocalisation of ACTH and FPR3.    
3.4.1 Fpr2/3-/- adrenals had reduced loss of sterol vacuolation but increased GFP following LPS 
To the author’s knowledge, this is the first report of the use of well-validated antibodies to map the spatial 
distribution of GFP within endocrine, cerebral, and lymphoid tissues taken from the Fpr2/3
-/-
 mouse. At 
the time of investigation, this novel approach was necessary owing to the lack of commercially available 
primary antibodies with sufficient specificity for murine Fpr2 or Fpr3 epitopes in spatial applications such 
as IHC. In this regard, the observation of immunoreactive GFP within the Fpr2/3
-/-
 adrenal ZF following 
intraperitoneal LPS is novel, whereas the reduced loss of sterol vacuolation versus WT animals is 
concordant with previous work. The histochemical methods of Buss (2010), for instance, used 
haematoxylin and eosin (H&E) staining to ascertain the effect of intraperitoneal LPS on the structure of 
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the adrenal cortex from Fpr2/3
-/-
 and WT mice. The WT adrenal gland sections had reduced sterol 
vacuolation in response to LPS versus vehicle, but this effect of LPS was not seen in the Fpr2/3
-/-
 mice 
(Buss 2010). Whilst the present study also used haematoxylin, in contrast with previous work, this study 
used primary antibodies to target epitopes of GFP and ascertain its spatial distribution as a proxy of 
Fpr2/3. In addition, the present study quantified vacuolated and GFP-positive cells as well as total cell 
counts, whereas the observations of Buss were recorded based on the number of animals affected. In this 
regard, the present study has put forward evidence of reduced sterol vacuolation following LPS that has 
been quantified and shown to be statistically significant.  
Other studies in mice receiving intraperitoneal injections of LPS or saline, have observed both routine 
histochemical and terminal deoxyribonucleotidyl transferase (TDT)-mediated deoxyuridine triphosphate 
(dUTP)-digoxigenin nick end labeling (TUNEL) evidence of increased adrenocortical and medullary 
apoptosis and infiltration of inflammatory leukocytes, alongside increased ACTH and GC secretion 
within 3 hours of LPS treatment (Kanczkowski et al. 2013). There is also evidence that inflammogenic 
stress elicits a loss of steroidogenic cells within the adrenal glands from other species. In rats undergoing 
polymicrobial sepsis, there was evidence of complement C5a anaphylatoxin activation along with 
widespread apoptosis of adrenal cells (Flierl et al. 2008). In a study of rats that received an intraperitoneal 
injection of LPS or saline, there was immunohistochemical evidence that CD14, TLR-4, iNOS, and COX-
II were upregulated especially within the ZG and ZF, however in this study, sterol vacuolation was not 
measured (Mohn et al. 2011). In a similar study, Liu and colleagues (2011) used confocal microscopy to 
detect evidence of LPS receptor expression in TLR4-positive cells and was colocalised with the MC2 
receptor for ACTH in steroidogenic cells marked with steroidogenic acute response (StAR) protein and 
cytochrome P450 11β-hydroxylase (CYP11B1). In addition, it was found that a 24 hour pre-treatment of 
ZF and ZR cocultures with LPS led to a dose-dependent decrease in GC secretion in response to further 
LPS or ACTH treatment, along with reduced MC2 receptor, TLR4, StAR, and CYP11B1 expression (Liu 
et al. 2011). This suggests that LPS is able to downregulate the steroidogenic capacity of the adrenal 
gland, leaving the gland refractory to either LPS or ACTH. Interestingly, TLR4
-/-
 mice have significantly 
larger adrenal glands, owing to a larger adrenal cortex than WT littermates, further implicating the LPS 
signalling cascade in modulating adrenal steroidogenesis (Zacharowski et al. 2006). The present finding 
of an LPS-induced loss of sterol vacuolation in the wildtype mouse adrenal, and that this effect of LPS is 
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attenuated in Fpr2/3
-/-
 mice, is therefore consistent with previous work. Taken together, this means that 
Fpr2/3 could be involved in the regulation of adrenal steroidogenic capacity in response to inflammogenic 
stress. This has implications for the understanding of inflammogenic stress and disease states such as 
sepsis. 
3.4.2 The anterior pituitary gland of Fpr2/3-/- mice contained GFP immunoreactivity within ACTH-, 
GH-, and PRL-positive cells 
Prior to this work, it has been shown that the Fpr1 gene was not expressed within the pituitary of rats or 
mice (John et al. 2007). In addition, the Fpr2 and Fpr3 genes were shown to be expressed as mRNA 
transcripts within the mouse and rat pituitary, but it was not clear in which cell types these were 
expressed, or, whether the products of these gene loci were translated into immunoreactive proteins (John 
et al. 2007; Buss 2010). With regard to the distribution of the hormone cell types within the anterior 
pituitary gland, the observations of this study are consistent with previous work. The lateral wings of the 
pars distalis contained an abundance of GH-positive cells, the medial region between the wings contained 
ACTH-positive cells and also non-uniformly distributed PRL-positive cells (see Stevens & Lowe 2011). 
In this study of the spatial distribution of GFP as a surrogate marker for Fpr2/3 across the anterior 
pituitary, GFP was evidently distributed across several endocrine cell subtypes, although not within the 
glial-like S100b-positive cells, ostensibly the folliculostellate cells. Specifically, the fluorescence 
micrographs revealed punctate fluorescence from antibodies against GFP with a consistent nuclear 
expression. In addition, this was colocalised to a given cell with signals from antibodies raised against 
ACTH, GH, and PRL, each with cytoplasmic signals. To the author’s knowledge, this is the first reported 
use of pituitary tissue from Fpr2/3
-/-
 mice with specific and well-validated antibodies against GFP and 
proteins specific to endocrine and non-endocrine pituitary cell subtypes, in order to determine the spatial 
distribution of Fpr2 and/or Fpr3 by proxy.  
These findings are consistent with other data on the expression of the Fpr transcripts. There is evidence 
for the expression of Fpr2, Fpr3, Fpr-rs6, and Fpr-rs7, but not Fpr1, within the C57BL/6 mouse pituitary 
(John et al. 2007). This study has provided evidence towards elucidation of the distribution of Fpr2/3 
within specific pituitary cell sub-populations identified by lineage markers, namely the corticotrophs 
(ACTH), somatotrophs (GH), and lactotrophs (PRL), whereas GFP was not expressed within the 
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folliculostellates (S100b). The lack of GFP signal, as a proxy for Fpr2/3, within the folliculostellate cells 
is consistent with previous data that suggests these cells are a source of Fpr/FPR ligands such as ANXA1 
(Traverso et al. 1999). The folliculostellates show immunogold localisation of ANXA1 at sites in contact 
with endocrine cells (Christian et al. 1997), and the folliculostellate-like TtTGF cell line expresses S100b 
(Inoue et al. 1992; McArthur et al. 2009) and ANXA1 (Chapman et al. 2002), but do not possess the 
ANXA1 binding sites found on endocrine cells (Christian et al. 1997). The evidence of GFP 
immunoreactivity within the PRL-, GH-, and ACTH-positive cells of the anterior pituitaries from Fpr2/3
-/-
 
mice is compatible with the evidence that putative Fpr ligands such as ANXA1, have been shown to 
inhibit the release of PRL (Taylor et al. 1995b), GH (Philip et al. 2001), LH, and TSH (Taylor et al. 
1995b) in vitro, and also of ACTH in vivo (John et al. 2007). In summary, the present findings are 
concordant with the hypothesis that Fpr2 and Fpr3, and their ligands, could modulate the release of 
ACTH, GH, PRL, and possibly other hormones from the anterior pituitary. The observation that the 
inflammogen LPS upregulates the expression of GFP as a surrogate of Fpr2/3 distributed in ACTH-, GH-, 
and PRL-positive cells gives reason to investigate whether Fpr2/3 is involved in modulating the secretion 
of these hormones specifically. This could have implications for the pituitary stress response, particularly 
in conditions of inflammogenic stress such as sepsis. 
3.4.3 No GFP immunoreactivity was observed within native cells of the hippocampus, hypothalamus, 
or thymus of Fpr2/3
-/-
 mice 
The absence of immunoreactive GFP as a proxy for Fpr2/3 within the hippocampus is interesting. This 
finding is partly discordant, however, with previous research that found evidence of Fpr1/2 expression 
within the mouse hippocampus but from APP/PS1 transgenic mice. Briefly, Slowik and coworkers (2012) 
investigated whether Fpr2 and the receptor-for-advanced-glycation-end-products (RAGE) were involved 
in the response to inflammogenic stress of relevance to AD, by determining the gene expression and 
immunolocalisation of mouse Fpr1, Fpr2, and RAGE in APP/PS1 mice, rat primary microglia and 
astrocytes. Possible reasons for the discrepancy with the present findings could lie in the fact that the 
authors used an antibody that was raised against an epitope on human FPR2/ALX, but which nonetheless 
binds non-specifically to both murine Fpr2 and murine Fpr3. This was the same antibody that was used in 
the present study to perform a western blot on lung tissue from the Fpr2/3
-/-
 and WT mice and confirm the 
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genotyping results are applicable at the protein level, namely, anti-FPR2/anti-Fpr2/3 (Cat: sc-18191; 
Santa Cruz, Inc.). The affinity for the anti-FPR2/ALX antibody for murine Fpr2 and Fpr3 might well be 
greater than that of the rabbit anti-GFP used in the present study. An alternative explanation worthy of 
investigation would be that the inflammogen used in the present study, LPS, might not have passed 
through the BBB in sufficient quantities to initiate the NfκB-mediated transcription of the GFP transgene 
from the Fpr2/3 gene loci in Fpr2/3
-/-
 mice. Whilst LPS has been shown to upregulate the expression of 
Fpr2 in cell lines such as the murine microglial N9 cell line (Cui et al. 2002; Iribarren et al. 2003), other 
studies have found that expression of Fpr2 within microglia and macrophages native to tissues are not 
responsive to LPS treatment (Waechter et al. 2012).  
The absence of immunoreactive GFP within the hypothalamic PVN in the present study is partly 
discordant with the work of Buss (2010), which found evidence of gene expression for Fpr1, Fpr2, and 
Fpr3/Alx within the hypothalamus of C57BL/6 mice. Specifically, the level of these transcripts were 
determined using quantitative PCR, which found that all three genes were expressed at levels at least two-
fold higher than the GAPDH housekeeping gene. It is plausible that the discrepancy with the present work 
is because mRNA transcripts are not necessarily translated, and so the concentration of Fpr1, Fpr2, and 
Fpr3/Alx mRNA found by Buss would not necessarily correlate with the distribution of their proteins. In 
the present study, there was no effect of LPS on the spatial distribution of GFP within the hypothalamus 
of the Fpr2/3
-/-
 or WT mice at any of the time points observed (2 and 6 hours), versus saline. In this 
regard, the work of Buss (2010) also found that there was no effect of LPS on the gene expression of 
Fpr1, Fpr2, or Fpr3 at any of the time points observed (0, 2, 4, and 8 hours). This was also true of the 
hippocampus. The expression of all three genes was however upregulated by LPS in tissues that are not 
protected by the BBB, namely, the anterior pituitary and adrenal glands. Whether the protection afforded 
by the BBB could explain why the hypothalamic and hippocampal expression of Fpr subtypes was not 
modulated by LPS or detected as GFP in the present study, deserves further investigation. 
The lack of immunoreactive GFP within native cells of the thymus requires further investigation. One 
possible reason why there were so few inflammatory infiltrates detected within the thymus of the LPS 
injected Fpr2/3
-/-
 mice versus those observed by Buss (2010), could be due to the differences in the 
histochemical methods used. The present study targeted immunoreactive GFP along with haematoxylin 
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counterstaining whereas Buss used H&E staining to detect general changes in tissue structure and 
inflammatory cells. It is plausible that the trade-off between detecting GFP and staining other cell types 
with eosin meant that it was not possible to detect all inflammatory infiltrates apart from those that were 
positive for GFP. 
3.4.4 The Fpr2/3-/- genotype was consistent with previous work 
The genotyping of the Fpr2/3
-/- 
mice is consistent with the findings from previous work of Dufton and 
colleagues (2010) who initially generated  and phenotyped the mouse colony, and who subsequently 
published a correction to their original paper (Dufton et al. 2011). They originally reported phenotypic 
data on what they thought were Fpr2
-/- 
mice with a genetic background of the 129SvEv, and C57BL/6 
inbred strains (Dufton et al. 2010). In their correction, however, they explain that it is more likely they 
were working with Fpr2/3
-/- 
mice (Dufton et al. 2011). They reported that this arose partly out of the 
misidentification of the two “isoforms” of the Fpr3 gene (formerly Fpr-rs1), one being the renamed Fpr3 
itself, and the other being the mouse lipoxin receptor (Alx). Since the human (FPR) and mouse (Fpr) 
IUPHAR nomenclature was updated by Ye and colleagues (2009), what were termed Fpr-rs1 and Alx are 
now recognised as being transcribed from the same Fpr3 gene and give rise to the same receptor. This is 
comparable with the human FPR2/ALX, with ALX denoting its lipoxin binding ability. In re-evaluating 
their gene targeting strategy, they describe that in wildtype littermates, the Fpr2 gene is transcribed from 
exons 1, 2, and 3, and the Fpr3 gene from the same exons 1 and 3, skipping exon 2. In their Fpr2/3
-/- 
mice, 
however, a GFP sequence at intron 1 preceded a PGK-Neo cassette at exon 2 of the Fpr2 gene. As exon 2 
is required for Fpr3 transcription, they conclude that this strategy resulted in loss of Fpr3 as well as Fpr2, 
as suggested by their PCR results (Dufton et al. 2011). For this reason, they believe they had different 
phenotypic results (including loss of LXA4 responses) from those of Chen and coworkers (2010) who had 
developed an Fpr2
-/- 
mouse. Taken together, the insertion of GFP in intron 1 and the PGK-Neo cassette at 
exon 2 of the Fpr2 gene in the Fpr2/3
-/-
 mice has also resulted in Fpr3 alongside the Fpr2 gene being 
knocked out in place of the GFP transgene. In the context of the PCR results of Dufton and colleagues 
(2011), Fpr2 and Fpr3 were both knocked out versus wildtype littermates, and thus confirms the Fpr2/3
-/-
 
mouse genotype. 
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3.4.5 Colocalisation of FPR3 and ACTH detected within the human anterior pituitary gland  
Prior to the present work, it was not known which FPR subtypes were expressed within the human 
anterior pituitary gland. To the author’s knowledge, this is the first report of the spatial distribution of 
human FPR1, FPR2/ALX, and FPR3 within the human anterior pituitary gland. The human anterior 
pituitary glands were obtained from the UK Multiple Sclerosis (MS) and Parkinson’s Disease (PD) tissue 
bank. The colocalisation of FPR subtypes with ACTH and S100b was quantified using both manual and 
automated methods. The manual method involved counting cells across a .464 mm
2
 area of the pars 
distalis observed for evidence of immunolocalisation of FPR1, FPR2/ALX, and FPR3. Immunoreactive 
FPR1 was found in only a few cells, none of which contained immunoreactive ACTH or S100b and were 
possibly infiltrated leukocytes. This FPR1 staining, therefore, is probably a result of leukocytic 
infiltration, possibly monocytes or macrophages (Müller-Ladner et al. 1996). This is consistent with a 
lack of human FPR1 immunoreactivity in anterior pituitary tissue (Becker et al. 1998) and lack of Fpr1 
expression within the mouse and rat anterior pituitary (John et al. 2007). Immunoreactive FPR2/ALX was 
not found in any S100b-positive cell, but was occasionally identified in ACTH-positive cells. However, 
ACTH-positive cells in general were largely FPR2-negative. The observation that FPR3-positive cells 
were the most numerous across the anterior pituitary, plus, the close apposition of FPR3-positive cells 
with ACTH-positive cells in clusters within acini of the pars intermedia, suggested that the single FPR3-
positive cells are possibly GH-producing sommato-lactotrophic cells (Pantić 1995; Wheater & Young 
2006). The manual method of enumerating colocalisation indicated that ACTH-positive cells rarely 
contained FPR immunoreactivity of which between 1 and 10 were FPR3- or FPR2-positive cells, whereas 
the S100b-positive cells contained no immunoreactivity for any FPR subtype. As a whole, the FPR 
subtypes most abundantly distributed across the pituitaries were FPR3 >> FPR2/ALX > FPR1, and the 
automated method of quantifying colocalisation found a significant colocalisation of FPR3 with ACTH.  
3.4.6 Biological significance and scope of findings 
The finding that the ACTH-positive corticotrophs contain co-immunoreactivity for GFP—as a proxy for 
Fpr2/3 from mice with these genes knocked out—or FPR3 in the human pituitary is novel. This opens up 
avenues of research into whether Fpr2/3 or FPR3 ligands modulate pituitary ACTH release. This would 
be of particular importance in managing the response inflammogenic stress during acute conditions such 
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as sepsis and septic shock, or in chronic neurodegenerative conditions such as MS, PD, and AD. 
Although GCs are potent anti-inflammatory and immunosuppressive agents, they have undesirable side 
effects such as the acceleration of apoptosis within the hippocampus (Gould et al. 1992), and are thus 
contraindicated in neurodegenerative conditions. With regard to sepsis, the risk of patient mortality is still 
high even with GC treatment, underscoring the importance of research into alternative treatments (Sligl et 
al. 2009). Given the finding that LPS upregulated adrenal Fpr2/3 surrogated by GFP and reduced adrenal 
vacuolation of steroids including GCs, this implicates Fpr/FPR subtypes in the response to inflammogenic 
stressors such as LPS which are of relevance to sepsis. In context of wider literature, there is already 
evidence that the Fpr/FPR ligand ANXA1 is involved with the regulation of TLR4-mediated IFN-β 
production (Bist et al. 2013). Taken together, this highlights the importance of further research to increase 
our understanding of the expression and function of Fpr2/3 in rodents, and FPR3 in man. These findings 
have thus brought us a step closer to understanding the pituitary-adrenal response to inflammogenic 
stress, and could facilitate in the search for safer, efficacious alternatives to GCs in the treatment of 
conditions such as sepsis. 
The study will now be discussed in terms of: the strengths and weaknesses of the study design; the 
limitations of the methodology, and the validity of assumptions in terms of precision, accuracy, and 
control of bias. 
In terms of the study design, there are several features that enabled evidence to be obtained with optimal 
use of resources. A factorial study design, for instance, was adopted for the study of the Fpr2/3
-/-
 and WT 
mouse tissues by IHC. This meant that multiple factors were tested simultaneously: 1) genotype, with two 
levels (Fpr2/3
-/-
 and WT); 2) intraperitoneal injection of either LPS or PBS; and also 3) time after 
injection (0, 2, 4, and 6 h). The purpose of this was to obtain information on the spatial distribution of 
GFP as a surrogate for Fpr2/3 within tissues from the Fpr2/3
-/-
 mice, with WT mice serving as a negative 
control. The injection of LPS was expected to enhance the signal for GFP as LPS has been shown to 
enhance the expression of Fpr2 in other systems (Cui et al. 2002; Iribarren et al. 2003). The time course 
was chosen with the view to understand the dynamics of the signal for GFP to enable functional studies to 
be performed over an appropriate duration for comparison. If the work were to be performed again, it 
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would be beneficial to analyse the Fpr2/3
-/-
 and wildtype mouse pituitary sections by immunofluorescence 
confocal microscopy to allow for better comparison with the human pituitary staining. 
The validity of the experiments will now be discussed in terms of the accuracy and precision of the 
methods used. With regard to the immunohistochemical detection of GFP and markers of pituitary cell 
subtypes, the choice of strategy was qualified by the specification and availability of the reagents at the 
time of investigation. The antibody for GFP was originally raised against epitopes from the jellyfish 
Aequoria victoria, and was supplied as a polyclonal anti-GFP preparation (ab6673, Abcam, Cambridge, 
UK). The sequences for GFP do not appear in any other known proteins or species other than the 
jellyfish, and genetically altered animals expressing the GFP transgene. The affinity and avidity of the 
anti-GFP for immunoreactive GFP is evident in the fact that it was able to detect GFP, and the LPS 
treatment enhanced the expression of GFP further, ostensibly via the mechanism by which LPS 
upregulates Fpr2 expression in microglia (Cui et al. 2002; Iribarren et al. 2003). 
The precision of the immunostaining work is supported by the manufacturer’s data on the antibodies 
used. The precision of the antibodies used is defined by the degree of cross-reactivity and the method of 
purification. The antibody for ACTH, for instance, is a well-characterised primary antibody that was 
raised in rabbit against human ACTH1-39, (Cat: AFP6328031, National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK), Torrance, CA, USA), with cross-reactivity at human, rat, mouse, and 
porcine ACTH, and was purified by immunoaffinity chromatography to be devoid of hormonal 
contaminants. The primary antibodies for GH, PRL, LH, and TSH were all from the same manufacturer 
and purified with similar immunoaffinity chromatography method and species cross-reactivity as for the 
anti-ACTH. The immunofluorescence staining for LH and TSH did not work and were not investigated 
further because they were not central to testing the hypothesis. The high similarity in amino acid 
sequences of the human anterior pituitary hormones with those of rats and mice enabled the use of the 
same antibodies raised against human epitopes to perform IHC in each of these species. 
In terms of the human anterior pituitary confocal study, there were two methods used to quantify 
colocalisation. The first involved manual analysis of images and cell counts, whereas the second used an 
automated statistical approach to quantify pixel intensity. The manual approach is potentially confounded 
by random error and the bias of visual interpretation of patterns and structures. Manual, or visual 
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approaches can yield acceptable results if the compartments are spatially separated enough for the human 
eye to resolve and distinguish reproducibly. In order to eliminate bias, however, an automated approach 
was also used. The automated statistical approach provided three indices of colocalisation, Pearson’s r, 
Manders’ colocalisation coefficients (M1 and M2), and Costes’ P-value for the colocalisation statistics. 
The Costes’ automated statistical approach defines colocalisation as the degree to which spatial variation 
in pixel intensity in one channel is explained by another channel. Pearson’s r provided a quantitative 
estimate of colocalisation that relates to the amount of colocalised signals in both channels in a nonlinear 
manner. Manders’ coefficients quantify the colocalised fraction in one channel above a threshold of 
background noise, defined by Costes’ automated method. The automated method is designed to reduce 
the frequency of type I errors or false positive for the existence of colocalisation. The strict conditions of 
Costes’ method could have feasibly increased the rate of type II errors or false negatives for the existence 
of colocalisation of FPR1 and FPR2/ALX with either ACTH or S100b. Apart from this, the finding that 
only one FPR subtype, namely FPR3, was significantly colocalised with ACTH is plausible given the 
evidence of expression of Fpr subtypes in other species (John et al. 2007; McArthur et al. 2009).  
The human anterior pituitary immunostaining for FPR subtypes along with ACTH and S100b involved 
the use of diseased tissue from donors who died with MS. It was not possible to obtain pituitaries from 
non-diseased donors, as these are more difficult to come by. It is noteworthy that both FPR and ANXA1 
are upregulated in the CNS of MS patients (Elderfield et al. 1992; Müller-Ladner et al. 1996). With this 
in mind, it cannot be ruled out that the distribution of FPR subtypes and the overall lack of colocalisation 
with either ACTH or S100b, except for FPR3 and ACTH, might only be applicable within a population of 
MS sufferers.  
3.4.7 Conclusion 
These studies have provided evidence for a distribution of mouse Fpr2 and/or Fpr3, surrogated by GFP, 
within the mouse anterior pituitary that aligns with GH-, PRL-, and ACTH-immunoreactivity. This is 
complemented by a distribution of human FPR3 and FPR2/ALX immunoreactivity within the human 
anterior pituitary, albeit with fewer cells demonstrating co-immunoreactivity for ACTH and FPR2/ALX 
or FPR3, than for either FPR2/ALX or FPR3. Although these findings are novel, they are plausible given 
that the hypothesis was founded on existing evidence that Fpr transcripts are expressed within the mouse 
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and rat anterior pituitary gland, and also the mouse adrenal gland. These findings have implications for 
understanding the potential role of Fpr/FPR subtypes as targets of GC secondary mediators or mimetics 
with relevance to the management of response to inflammogenic stressors such as during sepsis and septic 
shock. Further research is needed and could take advantage of advances in three-dimensional cultures of 
human stem cells that have been shown to self-organise into functional networks similar to those found in 
intact pituitary glands (Suga et al. 2011). Combined with two-photon microscopy (Lafont et al. 2010),  
this would allow functional and spatial information to be obtained simultaneously, and on tissues that are 
relevant to the human system. Prior to this, it would be useful to expand on the present study with 
appropriate controls for the MS diseased pituitaries.   
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4.1 Introduction 
The following paragraphs describe the existing evidence for the role of formyl peptide receptor (Fpr/FPR) 
ligands in the modulation of adrenal function; the available experimental models for assessing adrenal 
function in vitro; the comparative physiology of the adrenal glands between humans, rats, and mice; and 
the basic regulation of adrenal glucocorticoid (GC) by adrenocorticotrophic hormone (ACTH) and its 
receptor. 
4.1.1 Comparative anatomy and physiology of the adrenal gland 
The adrenal gland is a composite organ that has evolved in all vertebrate species, and is derived from two 
embryological sources. The splanchnic mesoderm gives rise to the development of adrenocortical tissues 
that synthesises and secretes the mineralocorticoids and GCs in the adult. On the other hand, part of the 
neural crest develops into the chromaffin tissue within the adrenal medulla that produces the 
catecholamines epinephrine and norepinephrine. This development of the adrenal gland in humans is 
different from rodents in several features. During most of development in utero, up to 90% of the volume 
of the human adrenal is comprised of a fetal zone with a high steroidogenic capacity (Mesiano & Jaffe 
1997). Surrounding this is the transitional zone that produces cortisol as the forerunner of the zona 
fasciculata, and this is enveloped by the definitive zone that later becomes the zona glomerulosa 
(Crickard et al. 1982). Following birth, the fetal zone regresses and the formation of the three layers of 
the adrenal cortex is apparent (Mesiano & Jaffe 1997). From 33 days post coitum (dpc), the adrenal gland 
differentiates and expression of the nuclear receptor, steroidogenic factor-1 (SF-1) is evident throughout 
the cortex (Hanley et al. 2001). In rodents, the adrenal glands (and gonads) are derived from the 
adrenogenital primordium (AGP) and this appears at 9 and 11.5 dpc in mice (Ikeda et al. 1994) and rats 
(Hatano et al. 1996) respectively, and marks the appearance of nerve cells that constitute the medulla, 
which becomes distinct from the cortex by 16 dpc. Despite the differences in the development of the 
adrenal gland in rodents and humans, they are very similar in form and function. 
The main function of the adrenal gland is the production of two major classes of stress hormones. The 
adrenal medulla synthesises the catecholamines, and the adrenal cortex produces the GCs through 
steroidogenesis. Cholesterol is the substrate for steroidogenesis, but with very little de novo synthesis 
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within the cortex, the main cholesterol sources available to the adrenal are from circulating low-density 
and high-density lipoproteins (LDL and HDL), and local cholesterol stores. Steroidogenesis involves five 
isozymes of cytochrome P450 and 3β-hydroxysteroid dehydrogenase (3β-HSD) (Koritz 1964; Basch & 
Finegold 1971) separated by the mitochondria and endoplasmic reticulum (Moustafa & Koritz 1975; 
Ishimura & Fujita 1997). Beginning with the conversion of cholesterol to pregnenolone by the P450 side-
chain cleavage enzyme (P450scc), the process of steroidogenesis is very similar in humans, rats, and mice 
(Hanukoglu et al. 1981). After this step, there are some key differences between the species. Firstly, in 
humans, pregnenolone is converted to 17α-hydroxy-pregnenolone by 17α-hydroxylase (P450C17) before 
conversion to 17α-hydroxyprogesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD). In rodents, 
however, pregnenolone is instead converted directly into progesterone by 3βHSD (Brock & Waterman 
1999; Gilep et al. 2011). From this point, the enzyme 21-hydroxylase (P450C21) produces 11-
deoxycorticosterone in rodents or 11-deoxycortisol in humans (Dorfman & Hayano 1952; Kominami et 
al. 1980). These steroids are the final precursors for 11β-hydroxylase to synthesise the principal GCs in 
rodents and man, corticosterone or cortisol, respectively.  
Glucocorticoid release is primarily under the regulation of ACTH released from the pituitary gland. In 
humans, the 39 a amino acid polypeptide is a full agonist for the type 2 melanocortin receptor (MC2R) 
with a pKd of 9.8, whereas the truncated synthetic form ACTH1-24 has a lower affinity with a pKd of 9.1 
(Kapas et al. 1996). The human MC2R is 297 amino acids long and the mouse and rat equivalents are 296 
amino acids. The MC2R is the main receptor for ACTH and is expressed predominantly within the zona 
glomerulosa and zona fasciculata cortex of the human (Chhajlani 1996), mouse (Xia & Wikberg 1996), 
and rat (Izumi et al. 2004) adrenal glands. The MC2R was first cloned by Mountjoy and colleagues (1992) 
and responds exclusively to ACTH (Holder & Haskell-Luevano 2004), although ACTH also binds to the 
other four melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R, along with α, β, or γ-
melanocyte stimulating hormone (MSH) (Mountjoy et al. 1994).  
The synthesis and release of adrenal GCs are under the control of ACTH. Upon binding to ACTH, MC2R 
undergoes a conformational change that opens it up to interact with G proteins. This is followed by an 
exchange of GDP for GTP and dissociation of the heterotrimeric G proteins into an α subunit and a βγ 
subunit. This increases the production of cAMP and this acts as a second messenger of ACTH to induce 
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protein kinase A (PKA) to phosphorylate cAMP response element binding protein (CREB) as a 
transcription factor for steroidogenic acute regulatory protein (StAR) and enzymes (Lehoux et al. 1998). 
The phosphorylation of serine and threonine residues by PKA have been shown to be necessary for 
steroidogenesis (Green & Orme-Johnson 1991). The intracellular Ca
2+
 is also increased by the inhibitory 
action of cAMP on potassium channels (Enyeart & Enyeart 1998). In humans, the expression of MC2R is 
also upregulated by ACTH through a pathway dependent on cAMP (Sarkar et al. 2000) and PKA 
(Blondet et al. 2002). This also involves interactions of MC2R with AP-1 and steroidogenic factor-1 (SF-
1) binding elements (Naville et al. 1999) in humans, whereas in mice the SF-1 complex assembles on the 
Mc2r promoter (Winnay & Hammer 2006), and modulates the CREB-mediated activation of the rat 
steroidogenic enzymes (Zhang & Mellon 1996; Yan et al. 2006). Following activation by ACTH, the 
MC2R internalises by clathrin-mediated endocytosis (Wenzel-Seifert & Seifert 1993; Kilianova et al. 
2006), and a similar process occurs in the mouse (Ghatei et al. 1993; Baig et al. 2001), and presumably in 
rats. 
Although the affinity and the capacity of the human adrenocortical MC2R are very similar to those of the 
rat, there are however some differences between the species. Human adrenocortical cells are 
approximately 20 times more sensitive to ACTH than rat adrenocortical cells, possibly owing to a more 
efficient coupling of MC2R with adenylate cyclase and subsequent steroidogenesis. This is substantiated 
by ACTH having a pKd of 9.8 with MC2R in human adrenocortical cells, but also has an EC50 for cAMP 
(120-140 pM) that is 20-fold lower, and an EC50 for steroidogenesis (3-8 pM) that is 720-times lower than 
its Kd (Kolanowski & Crabbe 1976; Catalano et al. 1986; Andreis et al. 1995). Conversely, in rats, the Kd 
for ACTH broadly equals its EC50 for cAMP, and the EC50 for steroidogenesis is only 40-times lower than 
its Kd (Sayers et al. 1971a; see Ramachandran 1987).   
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4.1.2 Adrenal function and expression of Fpr/FPR subtypes and their ligands 
The Fpr/FPR subtypes known to be expressed within the adrenal gland are human FPR1 and FPR2/ALX 
(Becker et al. 1998) and mouse Fpr1, Fpr2, and Fpr3/Alx (Buss 2010). Very few of the hundred or so 
currently known ligands for these Fpr/FPR subtypes, however, have been studied for their effects on 
adrenal function. Of those that have, they were either not known as Fpr/FPR ligands at the time of the 
experiments, or they were studied by colleagues of the author. Beginning with the former, these include 
cyclosporine A, cyclosporine H, and pituitary adenylate cyclase activating protein (PACAP).  
Cyclosporine A is a cyclic peptide obtained from the Trichoderma polysporum fungus and has 
immunosuppressive antibiotic properties. It was shown that Cyclosporine A administered to rats in vivo 
also has a suppressive effect on the steroidogenic capacity and impairs the stress response (Hirano et al. 
1988; Rebuffat et al. 1989) of the adrenal gland where it can also accumulate (Niederberger et al. 1983; 
Ried et al. 1983). Since then, it has been shown that human FPR1 is antagonised by Cyclosporine A (Yan 
et al. 2006), and the related peptide, cyclosporine H is a potent antagonist for human FPR1 and 
FPR2/ALX (Wenzel-Seifert & Seifert 1993; de Paulis et al. 1996). At the time of writing, it is not known 
whether either of these antagonise the equivalent receptor subtypes in rat or mouse systems. Unlike the 
cyclosporines, PACAP is an endogenous peptide expressed within the adrenal medulla of rats, and 
humans (Sharma & Brush 1973; Ghatei et al. 1993), and possibly in mice, and has been shown to agonise 
human FPR2/ALX (Gazdar et al. 1990; Kim et al. 2006; Zein et al. 2008a). PACAP had no effect on 
basal GC secretion in dispersed cortical cells from rat or human adrenals, but micromolar PACAP 
stimulated GC release in rat adrenal slices that contained the medulla (Mountjoy et al. 1994; Andreis et 
al. 1995). 
Work performed in this lab found evidence of ANXA1Ac2-26–mediated inhibition of corticosterone release 
in dispersed mouse adrenal cultures, and ANXA1-knockout mice had higher basal corticosterone release 
than wildtype mice (Davies et al. 2007; Buss 2010). ANXA1Ac2-26 is the N-terminal peptide of ANXA1 
which is expressed within the mouse (Buss 2010) and human adrenal cortex (Horvath et al. 2006). 
ANXA1Ac2-26 is a non-selective agonist with effects via human FPR1, FPR2/ALX, and FPR3, with pEC50 
values between 5.30 and 6.80 (Walther et al. 2000; Ernst et al. 2004b; Hayhoe et al. 2006). Similarly, 
fMLF, the synthetic variant of the bacterial prototypical Fpr/FPR ligand, was also shown to elicit 
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inhibition of adrenal GC release the same model (Buss 2010). It is not known, however, which receptor 
subtype mediated the effects of these ligands. 
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4.1.3 Models of adrenal function 
Cell lines generally have some practical advantages over primary cultures. Once generated, the cells are 
more autonomous and have fewer requirements for growth. 
The murine Y1 cell line is derived from an adrenocortical tumour in a male LAF1 (C57L x A/HeJ) mouse 
exposed to radiation. The tumour initially produced corticosterone in response to ACTH (Cohen et al. 
1957), but lost this ability in sub-culturing steps (Bloch & Cohen 1960) due to a deficiency in 21-
hydroxylase (P450C21) (Parker et al. 1985). Investigating whether ligands modulate corticosterone 
release would necessitate transfection with a P450C21 clone (Parker et al. 1985; Szyf et al. 1990).  
There have been some attempts towards establishing a rat adrenocortical cell line through viral 
transformation. The transformed rat adrenocortical (TRA) cell line, for instance, was derived from a 
culture of an adrenocortical tumour of a virally infected Fischer rat (Auersperg et al. 1977). The TRA 
cells could not synthesise the 11- or 21-hydroxylated steroidogenic precursors of GCs, and had a low 
density of steroidogenic apparatus, namely, lipids, smooth endoplasmic reticulae, and mitochondria, 
versus untransformed cells (Auersperg 1978). Steroidogenic apparatus was also reduced in the Snell 
carcinoma-494 cell line versus normal adrenocortical cells from an Osborne-Mendel rat (Snell & Stewart 
1959), and so this cell line produces only very low amounts of corticosterone (Sharma & Brush 1973). 
The human NCI-H295R adrenocortical cell line is derived from an adrenocortical carcinoma (Gazdar et 
al. 1990), and although it expresses most steroidogenic enzymes, it exhibits only a limited response to 
ACTH. Most variant strains are totally resistant to ACTH in terms of cortisol production, possibly owing 
to the low expression of MC2R (Mountjoy et al. 1994). Studies using this cell line therefore typically 
involve the use of forskolin or cAMP analogues.  
Overall, the abnormal production of steroids or response to ACTH in terms of impaired or blocked ability 
to produce either corticosterone or cortisol limits the usefulness of currently available cell lines as a 
model for investigating whether Fpr/FPR ligands modulate GC release. Although primary tissue cultures 
typically have greater unsystematic variability versus cell lines, there are dispersed adrenal culture 
methods characterised by a high degree of reproducibility, mainly because of the elimination of inter-
animal variation compared with adrenal slice cultures. The original dispersed rat adrenal bioassay 
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technique was performed by Swallow and Sayers (1969) and was 1000-fold more sensitive to ACTH than 
cultured adrenal quarters, and was in this regard comparable with radioimmunoassay technology at the 
time (Sayers et al. 1971b). The adrenals from several rats are dispersed into a pooled suspension of 
isolated cells, from which multiple aliquots are obtained. Primary dispersed adrenal protocols have been 
described for human, rat, and mouse adrenals (Armato et al. 1974; Buss 2010), but the smaller size of the 
mouse adrenal would necessitate killing more to achieve the same cell yield obtained from rats. 
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4.2 Methodology 
Based on the above evidence, it was hypothesised that Fpr/FPR ligands will modulate adrenal function in 
basal or ACTH-stimulated conditions. In order to test this hypothesis, intact rats were killed by 
decapitation and the adrenal glands were pooled into Earle’s balanced salt solution (EBSS). This was to 
provide a physiological buffer system for the adrenal cells prior to dispersal by cutting the glands with a 
razor blade in EBBS containing collagenase. Whilst not as effective at dispersing adrenal cells as trypsin 
(Sayers et al. 1971b), there is evidence that trypsin downregulates binding sites for Fpr/FPR ligands such 
as ANXA1 (Christian et al. 1997) but none for collagenase. Once dispersed, the adrenals were then 
aliquotted into 96-well plates prior to centrifugation, then allowed to equilibrate at 37 °C at 95% O2/5% 
CO2 for an hour. The cells were then incubated for 4 hours of contact with fresh EBSS containing 
Fpr/FPR ligands and/or ACTH1-24, vehicle, or EBSS alone. The Fpr/FPR ligands included agonists with 
different relative affinities for each Fpr/FPR subtype, and the Fpr2-/FPR2/ALX-selective antagonist, 
WRW4 with a pIC50 for human FPR2/ALX, and mouse and rat Fpr2 of between 6.6 and 6.9, (Bae et al. 
2004; Önnheim et al. 2008; Braun et al. 2011). The Fpr/FPR agonists tested were the Fpr1-/FPR1-
selective agonist fMLF, the Fpr2-/FPR2/ALX-selective agonist WKYMVm, the Fpr2-/FPR3-selective 
F2L, the Fpr3/Alx-/FPR2/ALX-selective agonist 15-epi-LXA4, and the non-selective Fpr agonist 
ANXA1Ac2-26.  The conditioned media were then removed and frozen at -20 °C, before being assayed for 
corticosterone using a proprietary enzyme-immunoassay (EIA) kit and a spectrophotometer. 
The suppressive effect on pituitary-adrenal function remains one of the major drawbacks of long term GC 
treatment (Schlaghecke et al. 1992). Pituitary-adrenal function is also dissociated during sepsis-relevant 
endotoxaemia, and GC treatment alone is not sufficient to prevent death during sepsis (Marik 2009). The 
aim of these experiments therefore was to advance the knowledge on the modulation of adrenal GC 
release through Fpr/FPR ligands before further testing of whether such ligands protect adrenal 
steroidogenic capacity during sepsis-related endotoxaemia. 
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4.3 Results 
4.3.1 The effect of ACTH1-24 on corticosterone release from dispersed adrenal cells 
Figure 4.1 shows the effects of graded concentrations 10
-10 – 10-6 mol.l-1 ACTH1-24 (tetracosactide 
actetate, Alliance Pharmaceuticals) from dispersed adrenal cells from male Wistar rats in vitro. This 
resulted in concentration-related increases in corticosterone release with sub-maximal responses evident 
at the 10
-7
 mol.l
-1
 concentration (* = P < .05 vs. drug-free). Therefore, this concentration of ACTH1-24 was 
selected for all future experiments. 
 
  
 187 
 
Figure 4.1: Effect of graded concentrations of adrenocorticotrophic hormone (ACTH1-24) on the 
release of corticosterone from dispersed rat adrenal cells. 
Points and error bars are arithmetic mean ± standard error of mean of n = 8 replicate wells. Data 
compared by one-way ANOVA with Dunett’s post hoc test, *P < .05, vs. drug-free. 
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4.3.2 The effects of fMLF on corticosterone release from dispersed adrenal cells 
Formyl-methionyl-leucyl-phenylalanine (fMLF) is a selective agonist for human FPR1, mouse Fpr1, and 
rat Fpr1. Figure 4.2 shows the effects of graded concentrations (10
-7
, 10
-6
, 10
-5
 mol.l
-1
) of fMLF on the 
increases in corticosterone release induced by a sub-maximal concentration of ACTH1-24 (10
-7
 mol.l
-1
), in 
the presence and absence of a selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
) from dispersed rat adrenal 
cells in vitro. 
ACTH1-24 (10
-7
 mol.l
-1
) caused a significant increase in corticosterone release (* = P < .05 vs. basal). At 
all concentrations tested, fMLF reduced basal corticosterone release (*** = P < .001 vs. drug-free) and 
inhibited the steroidogenic response to ACTH1-24 (*** = P < .001 vs. ACTH1-24 alone). WRW4 alone (10
-6
 
mol.l
-1
) or co-incubated with ACTH1-24 had no effect on basal corticosterone release (ns = P > .05) but it 
reduced the response to ACTH1-24 (††† = P < .001 vs. ACTH1-24). 
WRW4 also reversed the inhibition of basal corticosterone release induced by the lower concentration of 
fMLF (10
-7
 mol.l
-1
, *** = P < .001) but failed to modify the responses to the two higher concentrations of 
fMLF tested. WRW4 appeared to partly reverse the inhibitory effects of fMLF on the secretory responses 
to ACTH1-24 (# = P < .05 vs. fMLF + ACTH1-24).  
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Figure 4.2: Effects of graded concentrations of the formyl peptide receptor 1 (FPR1)-selective 
agonist formyl-methionyl-leucyl-phenylalanine (fMLF) in the presence and absence of 
adrenocorticotrophic hormone (ACTH1-24) and/or the FPR2/ALX-selective antagonist Trp-Arg-
Trp-Trp-Trp-Trp (WRW4) on corticosterone release from dispersed adrenal cells derived from 
male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with or without (basal) the ligands ACTH1-
24 (10
-7
 mol.l
-1
), WRW4 (10
-6
 mol.l
-1
), and fMLF (10
-7
, 10
-6
, 10
-5
 mol.l
-1
). The vehicle (Veh) for fMLF was 
.025% acetate. Data are arithmetic mean ± standard error of mean of n = 8 replicate wells, compared by 
three-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < .001 vs. drug-free; 
††† = P < .001 vs. ACTH1-24; § = P < .05 vs. WRW4; ‡‡ = P < .01 vs. ACTH1-24+WRW4; and # = P < .05 
vs. fMLF ± ACTH1-24 ± WRW4.  
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4.3.3 The effects of WKYMVm on corticosterone release from dispersed adrenal cells 
Figure 4.3 shows the effects of graded concentrations (10
-8
, 10
-7
, and 10
-6
 mol.l
-1
) of the selective agonist 
for human FPR2/ALX and mouse Fpr2, Trp-Lys-Tyr-Met-Val-D-met (WKYMVm), on the increases in 
corticosterone release induced by a sub-maximal concentration of ACTH1-24 (10
-7
 mol.l
-1
), in the presence 
and absence of a selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
) from dispersed rat adrenal cells in vitro. 
ACTH1-24 (10
-7
 mol.l
-1
) caused a significant increase in corticosterone release (*** = P < .001 vs. basal). 
At all concentrations tested, WKYMVm reduced basal corticosterone release (*** = P < .001 vs. drug-
free) and inhibited the steroidogenic response to ACTH1-24 (*** = P < vs. ACTH1-24 alone).   
WRW4 (10
-6
 mol.l
-1
) had no effect on basal corticosterone release (ns = P > .05), but it reduced the 
response to ACTH1-24 (††† = P < .001). WRW4 failed to modify the response to WKYMVm except at the 
highest concentration tested (10
-6
 mol.l
-1
) where it reversed the inhibitory effects of WKYMVm, and thus 
increased corticosterone release (*** = P vs. 10
-6
 mol.l
-1
 WKYMVm alone). In combination with 
WRW4+ACTH1-24, the inhibitory effect of low concentration WKYMVm (10
-8
 mol.l
-1
) was partly 
reversed (# = P < .05).  
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Figure 4.3: Effects of graded concentrations of the formyl peptide receptor 2 (FPR2/ALX)-selective 
agonist tryptophan-lysine-tyrosine-methionine-valine-dextro-methionine (WKYMVm) in the 
presence and absence of adrenocorticotrophic hormone (ACTH1-24) and/or the FPR2/ALX-selective 
antagonist Trp-Arg-Trp-Trp-Trp-Trp (WRW4) on corticosterone release from dispersed adrenal 
cells derived from male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with or without (basal) the ligands ACTH1-
24 (10
-7
 mol.l
-1
), WRW4 (10
-6
 mol.l
-1
), and fMLF (10
-7
, 10
-6
, 10
-5
 mol.l
-1
). The vehicle (Veh) for 
WKYMVm was .025% acetate. Data are arithmetic mean ± standard error of mean of n = 8 replicate 
wells, compared by three-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < 
.001 vs. drug-free; †† = P < .01,  ††† = P < .001 vs. ACTH1-24; § = P < .05, §§§ = P < .001 vs. WRW4; 
‡‡‡ = P < .001 vs. ACTH1-24+WRW4; and # = P < .05 vs. WKYMVm ± ACTH1-24 ± WRW4. 
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4.3.4 The effects of F2L on corticosterone release from dispersed adrenal cells 
F2L is a selective agonist for human FPR3 and mouse Fpr2 derived from an amino-acetylated haem-
binding protein fragment. Figure 4.4 shows the effects of graded concentrations (4 x 10
-9
, 4 x 10
-8
, and 4 x 
10
-7
 mol.l
-1
) of F2L on the increases in corticosterone release induced by a sub-maximal concentration of 
ACTH1-24 (10
-7
 mol.l
-1
), in the presence and absence of a selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
) 
from dispersed rat adrenal cells in vitro.  
ACTH1-24 (10
-7
 mol.l
-1
) failed to raise corticosterone release significantly (ns = P > .05 vs. basal). ACTH1-
24 increased corticosterone release when co-incubated with F2L (# = P < .05 vs. F2L alone), except at 10
-9
 
mol.l
-1
 F2L where ACTH1-24 inhibited release vs. F2L alone (### = P < .001). At the concentrations 
tested, F2L had no effect on basal corticosterone release except at 4 x 10
-9
 mol.l
-1
 when it increased 
corticosterone release (*** = P < .001 vs. drug-free). 
WRW4 (10
-6
 mol.l
-1
) had no effect on basal or ACTH1-24-stimulated corticosterone release (ns = P > .05), 
but in the presence of ACTH1-24 and 4 x 10
-8
 mol.l
-1
 F2L, it potentiated the response to ACTH1-24 (### = P 
< .001). 
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Figure 4.4: Effects of graded concentrations of the formyl peptide receptor 3 (FPR3)-selective 
agonist amino-acetylated haem-binding protein fragment (F2L) in the presence and absence of 
adrenocorticotrophic hormone (ACTH1-24) and/or the FPR2/ALX-selective antagonist Trp-Arg-
Trp-Trp-Trp-Trp (WRW4) on corticosterone release from dispersed adrenal cells derived from 
male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with or without (basal) the ligands ACTH1-
24 (10
-7
 mol.l
-1
), WRW4 (10
-6
 mol.l
-1
), and fMLF (10
-7
, 10
-6
, 10
-5
 mol.l
-1
). The vehicle (Veh) for F2L was 
0.4% dimethyl sulphoxide (DMSO). Data are arithmetic mean ± standard error of mean of n = 8 replicate 
wells, compared by three-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < 
.001 vs. drug-free; †† = P < .01 vs. ACTH1-24; § = P < .05, §§§ = P < .001 vs. WRW4; ‡‡ = P < .01 vs. 
ACTH1-24+WRW4; and # = P < .05, ## = P < .01, ### = P < .001 vs. F2L ± ACTH1-24 ± WRW4. 
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4.3.5 The effects of 15-epi-LXA4 on corticosterone release from dispersed adrenal cells, in the presence 
and absence of ACTH1-24 and/or WRW4 
15-epi-lipoxin A4 (15-epi-LXA4) is a selective agonist for human FPR2/ALX, mouse Fpr3/Alx, and rat 
Fpr2l/Alx. Figure 4.5 shows the effects of graded concentrations (10
-9
, 10
-8
, and 10
-7 
mol.l
-1
) of 15-epi-
LXA4 on the increases in corticosterone release induced by a sub-maximal concentration of ACTH1-24 
(10
-7
 mol.l
-1
), in the presence and absence of a selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
) from 
dispersed rat adrenal cells in vitro. 
ACTH1-24 (10
-7
 mol.l
-1
) caused a significant increase in corticosterone release (*** = P < .001 vs. drug-
free). At all concentrations tested, 15-epi-LXA4 reduced basal corticosterone release (*** = P < .001 vs. 
drug-free) and inhibited the steroidogenic response to ACTH1-24. WRW4 had no effect on either basal 
corticosterone release (ns = P > .05) or the reduction in basal corticosterone release induced by each 
concentration of 15-epi-LXA4 tested (*** = P < .001 vs. drug-free).  
As in previous experiments, WRW4 reduced the corticosterone response to ACTH1-24. However, in the 
presence of the lowest concentration of 15-epi-LXA4, WRW4 did not affect the secretory response to 
ACTH1-24 (10
-7
 mol.l
-1
, ### = P < .001 vs. 15-epi-LXA4 + ACTH1-24), although in the presence of the two 
higher concentrations of 15-epi-LXA4, WRW4 again reduced the response to ACTH1-24. 
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Figure 4.5: Effects of graded concentrations of the formyl peptide receptor 2 (FPR2/ALX)-selective 
agonist 15-epi-lipoxin A4 (15-epi-LXA4) in the presence and absence of adrenocorticotrophic 
hormone (ACTH1-24) and/or the FPR2/ALX-selective antagonist Trp-Arg-Trp-Trp-Trp-Trp 
(WRW4) on corticosterone release from dispersed adrenal cells derived from male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with or without (basal) the ligands ACTH1-
24 (10
-7
 mol.l
-1
), WRW4 (10
-6
 mol.l
-1
), and fMLF (10
-7
, 10
-6
, 10
-5
 mol.l
-1
). The vehicle (Veh) for 15-epi-
LXA4 was .014% ethanol. Data are arithmetic mean ± standard error of mean of n = 8 replicate wells, 
compared by three-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < .001 vs. 
drug-free; ††† = P < .001 vs. ACTH1-24; §§ = P < .01 vs. WRW4; ‡‡ = P < .01 vs. ACTH1-24+WRW4; and 
# = P < .05, ## = P < .01 vs. 15-epi-LXA4 ± ACTH1-24 ± WRW4. 
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4.3.6 The effects of ANXA1Ac2-26 on corticosterone release from dispersed adrenal cells, in the presence 
and absence of ACTH1-24 and/or WRW4 
Annexin Al acetylated peptide (ANXA1Ac2-26) is a non-selective agonist of the mouse and human 
Fpr/FPR subtypes, but so far is only known to bind to Fpr2 of the rat subtypes. 
Figure 4.6 shows the effects of graded concentrations (3 x 10
-7
, 3 x 10
-6
, and 3 x 10
-5
 mol.l
-1
) of 
ANXA1Ac2-26 on the increases in corticosterone release induced by a sub-maximal concentration of 
ACTH1-24 (10
-7
 mol.l
-1
), in the presence and absence of a selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
) 
from dispersed adrenal cells in vitro. 
ACTH1-24 (10
-7
 mol.l
-1
) caused a significant increase in corticosterone release (* = P < .05 vs. drug-free). 
At all concentrations tested, ANXA1Ac2-26 reduced basal corticosterone release (*** = P < .001 vs. drug-
free) and inhibited the steroidogenic response to ACTH1-24 (*** = P < vs. ACTH1-24 alone).  
WRW4 alone (10
-6
 mol.l
-1
) had no effect on basal corticosterone release (ns = P > .05) but reduced the 
steroidogenic response to ACTH1-24 (††† = P < .001). However, WRW4 did not affect the inhibition of 
basal corticosterone release induced by each concentration of ANXA1Ac2-26 (*** = P < .001 vs. drug-
free). WRW4 potentiated the steroidogenic response to ACTH1-24 in the presence of ANXA1Ac2-26 (10
-7
 
mol.l
-1
) but not in the presence of the two higher concentrations of ANXA1Ac2-26 tested.  
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Figure 4.6: Effects of graded concentrations of the non-selective formyl peptide receptor (FPR) 
agonist annexin A1 amino-acetylated peptide 2-26 (ANXA1Ac2-26) in the presence and absence of 
adrenocorticotrophic hormone (ACTH1-24) and/or the FPR2/ALX-selective antagonist Trp-Arg-
Trp-Trp-Trp-Trp (WRW4) on corticosterone release from dispersed adrenal cells derived from 
male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with or without (basal) the ligands ACTH1-
24 (10
-7
 mol.l
-1
), WRW4 (10
-6
 mol.l
-1
), and fMLF (10
-7
, 10
-6
, 10
-5
 mol.l
-1
). Data are arithmetic mean ± 
standard error of mean of n = 8 replicate wells, compared by three-way ANOVA with Bonferroni 
correction for multiple comparisons: *** = P < .001 vs. drug-free; ††† = P < .001 vs. ACTH1-24; §§§ = P 
< .001 vs. WRW4; ‡‡‡ = P < .001 vs. ACTH1-24+WRW4; and # = P < .05, ## = P < .01, ### = P < .001 vs. 
ANXA1Ac2-26 ± ACTH1-24 ± WRW4. 
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4.4 Discussion 
The main findings can be drawn from (1) the efficacy of each agonist, compared at broadly the same 
concentration level, that is, around 10
-7
 mol.l
-1
; (2) whether the given agonist is effective in basal and/or 
ACTH1-24-stimulated conditions, and (3) the sensitivity of each agonist to the effects of the Fpr2-
/FPR2/ALX-selective antagonist, WRW4. It is evident, then, that fMLF elicited the most powerful 
inhibition of corticosterone release irrespective of whether ACTH1-24 was present. Despite being generally 
Fpr1-/FPR1-selective elsewhere, fMLF was the only agonist to be at least partly inhibited by WRW4. On 
the other hand, 15-epi-LXA4 and ANXA1Ac2-26 were unaffected by WRW4, although they each suppressed 
both basal and ACTH1-24-induced corticosterone release. WKYMVm partly suppressed basal 
corticosterone release, and was unaffected by ACTH1-24 or WRW4. The effects of F2L cannot be 
interpreted with any accuracy, as the cells in this experiment were unresponsive to ACTH1-24 (discussed 
later). Overall, a host of agonists with known activity via human FPR2/ALX and mouse Fpr2 or 
Fpr3/Alx, all suppressed basal or ACTH1-24-induced corticosterone release from dispersed adrenal cells 
from rats. These effects were not as convincing, however, as the human FPR1 and mouse/rat Fpr1 
agonist, fMLF, which was the only agonist tested to have effects which were sensitive to the Fpr2-
/FPR2/ALX-selective antagonist, WRW4. Thus, the potency of the tested FPR agonists for inhibition of 
basal and ACTH1-24-stimulated corticosterone release can be summarised as: fMLF >>> WKYMVm > 
ANXA1Ac2-26 > 15-epi-LXA4 >> F2L. The only agonist that was affected by WRW4 was fMLF. 
4.4.1 fMLF 
Prior to this study, various published reports on the pharmacological actions of fMLF indicated that when 
it is used at low nanomolar concentrations, it is a selective agonist for human FPR1 and mouse Fpr1, with 
a pEC50 value of around 9 (Freer et al. 1980; Koo et al. 1982; He et al. 2000). Whilst fMLF is selective 
for Fpr1/FPR1, it does not bind to these subtypes exclusively. Although it binds with five-times lower 
affinity than at Fpr1/FPR1, fMLF is an agonist for human FPR2/ALX with a pEC50 of 4 (Schiffmann et 
al. 1975b; Mills et al. 2000), and for mouse Fpr2 with a pEC50 between 5 and 6.37 (Quehenberger et al. 
1997; Mills et al. 2000). Even when used at 100 micromolar concentrations, fMLF did not bind or elicit 
responses with either human FPR3 or mouse Fpr3, and so can be safely assumed to have negligible 
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efficacy via these receptors (Hartt et al. 1999; Liang et al. 2000). Thus the relative affinities of fMLF for 
mouse Fpr1 over Fpr2 and for human FPR1 over FPR2/ALX, suggests these subtypes are functionally 
similar, at least for fMLF. Unfortunately, there are no binding or efficacy data currently available for the 
effects of fMLF via the equivalent of Fpr1/FPR1 in rats, or indeed, any other rat receptors.  
This study has shown that fMLF potently inhibits basal and ACTH1-24-stimulated corticosterone release 
from dispersed rat adrenal cells in vitro. The concentrations of fMLF used here (10
-7
 – 10-5 mol.l-1) were 
chosen to match those of others researching its actions via human FPR1 and mouse Fpr1. The inhibition 
of fMLF on basal corticosterone release was partly reversed by a micromolar concentration of WRW4, 
but only at the lowest tested concentration of fMLF (10
-7
 mol.l
-1
). Given that WRW4 is an Fpr2-
/FPR2/ALX-selective antagonist (Bae et al. 2004; Önnheim et al. 2008), this finding suggests that WRW4 
antagonises the rat fMLF receptor/s.  
To the author’s knowledge, this is the first time that fMLF has been tested on dispersed adrenal cells from 
rats, and shown to inhibit both basal and ACTH1-24-stimulated corticosterone release. To assess the 
plausibility of these findings, it is worthwhile comparing them to those of other studies using fMLF or 
other Fpr1-/FPR1-selective ligands. Similar experiments looking at the effects of fMLF alone or with 
ACTH1-24 and WRW4, on adrenal function have been performed on dispersed adrenal cells from mice. 
Corticosterone release was unaffected by fMLF when used at up to 100 micromolar concentrations, but 
was inhibited by as much as 70% when micromolar fMLF was incubated with ACTH1-24 (Buss 2010). As 
is the case here, and consistent with its antagonist status, WRW4 had no effect on corticosterone release 
either on its own or with ACTH1-24 (Buss 2010). From the present data, it is not clear why the FPR1/Fpr1 
agonist fMLF inhibited both basal and ACTH1-24-stimulated corticosterone release from dispersed adrenal 
cells from rats, but only inhibited ACTH1-24-stimulated release in the mouse model (Buss 2010). All 
conditions other than the source species and incubation period (4 hours here vs. 2 hours by Buss) were 
identical. At the time of writing, however, there were no other instances of fMLF being tested on 
dispersed adrenal cells. Therefore, to understand further the present results, they ought to be compared to 
the effects of different ligands that share receptors with fMLF.  
Fpr1/FPR1 ligands other than fMLF have been shown to inhibit adrenal corticosteroid release. 
Cyclosporin A (CSA), for instance, is an Fpr1/FPR1 antagonist (Yan et al. 2006) that inhibits adrenal 
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steroidogenesis (Rebuffat et al. 1989). Having potent immunosuppressive effects on lymphocyte function, 
CSA is particularly useful as an anti-rejection drug following organ transplantation. In addition, CSA has 
been shown to inhibit the secretion of ACTH and corticosterone in Wistar rats under basal and stressed 
conditions (Hirano et al. 1988), and comparable observations have been made in humans (Oka et al. 
1993). Other antagonists of Fpr1/FPR1 have similar effects. Boc2, for instance, is a synthetic compound 
(N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanine) that antagonises 
Fpr1/FPR1 when used at sub-micromolar concentrations (Wenzel-Seifert & Seifert 1993). Boc2 has been 
shown to inhibit corticosterone release in dispersed adrenal cells from mice when used at 10 micromolar 
concentrations. Again, this was only observed when ACTH1-24 was applied with Boc2 (Buss 2010). 
The present finding of an inhibitory effect of fMLF on adrenal corticosterone appears to be contradictory 
to the fact that antagonists selective for Fpr1/FPR1, namely, Boc2 and CSA, have been shown to inhibit 
adrenal steroidogenesis. Explanations for this can be drawn from what is known about the activation and 
signalling mechanisms of Fpr1/FPR1. One possibility is that the fMLF receptors in the dispersed rat 
adrenal cells are internalised following activation by fMLF, through a process known as homologous 
desensitisation. Alternatively, ligands binding to Fpr1/FPR1 have also been shown to internalise other 
GPCRs through heterologous or cross-desensitisation (Le et al. 2001b), as is the case with the chemokine 
receptors for IL-8 and CXCL8 (CXCR1 and CXCR2) or the two HIV co-receptors (Suvorova et al. 2004; 
Migeotte et al. 2005; Suvorova et al. 2009). Both mechanisms involve PKC activation, and subsequent 
phosphorylation of serine residues in the carboxylic acid terminals of the target GPCRs before 
internalisation (Christophe et al. 2001; Le et al. 2001b). If Fpr1, or the rat equivalent, were to exert tonic 
stimulation on adrenal corticosterone release as has been suggested by Buss (Boxio et al. 2005; Buss 
2010), then fMLF might be inhibiting basal release by internalising the rat fMLF receptor, and inhibiting 
the ACTH1-24-stimulated release through cross-desensitisation of MC2R (Migeotte et al. 2005; 2006). 
Taken together, the overall inhibitory effect of fMLF on corticosterone release in the study, at 
concentrations known to stimulate human FPR1 and mouse Fpr1, reaffirms the existing evidence that 
Fpr1 mediates inhibition of adrenal corticosterone release (Christophe et al. 2001; Buss 2010). Previous 
work with mouse adrenals co-incubated with WRW4 and ACTH1-24 found that WRW4 had no effect on 
basal or ACTH1-24-stimulated release of corticosterone (Boxio et al. 2005; Buss 2010). At the time of 
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writing, however, this is the first time that the Fpr2-/FPR2/ALX-selective antagonist WRW4 has been co-
incubated with both fMLF and ACTH1-24 in any dispersed adrenal cell culture. The fact that micromolar 
WRW4, an Fpr2-/FPR2/ALX-selective antagonist (Bae et al. 2004; Prat et al. 2006; Önnheim et al. 2008), 
when co-incubated with ACTH1-24, attenuated the inhibitory effect of fMLF is worthy of further 
investigation. In this context, the combined findings from mouse (Bae et al. 2003b; Buss 2010) and rat 
adrenal studies, support the assertion that at least one of the rat receptors for fMLF is WRW4-sensitive 
and coupled with signal cascades that inhibit corticosterone release in ACTH1-24-stimulated and basal 
conditions. This effect of WRW4 was surprising, as elsewhere, higher Fpr2-relevant 10
-4
 mol.l
-1
 
concentrations of fMLF (Schiffmann et al. 1975b; Mills et al. 2000), did not inhibit corticosterone release 
from mouse adrenals (Buss 2010). There are currently no pIC50 data for WRW4 in rat systems, and so this 
limits the scope of determining which receptors are blocked by WRW4 in these dispersed rat adrenal 
studies. 
4.4.2 WKYMVm 
WKYMVm (Trp-Lys-Tyr-Met-Val-D-met-NH2) is a synthetic hexapeptide (Migeotte et al. 2006) and 
selective agonist for human FPR2/ALX and mouse Fpr2 with a pEC50 of 10.13 (Migeotte et al. 2005). 
WKYMVm also has activity through human FPR3 with a pEC50 of 8.52 (Christophe et al. 2001) and 
mouse Fpr3 with a pEC50 of 7.48 (Boxio et al. 2005). The present data reveal that WKYMVm, at all 
concentrations tested, caused a significant reduction in basal and ACTH1-24-stimulated corticosterone 
release, except at micromolar WKYMVm, where a slight increase in corticosterone release occurred 
when WKYMVm was co-incubated with WRW4. To the author’s knowledge, this is the first recorded use 
of WKYMVm in dispersed adrenal cells from rats or any other species.  
At all concentrations tested, WKYMVm caused a significant reduction in basal and ACTH1-24-stimulated 
corticosterone release. At the micromolar concentration of WKYMVm, there was a slight increase in 
corticosterone release when co-incubated with WRW4. The inclusion of WRW4 reversed the inhibitory 
effects of higher concentrations of WKYMVm on basal corticosterone release. WKYMVm potently 
induces superoxide production, calcium cation mobilisation, and chemotaxis via human FPR2/ALX in 
neutrophils (Migeotte et al. 2005) and FPR3 in monocytes (Christophe et al. 2001), and via Fpr2 or Fpr3 
in mouse neutrophils (Boxio et al. 2005). Similarly, incubations of HL-60 cells over-expressing Fpr2 with 
 202 
micromolar WKYMVm result in upregulated calcium cation mobilisation traced by the Fluo3 marker 
(Prat et al. 2006). The role of calcium mobilisation in the promotion of secretory granule exocytosis by 
WKYMVm has been indexed by β-hexosaminidase activity in human FPR2-positive rat basophilic 
leukaemia cells (RBL-2H3), and by Fluo3 in mouse Fpr2-positive HL-60 cells, and is blocked by the 
calcium chelator BAPTA (Bae et al. 2003b).  
Given that the evidence suggests that WKYMVm-induced effects are mediated via human FPR2/ALX 
(Migeotte et al. 2005) or FPR3 (Christophe et al. 2001), and mouse Fpr2 or Fpr3 (Boxio et al. 2005), it 
seems plausible that the inhibitory effect of WKYMVm on corticosterone release evident in the present 
studies could also be mediated via rat Fpr2 or Fpr3. Interestingly, WKYMVm is associated with ERK 
phosphorylation in macrophages (Kang et al. 2005) which is reduced in Fpr2/3-null mice (Dufton et al. 
2010). However, ERK phosphorylation is associated with enhanced transcription of the StAR gene and 
increased corticosterone release from dispersed adrenal cells (Gyles et al. 2001; Ferreira et al. 2007; 
Hoeflich & Bielohuby 2008). This raises questions as to whether the inhibitory effects of WKYMVm 
seen here are mediated via Fpr2, Fpr3, or another receptor. This problem reflects the conclusions of Boxio 
and coworkers (2005) who showed that the stimulatory effects of WKYMVm on neutrophil granule 
release are reduced by 50% with a human FPR2/ALX antagonist termed C2 (WPLTHTLRHTIW) used at 
a concentration of 10
-5
 mol.l
-1
. Despite this, they could not determine whether the effects were Fpr2 or 
Fpr3-mediated. In the present data, the inhibition of corticosterone release by micromolar WKYMVm 
was reversed partly by WRW4, suggesting WKYMVm mediates its inhibition via a WRW4-sensitive 
receptor. WRW4 is a selective antagonist of human FPR2/ALX, mouse Fpr2, and rat Fpr2 (Braun et al. 
2011). Therefore, further work is required to elucidate precisely which Fpr subtype, mediates these 
inhibitory effects of WKYMVm, and the reversal by WRW4, in dispersed adrenal cells from rats. Given 
the non-endocrine effects of WKYMVm via mouse Fpr2 or Fpr3, it is reasonable to suggest that one or 
both of these receptors have equivalents that mediate the inhibitory effects in this rat system. 
4.4.3 F2L 
The present data show the effects of graded concentrations of the human FPR3-, mouse Fpr2-selective 
agonist, F2L, on corticosterone release from dispersed adrenal cells obtained from rats. F2L is an 
acetylated 21 amino acid oligopeptide derived from the amino terminal of the intracellular haem-binding 
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protein and has a pEC50 for human FPR3 of 8.02 (Migeotte et al. 2005) and 6.4 for mouse Fpr2 (Gao et 
al. 2007). Unfortunately, the results from the F2L study cannot be interpreted with any accuracy, as the 
response to ACTH1-24 was not significant. This is likely due to the CO2 regulator supplying the incubator 
failing at the time of the experiment.  
4.4.4 ANXA1Ac2-26 and 15-epi-LXA4 
The results show that ANXA1Ac2-26 and 15-epi-LXA4 each suppressed both basal and ACTH1-24-
stimulated corticosterone release, but were unaffected by the Fpr2-/FPR2/ALX-selective antagonist 
WRW4. To the author’s knowledge, this is the first time that 15-epi-LXA4 has been shown to inhibit 
corticosterone release from dispersed adrenal cells. ANXA1Ac2-26, however, at 10
-5
 and 3 x 10
-5
 mol.l
-1
 
concentrations inhibited ACTH1-24-stimulated corticosterone release from dispersed mouse adrenals (Buss 
2010), and so is consistent with the present findings. Elsewhere, concentrations of ANXA1Ac2-26 ranging 
from 3 x 10
-7
 to 3 x 10
-5
 mol.l
-1
 have inhibited ACTH1-24-stimulated corticosterone release from dispersed 
mouse adrenals (Davies et al. 2007). ANXA1Ac2-26 is the N-terminal active peptide from ANXA1, and it 
elicits effects via human FPR1 with a pEC50 of 5.30 (Walther et al. 2000), and the structurally similar 
peptide ANXA1Ac1-25 binds human FPR1, FPR2/ALX, and FPR3 with a pEC50 between 5.00 and 6.80 
(Ernst et al. 2004b). There are various data suggesting that effects of ANXA1Ac2-26 in mice in vivo are 
mediated via mouse Fpr1 or Fpr2 with approximate values for pED50 of around 6.00 (Gavins et al. 2007), 
or more conservatively, 4.48 (Perretti et al. 1995). In HEK293 cells transformed with Fpr2l, the rat 
lipoxin receptor, concentrations of ANXA1Ac2-26 ranging from 10
-8
 to 10
-5
 have been shown to bind to 
Fpr2l with a pKd of 6.09 (Chiang et al. 2003). 
Biosynthesis of the eicosanoid 15-epi-LXA4 is stimulated by aspirin (Clària & Serhan 1995; Gewirtz et 
al. 1999). As the epimeric form of lipoxin A4 (LXA4), 15-epi-LXA4 is a more potent and stable agonist 
for the human lipoxin receptor FPR2/ALX with a pEC50 of 10.10 (Maddox et al. 1997; Chiang et al. 
2000) versus LXA4 with a pEC50 of 9.10 (Maddox et al. 1997; Chiang et al. 2000). This relative stability 
has been attributed to 15-epi-LXA4 being more resistant to the action of the 15-hydroxy prostaglandin 
dehydrogenase (Serhan et al. 1995). 15-epi-LXA4 and LXA4 bind to the mouse lipoxin receptor, 
Fpr3/Alx, with equal affinity and a pKd of 8.82 (Takano et al. 1997). On the other hand, in terms of their 
anti-inflammatory effects, equimolar 15-epi-LXA4 was found to be more potent than LXA4, but broadly 
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similar in potency to dexamethasone (Takano et al. 1997), whose anti-inflammatory effects coincide with 
upregulated FPR2/ALX expression (Hashimoto et al. 2007). In rats, LXA4 binds to the rat Fpr2l/Alx with 
a pKd of 8.30 and this receptor has 74% and 84% sequence homology with human FPR2/ALX and mouse 
Fpr3/Alx respectively (Chiang et al. 2003). 
To the author’s knowledge, there are no other instances of 15-epi-LXA4, the human FPR2/ALX and 
mouse Fpr3/Alx agonist, and rat Fpr2l/Alx agonist, inhibiting corticosterone from dispersed adrenal cell 
cultures. Given the similar effects of 15-epi-LXA4 and ANXA1Ac2-26 in the present work, and the fact that 
they bind to the same rat Fpr2l/Alx (Chiang et al. 2003), it is reasonable to discuss the role of the rat 
Fpr2l/Alx in the context of the role of ANXA1Ac2-26 and full length ANXA1 in the adrenal glands. There 
is evidence of ANXA1 message and protein in the adrenal glands of mice (Davies et al. 2007). The 
adrenal glands respond to ACTH by upregulating the expression of steroidogenic enzymes and their 
glucocorticoid production. Within 3 hours of GC treatment, ANXA1 is upregulated, particularly within 
the cytosol of cells in the steroidogenic cortex and externalised in the sub-capsular zones (Davies et al. 
2007). Consistent with the present findings, ANXA1Ac2-26 (3 x 10
-9
 mol.l
-1
 - 3 x 10
-4
 mol.l
-1
) was also 
shown to inhibit corticosterone release, and ANXA1-null mice have increased ACTH1-24-stimulated 
corticosterone release (Davies et al. 2007). The present data showed that ANXA1Ac2-26 suppresses 
corticosterone release in both basal and ACTH1-24-stimulated conditions. Taken together, this suggests 
ANXA1 may mediate negative feedback within the adrenal gland. Given the evidence of non-endocrine 
actions of ANXA1Ac2-26 and 15-epi-LXA4 are mediated via high affinity rat Fpr2l/Alx (Chiang et al. 
2003), it is not unreasonable to suggest that the pattern of inhibited corticosterone release shared by these 
ligands, is mediated by the common target of rat Fpr2l/Alx.  
4.4.5 Biological significance and scope of findings 
The finding that ligands such as fMLF, which are based on the prototypical Fpr/FPR ligand first obtained 
from gram negative bacteria, are able to modulate adrenal GC release has implications for our 
understanding of the adrenal insufficiency that can occur in up to 65% of patients with bacterial sepsis 
(Briegel et al. 1996; Marik 2002; Marik & Zaloga 2003). Interestingly, a modified form of fMLF has 
been found to function as an antimicrobial and opsonisation compound and facilitates the actions of the 
antibiotic erythromycin, and protects mice during sepsis-related endotoxaemia (Tsubery et al. 2005). It is 
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not presently clear from this work, whether adrenal function was involved in the protection afforded by 
fMLF. It is noteworthy that even LPS-primed macrophages are able to inhibit adrenal steroidogenesis 
(Mathison et al. 1983). Clearly, the subtypes of the Fpr/FPR family and their role in the dynamics 
between the immune and endocrine systems in response to sepsis-related endotoxaemia, are worthy of 
further investigation. 
One key assumption in designing the study was that the selectivity of the ligands for the murine receptors 
is complemented by the rat receptors. Elsewhere, the anti-inflammatory effects of ANXA1 are evidently 
signalled through the rat Fpr2 subtype (Braun et al. 2011; Pei et al. 2011; Slowik et al. 2012), whereas the 
effects of LXA4 and 15-epi-LXA4 have been shown to be mediated via rat Fpr2l/Alx which was 
upregulated in a rat model of endometriosis (Chiang et al. 2003; Motohashi et al. 2005). 
The dispersed adrenal cell studies involved a factorial study design. In practice this meant testing multiple 
factors simultaneously: graded concentrations of an Fpr/FPR agonist, with or without the Fpr2-
/FPR2/ALX-selective antagonist and the MC2R agonist ACTH1-24. The concentrations of the Fpr agonists 
used in these experiments were selected based on existing data on their potency (EC50), or affinity (Kd) 
via the Fpr subtype for which they have the highest affinity. The three concentrations chosen straddled 
this EC50 or Kd for each ligand. In hindsight, it would have been more beneficial to test the effects of the 
agonists over a wider range of concentrations, a minimum of six perhaps. This would have allowed 
calculation of an EC50 for each Fpr ligand tested in this dispersed rat adrenal cell system. Only three 
concentrations were used because we sought to test the agonists in a factorial study design, involving the 
coincubation of the agonists with ACTH1-24 and/or WRW4. This was because WRW4 is an Fpr2-
/FPR2/ALX-selective antagonist (Braun et al. 2011) and much of the evidence at the time suggested that 
Fpr2 was involved in the regulation of GC release (John et al. 2007). To have both a factorial study 
design and a wider range of concentrations would have required more cells than could be viably 
generated in a single experiment (Carsia et al. 1996).  
The supply of CO2 to the incubator failed during the F2L experiment and could have affected viability. 
The viability of the cells was only checked before the addition of drugs and would benefit from checking 
the cells following the incubation period to ensure that the vehicle or the drug did not affect the release of 
corticosterone through the induction of cell death. Cell viability is typically between 80 – 95% in 
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conditions similar to the present work (Ramachandran & Suyama 1975). The adrenal gland undergoes 
atrophy following hypophysectomy or suppression of ACTH release through inhibition by exogenous 
GCs, and is partly reversed by exogenous ACTH (Ceccatelli et al. 1995). This atrophy is characterised by 
adrenocortical apoptosis, and the cortex size is markedly reduced in animals given GCs. Following 
hypophysectomy in rats, the adrenal cortex undergoes atrophy between 12 and 24 hours later, whereas 
cultured adrenal cells undergo apoptosis much earlier, around 1 hour following (Carsia et al. 1996).  
Since the dispersed adrenal cells were generated from a single pool of multiple glands, the experiment 
would need to be repeated to confirm the reproducibility of the findings. Alternatively, a modified 
protocol for the experiments would involve multiple pools of dispersed glands, for instance, n = 8 pools 
of 2 glands each, per 96-well plate experiment. Such a protocol would have to be optimised to ensure that 
generating several pools rather than just one did not affect cell viability. Otherwise, multiple personnel 
would have to be involved and this was not an option available at the time of the experiments.  
Some aspects of the experiments could be improved upon in future work. The adrenal glands were not 
decapsulated before incubation. This might have increased the mitotic and proliferative capacity of the 
adrenal cells versus a culture of dispersed cells from decapsulated glands (see Armato & Nussdorfer 
1972; O'Hare & Neville 1973). Other dispersed adrenal cell monoculture protocols involve the removal of 
the surrounding fat and the adrenal capsule (Giroud et al. 1956), in order to take off the zona glomerulosa 
(Bankiewicz et al. 1968). The adrenal glands obtained were from control rats from in vivo experiments of 
colleagues. To reduce the number of animals required, one could consider using female rats, as their 
adrenals are larger and have a thicker cortex with respect to their body mass, and thus release around 
twice as much GCs (Kitay 1961; Biswas et al. 1967).   
4.4.6 Conclusion 
These studies have provided evidence in support of the hypothesis, that Fpr/FPR ligands are able to 
modulate GC release from dispersed adrenal cells in vitro, in basal and ACTH1-24-stimulated conditions.  
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5.1 Introduction 
The following paragraphs describe the existing evidence for the role of formyl peptide receptor (Fpr/FPR) 
ligands in the modulation of pituitary function; the available experimental models for assessing pituitary 
function in vitro; the comparative physiology of the pituitary gland between humans, rats, and mice; and 
the basic regulation of pituitary adrenocorticotrophic hormone (ACTH) by corticotrophic releasing 
hormone (CRH), arginine vasopressin (AVP), and their receptors. 
5.1.1 Comparative anatomy and physiology of the pituitary gland 
As with the adrenal gland, the pituitary gland is a composite organ that has evolved in all vertebrate 
species, and is derived from two embryological sources. The posterior lobe of the pituitary gland is made 
from the neural tube that also forms the brain and nervous system, whereas the anterior lobe is made from 
Rathke’s pouch in a folding of the stomodeum, which also forms the gut and mouth. The anterior lobe 
then differentiates into three major epithelial subdivisions: the pars distalis, pars intermedia, and the pars 
tuberalis. The developed pituitary gland in humans is a bean-sized hypophysis (under-growth) that sits 
within the sella turcica (Turkish saddle) of the sphenoid bone at the base of the brain above the nasal 
sinuses. The course of cell differentiation behind the diverse hormone secreting cells within the human 
anterior pituitary gland is similar in rats and mice. The effective differentiation of the endocrine cells of 
the anterior pituitary gland requires an exchange of signals with the developing hypothalamus. Explant 
studies of the Rathke’s pouch taken from mice (Takuma et al. 1998; Treier et al. 1998) and rats 
(Nemeskéry et al. 1976; Dubois & Hemming 1991) demonstrated a critical period for this 
communication—between embryonic (E) day E12 and E13. After this period, the first hormone producing 
cells to develop are the corticotrophs expressing proopiomelanocortin (POMC), which begin to appear at 
E13.5 in mice (Japón et al. 1994) and rats (Watanabe 1982). This is followed by the appearance of the 
thyrotrophs (thyroid stimulating hormone-β (TSHβ) positive) in the rostral tip at E14.5, followed by 
somatotrophs (growth hormone (GH) positive), lactotrophs (prolactin (PRL) positive), and gonadotrophs 
(luteinising hormone-β (LHβ), or follicle stimulating hormone-β (FSHβ) positive) at E15-17.5 (Burrows 
et al. 1999). One major difference in pituitary development between humans and rodents, however, is that 
the terminal differentiation of the anterior pituitary cell types is reached during the first trimester, whereas 
this extends into the perinatal period in rodents (Cushman et al. 2001; Polin et al. 2011). Indeed, the 
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pituitary-adrenal axis in rats (Schapiro et al. 1962) and mice (Schmidt et al. 2003) undergoes a clear 
period of postnatal hyposensitivity to stressors. To some extent, this might also occur during human 
infancy (Gunnar et al. 1989), but by adulthood, the basic mechanisms behind the pituitary-adrenal stress 
response in these species is broadly similar.  
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5.1.2 Pituitary function and expression of Fpr/FPR subtypes and their ligands 
The secretion of pituitary ACTH is primarily under the control of CRH and AVP, whose actions are 
synergistic but each have different signalling mechanisms (Gillies et al. 1982). Upon reaching the 
corticotrophs, CRH activates the type 1 CRH receptor (CRH-R1) coupled with adenylate cyclase leading 
to the formation of cyclic adenosine monophosphate (cAMP) which triggers protein kinase A (PKA) 
activation and an influx of extracellular Ca
2+
 via L-type voltage-sensitive channels (Won & Orth 1990). 
AVP binds to its vasopressin receptor type 1b (V1bR) and activates phospholipase C (PLC) to generate 
inositol trisphosphate (IP3) and diacylglycerol (DAG) that induces intracellular Ca
2+
 mobilisation and 
activation of protein kinase C (PKC) for a further influx of Ca
2+
 (Won et al. 1990). One of the main 
mechanisms of inhibiting ACTH secretion, however, involves the negative feedback effects of 
glucocorticoids (GCs). Although the precise mechanism of this feedback inhibition remains to be 
elucidated, GCs are known to induce the expression of the second mediator protein annexin A1 (ANXA1) 
within the pituitary, and elsewhere (Strijbos et al. 1991). In addition, ANXA1 mimics, while treatment 
with ANXA1 antisera attenuates the actions of GCs in models of inflammation, and hormone release 
(Taylor et al. 1997). Dartois and Bouton (1986) suggested an ANXA1-like protein is likely to be involved 
in the inhibition of ACTH release. Later, expression of ANXA1 was found to be localised within the 
folliculostellate cells of the anterior pituitary (Traverso et al. 1999) with ANXA1 binding sites evident on 
adjacent corticotrophs (Christian et al. 1997). These binding sites were suggested to be populated by an 
Fpr/FPR subtype on the basis that ANXA1 had been shown to mediate its effects via FPR expressed in 
leukocytes (Walther et al. 2000).  
The potential for using Fpr/FPR ligands as tools to improve our understanding of the regulation of 
pituitary ACTH release, relates to the diversity of the currently known Fpr/FPR ligands, of which there 
are at least one hundred (Ye et al. 2009). This is partly restricted, of course, by the Fpr/FPR subtypes that 
are expressed within the pituitary gland. These are Fpr2, Fpr3, Fpr-rs6, and Fpr-rs7 within the mouse 
anterior pituitary (John et al. 2007; Buss 2010), and, based on the sequence homology with their mouse 
equivalents, Fpr2 and Fpr3 have been detected within the rat anterior pituitary (John et al. 2007). (The 
nucleotide sequences for the rat Fpr subtypes are still based on expressed sequence tags (ESTs) from 
cDNA libraries and so their predicted sequences have not yet been confirmed). Until the present work, 
 211 
relatively little was known about the expression of FPR within the human pituitary, although FPR1 
epitopes were not detectible (Becker et al. 1998). If an FPR were involved in the modulation of pituitary 
ACTH release, then this would leave only FPR2/ALX and FPR3 to investigate in the human case, as well 
as their equivalent Fpr subtypes in rodents, namely, Fpr2 and Fpr3 in both mice and rats. 
Many of the ligands that mediate effects via human FPR2/ALX and FPR3 also exert effects via the 
structural equivalents of these receptors in rodents. The main endogenous ligands for FPR2/ALX and 
FPR3 include, the anti-inflammatory lipids lipoxin A4 (LXA4) and 15-epi-LXA4 (Fiore et al. 1994); 
resolvins (Norling et al. 2012); urokinase-type plasminogen activator (uPA) and its receptor (uPAR) 
(Resnati et al. 2002); amyloidogenic proteins such as serum amyloid A (SAA), beta amyloid (Aβ-42) and 
prion protein (Prp)106-125 (Su et al. 1999; Le et al. 2001a, c); humanin (Harada et al. 2004); ANXA1 
and its peptide derivatives such as ANXA1Ac2-26 (Walther et al. 2000; Hayhoe et al. 2006); chemokines 
such as β-chemokine (Elagoz et al. 2004); as well as neuropeptides such as vasoactive intestinal peptide 
(VIP) (Zein et al. 2008b), and pituitary adenylate cyclase activating polypeptide (PACAP)-27 (Kim et al. 
2006), and numerous mitochondrial peptides.  
Of the endogenous Fpr/FPR ligands, those that have been detected within the pituitary gland include 
ANXA1, VIP, and PACAP-27. In rats, ANXA1 is expressed within the hippocampus, striatum, cortex, 
hypothalamus, and the pituitary gland (Smith et al. 1993), and has a similar distribution in humans 
(Dreier et al. 1998). Within the anterior pituitary, ANXA1 is expressed within the folliculostellate cells 
(Traverso et al. 1999) and has been shown to mediate the inhibitory effects of GCs on the secretion of 
ACTH, PRL, GH, and TSH (Taylor et al. 1993-b; 2000a). VIP and PACAP-27 are particularly evident 
within dispersed rat pituitary cells expressing ACTH, GH, PRL, or S100b (Vigh et al. 1993). Despite 
these similarities, the ligands differ in terms of their effects on pituitary function. PACAP-27, and full 
length PACAP-38 are synthesised within the hypothalamus and have been investigated along with VIP 
for their effects on pituitary-adrenal axis function. Unlike VIP, intravenous PACAP was able to stimulate 
ACTH release in humans (Chiodera et al. 1996), but the stimulatory effect takes up to 24 hours in 
dispersed rat pituitaries (Hart et al. 1992; Koch & Lutz-Bucher 1993). This suggested PACAP does not 
act directly on corticotrophs but possibly via upregulation of hypothalamic CRH expression (Grinevich et 
al. 1997).  
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The enzymes that produce the lipid Fpr/FPR ligands such as LXA4, 15-epi-LXA4, and resolvin D1, are all 
expressed within the pituitary gland (Won & Orth 1994; Ikawa et al. 1996) and elsewhere within the HPA 
axis (Cover et al. 2001). Interestingly, LXA4 has been shown to prevent LPS-induced miscarriages in 
mice (Walker et al. 2011), and its serum concentration is inversely correlated with miscarriage in women 
(Xu et al. 2013). PACAP has also been shown to have an anti-inflammatory effect in sepsis (Martínez et 
al. 2002). The Fpr/FPR ligands are being investigated as candidate alternatives to corticosteroids, whose 
long-term use can suppress pituitary-adrenal function (Schlaghecke et al. 1992), or as tools to help us 
understand pituitary-adrenal function, that can often be dissociated in disease states, including sepsis 
(Marik 2009).  
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5.1.3 Models of pituitary function 
A pituitary tumour from a LAF1 mouse gave rise to the corticotroph-like AtT20 D16:16 line of cells. 
These were serially selected and cultured for their production of ACTH and extended growth as non-
adherent aggregates (Buonassisi et al. 1962). They express prohormone convertase-1 (PC-1) to process 
POMC into vesicles that secrete ACTH and β-endorphin in response to the secretagogues CRH, VIP, 
phorbol ester, forskolin, IL-1 and IL-6 (Făgărăsan et al. 1989; Fukata et al. 1989). Ligands that have later 
been shown to activate Fpr/FPR subtypes, including VIP and PACAP, have been shown to simulate the 
folliculostellate-like TtT/GF cells (Inoue et al. 1992) to release IL-6, which is known to induce secretion 
of PRL, GH, LH, FSH (Spangelo et al. 1989; Yamaguchi et al. 1990), and ACTH (Naitoh et al. 1988). 
Inhibitors of ACTH secretion have also been studied in the AtT20 D16:16 cell line. For instance, ACTH 
release was inhibited from AtT20 D16:16 cells incubated with ANXA1 (Pompeo et al. 1997), or when 
co-cultured with the TtT/GF line and incubated with GCs (Tierney et al. 2003). This prompted the 
hypothesis that ANXA1 induced by GCs inhibited the secretion of ACTH through a paracrine 
mechanism. 
One major drawback to experimental setups of cell lines relates to their neoplastic and typically 
aneuploidy origin, and are thus indicative of either previous or ongoing chromosomal instability and 
defects in molecular signalling pathways (Levy & Lightman 2003). Conversely, static incubation of 
dispersed anterior pituitary cells can provide a convenient way of analysing the effects of numerous 
ligands on pituitary function that closely recapitulates that of the native gland in vivo (Cowell et al. 1991; 
Gillies & Buckingham 1995). In this regard, the larger rat pituitary gland is favoured over the mouse, 
because the yield of cells per animal is correspondingly greater. 
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5.2 Methodology 
Based on the above evidence, it was hypothesised that Fpr/FPR ligands will modulate pituitary function 
in basal or CRH-stimulated conditions. In order to test this hypothesis, intact rats were killed by 
decapitation and the anterior pituitary glands were pooled into Dulbecco’s modified Eagle’s medium 
(DMEM). Once dispersed, the pituitaries were then aliquotted into 24-well plates then cultured at 37 °C at 
95% O2/5% CO2 for three days. The cells were then incubated for 4 hours of contact with fresh DMEM 
containing Fpr/FPR ligands and/or CRH, vehicle, or DMEM alone. The 100 nmol.l
-1
 concentration of 
CRH was selected on the basis that it has been shown to have a submaximal, stimulatory effect on the 
release of ACTH from dispersed pituitary cells (Cowell et al. 1991). The Fpr/FPR ligands included 
agonists with different relative affinities for each Fpr/FPR subtype, as well as the Fpr2-/FPR2/ALX-
selective antagonist, WRW4 with a pIC50 value between 6.6 and 6.9 for Fpr2/FPR2/ALX in mouse, rat, 
and human cells (Bae et al. 2004; Önnheim et al. 2008; Braun et al. 2011). The Fpr/FPR agonists tested 
were the Fpr1-/FPR1-selective agonist fMLF, the Fpr2-/FPR2/ALX-selective agonist WKYMVm, the 
Fpr2-/FPR3-selective F2L, the Fpr3/Alx-/FPR2/ALX-selective agonist 15-epi-LXA4, and the non-
selective Fpr agonist ANXA1Ac2-26. The conditioned media were then removed and frozen at -20 °C, 
before being assayed for ACTH by radioimmunoassay (RIA).  
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5.3 Results 
5.3.1 The effects of fMLF on ACTH release from dispersed rat anterior pituitary cells, in the presence 
and absence of CRH 
fMLF is a selective agonist for human FPR1, mouse Fpr1, and rat Fpr1. Figure 5.1 shows the effects of 
graded concentrations (10
-9
 – 10-5 mol.l-1) of fMLF on the increases in ACTH release induced by a 
submaximal concentration of CRH (10
-7
 mol.l
-1
) from dispersed rat anterior pituitary cells in vitro. 
CRH (10
-7
 mol.l
-1
) caused a significant increase in ACTH release (*** = P < .001 vs. drug-free). fMLF 
(10
-9
 – 10-5 mol.l-1) had no effect on basal ACTH release (ns = P > .05 vs. drug-free), or on the secretory 
responses to CRH, except at a concentration of 10
-6
 mol.l
-1
 fMLF when a small but significant in basal 
ACTH release occurred (* = P < .05 vs. drug-free) and at 10
-5
 mol.l
-1
 when the response to CRH was 
attenuated († = P < .05 vs. CRH alone). 
In summary, fMLF had no effect on basal or CRH-stimulated ACTH release, except at 10
-5
 mol.l
-1
 where 
fMLF inhibited CRH-stimulated ACTH release. 
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Figure 5.1: Effects of graded concentrations of the formyl peptide receptor 1 (FPR1)-selective 
agonist formyl-methionyl-leucyl-phenylalanine (fMLF) in the presence and absence of 
corticotrophic releasing hormone (CRH) on adrenocorticotrophic hormone (ACTH) release from 
dispersed anterior pituitary cells derived from male Sprague-Dawley rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with the agonist fMLF (10
-9
 – 10-5 mol.l-1), 
along with or without (basal) the secretagogue CRH (10
-7
 mol.l
-1
). The vehicle (Veh) for fMLF was 
.025% acetate. Data are arithmetic mean ± standard error of mean of n = 6 replicate wells, compared by 
two-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < .001, ** = P < .01, * = 
P < .05, vs. drug-free; ††† = P < .001, † = P < .05, vs. CRH alone; ### = P < .001 vs. fMLF alone. 
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5.3.2 The effects of WKYMVm on ACTH release from dispersed rat anterior pituitary cells, in the 
presence and absence of CRH 
WKYMVm is a selective agonist for human FPR2/ALX, and mouse Fpr2, but with unknown activity via 
the rat Fpr subtypes. Figure 5.2 shows the effects of graded concentrations (10
-10
 – 10-6 mol.l-1) of 
WKYMVm on the increases in ACTH release induced by a submaximal concentration of CRH (10
-7
 
mol.l
-1
) from dispersed rat anterior pituitary cells in vitro. 
CRH (10
-7
 mol.l
-1
) caused a significant increase in ACTH release (*** = P < .001 vs. drug-free). At all 
concentrations tested, WKYMVm stimulated basal ACTH release (*** = P > .001 vs. drug-free). No 
further increases in ACTH release were observed in the presence of WKYMVm when CRH was included 
in the medium. 
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Figure 5.2: Effects of graded concentrations of the formyl peptide receptor 2 (FPR2/ALX)-selective 
agonist tryptophan-lysine-tyrosine-methionine-valine-dextro-methionine (WKYMVm) in the 
presence and absence of corticotrophic releasing hormone (CRH) on adrenocorticotrophic 
hormone (ACTH) release from dispersed anterior pituitary cells derived from male Sprague-
Dawley rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with the agonist WKYMVm (10
-10
 – 10-6 
mol.l
-1
), along with or without (basal) the secretagogue CRH (10
-7
 mol.l
-1
). The vehicle (Veh) for 
WKYMVm was .025% acetate. Data are arithmetic mean ± standard error of mean of n = 6 replicate 
wells, compared by two-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < 
.001, vs. drug-free; ††† = P < .001, † = P < .05, vs. CRH alone. 
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5.3.3 The effects of F2L on ACTH release from dispersed rat anterior pituitary cells, in the presence 
and absence of CRH 
F2L is a selective agonist for human FPR3 and mouse Fpr2 derived from an amino-acetylated haem-
binding protein fragment. Figure 5.3 shows the effects of graded concentrations (0.5 x 10
-7
 – 8 x 10-7 
mol.l
-1
) of F2L on the increases in ACTH release induced by a submaximal concentration of CRH (10
-7
 
mol.l
-1
) from dispersed rat anterior pituitary cells in vitro.  
CRH (10
-7
 mol.l
-1
) caused a significant increase in ACTH release (*** = P < .001 vs. drug-free). At all 
concentrations tested, F2L increased basal ACTH release (*** = P > .001 vs. drug-free). However, at the 
lower concentrations tested (0.5 x 10
-7
 – 4 x 10-7 mol.l-1), F2L slightly reduced the CRH-induced 
increment in ACTH release, but the trend was not significant (ns = P > .05). At the highest concentration 
of F2L tested (8 x 10
-7
 mol.l
-1
), co-incubation of F2L with CRH stimulated the release of ACTH to a level 
greater than that induced by CRH alone († = P < .05 vs. CRH alone). 
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Figure 5.3: Effects of graded concentrations of the formyl peptide receptor 3 (FPR3)-selective 
agonist amino-acetylated haem-binding protein fragment (F2L) in the presence and absence of 
corticotrophic releasing hormone (CRH) on adrenocorticotrophic hormone (ACTH) release from 
dispersed anterior pituitary cells derived from male Sprague-Dawley rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with the agonist F2L (0.5 x 10
-7
 – 8 x 10-7 
mol.l
-1
), along with or without (basal) the secretagogue CRH (10
-7
 mol.l
-1
). The vehicle (Veh) for F2L 
was .4% dimethyl sulphoxide (DMSO). Data are arithmetic mean ± standard error of mean of n = 6 
replicate wells, compared by two-way ANOVA with Bonferroni correction for multiple comparisons: *** 
= P < .001, vs. drug-free; † = P < .05, vs. CRH alone; ### = P < .001 vs. F2L alone. 
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5.3.4 The effects of 15-epi-LXA4 on ACTH release from dispersed rat anterior pituitary cells, in the 
presence and absence of CRH 
15-epi-lipoxin A4 (15-epi-LXA4) is a selective agonist for human FPR2/ALX, mouse Fpr3/Alx, and rat 
Fpr2l/Alx. Figure 5.4 shows the effects of graded concentrations (10
-10
 – 10-7 mol.l-1) of 15-epi-LXA4 on 
the increases in ACTH release induced by a submaximal concentration of CRH (10
-7
 mol.l
-1
) from 
dispersed rat adrenal cells in vitro. 
CRH (10
-7
 mol.l
-1
) caused a significant increase in ACTH release (*** = P < .001 vs. drug-free). At the 
lower concentrations tested (10
-10
 and 10
-9
 mol.l
-1
), 15-epi-LXA4 caused a significant two-fold increase in 
basal ACTH release (*** = P < .001 vs. drug-free) but did not cause a further increase in ACTH release 
in the presence of CRH. By contrast, the two higher concentrations of 15-epi-LXA4 (10
-8
 and 10
-7
 mol.l
-1
) 
had no effect on basal ACTH release but significantly reduced the response to CRH (††† = P < .001). 
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Figure 5.4: Effects of graded concentrations of the formyl peptide receptor 2 (FPR2/ALX)-selective 
agonist 15-epi-lipoxin A4 (15-epi-LXA4) in the presence and absence of corticotrophic releasing 
hormone (CRH) on adrenocorticotrophic hormone (ACTH) release from dispersed anterior 
pituitary cells derived from male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with the agonist 15-epi-LXA4 (10
-10
 – 10-7 
mol.l
-1
), along with or without (basal) the secretagogue CRH (10
-7
 mol.l
-1
). The vehicle (Veh) for 15-epi-
LXA4 was .014% ethanol. Data are arithmetic mean ± standard error of mean of n = 6 replicate wells, 
compared by two-way ANOVA with Bonferroni correction for multiple comparisons: *** = P < .001, ** 
= P < .01, vs. drug-free; ††† = P < .001, † = P < .05, vs. CRH alone; ### = P < .001, #  = P < .05, vs. 15-
epi-LXA4 alone. 
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5.3.5 The effects of ANXA1Ac2-26 on ACTH release from dispersed rat anterior pituitary cells, in the 
presence and absence of CRH and/or WRW4 
Annexin Al acetylated peptide (ANXA1Ac2-26) is a non-selective agonist of the mouse and human 
Fpr/FPR subtypes, but so far is only known to bind to Fpr2 of the rat subtypes. Figure 5.5 shows the 
effects of graded concentrations (3 x 10
-7
, 3 x 10
-6
, and 3 x 10
-5
 mol.l
-1
) of ANXA1Ac2-26 on the increases 
in ACTH release induced by a submaximal concentration of CRH (10
-7
 mol.l
-1
), in the presence and 
absence of the selective Fpr2 antagonist WRW4 (10
-6
 mol.l
-1
), from dispersed rat anterior pituitary cells in 
vitro. 
CRH (10
-7
 mol.l
-1
) had no effect on ACTH release (ns = P < .05 vs. drug-free). At all concentrations 
tested, ANXA1Ac2-26 had no effect on basal ACTH release (ns = P > .05 vs. drug-free). Co-incubation of 
CRH with ANXA1Ac2-26 also had no effect on the release of ACTH, except for a slight increase at 3 x 10
-6
 
mol.l
-1
 ANXA1Ac2-26 (* = P < .05 vs. drug-free). Co-incubation of WRW4 (10
-6
 mol.l
-1
) with ANXA1Ac2-26 
inhibited the release of ACTH (* = P < .05 vs. drug-free) at all but the highest concentration of 
ANXA1Ac2-26 (ns = P > .05 vs. drug-free). This inhibition of ACTH release was reversed when 
ANXA1Ac2-26 was co-incubated with WRW4 and CRH to levels equivalent to basal (ns = P > .05). 
In summary, micromolar ANXA1Ac2-26 inhibited ACTH release but only when co-incubated with WRW4. 
This effect was reversed when ANXA1Ac2-26 was co-incubated with both WRW4 and CRH, and lost 
altogether at ten micromolar ANXA1Ac2-26. 
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Figure 5.5: Effects of graded concentrations of the non-selective formyl peptide receptor (FPR) 
annexin A1 amino-acetylated peptide 2-26 (ANXA1Ac2-26) in the presence and absence of 
corticotrophic releasing hormone (CRH) and/or the FPR2/ALX-selective antagonist Trp-Arg-Trp-
Trp-Trp-Trp (WRW4) on adrenocorticotrophic hormone (ACTH) release from dispersed anterior 
pituitary cells derived from male Wistar rats.  
The cells were incubated at 37 °C in 95% O2/5% CO2 for 4 h with the agonist ANXA1Ac2-26 (3 x 10
-7
 – 3 x 
10
-5
 mol.l
-1
), along with or without (basal) the secretagogue CRH (10
-7
 mol.l
-1
) and/or the antagonist 
WRW4 (10
-6
 mol.l
-1
). Data are arithmetic mean ± standard error of mean of n = 8 replicate wells, 
compared by three-way ANOVA with Bonferroni correction for multiple comparisons: ** = P < .01, * = 
P < .05, vs. drug-free; ## = P < .01, # = P < .05, vs. ANXA1Ac2-26 ± CRH ± WRW4. 
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5.4 Discussion 
The study of Fpr/FPR ligands and their effect on the release of ACTH from dispersed anterior pituitary 
cells led to several observations which are discussed below in terms of: the relative affinity of the ligands 
for both human (FPR) and rodent (Fpr) receptors; the evidence of their effects via high affinity receptor 
subtypes; and the literature on effects mediated via receptors with lower affinity. 
To the author’s knowledge, this is the first time that dispersed anterior pituitary cells from rats have been 
incubated with known Fpr/FPR ligands to investigate whether they modulate ACTH secretion in basal 
and CRH-stimulated conditions. Of the ligands tested, only F2L, 15-epi-LXA4 and ANXA1Ac2-26 are 
endogenous mammalian Fpr/FPR ligands, whereas WKYMVm is a synthetic peptide agonist, and fMLF 
is a bacterial chemotactic peptide and the prototypical Fpr1/FPR1 ligand. 
5.4.1 fMLF 
fMLF is a selective agonist for the rat Fpr1, with a pEC50 of 7.5 (Marasco et al. 1983). The lack of effect 
of fMLF on the release of ACTH from dispersed rat anterior pituitary cells suggests that Fpr1 is not 
involved in the modulation of ACTH release. This is consistent with evidence from slice cultures of 
anterior pituitaries, where neither Fpr1 gene deletion or sub-micromolar fMLF had any effect on ACTH 
release, and there was no evidence for Fpr1 expression (John et al. 2007). The lower range of 
concentrations of fMLF used here have been shown to activate the rat Fpr1 in neutrophils (Marasco et al. 
1983), but these had no significant effect on the increase in ACTH release induced by CRH here, or by 
forskolin previously (John et al. 2007). Whilst fMLF does bind to receptors other than Fpr1 in rodents 
and FPR1 in man, these receptors have much lower affinity for fMLF. The small, but significant 
reduction in CRH-stimulated ACTH release elicited by fMLF at the ten micromolar concentration could 
be due to the activation of a rat Fpr subtype with lower affinity, possibly Fpr2 or Fpr3. This is comparable 
to the binding of supra-micromolar concentrations of fMLF to lower affinity receptors in other species, 
such as human FPR2/ALX (Fiore & Serhan 1995) or mouse Fpr2 (He et al. 2000) where fMLF has a 
similar affinity at each receptor, with a pKd/pEC50 of 5.3. 
The lack of effect of fMLF at Fpr1-relevant concentrations can be further explained with the existing 
knowledge of its pharmacology. Firstly, compared with other ligands, the evidence for the relative affinity 
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of fMLF for human FPR1 is clear, surpassing other ligands such as cathepsin G and annexin I (Le et al. 
2002; Sun et al. 2004a). This contrasts with the affinity of fMLF for human FPR2/ALX, where fMLF has 
perhaps the lowest known affinity of all the agonists this receptor binds, and has a pKd of 7.65 (Koo et al. 
1982). In systems involving the mouse Fpr1, there are some data that show fMLF elicits responses via 
mouse Fpr1 with a pEC50 of 9, and activates Fpr2 with 40 times lower potency, having a pEC50 of 5 
(Mills et al. 2000). To date, functional responses of rat Fpr2 or Fpr3 to fMLF have yet to be reported, but 
the structurally similar mouse Fpr3 has been shown to not bind fMLF even at 100 μmol.l-1 concentrations. 
Secondly, much of the functional data for fMLF is from studies of its chemotactic effects downstream of 
Fpr1, particularly within leukocytes. In this case, fMLF is associated with NFκB-mediated transcription 
of chemokines and endoplasmic reticular Ca
2+
 release via Gβ-mediated up-regulation of phospholipase C-
β (PLC-β) and activation of protein kinase C (PKC) (Naccache et al. 1979). This occurs alongside 
cytoskeletal actin reorganisation which follows the Gγ-mediated up-regulation of phosphoinositide 3-
kinase (PI3K) activity (Homma et al. 1985). In addition, fMLF upregulates superoxide anion production 
and ultimately cell degranulation in mouse neutrophils (Gao & Murphy 1993; Pivot-Pajot et al. 2010). If 
Fpr1 were present within the rat pituitary, such signalling mechanisms and Ca
2+
 mobilisation would be 
expected to facilitate an increase in ACTH secretion.  
Finally, the remaining literature on fMLF is for its effects via receptors other than Fpr1. For instance, 
fMLF elicits responses via Fpr2 at supra-micromolar concentrations, where it has a pEC50 of 5 (Mills et 
al. 2000). Studies of HEK293 cells transfected with mouse Fpr3, in contrast with Fpr1 and Fpr2, have 
confirmed that fMLF does not elicit Ca
2+
 mobilisation via Fpr3, even at 100 μmol.l-1 when co-incubated 
with the Fura-2AM fluorescent Ca
2+
 indicator (Hartt et al. 1999; Liang et al. 2000). Given the nucleotide 
sequence homology of mouse Fpr3 and rat Fpr3, these findings suggest that rat Fpr3 is unlikely to be 
mediating the inhibitory effect of fMLF at the ten micromolar concentration. 
Taken together, the lack of an overall inhibitory effect of fMLF on ACTH release in the present studies, 
at concentrations known to stimulate Fpr1 in leukocytes, reaffirms the existing evidence that Fpr1 is not 
expressed within the pituitary, or involved in the regulation of ACTH secretion (John et al. 2007). The 
prototypical Fpr1 ligand does not mediate effects via mouse Fpr3 at supra-micromolar concentrations 
(Hartt et al. 1999; Liang et al. 2000), therefore, the inhibition of ACTH release at such concentrations is 
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likely to be mediated via a lower affinity receptor such as Fpr2, whose transcripts have been found within 
the mouse and rat pituitary (John et al. 2007). 
5.4.2 WKYMVm 
The data indicate that WKYMVm has pharmacological effects on the release of ACTH from primary 
dispersed anterior pituitary cells. At all concentrations tested, WKYMVm was associated with 
significantly upregulated basal ACTH release versus the untreated control. The effect of WKYMVm on 
ACTH release was similar both in the presence and absence of the secretagogue CRH. At micromolar 
WKYMVm, there was a slight decrease in ACTH release, even when co-incubated with CRH. To the 
author’s knowledge, this is the first report of WKYMVm-mediated modulation of ACTH release from 
dispersed anterior pituitary cells. 
WKYMVm is a synthetic hexapeptide originally identified from a peptide library. It is different from 
WKYMVM, structurally, because of the dextro-methionine about a C-terminal amide, and functionally 
with respect to its affinity for FPR/Fpr subtypes, particularly in leukocytes. Human neutrophils express 
FPR1 and FPR2/ALX, whereas monocytes express FPR1, FPR2/ALX, and FPR3 (Ye et al. 2009). 
Literature concerning the relative affinity of WKYMVm is largely based on its effects via human 
FPR2/ALX in neutrophils with a pEC50 of 10.12 (Migeotte et al. 2005), and via human FPR3 in 
monocytes, where it acts with a pEC50 of 8.52 (Christophe et al. 2001). However, WKYMVm also has 
some effects via FPR1 with a pEC50 of 7.60 (Le et al. 1999).  
Initial characterisation of the effects of WKYMVm on mouse neutrophils, suggested the agonist 
upregulated lytic granule release via Fpr1 with a pEC50 of 8.82 (He et al. 2000), with activity at Fpr2 or 
Fpr3 with a pEC50 of 7.48 (Boxio et al. 2005). The relative affinities of WKYMVm with the major mouse 
Fpr subtypes have since been updated to Fpr1 > Fpr2 >>> Fpr3, with respective pEC50 values of 10.1, 9.3, 
and approximately 6 (He et al. 2013a). In terms of mechanistic details, the mobilisation of Ca
2+
 appears to 
be important in eliciting the pro-exocytotic effects of WKYMVm. The incubation of micromolar 
WKYMVm with HL-60 cells overexpressing Fpr2, for instance, readily permits the detection of Ca
2+
 with 
the Fluo3 tracer versus vehicle-treated cells (Prat et al. 2006). An alternative approach to demonstrating 
the role of Ca
2+
 involves its chelation with the compound BAPTA (1,2-bis(o-aminophenoxy)ethane-
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N,N,N',N'-tetraacetic acid), and then indexing the exocytosis of lytic granules by a β-hexosaminidase 
assay. Using this approach in the rat basophilic leukaemia cell line (RBL-2H3) expressing human 
FPR2/ALX, resulted in a blockade of the pro-exocytotic effect of WKYMVm (Gomperts 1990; Bae et al. 
2003b). 
In the context of the present pro-exocytotic effects of WKYMVm on ACTH release, there are several 
strands of evidence from the literature on signalling cascades downstream of Fpr/FPR that corroborate 
these findings. There is evidence for the role of Ca
2+
 mobilisation within the corticotrophs (Gomperts 
1990) and also the phosphorylation of extracellular regulated kinase (ERK) (Sullivan et al. 2005), with 
each of these associated with an increased secretion of ACTH (Leong 1988). The incubation of 
WKYMVm in wildtype macrophages has been found to increase the concentration of phosphorylated 
ERK (Kang et al. 2005). Importantly, the phosphorylation of ERK has been shown to be significantly 
reduced in leukocytes obtained from Fpr2/3
-/-
 mice versus wildtypes (Dufton et al. 2010), but it was not 
possible to conclude whether Fpr2 or Fpr3 has a greater contribution to this effect. This also applies to the 
experiments of Boxio and coworkers (2005), who showed the pro-exocytotic effect of WKYMVm on 
neutrophil granule release is halved by the human FPR2/ALX antagonist C2 (WPLTHTLRHTIW, 10
-5
 
mol.l
-1
), but could not stipulate whether this was Fpr2 or Fpr3-mediated. Given the findings of a pro-
exocytotic effect of WKYMVm, here on ACTH secretion, and elsewhere on lytic granule release via 
human FPR2/ALX, along with the loss of effects following blockade or knockout of Fpr2 and Fpr3, it 
seems plausible to suggest that the WKYMVm-stimulated release of ACTH is mediated via Fpr2 or Fpr3, 
or perhaps both, since these are expressed within mouse and rat pituitary, where Fpr1 is not (John et al. 
2007).  
5.4.3 F2L 
These data show F2L—an acetylated 21 amino acid oligopeptide derived from the amino terminal end of 
the intracellular haem-binding protein (Migeotte et al. 2005)—upregulates ACTH release from dispersed 
rat anterior pituitary cells when co-incubated with CRH, versus the untreated control cells. To the 
author’s knowledge, this is the first report of F2L-mediated stimulation of ACTH release from dispersed 
anterior pituitary cells. The vehicle treatment of 2.5% DMSO, however, also had a stimulatory effect on 
ACTH release, which was roughly equal to the effect of CRH treatment. F2L was inhibitory, however, 
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when used at a low concentration (0.5 x 10
-7
 – 2 x 10-7 mol.l-1) versus the vehicle group. This inhibitory 
effect of F2L versus vehicle was reduced by higher concentrations of F2L (4 x 10
-7
 – 8 x 10-7 mol.l-1) and 
reversed when co-incubated with CRH at the top concentration of F2L (8 x 10
-7
 mol.l
-1
).  
The stimulatory effect of F2L on ACTH secretion observed here might be explained in the context of 
existing pharmacological data. Early experiments with F2L identified it as the first endogenous ligand 
with both potent and selective chemotactic actions via human FPR3 with a pKd/pEC50 of 8.2, and only 
weak activity at FPR2/ALX with a pKd/pEC50 of 6.3, and none via FPR1 (Migeotte et al. 2005). High 
concentrations (above 10 micromolar) of the Fpr2-/FPR2/ALX-selective antagonist WRW4 have been 
shown to also antagonise FPR3 (Bae et al. 2004). Blockade of FPR3, the high affinity receptor for F2L, 
with WRW4 has been shown to inhibit completely the F2L-induced influx of Ca
2+
 and its activation of 
NFκB (Shin et al. 2006). WRW4 is also a selective antagonist of mouse Fpr2 (Önnheim et al. 2008) and 
rat Fpr2 (Braun et al. 2011), and have broadly similar pIC50 values, 6.6 and 6.9 respectively. Taken 
together, the present data do not refute the observation that F2L is a pure agonist of mouse Fpr2 in the 
nanomolar range with a pEC50 of 6.70, from a study that confirmed F2L has negligible binding at mouse 
Fpr1 or Fpr3 (Gao et al. 2007). Thus, the pEC50 of F2L via mouse Fpr2 informed the choice of the central 
concentration in the present study (10
-6.7
 = 2 x 10
-7
 mol.l
-1
), as there are no published data on the effects of 
F2L via the rat Fpr subtypes. 
The molecular mediators known to be involved in CRH-stimulated ACTH secretion are concordant with 
those invoked downstream of Fpr/FPR subtypes following activation by F2L. These include, for instance, 
the increased cytosolic concentration of Ca
2+
, cAMP, pERK1/2, and pMAPK, each of which is invoked 
by F2L via human FPR3 (Kang et al. 2005; Migeotte et al. 2005), via mouse Fpr2 (Gao et al. 2007), as 
well as by CRH via CRH-R1 in corticotrophs. The mechanisms induced by F2L acting via human FPR3, 
and via mouse Fpr2, are therefore consistent with secretagogues of ACTH such as CRH, and might 
therefore explain the observed stimulation of ACTH secretion by F2L.  
5.4.4 15-epi-LXA4 
Unlike other leukotrienes and prostaglandins, the lipoxins are a class of eicosanoid that downregulate 
leukocyte recruitment and are anti-inflammatory (Gewirtz et al. 1999). Lipoxin A4 (LXA4) is a metabolite 
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derived from a double lipoxygenation of arachidonic acid (Serhan & Chiang 2008). In addition to its 
potent anti-inflammatory effects, LXA4 has also been shown to inhibit ACTH secretion, ostensibly via rat 
Fpr2 or Fpr3 (John et al. 2007). The present results show that the 15-epimeric isomer of LXA4, 15-epi-
LXA4 suppressed both basal and CRH-stimulated ACTH release. To the author’s knowledge, this is the 
first time that 15-epi-LXA4 has been shown to inhibit ACTH release from dispersed anterior pituitary 
cells from rats.  
LXA4 and 15-epi-LXA4 are each biosynthesised from arachidonic acid derivatives by 5-, 12-, or 15-
lipoxygenase (LOX), except that the synthesis of 15-epi-LXA4 also requires the acetylation of 
cyclooxygenase 2 (COX-2) by aspirin (Clària & Serhan 1995; Gewirtz et al. 1999). Although the lipoxins 
have not been directly measured within the pituitary, there is evidence of expression of these biosynthetic 
enzymes (Cover et al. 2001), and the major precursors 5-, 12-, and 15-hydroxyeicosatetraenoic acid are 
detectible within the tissue (Pilote et al. 1982). Functional evidence for the endogenous role of the LOX 
enzymes on pituitary ACTH release comes from studies that inhibit the enzymes or test the effect of their 
metabolites. Incubation of dispersed rat pituitary cells with the lipoxygenase inhibitor AA861 resulted in 
a reduction in secretagogue-stimulated ACTH release (Cowell et al. 1991), whereas the LXA4 precursor 
15(S)-hydroxyeicosatetraenoic acid had a stimulatory effect on ACTH release (Won & Orth 1994).  
Previous work from this laboratory has shown that low, sub-micromolar concentrations of LXA4 inhibited 
ACTH release from rat pituitary segments in forskolin-stimulated, but not basal conditions (John et al. 
2007). This inhibitory effect of LXA4 was comparable to the effect of the synthetic GC, dexamethasone. 
The anti-inflammatory effects of 15-epi-LXA4 have also been shown to be similar in potency to 
dexamethasone (Takano et al. 1997), and occur along with an upregulation of human FPR2/ALX 
(Hashimoto et al. 2007). Aspirin-triggered lipoxin, 15-epi-LXA4 is ten times more potent an agonist for 
human FPR2/ALX with a pEC50 of 10.10 (Maddox et al. 1997; Chiang et al. 2000) compared with a 
pEC50 of 9.10 for LXA4 (Maddox et al. 1997; Chiang et al. 2000), which is also less stable
6
 (Serhan et al. 
1995). In mice, the anti-inflammatory effects of these lipoxins are mediated via Fpr3/Alx, and have equal 
affinity with a pKd of 8.82 (Takano et al. 1997), and their affinity for rat Fpr2l/Alx is similar with a pKd 
                                                          
6
 Due to 15-hydroxy prostaglandin dehydrogenase activity. 
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of 8.30 (Chiang et al. 2003). The similar affinities of the lipoxins for the mouse and rat Fpr subtypes is 
perhaps explained by the 84% sequence homology of these rodent receptors, compared with 74% 
homology to the higher affinity human FPR2/ALX (Ye et al. 2009).  
5.4.5 ANXA1Ac2-26 
Here, ANXA1Ac2-26 inhibited ACTH release at the micromolar level but only when co-incubated with 
WRW4. This effect was reversed when ANXA1Ac2-26 was co-incubated with both WRW4 and CRH, and 
lost altogether at 3 x 10
-5
 mol.l
-1
 ANXA1Ac2-26. This suggests that ANXA1Ac2-26 is not stimulatory when a 
WRW4-sensitive receptor is blocked, ostensibly the rat Fpr2, and so could exert inhibitory effects via 
Fpr3 or Fpr1. This could mean that the inhibitory effect of ANXA1Ac2-26 on pituitary ACTH release is 
conditional on Fpr2 blockade.  
This finding is partly consistent with previous studies from this lab which demonstrated a role for 
ANXA1 as a mediator of the negative feedback effects of glucocorticoids on hormone release (Taylor et 
al. 1993; John et al. 2002; 2007). Evidence was also found for ANXA1 binding sites on the endocrine 
cells of the anterior pituitary, and thus gave credence to the hypothesised paracrine/juxtacrine mode of 
ANXA1 action (Christian et al. 1997). Walther and coworkers (2000) identified human FPR1 as the first 
receptor target of ANXA1 action on leukocytes. When the FPR2/ALX and FPR3 subtypes were also 
identified in human tissues, their functional relationship with ANXA1 seemed to be more significant than 
FPR1 (Perretti et al. 2002; Gavins et al. 2003; Ernst et al. 2004b; Hayhoe et al. 2006).  
Taken together, the present observations do not refute those made previously of ANXA1 or ANXA1Ac2-26-
mediated inhibition on secretagogue-stimulated ACTH release. Given that the CO2 regulator failed during 
this experiment however, the current data should be interpreted with caution until the experiment can be 
repeated. 
5.4.6 Biological significance and scope of findings 
The present data militate against a role for the rat equivalent of mouse Fpr1 and human FPR1, as a target 
for ANXA1 action within the anterior pituitary gland. fMLF had no effect on basal or CRH-stimulated 
ACTH release at the sub-micromolar concentrations at which rat Fpr1 is selectively bound (Marasco et al. 
1983). This is in accord with previous data from this lab, where the inhibitory effects of ANXA1Ac2-26 
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were unaffected by either the genetic knockout of Fpr1, or pharmacological blockade of Fpr1 with the 
human FPR1/mouse Fpr1 antagonist Boc1 used at 50 μmol.l-1 (John et al. 2007). This suggests that the rat 
Fpr1 is functionally, as well as structurally, equivalent to mouse Fpr1 and human FPR1. 
Further support for this is evident in that while ANXA1 suppressed ACTH release (Taylor et al. 1993; 
John et al. 2007) it did not bind to FPR1 in human systems (Perretti et al. 2002) and FPR1/Fpr1 is not 
expressed within the anterior pituitary gland from humans (Becker et al. 1998) mice, or rats (John et al. 
2007). As for other Fpr subtypes, this group found evidence of Fpr2 and Fpr3 expression within the rat 
pituitary, and the mouse pituitary also contained the subtypes Fpr2, Fpr3, Fpr-rs6, and Fpr-rs7 (John et al. 
2007). Rat Fpr2l/Alx has been described as the orthologue of human FPR2/ALX (Chiang et al. 2003), 
which mediates the effects of LXA4, 15-epi-LXA4, ANXA1, and ANXA1Ac2-26 (Takano et al. 1997; Hartt 
et al. 1999; Wang & Ye 2002). The observation that the aspirin-triggered lipoxin, 15-epi-LXA4, when 
used at 10
-8
 mol.l
-1
 was able to inhibit the CRH-stimulated ACTH release is consistent with its affinity for 
mouse Fpr3/Alx (Takano et al. 1997) and rat Fpr2l/Alx (Chiang et al. 2003), and with the inhibition 
elicited by the less potent LXA4 used at 2 μmol.l
-1
 (John et al. 2007).  
The stimulated release of ACTH by CRH is dependent on an intact signalling mechanism downstream of 
CRH-R1 receptors on corticotrophs. First, production of cAMP activates protein kinase A, and this 
triggers an influx of Ca
2+
 via L-type Ca
2+
 channels which, results in membrane fusion of secretory 
vesicles and exocytosis of their ACTH (Aguilera et al. 1983; Taylor et al. 1993). Previous data have 
shown that the inhibition of ACTH release mediated by ANXA1 does not interfere with Ca
2+
 influx, and 
might instead involve a mechanism downstream of an FPR/Fpr subtype (Taylor et al. 1993; John et al. 
2002). Indeed, activation of the FPR/Fpr subtypes coupled with heterotrimeric Gi proteins have resulted 
in reduced CRH-stimulated ACTH release in the corticotrophic AtT20 cell line (Aguilera et al. 1983; 
Luini & Matteis 1990); an effect that can be blocked by pertussis toxin (Le et al. 2002). The rest of the 
signalling pathway downstream of ANXA1/Fpr activation is unclear, but some evidence has shown that 
ANXA1 induces actin polymerisation beneath the cell membrane, blocking the exocytosis of lytic 
granules and hormones from leukocytes and corticotrophs, respectively (Castellino et al. 1992; Maderna 
et al. 2002; McArthur et al. 2009).  
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In the context of previous literature, the evidence above suggests that the effects of 15-epi-LXA4, 
ANXA1Ac2-26, WKYMVm, and F2L on the secretion of ACTH from the anterior pituitary might be 
mediated via rat Fpr2 or Fpr3. The Fpr2 and Fpr3 in mice and rats have 84% nucleotide sequence 
homology, and all share functional properties and structural homology with human FPR2/ALX and FPR3. 
However, there are conflicting reports in the literature as to whether Fpr2 or Fpr3 in these rodents is the 
functional orthologue of human FPR2/ALX, FPR3, or both (Hartt et al. 1999). This is partly because both 
mouse receptors are responsive to LXA4 although Fpr2 requires G-alpha subunit 16 coupling (Vaughn et 
al. 2002) but Fpr3 has an ANRV inserted after Leu141 in transmembrane domain 4 which readily permits 
LXA4 binding (Takano et al. 1997; Gao et al. 1998). Dufton and coworkers (2010) found that in the 
mouse air pouch model, Fpr2/3 ligands such as LXA4 and ANXA1Ac2-26 reduced granulocyte migration 
whereas serum amyloid A (SAA) increased granulocyte recruitment, despite each having similar affinity 
for Fpr2. All of these effects were absent in Fpr2/3
-/-
 mice, suggesting that Fpr2 or Fpr3 mediate the 
opposing effects of these Fpr ligands in vivo. Therefore, it is possible that two separate Fpr subtypes exist 
to produce opposing effects on pituitary hormone secretion, with Fpr2 mediating a positive stimulatory 
effect and Fpr3 producing an inhibitory effect. Another possibility that is under ongoing research, is that 
these Fpr subtypes possess bidirectional functions that are ligand-dependent (Bae et al. 2003b; 
Brancaleone et al. 2011; Bena et al. 2012). 
The vehicles for some of the drugs were perhaps used unnecessarily. The manufacturer’s data sheets for 
the drugs mostly suggested the use of a diluent such as glacial acetic acid, DMSO, or ethanol. It may have 
been cogent to perform concentration-effect curves with some of these vehicles, particularly in the case of 
DMSO (for F2L), as this appeared to have a potent stimulatory effect on pituitary ACTH release. This is 
consistent with the finding that DMSO has been associated with stimulated ACTH release in vivo (Ni et 
al. 1995). Further experiments should either use an alternative diluent, or use a lower proportion of 
DMSO (1% total volume as per John et al. (John et al. 2007), rather than the 2.5% used here). There is no 
reason to believe that this effect results from a ligand-receptor interaction however, and the simplest 
explanation is likely to be non-specific cell death. Incidentally, the trypan blue exclusion test for cell 
death was only performed to count cells and as a check for their viability prior to the incubation with 
drugs. It would have been worthwhile checking cell viability both before and after the incubation of 
drugs. 
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The dispersed anterior pituitary cell culture was generated from a pool of multiple glands into a 
monolayer of cells. It is assumed that the process of filtration through nylon mesh and the dispersal 
facilitated by trypsin did not affect the proportion of each pituitary cell subtype. There is no reason to 
believe, for instance, that any fewer folliculostellate cells were in the monolayer than would be found 
within the native gland. It has been demonstrated, however, that the communication between the various 
cell subtypes depends to a great extent on the interaction of these cells within three-dimensional networks 
(Lafont et al. 2010). In this regard, and for further work, aggregate culture of dispersed anterior pituitary 
cells, or pituitary segments, would be favoured over the static incubation of dispersed cells used here.  
5.4.7 Conclusion 
These functional data have demonstrated that Fpr/FPR ligands are able to modulate the release of ACTH 
from dispersed anterior pituitary cells, with the following rank of efficacy: WKYMVm >>> 15-epi-LXA4 
> F2L >> fMLF > ANXA1Ac2-26. The secretion of ACTH from dispersed rat anterior pituitary cells was 
stimulated by the mouse Fpr2-selective ligands, F2L (human FPR3-selective) and WKYMVm (human 
FPR2/ALX-selective), but inhibited by agonists with similar affinity for human FPR2/ALX and the rat 
Fpr2l/Alx, namely, ANXA1Ac2-26 and 15-epi-LXA4. Given the slight inhibition of ACTH release induced 
by fMLF and WKYMVm at high concentrations associated with a loss of their Fpr1/Fpr2-selectivity, it 
seems plausible to suggest that these inhibitory effects might also mediated by the rat Fpr2l/Alx. 
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6.1 Introduction 
Intraperitoneal injection of lipopolysaccharide (LPS) is a commonly used experimental model of sepsis-
related endotoxaemia, and has been shown to induce changes in both the structure and function of the 
adrenal cortex, and there is some evidence that formyl peptide receptor (Fpr/FPR) subtypes and their 
ligands might be important in this regard. In wildtype mice, for instance, intraperitoneal administration of 
LPS leads to a reduction in adrenocortical sterol vacuolation and refractory responses to 
adrenocorticotrophic hormone 1-24 (ACTH1-24) in dispersed adrenal cells (Buss 2010). This effect was 
limited however, in Fpr2/3
-/-
 mice, suggesting a role of Fpr2 and/or Fpr3 in the adrenal response to LPS 
(Buss 2010). Inflammogenic stressors such as LPS, have been shown to upregulate the expression of 
Fpr/FPR subtypes, particularly Fpr2/FPR2/ALX (Iribarren et al. 2003). In the preceding chapters, we 
have seen evidence that the Fpr2-/FPR2/ALX-selective antagonist Trp-Arg-Trp-Trp-Trp-Trp (WRW4) 
was able to limit the inhibition of corticosterone secretion elicited by the bacterial Fpr/FPR ligand formyl-
methionyl-leucyl-phenylalanine (fMLF) (see section 4.3.2). WRW4 has a pIC50 for FPR2/Fpr2 in human, 
mouse and rat cells of between 6.6 and 6.9 (Bae et al. 2004; Önnheim et al. 2008; Braun et al. 2011). 
Based on the above evidence however, it is not clear whether pharmacological blockade of the rat Fpr2 in 
vivo will modulate the response to LPS, in terms of the structure and function of the adrenal cortex. 
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6.2 Methodology 
Based on the above evidence, it was hypothesised that: 1) the inflammogenic stressor LPS would reduce 
sterol vacuolation of the adrenal cortex within 24 hours; and 2) the Fpr2-/FPR2/ALX-selective antagonist, 
namely, WRW4, would inhibit this effect. In order to test this hypothesis, groups of male Wistar rats were 
injected with either saline, or LPS (750 μg.kg-1 i.p.) and then decapitated either immediately, or after 2, 4, 
or 24 hours, respectively (four groups), to collect the following tissues: brain, pituitary, thymus, and 
spleen (n = 4), and adrenal (n = 1) for histological analysis; and trunk blood for the assay of plasma 
corticosterone and ACTH concentrations (n = 4). The animals were injected and killed in a time course 
staggered over two weekdays to ensure the time of day for the injections and blood collection for each 
group was the same (12.30 pm), plus or minus thirty minutes. The remaining adrenals (n = 3) were 
dispersed in Earle’s balanced salt solution (EBSS) and collagenase and aliquotted into 96-well plates 
prior to centrifugation, then equilibrated at 37 °C at 95% O2/5% CO2 for an hour. The cells were then 
incubated for 4 hours of contact with fresh EBSS containing graded concentrations of ACTH1-24.  
The above experiments were able to determine the approximate time at which LPS had maximal effects 
on adrenocortical sensitivity to ACTH1-24 and sterol vacuolation. To determine whether the Fpr2-
/FPR2/ALX-selective antagonist WRW4 was able to inhibit these effects, male Wistar rats (n = 6) 
received intraperitoneal injections of either saline, LPS (750 μg.kg-1), WRW4 (250 μg.kg
-1
), or LPS and 
WRW4. After 4 hours, tissues were collected as above, except the dispersed adrenal experiments and the 
determination of plasma ACTH were not performed for this part of the study owing to time constraints.  
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6.3 Results 
6.3.1 The effect of an intraperitoneal injection of LPS on the concentration of ACTH in plasma 
obtained from groups of male Wistar rats after 2, 4, or 24 hours 
Figure 6.1 shows the concentration of ACTH in plasma obtained from groups of male Wistar rats injected 
intraperitoneally with either saline, or LPS (750 μg.kg-1 i.p.), and then decapitated immediately, or after 2, 
4, or 24 hours, respectively. 
The concentration of ACTH was significantly increased in plasma obtained from rats after 2 hours (*** = 
P < .001), and 4 hours (** = P < .01) following the administration of LPS, versus the saline control group. 
After 24 hours, the plasma ACTH concentration in rats injected with LPS was no different from the saline 
control group (ns = P > .05).  
The highest concentration of ACTH observed was in plasma obtained from rats after 2 hours following 
LPS administration, and was significantly higher than from the four-hour group (*** = P < .001) and the 
twenty-four-hour group (*** = P < .001). Although the plasma ACTH concentration after 4 hours was 
lower than in the two-hour group (*** = P < .001 vs. LPS 2 h), it was still significantly greater than in the 
twenty-four-hour (* = P < .05) and saline control (* = P < .05) groups. 
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Figure 6.1: Effect of an intraperitoneal injection of lipopolysaccharide (LPS) on the concentration 
of adrenocorticotrophic hormone (ACTH) in plasma obtained from groups of male Wistar rats 
after 2, 4, or 24 h. 
Male Wistar rats (n = 4) received an intraperitoneal (i.p.) injection of either saline (control), or LPS (750 
μg.kg-1 i.p.), and then decapitated immediately, or after 2, 4, or 24 h, respectively. Trunk blood was 
collected into tubes coated with ethylenediaminetetraacetate (EDTA) and centrifuged for 10 min at 3,000 
rcf. Plasma samples were aliquotted, snap frozen in liquid nitrogen, and then stored at -80 °C until the 
ACTH concentration was determined by immuno-radiometric assay (IRMA) at two sites on the ACTH 
epitope. Data are arithmetic mean ± the standard error of mean of n = 4 animals, compared by one-way 
ANOVA with Bonferroni tests for multiple comparisons: *** = P < .001, ** = P < .01, * = P < .05, ns = 
not significant, vs. control or as indicated by significance bars. 
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6.3.2 The effect of an intraperitoneal injection of LPS on the concentration of corticosterone in plasma 
obtained from groups of male Wistar rats after 2, 4, or 24 hours 
Figure 6.2 shows the concentration of corticosterone in plasma obtained from groups of male Wistar rats 
injected intraperitoneally with either saline, or LPS (750 μg.kg-1 i.p.), and then decapitated immediately, 
or after 2, 4, or 24 hours, respectively. 
The concentration of corticosterone was not significantly different in plasma obtained from rats after two 
hours, four hours, or twenty-four hours following the administration of LPS, versus the saline control 
group (ns = P > .05). Despite this, there appears to be a downward trend from the highest plasma 
corticosterone concentration observed in rats two hours following LPS administration, towards the levels 
in the four-hour and twenty-four-hour groups.  
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Figure 6.2: Effect of an intraperitoneal injection of lipopolysaccharide (LPS) on the concentration 
of corticosterone in plasma obtained from groups of male Wistar rats after 2, 4, or 24 h. 
Male Wistar rats (n = 4) received an intraperitoneal (i.p.) injection of either saline (control), or LPS (750 
μg.kg-1 i.p.), and then decapitated immediately, or after 2, 4, or 24 h, respectively. Trunk blood was 
collected into tubes coated with ethylenediaminetetraacetate (EDTA) and centrifuged for 10 min at 3,000 
rcf. Plasma samples were aliquotted, snap frozen in liquid nitrogen, and then stored at -80 °C until the 
corticosterone concentration was determined by enzyme immunoassay (EIA). Data are arithmetic mean ± 
the standard error of mean of n = 4 animals, compared by one-way ANOVA with Bonferroni tests for 
multiple comparisons. 
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6.3.3 The effect of an intraperitoneal injection of LPS on the concentration of corticosterone released 
in response to graded concentrations of ACTH1-24 in dispersed adrenal cells obtained from 
groups of male Wistar rats after 2, 4, or 24 hours 
The following results are from experiments performed in order to explore the effects of LPS treatments 
on the capacity of the adrenal gland to secrete corticosterone when challenged with ACTH. 
Figure 6.3 shows the effects of graded concentrations (10
-11
 – 10-7) of ACTH1-24 on the release of 
corticosterone from dispersed adrenal cells obtained from male Wistar rats injected intraperitoneally with 
either saline, or LPS (750 μg.kg-1 i.p.), and then decapitated immediately, or after 2, 4, or 24 hours, 
respectively. 
Two-way ANOVA revealed there were significant main effects of ACTH1-24 concentration (F(4, 35) = 
9.293 (> 1), *** = P < .001) and time point (F(3, 35) = 39.840, *** = P < .001). There was also a significant 
interaction of these main effects (F(12, 35) = 4.826, *** = P < .001) on the release of corticosterone.  
ACTH1-24 caused significant, concentration-dependent increases in corticosterone release from dispersed 
adrenal cells taken from the saline control group (* = P < .05 vs. drug-free control, pEC50 = 8.02 ± .78). 
By contrast, the corticosterone secretory response to ACTH1-24 of adrenal cells from LPS-injected rats 
was refractory in all groups (ns = P > .05 vs. drug-free control). Thus, while basal corticosterone release 
was higher in dispersed adrenals following LPS administration in the two-hour group (*** = P < .001), 
the four-hour group (*** = P < .001), and the twenty-four-hour group (** = P < .01), versus the drug-free 
control from the saline group, these cells were unresponsive to ACTH1-24 (ns = P > .05 vs. drug-free 
control). Corticosterone release from adrenal cells of rats injected 24 hours previously with LPS was 
higher than the saline control group in basal conditions, but was unresponsive to ACTH1-24 (10
-11
 – 10
-6
 
mol.l
-1
, ns = P > .05 vs. drug-free control). 
The post hoc tests revealed the peripheral LPS administration resulted in a loss of ACTH1-24 
concentration-related increases in corticosterone release. The dispersed adrenals collected at 2 hours 
following LPS administration had a significantly higher corticosterone release versus the saline-injected 
controls (** = P < .01, LPS 2 h vs. saline) at all concentrations of ACTH1-24 except for 10
-7
 mol.l
-1
. The 
response to ACTH1-24 in dispersed adrenals from the four-hour group was broadly in line with the control 
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response but significantly inverse to the control adrenals at the highest (10
-7
 mol.l
-1
) and lowest (10
-11
 
mol.l
-1
) concentrations of ACTH1-24 (* = P < .05, *** = P < .001, LPS 4 h vs. saline). The response to 
ACTH1-24 in dispersed adrenals 24 hours following LPS administration was significantly lower than the 
saline control group, but only at the highest concentration of ACTH1-24 (10
-7
 mol.l
-1
, * = P < .05, LPS 24 h 
vs. saline). Between the different time points for collecting adrenals following LPS administration, the 
corticosterone release in response to ACTH1-24 in the four-hour LPS group was significantly lower than in 
the two-hour LPS group in the central part curve (10
-10
 mol.l
-1
 – 10-8 mol.l-1 ACTH1-24, && = P < .001, 
LPS 2 h vs. LPS 4 h). The corticosterone release in response to ACTH1-24 was also significantly lower in 
the twenty-four hour LPS group, than the two-hour LPS group, at each concentration of ACTH1-24 (** = P 
≤  .01) except for 10-7 mol.l-1 (ns = P > .05). 
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Figure 6.3: Effect of an intraperitoneal injection of lipopolysaccharide (LPS) on the concentration 
of corticosterone released in response to graded concentrations of adrenocorticotrophic hormone 1-
24 (ACTH1-24) in dispersed adrenal cells obtained from groups of male Wistar rats after 2, 4, or 24 
h. 
Male Wistar rats (n = 4) received an intraperitoneal (i.p.) injection of either saline (control), or LPS (750 
μg.kg-1 i.p.), and then decapitated immediately, or after 2, 4, or 24 h, respectively. Adrenal glands were 
excised from male Wistar rats, and dispersed enzymatically with collagenase in Earle’s balanced salt 
solution (EBSS), centrifuged, and equilibrated at 37 °C in 95% O2/5% CO2 for 1 h. Cells were then 
incubated for 4 h with or without (basal) ACTH1-24 (10
-11
 – 10-7) in EBSS. Data are arithmetic mean ± the 
standard error of mean of n = 6 wells, compared by one-way ANOVA with Dunnett's post hoc tests: * = P 
< .05, ** = P < .01 vs. control; and by two-way ANOVA with Bonferroni tests for multiple comparisons: 
&& = P < .01, &&& = P < .001 2 h vs. 4 h; # = P < .05, ## = P < .01, ### = P < .001 2 h vs. 24 h. 
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6.3.4 The effect of an intraperitoneal injection of LPS on the morphology of the zona fasciculata 
within adrenal glands obtained from groups of male Wistar rats after 2, 4, or 24 hours 
Figure 6.4 shows the morphology of the zona fasciculata within adrenal glands obtained from groups of 
male Wistar rats injected intraperitoneally with either saline, or LPS (750 μg.kg-1 i.p.), and decapitated 
either immediately, or after 2, 4, or 24 hours, respectively. 
The adrenal cortex is largely made up of endocrine steroid secreting cells. A modified haematoxylin and 
eosin (H&E) staining protocol allowed histological examination of the adrenocortical cells and sterol 
content. Unesterified cholesterol is typically localised to the cell membranes, and cholesteryl esters within 
the cytosol. Although the H&E technique does not differentiate between these sterol compartments, the 
presence of sterol vacuolations within the cortex are detecible.  
The control section in Figure 6.4 (a) shows a normal arrangement of confluent adrenocortical cells with 
large, haematoxylin stained (dark blue) nuclei, and sterol vacuolations. The effect of the intraperitoneal 
injection of LPS is apparent in sections from the two-hour group in (b) with fewer sterol vacuolations and 
more interstitial space, versus the controls. In sections from the four-hour group (Figure 6.4 c), the 
insterstitium is characterised by islands of cells and fewer sterol vacuolations than the control, along with 
more eosinophilic cytoplasms than in the two-hour group. After 24 hours (Figure 6.4 d), the interstitial 
space is markedly increased and although the presence of vacuolated cells remains evident, there are 
fewer eosinophilic cytoplasms than in the four-hour group.  
In contrast to these changes within the adrenal cortex, there were no obvious histological differences in 
the sections of the hypothalamus, pituitary, spleen, or thymus between each group in this study (data not 
shown).  
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Figure 6.4: Effect of an intraperitoneal injection of lipopolysaccharide (LPS) on the morphology of the zona fasciculata within adrenal glands obtained from 
groups of male Wistar rats after 2, 4, or 24 h. 
Male Wistar rats (n = 4) received an intraperitoneal (i.p.) injection of either saline (control), or LPS (750 μg.kg-1 i.p.), and then decapitated immediately, or after 2, 4, 
or 24 h, respectively. Transverse sections (4 μm) of adrenal glands were stained with Gill’s No 1 haematoxylin (75 s), rinsed in tap water (10 min) and counterstained 
(7 min) with Eosin Y solution (5% w/v dH2O) acidified with acetate (50 μl/200 ml). Sections were then dehydrated in 75% and 100% ethanol, each for 30 s, twice, 
before fixing in xylene for 1 min and mounting coverslips with DPX. The zona fasciculata was imaged by light microscopy (40x). The cytoplasm is stained pale 
blue/pink, nuclei are dark blue, and red blood cells are orange. Arrows denote sterol vacuolations. 
(b) LPS 2 h – Adrenal Z.f. 
(d) LPS 24 h – Adrenal Z.f. 
(a) Control – Adrenal Z.f. 
(c) LPS 4 h – Adrenal Z.f. 
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6.3.5 The effect of an intraperitoneal injection of LPS and/or WRW4 on the concentration of 
corticosterone in plasma obtained from groups of male Wistar rats after 4 hours 
The following results are from experiments performed in order to examine the effects of treatment of rats 
with the Fpr2-/FPR2/ALX-selective antagonist WRW4 on the adrenocortical responses to LPS. 
Figure 6.5 shows the effect of an intraperitoneal injection of LPS (750 μg.kg-1 i.p.), WRW4 (250 μg.kg
-1
 
i.p.), or LPS and WRW4 combined, versus saline, on the concentration of corticosterone in the plasma of 
male Wistar rats after 4 hours. 
WRW4 alone had no effect on basal corticosterone release (ns = P > .05 vs. control). The administration 
of LPS caused a significant increase in plasma corticosterone concentration within 4 hours (* = P < .05 
vs. control). The co-administration of LPS and WRW4 also resulted in a significant increase in plasma 
corticosterone concentration (* = P < .05 vs. control), but this was not different from the effect of LPS 
alone (ns = P > .05). 
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Figure 6.5: Effect of intraperitoneal injections of lipopolysaccharide (LPS) and/or Trp-Arg-Trp-
Trp-Trp-Trp (WRW4) on the concentration of corticosterone in plasma obtained male Wistar rats 
after 4 h.  
Male Wistar rats (n = 6) received intraperitoneal injections of either saline (control), LPS (750 μg.kg-1), 
the formyl peptide receptor 2 (FPR2/ALX)-selective antagonist WRW4 (250 μg.kg
-1
), or LPS and WRW4, 
and were then decapitated after 4 h. Trunk blood was collected into tubes coated with 
ethylenediaminetetraacetate (EDTA) and centrifuged for 10 min at 3,000 rcf. Plasma samples were 
aliquotted, snap frozen in liquid nitrogen, and then stored at -80 °C until the corticosterone concentration 
was determined by enzyme immunoassay (EIA). Data are arithmetic mean ± the standard error of mean of 
n = 6 animals, compared by one-way ANOVA with Bonferroni’s correction for multiple comparisons: * = 
P < .05 vs. control. 
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6.3.6 The effect of an intraperitoneal injection of LPS and/or WRW4 on the morphology of the zona 
fasciculata within adrenal glands obtained from groups of male Wistar rats after 4 hours 
Figure 6.6 shows the effect of an intraperitoneal injection of LPS (750 μg.kg-1 i.p.), WRW4 (250 μg.kg
-1
), 
or LPS and WRW4 combined, versus saline, on the morphology of the zona fasciculata within the adrenal 
glands of male Wistar rats after 4 hours. 
The control section in Figure 6.6 (a) shows a typical arrangement of confluent adrenocortical cells with 
large, nuclei stained dark blue with haematoxylin, and lipid globules within the insterstitium. The effect 
of the intraperitoneal injection of LPS is evident after 4 hours in (Figure 6.6 b) with observations of 
reduced sterol vacuolations and more interstitial space compared to the control group. In sections from 
the WRW4 group (Figure 6.6), the confluency of the adrenocortical cells remains largely unchanged, with 
an interstitial space and sterol vacuolations that compare with the control group. The effect of the 
combined administration of LPS and WRW4 is evident in Figure 6.6 (d), with more vacuolated cells and a 
loss of the lipid globules versus the WRW4 and control groups; however, these changes are broadly 
similar to those seen in the LPS group.  
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Figure 6.6: Effect of an intraperitoneal injection of lipopolysaccharide (LPS) and/or Trp-Arg-Trp-Trp-Trp-Trp (WRW4) on the morphology of the zona 
fasciculata within adrenal glands obtained from groups of male Wistar rats after 4 h. 
Male Wistar rats (n = 6) received an intraperitoneal (i.p.) injection of either saline (control), LPS (750 μg.kg-1 i.p.), WRW4 (250 μg.kg
-1
), or LPS and WRW4, then 
decapitated after 4 h. Transverse sections (4 μm) of adrenal glands were stained with Gill’s No 1 haematoxylin (75 s), rinsed in tap water (10 min) and counterstained 
(7 min) with Eosin Y solution (5% w/v dH2O) acidified with acetate (50 μl/200 ml). Sections were then dehydrated in 75% and 100% ethanol, each for 30 s, twice, 
before fixing in xylene for 1 min and mounting coverslips with DPX. The zona fasciculata was imaged by light microscopy (40x). The cytoplasm is stained pale 
blue/pink, nuclei are dark blue, and red blood cells are orange. Arrows denote sterol vacuolations. 
(b) LPS 4 h – Adrenal Z.f. 
(d) LPS + WRW4 4 h – Adrenal Z.f. 
(a) Control – Adrenal Z.f. 
(c) WRW4 4 h – Adrenal Z.f. 
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6.4 Discussion 
This study has provided evidence for the following main findings. First, LPS increases the plasma 
concentration of ACTH within 2 hours of administration. Second, LPS induces a time-dependent decrease 
in sterol vacuolation within the zona fasciculata that is maximal within 4 hours of administration. Third, 
the GC-secretory function of adrenal cells in vitro was elevated in basal conditions, but became 
maximally refractory to graded, physiological concentrations of ACTH1-24 within 4 hours of LPS 
administration in vivo. Fourth, intraperitoneal injections of the Fpr2-/FPR2/ALX-selective antagonist 
WRW4 had no effect on basal or the LPS-induced increase in the plasma concentration of corticosterone 
within 4 hours of administration.   
To the author’s knowledge, this is the first reported use of the Fpr2-/FPR2/ALX-selective antagonist, 
WRW4 (250 μg.kg
-1
 i.p.) to determine the contribution of Fpr2 on pituitary and adrenal stress hormone 
release in male Wistar rats during experimental endotoxaemia induced by LPS (750 μg.kg-1 i.p.). This 
work is important because of the need to find safe, efficacious alternatives to corticosteroids during 
sepsis. 
Previous research has assessed the effects of experimental endotoxaemia induced by intraperitoneal 
injection of LPS on pituitary and adrenal function in mice and rats. Studies of dispersed adrenals obtained 
from wildtype and Fpr2/3
-/-
 mice have also been performed to assess the contribution of Fpr2 and/or Fpr3 
in the regulation of GC secretion. Buss and colleagues (2010) found evidence of increased adrenocortical 
infiltration of leukocytes (eosinophils, neutrophils, and monocytes) and upregulated transcripts for Fpr1, 
Fpr2, and Fpr3, and sterol vacuolation within 4 hours of intraperitoneal injection of LPS in wildtype 
mice. In contrast, the LPS-induced sterol vacuolation was less pronounced in the Fpr2/3
-/-
 mice, 
suggesting Fpr2 and/or Fpr3 could be involved in the adrenal response to experimental endotoxaemia 
(Buss 2010). In the present study design, instead of using genetic knockout of Fpr2 and/or Fpr3 in mice, 
the Fpr2-/FPR2/ALX-selective antagonist WRW4 was used to pharmacologically block Fpr2 in rats. The 
present study aimed to advance the field by assessing the role of Fpr2 on pituitary and adrenal stress 
hormone function during sepsis-related endotoxaemia in male Wistar rats, through pharmacological 
blockade with the Fpr2-/FPR2/ALX-selective antagonist WRW4. This was intended to develop a model 
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that could be translated into a clinical therapy in the form of a drug, as opposed to the germ line knockout 
mouse models. 
Previous research is concordant with the finding that within 4 hours of in vivo administration, LPS 
induced maximal effects on adrenocortical cells in vitro, including sterol vacuolation and elevated basal 
GC secretion whilst the response to graded, physiological concentrations of ACTH1-24 was refractory. The 
stimulatory effect of LPS on adrenal corticosterone secretion has been well documented (Lenczowski et 
al. 1997; Grinevich et al. 2001; Campisi et al. 2003; Zimomra et al. 2011). Previous research has also 
found that peripheral injection of LPS in mice in vivo resulted in adrenocortical cells that were refractory 
to ACTH1-24 when dispersed and cultured in vitro (Buss 2010; Mohn et al. 2011). Repeated LPS 
injections result in further uncoupling of the corticosterone secretory response to ACTH1-24, despite 
increases in adrenal mass and expression of steroidogenic enzymes (Grinevich et al. 2001). Although the 
mechanisms behind adrenals being refractory to ACTH1-24 following LPS require further investigation, it 
has been shown that LPS-stimulated mouse macrophages produce a factor that inhibits the action of 
ACTH1-24 on rabbit adrenal cells in vitro (Mathison et al. 1983; 1984; Ehrhart-Bornstein et al. 1998). 
Also, mice knocked-out for scavenger receptor B-I (SR-BI)—an HDL receptor for the uptake of 
cholesterol ester—lack the upregulated corticosterone secretion in response to LPS, suggesting de novo 
synthesis of corticosterone from cholesterol/pregnenelone precursors contributes to the LPS-induced 
hypersecretion of corticosterone (Cai et al. 2008). In addition, macrophage and lymphocytes native to the 
adrenal cortex have been shown to be involved in the infiltration of eosinophils induced by LPS (Bozza et 
al. 1994). 
The lack of an effect of WRW4 alone on the plasma corticosterone concentration is not surprising. WRW4 
is a full, Fpr2-/FPR2/ALX-selective antagonist and as such will not elicit an effect on its own. Given the 
evidence that LPS has been shown to upregulate adrenal Fpr2 expression, and evidence that Fpr2 
mediates anti-inflammatory signalling mechanisms induced by endogenous ligands such as ANXA1 and 
LXA4 (Dufton et al. 2010), then it was thought that the blockade of Fpr2 might limit some of the effects 
of LPS on adrenal morphology and function. Given the intraperitoneal route of administration, and the 
250 μg.kg-1 dose of WRW4, it is conceivable that the blood concentration of WRW4 was not sufficient to 
block Fpr2 signalling within the adrenal cortex. 
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6.4.1 Biological significance and scope of findings 
Overall, the finding that intraperitoneal administration of LPS in a rat model of sepsis-related 
endotoxaemia reduced both the secretion of ACTH1-24-stimulated corticosterone and the presence of 
sterol vacuolations within the adrenal cortex has implications for our understanding of pituitary and 
adrenal function. As these effects were maximal after 4 hours, this implies that this time period could be 
investigated as a window for Fpr/FPR ligands that preserve the adrenal GC secretory response to ACTH. 
Although the dose and route of administration of WRW4 may not have been sufficient to block Fpr2 in 
this study, this does not rule out the potential importance of ligands that target Fpr2 in sepsis-related 
endotoxaemia.    
Intravenous (i.v.) administration of WRW4 was considered but was rejected in favour of the i.p. route 
which is less stressful for the animals. Colleagues have used WRW4 at 2.2 μg.kg
-1
 i.v. when observing 
leukocyte migration during experimental endotoxaemia in mice (Hughes 2012). Despite the present study 
using a considerably higher dose of 250 μg.kg-1 WRW4 i.p. in rats, it is possible that the intraperitoneal 
route of administration resulted in an insufficient blood concentration of WRW4 to have any effect on 
LPS-induced changes in adrenal morphology or function. Given that mice have an approximate blood 
volume of 58.5 ml.kg
-1
 body mass (Wolfensohn & Lloyd 2003), the maximum blood concentration of a 
2.2 μg.kg-1 dose of WRW4 given
 
intravenously to a 25 g mouse with 1.5 ml of blood would therefore be 
3.3 mmol.l
-1
. Similarly, in rats, blood volume is approximately 64 ml.kg
-1
 body mass, so the maximum 
blood concentration of a 250 μg.kg-1 dose of WRW4 given to a 250 g rat with 16 ml blood would be 3.5 
μmol.l-1. These concentrations are above the IC50 of 0.13 μmol.l
-1
 for WRW4 via Fpr2/FPR2/ALX Fpr2 
(Önnheim et al. 2008; Braun et al. 2011). Other researchers investigating the role of Fpr/FPR in alopecia, 
found that WRW4 was able to block the anti-alopecia effects of the Fpr1 agonist fMLF and the Fpr2 
agonist MMK-1, even though it was administered intraperitoneally (Tsuruki et al. 2007). The dose of 
WRW4 however, was given over several days and was 120 times higher (30 mg.kg
-1
 i.p.) than the single 
dose in the present study (250 μg.kg-1 i.p.). It seems likely that the dose in the present study was 
insufficient to account for the intraperitoneal route of administration. 
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6.4.2 Conclusion 
The finding that this rat model of LPS-induced, sepsis-related endotoxaemia led to an increased plasma 
concentration of ACTH within 2 hours, and refractory GC secretory responses to ACTH1-24 within 4 
hours, is consistent with previous research in mice (Buss 2010). The apparent lack of an effect of the 
Fpr2-/FPR2/ALX-selective antagonist WRW4 however, does not refute the previous findings that LPS led 
to reductions in both the secretion of ACTH1-24-stimulated corticosterone and the presence of sterol 
vacuolations within the adrenal cortex was limited by the removal of Fpr2 and/or Fpr3 in Fpr2/3
-/-
 mice. 
The present work has advanced the field by providing evidence for the disruptive effects of LPS on 
adrenocortical structure and function occur within 2 hours, and are maximal within 4 hours in rats, thus 
confirming previous findings in mice. These findings improve our understanding of the temporal nature 
of changes in pituitary and adrenal function during sepsis-related endotoxaemia.
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1. Microscopic evaluation of immunostained tissue sections from LPS-stimulated Fpr2/3-/- mice 
revealed nuclear GFP immunoreactivity within endocrine cells of the anterior pituitary gland, the 
adrenocortical cells of the adrenal glands, and the thymus, but not in the hypothalamus or the median 
blade of the dentate gyrus. The nuclear GFP signal was visible after 2 hours, but was absent at 6 
hours following LPS injection. 
2. Anterior pituitary gland sections from LPS-stimulated Fpr2/3-/- mice had nuclear GFP 
immunoreactivity in cells with cytoplasmic ACTH, PRL, and GH immunoreactivity, but not the 
S100b-positive folliculostellate cells. 
3. Human anterior pituitary gland sections from MS donors exhibited nuclear immunoreactivity for 
FPR3 that was colocalised to cells with cytoplasmic ACTH immunoreactivity but not the S100b-
positive folliculostellate cells. 
4. Although the human pituitary gland also contained FPR2/ALX and FPR1 immunoreactivity, the 
automated image analysis indicated these subtypes were not significantly colocalised with either 
ACTH or S100b immunoreactivity. 
5. Dispersed anterior pituitary cells from rats had a reduced CRH-stimulated release of ACTH when 
incubated with micromolar fMLF, micromolar WKYMVm, and 15-epi-LXA4. 
6. The Fpr1-/FPR1-selective agonist fMLF generally did not affect basal or CRH-stimulated ACTH 
release except at the high, 10 micromolar concentration, where CRH-stimulated ACTH release was 
inhibited. 
7. The Fpr2-/FPR2/ALX-selective agonist WKYMVm stimulated the basal release of ACTH, but 
generally did not affect CRH-stimulated ACTH release except at a high micromolar concentration of 
WKYMVm where this was inhibited, and the nanomolar concentration where it was enhanced. 
8. The Fpr2-/FPR3-selective agonist F2L stimulated basal release of ACTH at all concentrations, but 
only affected CRH-stimulated ACTH release at the highest 800 nanomolar concentration where it 
was enhanced. 
9. The Fpr3/Alx-/FPR2/ALX-selective agonist 15-epi-LXA4 stimulated basal ACTH release at low 
concentrations, but was reversed at concentrations of or above 10 nanomolar where it also potently 
inhibited CRH-stimulated ACTH release. 
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10. The non-selective Fpr/FPR agonist ANXA1Ac2-26 did not affect basal or CRH-stimulated ACTH 
release except at the 3 micromolar concentration where it enhanced it. Basal release of ACTH was 
inhibited by ANXA1Ac2-26 at concentrations of 3 micromolar or below, but only in the presence of the 
Fpr2-/FPR2/ALX-selective antagonist WRW4 in an experiment where CRH failed to stimulate 
ACTH release.  
11. The approximate efficacy of the tested Fpr/FPR agonists for their modulation of basal or CRH-
stimulated ACTH release can be summarised as: WKYMVm >>> 15-epi-LXA4 > F2L >> fMLF > 
ANXA1Ac2-26. 
12. Basal ACTH release was most potently modulated by the stimulatory effect of the Fpr2-/FPR2/ALX-
selective agonist WKYMVm. 
13. CRH-stimulated ACTH release was most potently modulated by the inhibitory effect of the 
Fpr3/Alx-/FPR2/ALX-selective agonist 15-epi-LXA4. 
14. Dispersed adrenal cells from male Wistar rats had reduced ACTH1-24-stimulated corticosterone 
release when incubated with fMLF, ANXA1Ac2-26, and 15-epi-LXA4. 
15. The Fpr1-selective agonist fMLF elicited the most powerful inhibition of corticosterone release 
irrespective of the presence of ACTH1-24, but was partly inhibited by the Fpr2-selective antagonist 
WRW4. 
16. The Fpr2-/FPR2/ALX-selective agonist WKYMVm partly suppressed basal corticosterone release, 
and was unaffected by ACTH1-24 or WRW4. 
17. The Fpr2-/FPR3-selective agonist F2L stimulated basal corticosterone release at a low concentration, 
but enhanced ACTH1-24-stimulated corticosterone in the presence of the Fpr2-/FPR2/ALX-selective 
antagonist WRW4. 
18. The Fpr3/Alx-/FPR2/ALX-selective agonist 15-epi-LXA4 suppressed both basal and ACTH1-24-
stimulated corticosterone release, but was unaffected by WRW4.  
19. The non-selective Fpr/FPR agonist ANXA1Ac2-26 suppressed both basal and ACTH1-24-stimulated 
corticosterone release. 
20. The approximate efficacy of the tested Fpr/FPR agonists for inhibition of basal and ACTH1-24-
stimulated corticosterone release after 4 hours of contact can be summarised as: fMLF >>> 
WKYMVm > ANXA1Ac2-26 > 15-epi-LXA4 >> F2L. 
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21. Despite being an Fpr1-/FPR1-selective agonist at low concentrations, the effects of fMLF were 
probably mediated via Fpr2 or Fpr3, especially since fMLF was the only agonist to be inhibited by 
WRW4. 
22. The basal, in vitro release of corticosterone from dispersed adrenal cells obtained from rats 
intraperitoneally injected with LPS four hours earlier, was higher than from rats injected with saline.  
23. At all time points following LPS administration, the release of corticosterone from dispersed adrenal 
cells was refractory to ACTH1-24, compared to the ACTH1-24 concentration-dependent increase in 
corticosterone release by adrenal cells from the saline control group. 
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8.1 Main findings 
To the author’s knowledge, this is the first time that antibodies targeting the human FPR subtypes have 
been used to detect their distribution within the human anterior pituitary gland. Secondly, the factorial 
study design for the functional investigations meant that co-incubation of dispersed anterior pituitary or 
adrenal cells with stress hormone secretagogues, and Fpr/FPR agonists and antagonists allowed their 
interactive effects to be detected. Thirdly, to the author’s knowledge, this is the first time that F2L, 
WKYMVm, and 15-epi-LXA4 have been used in both dispersed anterior pituitary, and adrenal cell 
systems. This combination of immunohistochemical and pharmacological approaches, together with 
novel aspects in the design of the studies, has resulted in the following main findings discussed in turn 
below. 
8.1.1 The anterior pituitary gland from organisms exposed to inflammogenic stressors exhibits 
colocalisation of ACTH with FPR3 in MS-diseased humans, and ACTH, GH, and PRL with 
GFP as a proxy for Fpr2 and Fpr3 in LPS-exposed mice 
Intraperitoneal injection of LPS into Fpr2/3
-/-
 mice with a GFP transgene in place of Fpr2 and Fpr3 
resulted in immunofluorescence for GFP that was colocalised with ACTH, GH, and PRL, but not with 
S100b. Within the anterior pituitary of deceased humans with MS, FPR3 was colocalised with ACTH 
immunofluorescence within corticotrophs. The present findings are concordant with those from previous 
research. Although folliculostellate cells express ANXA1 (Christian et al. 1997), they do not possess 
ANXA1-binding sites, putatively an Fpr/FPR subtype, either within tissue sections (Traverso et al. 1999) 
or in the folliculostellate-like TtT/GF cell line (Inoue et al. 1992; McArthur et al. 2009). The long thread-
like projections of folliculostellate cells do however, show immunogold localisation of ANXA1 at sites in 
contact with endocrine cells such as corticotrophs (Traverso et al. 1999). The distribution of GFP 
observed here in the Fpr2/3
-/-
 mouse is consistent with the expression of Fpr2 and Fpr3 transcripts within 
the anterior pituitary glands of C57BL/6 mice and Sprague-Dawley rats (John et al. 2007). The present 
data from the Fpr2/3
-/-
 mouse anterior pituitary was partly corroborated by immunostaining of FPR 
subtypes within the human anterior pituitary that found significant colocalisation of ACTH with FPR3, 
but not with FPR1 or FPR2/ALX, and S100b fluorescence was singular in both species. Not all FPR3 was 
colocalised with ACTH however, and further experiments with anti-GH antisera could confirm whether 
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the wide distribution of FPR3 is colocalised with GH within human somatotrophic cells. If so, this would 
be reflective of the widespread colocalisation of GFP and GH within the Fpr2/3
-/-
 mouse pituitary 
observed here, and consistent with somatotrophs being the dominant endocrine subpopulation within the 
anterior pituitary of these species (Philip et al. 2001; Ganong 2005). The sparse fluorescence for FPR1 is 
consistent with FPR1-positive leukocyte infiltration observed in brains from MS patients (Müller-Ladner 
et al. 1996). Unfortunately, non-diseased control tissues were not available at the time of the experiments. 
In summary, the anterior pituitary gland exhibits ACTH colocalisation with FPR3 in MS-diseased 
humans, and with GFP as a proxy of Fpr2 and Fpr3 in mice exposed to LPS but not in vehicle controls. 
Taken together, this suggests these subtypes could be targets for Fpr/FPR ligands such as ANXA1 in the 
control of ACTH secretion, particularly during the inflammogenic stress of MS or endotoxaemia.      
8.1.2 Fpr/FPR ligands modulate the secretagogue-induced secretion of pituitary and adrenal stress 
hormones from dispersed glands derived from rats in vitro  
Within four hours, a range of chemically diverse Fpr/FPR ligands exhibited a hierarchy of efficacy in 
terms of their modulation of basal and/or secretagogue-induced secretion of stress hormones from 
dispersed cells of both the rat anterior pituitary gland: WKYMVm >>> 15-epi-LXA4 > F2L >> fMLF > 
ANXA1Ac2-26; and adrenal glands: fMLF >>> WKYMVm > ANXA1Ac2-26 > 15-epi-LXA4 >> F2L. 
The modulatory effects of Fpr/FPR ligands on the CRH-stimulated release of ACTH from the dispersed 
anterior pituitary gland are plausible given what is known of the signal transduction events downstream of 
their receptors. Upon CRH binding, CRH-R1 recruits Gs to trigger adenylate cyclase to produce cAMP 
and activate PKA. The actions of PKA triggers an influx of Ca
2+
 via L-type Ca
2+
 channels which, results 
in membrane fusion of secretory vesicles and exocytosis of ACTH (Aguilera et al. 1983; Taylor et al. 
1993). Previous data have however shown that the ANXA1-mediated inhibition of ACTH release does 
not interfere with Ca
2+
 influx, but involves a different mechanism, ostensibly downstream of an Fpr/FPR 
subtype (Taylor et al. 1993; John et al. 2002). Indeed, activation of the Fpr/FPR subtypes coupled with 
heterotrimeric Gi proteins reduced the release of CRH-stimulated ACTH from the corticotrophic AtT20 
cell line (Aguilera et al. 1983; Luini & Matteis 1990), and this can be blocked by pertussis toxin (Le et al. 
2002). The other events downstream of ANXA1-Fpr activation are unclear, but some evidence suggests 
that ANXA1-activated FPR2/ALX leads to actin polymerisation and Grho/Grac/Grac-mediated inhibition of 
 264 
exocytosis of ACTH from corticotrophs (McArthur et al. 2009) and lytic granules from leukocytes 
(Castellino et al. 1992; Maderna et al. 2002). Consistent with John and coworkers (2007) the present data 
militate against a role for the rat equivalent of mouse Fpr1 and human FPR1, as a target for ANXA1 
action in the anterior pituitary gland. The Fpr1-/FPR1-selective agonist fMLF had no effect on basal or 
CRH-stimulated ACTH release at the sub-micromolar concentrations at which these subtypes are 
selectively bound (Prossnitz et al. 1991; He et al. 2000) and elicit exocytosis of lytic granules 
(Schiffmann et al. 1975a; Marasco et al. 1984). This is consistent with previous observations of inhibitory 
effects of ANXA1Ac2-26 that were unaffected by either the genetic knockout of Fpr1, or pharmacological 
blockade of Fpr1 with the human FPR1/mouse Fpr1 antagonist Boc1 (John et al. 2007). Further support 
for this is evident in that while ANXA1 suppressed ACTH release (Taylor et al. 1993; John et al. 2007), 
the Fpr1/FPR1 subtypes are not expressed in human (Becker et al. 1998) or rodent anterior pituitary tissue 
(John et al. 2007). As for the other Fpr subtypes, this laboratory previously found evidence of Fpr2 and 
Fpr3 expression within the rat pituitary, and the mouse pituitary also contained Fpr-rs6, Fpr-rs7 (John et 
al. 2007). The Fpr2l/Alx subtype in the rat (Chiang et al. 2003) and Fpr3/Alx in the mouse (Takano et al. 
1997) have been described as the orthologues of human FPR2/ALX which mediate the effects of LXA4, 
15-epi-LXA4, ANXA1, and ANXA1Ac2-26 (Takano et al. 1997; Hartt et al. 1999; Wang & Ye 2002). The 
present finding that the aspirin-triggered lipoxin, 15-epi-LXA4 at 10
-8
 mol.l
-1
, inhibited CRH-stimulated 
ACTH release is consistent with signalling via rat Fpr2l/Alx (Chiang et al. 2003), and the inhibition 
elicited by the less potent LXA4 used previously at 2 x 10
-6
 mol.l
-1
 (John et al. 2007). Conversely, the 
agonist WKYMVm had a stimulatory effect on ACTH release that is consistent with its pro-exocytotic 
effects on leukocytes at Fpr2-/FPR2/ALX-selective concentrations (Kim et al. 2006). Taken together, this 
might suggest that Fpr2 mediates stimulatory and Fpr2l/Fpr3 mediates inhibitory effects of Fpr/FPR 
ligands on the secretion of ACTH, at least from dispersed anterior pituitary glands from rats and over a 
period of four hours.  
The inhibitory effects of Fpr/FPR ligands on the ACTH1-24-stimulated release of corticosterone are 
plausible given what is known about the signalling mechanisms downstream of their receptors. Upon 
binding of ACTH, MC2R recruits Gsα and adenylate cyclase hydrolyses ATP, producing cyclic AMP. 
This activates PKA to phosphorylate cAMP response element binding (CREB) protein that then binds to 
cAMP response elements (CRE) to upregulate the transcription of genes for steroidogenic enzymes 
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including, P450scc in the rate-limiting conversion of pregnenelone from cholesterol (Richman et al. 1973; 
Simpson & Waterman 1988; Stocco et al. 2005; Manna et al. 2009). Conversely, upon binding of fMLF, 
Fpr1 recruits Giα and Gβ which activate PLC-β and in turn, PKC, which is then able to phosphorylate 
NFκB (Naccache et al. 1979). Prior to its phosphorylation, the NFκB heterodimer (p65 (Rel A) and p50) 
is kept in the cytosol by association with inhibitory factor IκB. Once phosphorylated, NFκB is free to 
enter the nucleus and bind to response elements including CRE, thereby enhancing the transcription of 
various genes (McKay & Cidlowski 1999). It is plausible to hypothesise, therefore, that the inhibition of 
corticosterone release induced by fMLF might somehow be achieved by the competition of NFκB with 
CREB for its DNA response element downstream of Fpr1 and MC2R activation, respectively, thereby 
limiting the ACTH1-24-induced expression of steroidogenic enzymes. This hypothesis requires further 
investigation, but given the bacterial origins of fMLF, this could have implications for bacterial sepsis. 
Intriguingly, the Fpr/FPR ligands in the dispersed anterior pituitary gland and adrenal gland experiments 
exhibited non-classical concentration-effect curves. Although the scope of the present studies was unable 
to obtain an explanation for this observation, it can be interpreted in the context of several strands of the 
existing literature. Firstly, the apparently opposing effects of ligands supposedly selective for a given 
Fpr/FPR subtype could be due to ligand-specific binding pockets. Bena and coworkers (2012) constructed 
chimeric FPRs to investigate this possibility, and found specific binding pockets for ANXA1Ac2-26, LXA4 
and serum amyloid A on human FPR2/ALX, which mediates both anti-inflammatory and pro-
inflammatory effects in polymorphonuclear leukocytes (Chiang et al. 2006a). Alternatively, given the 
high structural homology between the Fpr/FPR subtypes (Ye et al. 2009), ligand activity might involve 
recruitment of multiple Fpr/FPR subtypes or signal mechanisms. The amino acid residues Asp-106 and 
Arg-201 to Arg-205 in the mouse Fpr1, Fpr2, and Fpr3/Alx subtypes, for instance, are conserved in 
human FPR1 and FPR2/ALX, whereas FPR3 contains FLILH in this position and other substitutions in 
the third cytoplasmic loop that binds G proteins (Alvarez et al. 1996). This means that mice, and 
ostensibly rats, lack a direct structural homologue of FPR3 but instead have 3 genes closely related to 
FPR1 and FPR2/ALX (Gao et al. 1998), whereas Fpr-rs3, Fpr-rs4, and Fpr-rs5 have multiple substitutions 
in residues that are thought to be key to the ligand-specificity of Fpr1, Fpr2, and Fpr3/Alx (Mills et al. 
2000). 
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The decision to incubate Fpr/FPR agonists and antagonists with endogenous secretagogues in dispersed 
anterior pituitary and adrenal cells derived from rats rather than mouse was novel, and necessary to gain 
an adequate yield of cells to be incubated with a range of ligand concentrations. This came at the expense 
of limited availability of genetic and immunological tools for the rat Fpr subtypes, as well as disrupting 
the paracrine communication networks within the pituitary (Baes et al. 1987; Denef et al. 1989) and 
possibly the adrenal glands (Haidan 1998; Ehrhart-Bornstein & Bornstein 2008). 
8.1.3 Within two hours of experimental endotoxaemia, adrenocortical cells become refractory to 
ACTH-induced secretion of corticosterone in vitro with a loss of sterol vacuolation that is 
limited by the knockout of Fpr2 and Fpr3 genetically in mice, but not by pharmacological 
antagonism in rats 
Within two hours, experimental endotoxaemia induced by intraperitoneal injection of LPS (750 μg.kg-1 
i.p.) into rats, increased the secretion of ACTH in vivo, and of corticosterone from dispersed rat adrenal 
glands in vitro, which remained refractory to graded concentrations of ACTH1-24 for up to twenty-four 
hours. The morphology of the adrenal glands exhibited an LPS-induced decrease in sterol vacuolation 
within two hours in wildtype mice but was limited in Fpr2/3
-/-
 mice, with a similar effect observed in the 
rat adrenal gland within two hours that was maximal by four hours, but unaffected by the Fpr2-
/FPR2/ALX-selective antagonist WRW4. 
The LPS-induced decrease in adrenal sterol vacuolation that is evident within 4 hours in wildtype mice, 
but limited by the genetic deletion of mouse Fpr2 and Fpr3 is consistent with previous research (Buss 
2010). Following intraperitoneal injection, LPS enters the blood from the peritoneal cavity primarily via 
the hepatic portal vein (haematogenous route) or via the lymphatic system (lymphogenous route) 
(Romanovsky et al. 2000). From here, LPS is able to enter the well perfused adrenal cortex and exert a 
well-documented stimulation of adrenal GC secretion (Lenczowski et al. 1997; Grinevich et al. 2001; 
Campisi et al. 2003; Zimomra et al. 2011). The present observation that LPS in vivo precedes refractory 
GC secretion in response to graded concentrations of ACTH in adrenocortical cells in vitro, is supported 
by previous research which also found evidence of downregulated MC2R expression (Liu et al. 2011). 
Although LPS initially stimulates the production and release of GCs in a mechanism involving COX-2 
activation (Vakharia & Hinson 2004; Zacharowski et al. 2006), following this, the GC secretory response 
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to further LPS or ACTH becomes downregulated along with the expression of steroidogenic enzymes and 
MC2R (Liu et al. 2011). Since there is very little de novo synthesis of cholesterol, the cholesteryl ester 
within the adrenal cortex largely comes from LDL and HDL bound to SR-BI, in an uptake process that is 
critical for adrenocortical steroidogenesis (Temel et al. 1997; Prigent et al. 2004). Sepsis-related 
experimental endotoxaemia is associated with adrenocortical depletion of sterol vacuolation (Marik 2002; 
Buss 2010; Peng & Du 2010) that coincides with hypocortisolemia (Cai et al. 2008), an aberrant SR-BI 
pathway, and adrenocortical apoptosis (Kanczkowski et al. 2013).  
WRW4 is an antagonist selective for Fpr2/FPR2/ALX in cells from mice (Önnheim et al. 2008), rats 
(Braun et al. 2011), and humans (Bae et al. 2004). Although the intraperitoneal injection of WRW4 (250 
μg.kg-1), a dose intended to pharmacologically knockout the rat Fpr2, failed to significantly affect the 
plasma concentration of ACTH1-24 or corticosterone, or adrenal sterol vacuolation within 4 hours, the fact 
that genetic deletion of Fpr2 and Fpr3 limited the LPS-induced decrease in adrenal sterol vacuolation in 
mice has implications for the management of sepsis-related endotoxaemia. 
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8.2 Future directions and implications 
Advances in imaging techniques and mathematical modelling of endocrine tissues have allowed research 
to obtain spatial and functional data simultaneously. One such technique is two-photon imaging of 
pituitary cells in organised networks and how these impinge on endocrine function. Transgenic animals 
are typically used to visualise individual endocrine lineages, such as PRL-DsRed for lactotrophs (He et al. 
2011), and GH-eGFP for somatotrophs (Lafont et al. 2010), and so on. The technique can be applied to 
visualise the pituitary in vivo via cranial window and intravital microscopy or in vitro on pituitary slices 
(Lafont et al. 2010). The method creates three-dimensional reconstructions of the pituitary gland to allow 
optical planes to be selected and cell positions to be identified precisely. The tissue is subjected to a 
calcium indicator and a laser pulsed via an array of mirrors yielding 64 beamlets for rapid multi-photon 
imaging of a large tissue volume (100 μm x 100 μm x 40 μm) (see Hodson et al. 2010). These 
experiments could be combined with the administration of LPS conjugated with a fluorochome such as 
fluorescein isothiocyanate (FITC) or rhodamine, to monitor the effects of LPS on Ca
2+
-induced hormone 
secretion in Fpr2/3
-/-
 mice in vivo (Feng et al. 2011; Vagaja et al. 2013). In summary, this technique 
marries spatial information of pituitary cell networks with functional measurements of Ca
2+
-induced 
hormone exocytosis, and has also been applied to other endocrine cell types such as the pancreas (see 
Schaeffer et al. 2011). In addition, the two-photon microscopy technique could be applied to human stem 
cells that have undergone self-organisation into a three-dimensional culture of interacting pituitary cells 
akin to that of an intact pituitary gland (Suga et al. 2011). Further research could combine these advances 
in three-dimensional cultures of stem cell-derived human pituitary glands with two-photon microscopy, to 
allow functional and spatial information to be obtained simultaneously, and on tissues that are directly 
relevant to the human family of FPR subtypes.  
With regard to the adrenal gland, further work should seek to understand adrenal insufficiency in 
conditions such as sepsis-related endotoxaemia and Addison’s disease, as these can lead to septic shock 
or Addisonian crises which are fatal if poorly managed (Marik 2002). Corticosteroid therapies have 
undesirable side effects and the dosing regimen requires careful management to meet large variations in 
physiological demand. Recent advances in methods for obtaining, culturing, and transplanting 
adrenocortical stem cells could be used to investigate whether adrenal insufficiency, can be prevented by 
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targeting FPR subtypes with drugs, or treated by regeneration of the adrenal cortex with stem cells. 
Studies of the latter have been found to improve the survival rates of mice under stress following bilateral 
adrenalectomy (Zupekan & Dunn 2011). Adrenocortical stem cells can now be obtained by 
deformability-activated cell sorting (DACS) of progenitor cells which exhibit less clustering and 
steroidogenic capacity than differentiated cells, avoiding the use of lipophilic dyes such as Nile Red that 
are incompatible with clinical transplantation (Hur et al. 2012). Further work in this area is important 
because whilst corticosteroids can reverse septic shock, they are scarcely sufficient to reverse the 
underlying adrenal insufficiency in up to 65% of patients with sepsis (Briegel et al. 1996; Marik 2002; 
Marik & Zaloga 2003).  
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8.3 Conclusion 
These studies have contributed to a growing body of knowledge on the role of formyl peptide receptors in 
pituitary and adrenal function, and have provided evidence in support of the hypothesis. Within the 
pituitary gland, ACTH was colocalised with FPR3 in MS-diseased humans and with GFP in Fpr2/3
-/-
 
mice which retained more adrenocortical sterols following experimental endotoxaemia than wildtypes. 
The secretion of pituitary ACTH was generally stimulated by mouse Fpr2-selective, and inhibited by 
mouse Fpr3/Alx- or rat Fpr2l/Alx-selective agonists within four hours. The role of Fpr/FPR subtypes in 
adrenal corticosterone secretion remains complicated by the observation that the Fpr1-/FPR1-selective 
fMLF was the only agonist whose inhibitory effect was prevented by the Fpr2-/FPR2/ALX-selective 
antagonist WRW4 within four hours. Experimental endotoxaemia in rats induced adrenal insufficiency in 
terms of reduced adrenocortical sterol vacuolation and corticosteroid secretion in response to ACTH in 
vitro that was maximal within four hours. Taken together, these findings provide evidence in support of a 
modulatory role of formyl peptide receptor subtypes, particularly rodent Fpr2, Fpr2l/Alx, Fpr3/Alx and 
human FPR3, in terms of pituitary and adrenal stress hormone secretion following inflammogenic 
stressors and endogenous secretagogues. The findings could have implications for understanding the 
dissociation of pituitary and adrenal function in inflammogenic diseases such as sepsis-related 
endotoxaemia. 
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